[
    {
        "nctid": "NCT00818428",
        "text": "The Contribution of a Speech Perception Intervention to the Prevention of Phonological Awareness Deficits in Children With Speech Sound Disorders | Recent research reveals genetic and symptomatic overlap among children with speech sound disorders (i.e., those who (misarticulate more sounds than would be expected for their age) and children with dyslexia (i.e., those who struggle to learn to read). Children who have speech sound disorders as preschoolers are at risk for the later emergence of dyslexia, a risk that often reveals itself in the form of poor phonological awareness skills during the preschool period. Traditional speech therapy methods focus on articulation accuracy and do not focus on the child's more abstract knowledge of the sound system of the language. The ultimate objective of this research program is to prevent reading disability in children who present with speech sounds disorders. The relative effectiveness of different interventions to help these children achieve age-appropriate phonological processing skills prior to school entry will be investigated. It is expected that a combination of treatment approaches that focus on speech perception skills and vocabulary knowledge will have a superior impact on phonological awareness in comparison with a treatment approach that focuses solely on articulation accuracy.",
        "tokens": "['The', 'Contribution', 'of', 'a', 'Speech', 'Perception', 'Intervention', 'to', 'the', 'Prevention', 'of', 'Phonological', 'Awareness', 'Deficits', 'in', 'Children', 'With', 'Speech', 'Sound', 'Disorders', '|', 'Recent', 'research', 'reveals', 'genetic', 'and', 'symptomatic', 'overlap', 'among', 'children', 'with', 'speech', 'sound', 'disorders', '(', 'i.e.', ',', 'those', 'who', '(', 'misarticulate', 'more', 'sounds', 'than', 'would', 'be', 'expected', 'for', 'their', 'age', ')', 'and', 'children', 'with', 'dyslexia', '(', 'i.e.', ',', 'those', 'who', 'struggle', 'to', 'learn', 'to', 'read', ')', '.', 'Children', 'who', 'have', 'speech', 'sound', 'disorders', 'as', 'preschoolers', 'are', 'at', 'risk', 'for', 'the', 'later', 'emergence', 'of', 'dyslexia', ',', 'a', 'risk', 'that', 'often', 'reveals', 'itself', 'in', 'the', 'form', 'of', 'poor', 'phonological', 'awareness', 'skills', 'during', 'the', 'preschool', 'period', '.', 'Traditional', 'speech', 'therapy', 'methods', 'focus', 'on', 'articulation', 'accuracy', 'and', 'do', 'not', 'focus', 'on', 'the', 'child', \"'s\", 'more', 'abstract', 'knowledge', 'of', 'the', 'sound', 'system', 'of', 'the', 'language', '.', 'The', 'ultimate', 'objective', 'of', 'this', 'research', 'program', 'is', 'to', 'prevent', 'reading', 'disability', 'in', 'children', 'who', 'present', 'with', 'speech', 'sounds', 'disorders', '.', 'The', 'relative', 'effectiveness', 'of', 'different', 'interventions', 'to', 'help', 'these', 'children', 'achieve', 'age', '-', 'appropriate', 'phonological', 'processing', 'skills', 'prior', 'to', 'school', 'entry', 'will', 'be', 'investigated', '.', 'It', 'is', 'expected', 'that', 'a', 'combination', 'of', 'treatment', 'approaches', 'that', 'focus', 'on', 'speech', 'perception', 'skills', 'and', 'vocabulary', 'knowledge', 'will', 'have', 'a', 'superior', 'impact', 'on', 'phonological', 'awareness', 'in', 'comparison', 'with', 'a', 'treatment', 'approach', 'that', 'focuses', 'solely', 'on', 'articulation', 'accuracy', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O']",
        "entities": [
            {
                "start": 22,
                "end": 52,
                "text": "Speech Perception Intervention",
                "type": "OTHER"
            },
            {
                "start": 123,
                "end": 145,
                "text": "Speech Sound Disorders",
                "type": "CONDITION"
            },
            {
                "start": 224,
                "end": 246,
                "text": "speech sound disorders",
                "type": "CONDITION"
            },
            {
                "start": 419,
                "end": 441,
                "text": "speech sound disorders",
                "type": "CONDITION"
            },
            {
                "start": 888,
                "end": 911,
                "text": "speech sounds disorders",
                "type": "CONDITION"
            },
            {
                "start": 1111,
                "end": 1210,
                "text": "combination of treatment approaches that focus on speech perception skills and vocabulary knowledge",
                "type": "OTHER"
            },
            {
                "start": 1286,
                "end": 1349,
                "text": "treatment approach that focuses solely on articulation accuracy",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT00304291",
        "text": "A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease) | Neuromyelitis optica (NMO) is a severe demyelinating disease that selectively involves the optic nerves and the spinal cord but usually spares the brain. NMO is considered to have a B cell induced pathogenesis. Mitoxantrone (MITO, Novantrone\u00ae), a synthetic anthracenedione approved for worsening relapsing-remitting multiple sclerosis (MS) and secondary progressive MS, has been shown to primarily suppress the humoral response. We conducted a prospective 2-year study to evaluate the benefit of MITO in five relapsing NMO patients.",
        "tokens": "['A', 'Pilot', 'Study', 'of', 'Mitoxantrone', 'for', 'the', 'Treatment', 'of', 'Recurrent', 'Neuromyelitis', 'Optica', '(', 'Devic', \"'s\", 'Disease', ')', '|', 'Neuromyelitis', 'optica', '(', 'NMO', ')', 'is', 'a', 'severe', 'demyelinating', 'disease', 'that', 'selectively', 'involves', 'the', 'optic', 'nerves', 'and', 'the', 'spinal', 'cord', 'but', 'usually', 'spares', 'the', 'brain', '.', 'NMO', 'is', 'considered', 'to', 'have', 'a', 'B', 'cell', 'induced', 'pathogenesis', '.', 'Mitoxantrone', '(', 'MITO', ',', 'Novantrone', '\u00ae', ')', ',', 'a', 'synthetic', 'anthracenedione', 'approved', 'for', 'worsening', 'relapsing', '-', 'remitting', 'multiple', 'sclerosis', '(', 'MS', ')', 'and', 'secondary', 'progressive', 'MS', ',', 'has', 'been', 'shown', 'to', 'primarily', 'suppress', 'the', 'humoral', 'response', '.', 'We', 'conducted', 'a', 'prospective', '2', '-', 'year', 'study', 'to', 'evaluate', 'the', 'benefit', 'of', 'MITO', 'in', 'five', 'relapsing', 'NMO', 'patients', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O']",
        "entities": [
            {
                "start": 17,
                "end": 29,
                "text": "Mitoxantrone",
                "type": "DRUG"
            },
            {
                "start": 51,
                "end": 81,
                "text": "Recurrent Neuromyelitis Optica",
                "type": "CONDITION"
            },
            {
                "start": 83,
                "end": 98,
                "text": "Devic's Disease",
                "type": "CONDITION"
            },
            {
                "start": 102,
                "end": 122,
                "text": "Neuromyelitis optica",
                "type": "CONDITION"
            },
            {
                "start": 124,
                "end": 127,
                "text": "NMO",
                "type": "CONDITION"
            },
            {
                "start": 256,
                "end": 259,
                "text": "NMO",
                "type": "CONDITION"
            },
            {
                "start": 313,
                "end": 325,
                "text": "Mitoxantrone",
                "type": "DRUG"
            },
            {
                "start": 327,
                "end": 331,
                "text": "MITO",
                "type": "DRUG"
            },
            {
                "start": 333,
                "end": 343,
                "text": "Novantrone",
                "type": "DRUG"
            },
            {
                "start": 359,
                "end": 374,
                "text": "anthracenedione",
                "type": "DRUG"
            },
            {
                "start": 398,
                "end": 436,
                "text": "relapsing-remitting multiple sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 438,
                "end": 440,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 446,
                "end": 470,
                "text": "secondary progressive MS",
                "type": "CONDITION"
            },
            {
                "start": 598,
                "end": 602,
                "text": "MITO",
                "type": "DRUG"
            },
            {
                "start": 611,
                "end": 624,
                "text": "relapsing NMO",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04201132",
        "text": "Protection Against Emboli During Carotid Artery Stenting Using a 3-in-1 Delivery System Comprised of a Post-dilation Balloon, Integrated Embolic Filter and a Novel Carotid Stent II | A prospective, multicenter single-arm, open label study to evaluate the safety and effectiveness of the Neuroguard IEP System for the treatment of carotid artery stenosis in subjects at elevated risk for adverse events following carotid endarterectomy (CEA). The Neuroguard IEP System is a 3-in-1 carotid stent delivery system consisting of an angioplasty balloon, an integrated embolic protection device and a nitinol self-expanding stent loaded over the balloon and constrained by an outer sheath. Eligible patients between 20 and 80 years of age have been diagnosed with either de-novo atherosclerotic or post CEA restenotic lesion(s) in the internal carotid arteries (ICA) or at the carotid bifurcation with \u226550% stenosis if symptomatic or \u226580% stenosis if asymptomatic (both defined by angiography using NASCET methodology). Symptomatic patients are defined as having stroke or TIA ipsilateral to the carotid lesion within 180 days of the procedure within the hemisphere supplied by the target vessel. Enrolled subjects will be followed at 30 days, 6 months, 12 months, 24 months and 36 months.",
        "tokens": "['Protection', 'Against', 'Emboli', 'During', 'Carotid', 'Artery', 'Stenting', 'Using', 'a', '3', '-', 'in-1', 'Delivery', 'System', 'Comprised', 'of', 'a', 'Post', '-', 'dilation', 'Balloon', ',', 'Integrated', 'Embolic', 'Filter', 'and', 'a', 'Novel', 'Carotid', 'Stent', 'II', '|', 'A', 'prospective', ',', 'multicenter', 'single', '-', 'arm', ',', 'open', 'label', 'study', 'to', 'evaluate', 'the', 'safety', 'and', 'effectiveness', 'of', 'the', 'Neuroguard', 'IEP', 'System', 'for', 'the', 'treatment', 'of', 'carotid', 'artery', 'stenosis', 'in', 'subjects', 'at', 'elevated', 'risk', 'for', 'adverse', 'events', 'following', 'carotid', 'endarterectomy', '(', 'CEA', ')', '.', 'The', 'Neuroguard', 'IEP', 'System', 'is', 'a', '3', '-', 'in-1', 'carotid', 'stent', 'delivery', 'system', 'consisting', 'of', 'an', 'angioplasty', 'balloon', ',', 'an', 'integrated', 'embolic', 'protection', 'device', 'and', 'a', 'nitinol', 'self', '-', 'expanding', 'stent', 'loaded', 'over', 'the', 'balloon', 'and', 'constrained', 'by', 'an', 'outer', 'sheath', '.', 'Eligible', 'patients', 'between', '20', 'and', '80', 'years', 'of', 'age', 'have', 'been', 'diagnosed', 'with', 'either', 'de', '-', 'novo', 'atherosclerotic', 'or', 'post', 'CEA', 'restenotic', 'lesion(s', ')', 'in', 'the', 'internal', 'carotid', 'arteries', '(', 'ICA', ')', 'or', 'at', 'the', 'carotid', 'bifurcation', 'with', '\u226550', '%', 'stenosis', 'if', 'symptomatic', 'or', '\u226580', '%', 'stenosis', 'if', 'asymptomatic', '(', 'both', 'defined', 'by', 'angiography', 'using', 'NASCET', 'methodology', ')', '.', 'Symptomatic', 'patients', 'are', 'defined', 'as', 'having', 'stroke', 'or', 'TIA', 'ipsilateral', 'to', 'the', 'carotid', 'lesion', 'within', '180', 'days', 'of', 'the', 'procedure', 'within', 'the', 'hemisphere', 'supplied', 'by', 'the', 'target', 'vessel', '.', 'Enrolled', 'subjects', 'will', 'be', 'followed', 'at', '30', 'days', ',', '6', 'months', ',', '12', 'months', ',', '24', 'months', 'and', '36', 'months', '.']",
        "token_bio_labels": "['O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 19,
                "end": 25,
                "text": "Emboli",
                "type": "CONDITION"
            },
            {
                "start": 33,
                "end": 56,
                "text": "Carotid Artery Stenting",
                "type": "CONDITION"
            },
            {
                "start": 103,
                "end": 124,
                "text": "Post-dilation Balloon",
                "type": "SURGICAL"
            },
            {
                "start": 126,
                "end": 151,
                "text": "Integrated Embolic Filter",
                "type": "SURGICAL"
            },
            {
                "start": 158,
                "end": 180,
                "text": "Novel Carotid Stent II",
                "type": "SURGICAL"
            },
            {
                "start": 287,
                "end": 308,
                "text": "Neuroguard IEP System",
                "type": "SURGICAL"
            },
            {
                "start": 330,
                "end": 353,
                "text": "carotid artery stenosis",
                "type": "CONDITION"
            },
            {
                "start": 412,
                "end": 434,
                "text": "carotid endarterectomy",
                "type": "CONDITION"
            },
            {
                "start": 436,
                "end": 439,
                "text": "CEA",
                "type": "CONDITION"
            },
            {
                "start": 446,
                "end": 467,
                "text": "Neuroguard IEP System",
                "type": "SURGICAL"
            },
            {
                "start": 772,
                "end": 820,
                "text": "atherosclerotic or post CEA restenotic lesion(s)",
                "type": "CONDITION"
            },
            {
                "start": 1056,
                "end": 1062,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 1066,
                "end": 1069,
                "text": "TIA",
                "type": "CONDITION"
            },
            {
                "start": 1089,
                "end": 1103,
                "text": "carotid lesion",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04086004",
        "text": "Additional Effects of Motor Imagery Practice With Dual Task Training in Stroke Patients | The importance of potent rehabilitation with dual task balance and gait training is improving and also there have been divergent opinions about the effectiveness of Motor Imagery on balance and gait function. Dual tasking has also proved beneficial results on stroke patients. Mental stimulation with task performance is a new intervention.. So the purpose of my study is to investigate the combination of Motor Imagery Practice and dual task rehabilitative training on balance and gait targeting the population of post stroke patients",
        "tokens": "['Additional', 'Effects', 'of', 'Motor', 'Imagery', 'Practice', 'With', 'Dual', 'Task', 'Training', 'in', 'Stroke', 'Patients', '|', 'The', 'importance', 'of', 'potent', 'rehabilitation', 'with', 'dual', 'task', 'balance', 'and', 'gait', 'training', 'is', 'improving', 'and', 'also', 'there', 'have', 'been', 'divergent', 'opinions', 'about', 'the', 'effectiveness', 'of', 'Motor', 'Imagery', 'on', 'balance', 'and', 'gait', 'function', '.', 'Dual', 'tasking', 'has', 'also', 'proved', 'beneficial', 'results', 'on', 'stroke', 'patients', '.', 'Mental', 'stimulation', 'with', 'task', 'performance', 'is', 'a', 'new', 'intervention', '..', 'So', 'the', 'purpose', 'of', 'my', 'study', 'is', 'to', 'investigate', 'the', 'combination', 'of', 'Motor', 'Imagery', 'Practice', 'and', 'dual', 'task', 'rehabilitative', 'training', 'on', 'balance', 'and', 'gait', 'targeting', 'the', 'population', 'of', 'post', 'stroke', 'patients']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 22,
                "end": 44,
                "text": "Motor Imagery Practice",
                "type": "OTHER"
            },
            {
                "start": 50,
                "end": 68,
                "text": "Dual Task Training",
                "type": "PHYSICAL"
            },
            {
                "start": 72,
                "end": 78,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 135,
                "end": 170,
                "text": "dual task balance and gait training",
                "type": "PHYSICAL"
            },
            {
                "start": 255,
                "end": 268,
                "text": "Motor Imagery",
                "type": "OTHER"
            },
            {
                "start": 299,
                "end": 311,
                "text": "Dual tasking",
                "type": "PHYSICAL"
            },
            {
                "start": 350,
                "end": 356,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 496,
                "end": 518,
                "text": "Motor Imagery Practice",
                "type": "OTHER"
            },
            {
                "start": 523,
                "end": 576,
                "text": "dual task rehabilitative training on balance and gait",
                "type": "PHYSICAL"
            },
            {
                "start": 605,
                "end": 616,
                "text": "post stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00723866",
        "text": "Combined Botulinum Toxin Type A With Modified Constraint-Induced Movement Therapy for Chronic Stroke Patients With Upper Extremity Spasticity | Botulinum toxin type A (BtxA) injection and modified constraint-induced movement therapy (mCIMT) are both promising approaches to enhance recovery after stroke. However, the combined application of the two modalities has rarely been studied. The aim was to investigate whether combined BtxA and mCIMT would produce greater improvements in spasticity and upper extremity function than BtxA plus conventional rehabilitation in chronic stroke patients with upper extremity spasticity.",
        "tokens": "['Combined', 'Botulinum', 'Toxin', 'Type', 'A', 'With', 'Modified', 'Constraint', '-', 'Induced', 'Movement', 'Therapy', 'for', 'Chronic', 'Stroke', 'Patients', 'With', 'Upper', 'Extremity', 'Spasticity', '|', 'Botulinum', 'toxin', 'type', 'A', '(', 'BtxA', ')', 'injection', 'and', 'modified', 'constraint', '-', 'induced', 'movement', 'therapy', '(', 'mCIMT', ')', 'are', 'both', 'promising', 'approaches', 'to', 'enhance', 'recovery', 'after', 'stroke', '.', 'However', ',', 'the', 'combined', 'application', 'of', 'the', 'two', 'modalities', 'has', 'rarely', 'been', 'studied', '.', 'The', 'aim', 'was', 'to', 'investigate', 'whether', 'combined', 'BtxA', 'and', 'mCIMT', 'would', 'produce', 'greater', 'improvements', 'in', 'spasticity', 'and', 'upper', 'extremity', 'function', 'than', 'BtxA', 'plus', 'conventional', 'rehabilitation', 'in', 'chronic', 'stroke', 'patients', 'with', 'upper', 'extremity', 'spasticity', '.']",
        "token_bio_labels": "['O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 9,
                "end": 31,
                "text": "Botulinum Toxin Type A",
                "type": "DRUG"
            },
            {
                "start": 37,
                "end": 73,
                "text": "Modified Constraint-Induced Movement",
                "type": "PHYSICAL"
            },
            {
                "start": 86,
                "end": 100,
                "text": "Chronic Stroke",
                "type": "CONDITION"
            },
            {
                "start": 131,
                "end": 141,
                "text": "Spasticity",
                "type": "CONDITION"
            },
            {
                "start": 144,
                "end": 166,
                "text": "Botulinum toxin type A",
                "type": "DRUG"
            },
            {
                "start": 168,
                "end": 172,
                "text": "BtxA",
                "type": "DRUG"
            },
            {
                "start": 188,
                "end": 232,
                "text": "modified constraint-induced movement therapy",
                "type": "PHYSICAL"
            },
            {
                "start": 234,
                "end": 239,
                "text": "mCIMT",
                "type": "PHYSICAL"
            },
            {
                "start": 297,
                "end": 303,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 430,
                "end": 434,
                "text": "BtxA",
                "type": "DRUG"
            },
            {
                "start": 439,
                "end": 444,
                "text": "mCIMT",
                "type": "PHYSICAL"
            },
            {
                "start": 483,
                "end": 493,
                "text": "spasticity",
                "type": "CONDITION"
            },
            {
                "start": 528,
                "end": 532,
                "text": "BtxA",
                "type": "DRUG"
            },
            {
                "start": 538,
                "end": 565,
                "text": "conventional rehabilitation",
                "type": "CONTROL"
            },
            {
                "start": 569,
                "end": 583,
                "text": "chronic stroke",
                "type": "CONDITION"
            },
            {
                "start": 614,
                "end": 624,
                "text": "spasticity",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03446768",
        "text": "Monitoring and Peer Support to Improve Treatment Adherence and Outcomes in Patients With Overlap Chronic Obstructive Pulmonary Disease and Sleep Apnea Via a Large PCORnet Collaboration | The O2VERLAP study investigators would like to find out if individuals living with both COPD and OSA would benefit from an online, educational curriculum, coupled with access to peer support (i.e. telephone and online chatting with peers) and remote CPAP adherence monitoring data. The curriculum and peer coaching is meant to provide participants the information and tools they need to be more compliant in using their CPAP device.",
        "tokens": "['Monitoring', 'and', 'Peer', 'Support', 'to', 'Improve', 'Treatment', 'Adherence', 'and', 'Outcomes', 'in', 'Patients', 'With', 'Overlap', 'Chronic', 'Obstructive', 'Pulmonary', 'Disease', 'and', 'Sleep', 'Apnea', 'Via', 'a', 'Large', 'PCORnet', 'Collaboration', '|', 'The', 'O2VERLAP', 'study', 'investigators', 'would', 'like', 'to', 'find', 'out', 'if', 'individuals', 'living', 'with', 'both', 'COPD', 'and', 'OSA', 'would', 'benefit', 'from', 'an', 'online', ',', 'educational', 'curriculum', ',', 'coupled', 'with', 'access', 'to', 'peer', 'support', '(', 'i.e.', 'telephone', 'and', 'online', 'chatting', 'with', 'peers', ')', 'and', 'remote', 'CPAP', 'adherence', 'monitoring', 'data', '.', 'The', 'curriculum', 'and', 'peer', 'coaching', 'is', 'meant', 'to', 'provide', 'participants', 'the', 'information', 'and', 'tools', 'they', 'need', 'to', 'be', 'more', 'compliant', 'in', 'using', 'their', 'CPAP', 'device', '.']",
        "token_bio_labels": "['B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 27,
                "text": "Monitoring and Peer Support",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 97,
                "end": 134,
                "text": "Chronic Obstructive Pulmonary Disease",
                "type": "CONDITION"
            },
            {
                "start": 139,
                "end": 150,
                "text": "Sleep Apnea",
                "type": "CONDITION"
            },
            {
                "start": 275,
                "end": 279,
                "text": "COPD",
                "type": "CONDITION"
            },
            {
                "start": 284,
                "end": 287,
                "text": "OSA",
                "type": "CONDITION"
            },
            {
                "start": 310,
                "end": 340,
                "text": "online, educational curriculum",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 365,
                "end": 377,
                "text": "peer support",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 437,
                "end": 441,
                "text": "CPAP",
                "type": "OTHER"
            },
            {
                "start": 473,
                "end": 483,
                "text": "curriculum",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 488,
                "end": 501,
                "text": "peer coaching",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 607,
                "end": 611,
                "text": "CPAP",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT00142324",
        "text": "A Randomised Placebo Controlled Trial of a Cholinesterase Inhibitor in the Management of Agitation in Dementia That is Unresponsive to a Psychological Intervention | Primary Aim\n\nTo determine whether;\n\nDonepezil is significantly better than placebo in the management of agitation in Alzheimer's Disease that has not responded to, or is inappropriate for a standardised brief psychosocial treatment\n\nSecondary Aims\n\nTo determine whether;\n\nDonepezil has a significant positive or negative impact upon quality of life compared with placebo\nwhether there is a significant difference between Donepezil and placebo with respect to cognitive performance\nthe cost effectiveness of the pharmacological treatment for agitation",
        "tokens": "['A', 'Randomised', 'Placebo', 'Controlled', 'Trial', 'of', 'a', 'Cholinesterase', 'Inhibitor', 'in', 'the', 'Management', 'of', 'Agitation', 'in', 'Dementia', 'That', 'is', 'Unresponsive', 'to', 'a', 'Psychological', 'Intervention', '|', 'Primary', 'Aim', '\\n\\n', 'To', 'determine', 'whether', ';', '\\n\\n', 'Donepezil', 'is', 'significantly', 'better', 'than', 'placebo', 'in', 'the', 'management', 'of', 'agitation', 'in', 'Alzheimer', \"'s\", 'Disease', 'that', 'has', 'not', 'responded', 'to', ',', 'or', 'is', 'inappropriate', 'for', 'a', 'standardised', 'brief', 'psychosocial', 'treatment', '\\n\\n', 'Secondary', 'Aims', '\\n\\n', 'To', 'determine', 'whether', ';', '\\n\\n', 'Donepezil', 'has', 'a', 'significant', 'positive', 'or', 'negative', 'impact', 'upon', 'quality', 'of', 'life', 'compared', 'with', 'placebo', '\\n', 'whether', 'there', 'is', 'a', 'significant', 'difference', 'between', 'Donepezil', 'and', 'placebo', 'with', 'respect', 'to', 'cognitive', 'performance', '\\n', 'the', 'cost', 'effectiveness', 'of', 'the', 'pharmacological', 'treatment', 'for', 'agitation']",
        "token_bio_labels": "['O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND']",
        "entities": [
            {
                "start": 13,
                "end": 20,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 43,
                "end": 67,
                "text": "Cholinesterase Inhibitor",
                "type": "DRUG"
            },
            {
                "start": 89,
                "end": 98,
                "text": "Agitation",
                "type": "CONDITION"
            },
            {
                "start": 102,
                "end": 110,
                "text": "Dementia",
                "type": "CONDITION"
            },
            {
                "start": 202,
                "end": 211,
                "text": "Donepezil",
                "type": "DRUG"
            },
            {
                "start": 241,
                "end": 248,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 270,
                "end": 279,
                "text": "agitation",
                "type": "CONDITION"
            },
            {
                "start": 283,
                "end": 302,
                "text": "Alzheimer's Disease",
                "type": "CONDITION"
            },
            {
                "start": 438,
                "end": 447,
                "text": "Donepezil",
                "type": "DRUG"
            },
            {
                "start": 529,
                "end": 536,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 587,
                "end": 596,
                "text": "Donepezil",
                "type": "DRUG"
            },
            {
                "start": 707,
                "end": 716,
                "text": "agitation",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01826058",
        "text": "Spine Stereotactic Body Radiation Therapy for Metastatic Epidural Spinal Cord: Prospective Phase II Study | Metastatic epidural spinal cord compression (MESCC) is a frequent oncologic emergency that requires to be treated promptly. Although direct decompressive surgery is the most effective treatment, surgery is only used in selected patients because most patients have a poor overall condition and short life expectancy. Radiation therapy (RT), therefore, is the most commonly used for patients with MESCC, but conventional RT alone can achieve modest neurologic outcomes.\n\nThe hypothesis to use stereotactic body radiation therapy (SBRT) for MESCC is that the rapid decompression of epidural mass, durable local control and subsequently improved neurologic outcomes compared to conventional RT are expected when MESCC is treated with SBRT.",
        "tokens": "['Spine', 'Stereotactic', 'Body', 'Radiation', 'Therapy', 'for', 'Metastatic', 'Epidural', 'Spinal', 'Cord', ':', 'Prospective', 'Phase', 'II', 'Study', '|', 'Metastatic', 'epidural', 'spinal', 'cord', 'compression', '(', 'MESCC', ')', 'is', 'a', 'frequent', 'oncologic', 'emergency', 'that', 'requires', 'to', 'be', 'treated', 'promptly', '.', 'Although', 'direct', 'decompressive', 'surgery', 'is', 'the', 'most', 'effective', 'treatment', ',', 'surgery', 'is', 'only', 'used', 'in', 'selected', 'patients', 'because', 'most', 'patients', 'have', 'a', 'poor', 'overall', 'condition', 'and', 'short', 'life', 'expectancy', '.', 'Radiation', 'therapy', '(', 'RT', ')', ',', 'therefore', ',', 'is', 'the', 'most', 'commonly', 'used', 'for', 'patients', 'with', 'MESCC', ',', 'but', 'conventional', 'RT', 'alone', 'can', 'achieve', 'modest', 'neurologic', 'outcomes', '.', '\\n\\n', 'The', 'hypothesis', 'to', 'use', 'stereotactic', 'body', 'radiation', 'therapy', '(', 'SBRT', ')', 'for', 'MESCC', 'is', 'that', 'the', 'rapid', 'decompression', 'of', 'epidural', 'mass', ',', 'durable', 'local', 'control', 'and', 'subsequently', 'improved', 'neurologic', 'outcomes', 'compared', 'to', 'conventional', 'RT', 'are', 'expected', 'when', 'MESCC', 'is', 'treated', 'with', 'SBRT', '.']",
        "token_bio_labels": "['B-RADIO', 'I-RADIO', 'I-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'B-RADIO', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-RADIO', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 41,
                "text": "Spine Stereotactic Body Radiation Therapy",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 46,
                "end": 77,
                "text": "Metastatic Epidural Spinal Cord",
                "type": "CONDITION"
            },
            {
                "start": 108,
                "end": 151,
                "text": "Metastatic epidural spinal cord compression",
                "type": "CONDITION"
            },
            {
                "start": 153,
                "end": 158,
                "text": "MESCC",
                "type": "CONDITION"
            },
            {
                "start": 424,
                "end": 441,
                "text": "Radiation therapy",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 443,
                "end": 445,
                "text": "RT",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 503,
                "end": 508,
                "text": "MESCC",
                "type": "CONDITION"
            },
            {
                "start": 514,
                "end": 535,
                "text": "conventional RT alone",
                "type": "CONTROL"
            },
            {
                "start": 599,
                "end": 634,
                "text": "stereotactic body radiation therapy",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 636,
                "end": 640,
                "text": "SBRT",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 646,
                "end": 651,
                "text": "MESCC",
                "type": "CONDITION"
            },
            {
                "start": 782,
                "end": 797,
                "text": "conventional RT",
                "type": "CONTROL"
            },
            {
                "start": 816,
                "end": 821,
                "text": "MESCC",
                "type": "CONDITION"
            },
            {
                "start": 838,
                "end": 842,
                "text": "SBRT",
                "type": "RADIOTHERAPY"
            }
        ]
    },
    {
        "nctid": "NCT02699346",
        "text": "An Open-Label, Non-Randomized Study Designed to Evaluate the Correlation of HS-1000 Device Capabilities in the Diagnosis and Assessment of Patients After Concussion With Clinical Evaluation | The HeadSense (HS) HS-1000 device, a new non-invasive brain monitor is expected to safely and accurately monitor concussed patients with minimal discomfort, potentially providing a new modality for concussion measurement. The device is based on advanced signal analysis algorithms that analyze a very low frequency acoustic signal (within the audible range) generated by the device. The acoustic signal is transmitted using a small transmitter, placed in the participant's ear, and picked by an acoustic sensor placed in the other ear.",
        "tokens": "['An', 'Open', '-', 'Label', ',', 'Non', '-', 'Randomized', 'Study', 'Designed', 'to', 'Evaluate', 'the', 'Correlation', 'of', 'HS-1000', 'Device', 'Capabilities', 'in', 'the', 'Diagnosis', 'and', 'Assessment', 'of', 'Patients', 'After', 'Concussion', 'With', 'Clinical', 'Evaluation', '|', 'The', 'HeadSense', '(', 'HS', ')', 'HS-1000', 'device', ',', 'a', 'new', 'non', '-', 'invasive', 'brain', 'monitor', 'is', 'expected', 'to', 'safely', 'and', 'accurately', 'monitor', 'concussed', 'patients', 'with', 'minimal', 'discomfort', ',', 'potentially', 'providing', 'a', 'new', 'modality', 'for', 'concussion', 'measurement', '.', 'The', 'device', 'is', 'based', 'on', 'advanced', 'signal', 'analysis', 'algorithms', 'that', 'analyze', 'a', 'very', 'low', 'frequency', 'acoustic', 'signal', '(', 'within', 'the', 'audible', 'range', ')', 'generated', 'by', 'the', 'device', '.', 'The', 'acoustic', 'signal', 'is', 'transmitted', 'using', 'a', 'small', 'transmitter', ',', 'placed', 'in', 'the', 'participant', \"'s\", 'ear', ',', 'and', 'picked', 'by', 'an', 'acoustic', 'sensor', 'placed', 'in', 'the', 'other', 'ear', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 154,
                "end": 164,
                "text": "Concussion",
                "type": "CONDITION"
            },
            {
                "start": 305,
                "end": 314,
                "text": "concussed",
                "type": "CONDITION"
            },
            {
                "start": 390,
                "end": 400,
                "text": "concussion",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02726191",
        "text": "Computerized Cognitive Training in Epilepsy | The purpose of this randomized uncontrolled single-site trial is to evaluate the efficacy of two novel computerized cognitive enhancing software packages for improving cognitive and behavioral outcomes in patients with epilepsy.",
        "tokens": "['Computerized', 'Cognitive', 'Training', 'in', 'Epilepsy', '|', 'The', 'purpose', 'of', 'this', 'randomized', 'uncontrolled', 'single', '-', 'site', 'trial', 'is', 'to', 'evaluate', 'the', 'efficacy', 'of', 'two', 'novel', 'computerized', 'cognitive', 'enhancing', 'software', 'packages', 'for', 'improving', 'cognitive', 'and', 'behavioral', 'outcomes', 'in', 'patients', 'with', 'epilepsy', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 31,
                "text": "Computerized Cognitive Training",
                "type": "OTHER"
            },
            {
                "start": 35,
                "end": 43,
                "text": "Epilepsy",
                "type": "CONDITION"
            },
            {
                "start": 149,
                "end": 199,
                "text": "computerized cognitive enhancing software packages",
                "type": "OTHER"
            },
            {
                "start": 265,
                "end": 273,
                "text": "epilepsy",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01790880",
        "text": "Enhancing Written Communication in Persons With Aphasia: A Clinical Trial | The purpose of this study is to evaluate whether a computerized speech-language treatment delivered by a virtual therapist (Oral Reading for Language in Aphasia (ORLA) + Writing) results in improved written communication skills of study participants with aphasia (i.e., difficulty with the comprehension and expression of spoken and written language).",
        "tokens": "['Enhancing', 'Written', 'Communication', 'in', 'Persons', 'With', 'Aphasia', ':', 'A', 'Clinical', 'Trial', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'whether', 'a', 'computerized', 'speech', '-', 'language', 'treatment', 'delivered', 'by', 'a', 'virtual', 'therapist', '(', 'Oral', 'Reading', 'for', 'Language', 'in', 'Aphasia', '(', 'ORLA', ')', '+', 'Writing', ')', 'results', 'in', 'improved', 'written', 'communication', 'skills', 'of', 'study', 'participants', 'with', 'aphasia', '(', 'i.e.', ',', 'difficulty', 'with', 'the', 'comprehension', 'and', 'expression', 'of', 'spoken', 'and', 'written', 'language', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 48,
                "end": 55,
                "text": "Aphasia",
                "type": "CONDITION"
            },
            {
                "start": 127,
                "end": 165,
                "text": "computerized speech-language treatment",
                "type": "OTHER"
            },
            {
                "start": 181,
                "end": 198,
                "text": "virtual therapist",
                "type": "OTHER"
            },
            {
                "start": 200,
                "end": 236,
                "text": "Oral Reading for Language in Aphasia",
                "type": "OTHER"
            },
            {
                "start": 238,
                "end": 242,
                "text": "ORLA",
                "type": "OTHER"
            },
            {
                "start": 246,
                "end": 253,
                "text": "Writing",
                "type": "OTHER"
            },
            {
                "start": 331,
                "end": 338,
                "text": "aphasia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00895960",
        "text": "Phase I/II Trial of Dasatinib (Sprycel) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma | Phase I:\n\nPrimary Objectives:\n\n-To define the maximum tolerated dose (MTD) of dasatinib (Sprycel) with radiotherapy (RT) and 6 weeks of concomitant temozolomide (TMZ) administered at 75 mg/m^2/day in patients with newly-diagnosed glioblastoma (GBM).\n\nSecondary Objectives:\n\nTo characterize the safety profile of dasatinib (Sprycel) in combination with radiotherapy (RT) and concomitant TMZ in patients with newly-diagnosed GBM.\nTo characterize the safety profile of dasatinib (Sprycel) in combination with adjuvant TMZ in patients with glioblastoma after RT.\n\nSTUDY DID NOT PROGRESS TO PHASE II PORTION.\n\nPhase II:\n\nPrimary Objectives:\n\n-To determine the effectiveness of dasatinib (Sprycel) with radiotherapy (RT) and 6 weeks of concomitant temozolomide (TMZ) administered at 75 mg/m^2/day followed by adjuvant temozolomide with concurrent dasatinib in patients with newly-diagnosed glioblastoma (GBM) as measured by overall survival.\n\nSecondary Objectives:\n\nTo determine the efficacy of this treatment as measured by radiographic response (RR), progression-free survival (PFS) and time to progression (TTP).\nTo characterize the safety profile of dasatinib (Sprycel) in combination with RT and concomitant TMZ in patients with newly-diagnosed GBM.\nTo characterize the safety profile of dasatinib (Sprycel) in combination with adjuvant TMZ in patients with GBM after RT.\n\nExploratory Objectives:\n\n-To correlate tumor genotype, tumor expression of dasatinib target proteins (e.g. Src, EphA2, c-kit and PDGFR), and PTEN levels with response to therapy with dasatinib and temozolomide.",
        "tokens": "['Phase', 'I', '/', 'II', 'Trial', 'of', 'Dasatinib', '(', 'Sprycel', ')', 'With', 'Radiation', 'Therapy', 'and', 'Concomitant', 'and', 'Adjuvant', 'Temozolomide', 'in', 'Patients', 'With', 'Newly', '-', 'Diagnosed', 'Glioblastoma', '|', 'Phase', 'I', ':', '\\n\\n', 'Primary', 'Objectives', ':', '\\n\\n', '-To', 'define', 'the', 'maximum', 'tolerated', 'dose', '(', 'MTD', ')', 'of', 'dasatinib', '(', 'Sprycel', ')', 'with', 'radiotherapy', '(', 'RT', ')', 'and', '6', 'weeks', 'of', 'concomitant', 'temozolomide', '(', 'TMZ', ')', 'administered', 'at', '75', 'mg', '/', 'm^2', '/', 'day', 'in', 'patients', 'with', 'newly', '-', 'diagnosed', 'glioblastoma', '(', 'GBM', ')', '.', '\\n\\n', 'Secondary', 'Objectives', ':', '\\n\\n', 'To', 'characterize', 'the', 'safety', 'profile', 'of', 'dasatinib', '(', 'Sprycel', ')', 'in', 'combination', 'with', 'radiotherapy', '(', 'RT', ')', 'and', 'concomitant', 'TMZ', 'in', 'patients', 'with', 'newly', '-', 'diagnosed', 'GBM', '.', '\\n', 'To', 'characterize', 'the', 'safety', 'profile', 'of', 'dasatinib', '(', 'Sprycel', ')', 'in', 'combination', 'with', 'adjuvant', 'TMZ', 'in', 'patients', 'with', 'glioblastoma', 'after', 'RT', '.', '\\n\\n', 'STUDY', 'DID', 'NOT', 'PROGRESS', 'TO', 'PHASE', 'II', 'PORTION', '.', '\\n\\n', 'Phase', 'II', ':', '\\n\\n', 'Primary', 'Objectives', ':', '\\n\\n', '-To', 'determine', 'the', 'effectiveness', 'of', 'dasatinib', '(', 'Sprycel', ')', 'with', 'radiotherapy', '(', 'RT', ')', 'and', '6', 'weeks', 'of', 'concomitant', 'temozolomide', '(', 'TMZ', ')', 'administered', 'at', '75', 'mg', '/', 'm^2', '/', 'day', 'followed', 'by', 'adjuvant', 'temozolomide', 'with', 'concurrent', 'dasatinib', 'in', 'patients', 'with', 'newly', '-', 'diagnosed', 'glioblastoma', '(', 'GBM', ')', 'as', 'measured', 'by', 'overall', 'survival', '.', '\\n\\n', 'Secondary', 'Objectives', ':', '\\n\\n', 'To', 'determine', 'the', 'efficacy', 'of', 'this', 'treatment', 'as', 'measured', 'by', 'radiographic', 'response', '(', 'RR', ')', ',', 'progression', '-', 'free', 'survival', '(', 'PFS', ')', 'and', 'time', 'to', 'progression', '(', 'TTP', ')', '.', '\\n', 'To', 'characterize', 'the', 'safety', 'profile', 'of', 'dasatinib', '(', 'Sprycel', ')', 'in', 'combination', 'with', 'RT', 'and', 'concomitant', 'TMZ', 'in', 'patients', 'with', 'newly', '-', 'diagnosed', 'GBM', '.', '\\n', 'To', 'characterize', 'the', 'safety', 'profile', 'of', 'dasatinib', '(', 'Sprycel', ')', 'in', 'combination', 'with', 'adjuvant', 'TMZ', 'in', 'patients', 'with', 'GBM', 'after', 'RT', '.', '\\n\\n', 'Exploratory', 'Objectives', ':', '\\n\\n', '-To', 'correlate', 'tumor', 'genotype', ',', 'tumor', 'expression', 'of', 'dasatinib', 'target', 'proteins', '(', 'e.g.', 'Src', ',', 'EphA2', ',', 'c', '-', 'kit', 'and', 'PDGFR', ')', ',', 'and', 'PTEN', 'levels', 'with', 'response', 'to', 'therapy', 'with', 'dasatinib', 'and', 'temozolomide', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-RADIO', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'B-RADIO', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-RADIO', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O']",
        "entities": [
            {
                "start": 20,
                "end": 29,
                "text": "Dasatinib",
                "type": "DRUG"
            },
            {
                "start": 31,
                "end": 38,
                "text": "Sprycel",
                "type": "DRUG"
            },
            {
                "start": 45,
                "end": 62,
                "text": "Radiation Therapy",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 92,
                "end": 104,
                "text": "Temozolomide",
                "type": "DRUG"
            },
            {
                "start": 122,
                "end": 150,
                "text": "Newly-Diagnosed Glioblastoma",
                "type": "CONDITION"
            },
            {
                "start": 231,
                "end": 240,
                "text": "dasatinib",
                "type": "DRUG"
            },
            {
                "start": 242,
                "end": 249,
                "text": "Sprycel",
                "type": "DRUG"
            },
            {
                "start": 256,
                "end": 268,
                "text": "radiotherapy",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 270,
                "end": 272,
                "text": "RT",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 301,
                "end": 313,
                "text": "temozolomide",
                "type": "DRUG"
            },
            {
                "start": 315,
                "end": 318,
                "text": "TMZ",
                "type": "DRUG"
            },
            {
                "start": 367,
                "end": 395,
                "text": "newly-diagnosed glioblastoma",
                "type": "CONDITION"
            },
            {
                "start": 397,
                "end": 400,
                "text": "GBM",
                "type": "CONDITION"
            },
            {
                "start": 465,
                "end": 474,
                "text": "dasatinib",
                "type": "DRUG"
            },
            {
                "start": 476,
                "end": 483,
                "text": "Sprycel",
                "type": "DRUG"
            },
            {
                "start": 505,
                "end": 517,
                "text": "radiotherapy",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 519,
                "end": 521,
                "text": "RT",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 539,
                "end": 542,
                "text": "TMZ",
                "type": "DRUG"
            },
            {
                "start": 560,
                "end": 579,
                "text": "newly-diagnosed GBM",
                "type": "CONDITION"
            },
            {
                "start": 619,
                "end": 628,
                "text": "dasatinib",
                "type": "DRUG"
            },
            {
                "start": 630,
                "end": 637,
                "text": "Sprycel",
                "type": "DRUG"
            },
            {
                "start": 668,
                "end": 671,
                "text": "TMZ",
                "type": "DRUG"
            },
            {
                "start": 689,
                "end": 701,
                "text": "glioblastoma",
                "type": "CONDITION"
            },
            {
                "start": 708,
                "end": 710,
                "text": "RT",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 825,
                "end": 834,
                "text": "dasatinib",
                "type": "DRUG"
            },
            {
                "start": 836,
                "end": 843,
                "text": "Sprycel",
                "type": "DRUG"
            },
            {
                "start": 850,
                "end": 862,
                "text": "radiotherapy",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 864,
                "end": 866,
                "text": "RT",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 895,
                "end": 907,
                "text": "temozolomide",
                "type": "DRUG"
            },
            {
                "start": 909,
                "end": 912,
                "text": "TMZ",
                "type": "DRUG"
            },
            {
                "start": 965,
                "end": 977,
                "text": "temozolomide",
                "type": "DRUG"
            },
            {
                "start": 994,
                "end": 1003,
                "text": "dasatinib",
                "type": "DRUG"
            },
            {
                "start": 1021,
                "end": 1049,
                "text": "newly-diagnosed glioblastoma",
                "type": "CONDITION"
            },
            {
                "start": 1051,
                "end": 1054,
                "text": "GBM",
                "type": "CONDITION"
            },
            {
                "start": 1301,
                "end": 1310,
                "text": "dasatinib",
                "type": "DRUG"
            },
            {
                "start": 1312,
                "end": 1319,
                "text": "Sprycel",
                "type": "DRUG"
            },
            {
                "start": 1341,
                "end": 1343,
                "text": "RT",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 1360,
                "end": 1363,
                "text": "TMZ",
                "type": "DRUG"
            },
            {
                "start": 1381,
                "end": 1400,
                "text": "newly-diagnosed GBM",
                "type": "CONDITION"
            },
            {
                "start": 1440,
                "end": 1449,
                "text": "dasatinib",
                "type": "DRUG"
            },
            {
                "start": 1451,
                "end": 1458,
                "text": "Sprycel",
                "type": "DRUG"
            },
            {
                "start": 1489,
                "end": 1492,
                "text": "TMZ",
                "type": "DRUG"
            },
            {
                "start": 1510,
                "end": 1513,
                "text": "GBM",
                "type": "CONDITION"
            },
            {
                "start": 1520,
                "end": 1522,
                "text": "RT",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 1564,
                "end": 1569,
                "text": "tumor",
                "type": "CONDITION"
            },
            {
                "start": 1580,
                "end": 1585,
                "text": "tumor",
                "type": "CONDITION"
            },
            {
                "start": 1600,
                "end": 1609,
                "text": "dasatinib",
                "type": "DRUG"
            },
            {
                "start": 1708,
                "end": 1717,
                "text": "dasatinib",
                "type": "DRUG"
            },
            {
                "start": 1722,
                "end": 1734,
                "text": "temozolomide",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT05350124",
        "text": "The Effect of Vitamin C and E Therapy on Restless Leg Syndrome in Patients With End Stage Renal Disease on Haemodialysis | This study aims to measure the effectiveness of vitamins C and E on relieving RLS symptoms in end stage renal disease patients on HD",
        "tokens": "['The', 'Effect', 'of', 'Vitamin', 'C', 'and', 'E', 'Therapy', 'on', 'Restless', 'Leg', 'Syndrome', 'in', 'Patients', 'With', 'End', 'Stage', 'Renal', 'Disease', 'on', 'Haemodialysis', '|', 'This', 'study', 'aims', 'to', 'measure', 'the', 'effectiveness', 'of', 'vitamins', 'C', 'and', 'E', 'on', 'relieving', 'RLS', 'symptoms', 'in', 'end', 'stage', 'renal', 'disease', 'patients', 'on', 'HD']",
        "token_bio_labels": "['O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND']",
        "entities": [
            {
                "start": 14,
                "end": 29,
                "text": "Vitamin C and E",
                "type": "DRUG"
            },
            {
                "start": 41,
                "end": 62,
                "text": "Restless Leg Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 80,
                "end": 103,
                "text": "End Stage Renal Disease",
                "type": "CONDITION"
            },
            {
                "start": 107,
                "end": 120,
                "text": "Haemodialysis",
                "type": "CONDITION"
            },
            {
                "start": 171,
                "end": 187,
                "text": "vitamins C and E",
                "type": "DRUG"
            },
            {
                "start": 201,
                "end": 204,
                "text": "RLS",
                "type": "CONDITION"
            },
            {
                "start": 217,
                "end": 240,
                "text": "end stage renal disease",
                "type": "CONDITION"
            },
            {
                "start": 253,
                "end": 255,
                "text": "HD",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04357951",
        "text": "D-cycloserine Augmented Treatment: Enhancing Extinction Learning in Youth With Tic Disorders | This pilot study aims evaluate the feasibility and initial efficacy of behavior therapy augmented by d-cycloserine (DCS) compared to behavior therapy augmented by placebo. After an initial assessment to determine eligibility, youth with TD will be randomly assigned to receive four sessions of behavior therapy augmented by either DCS or placebo. D-cycloserine is an FDA-approved antibiotic medication that has been shown to enhance extinction learning in several studies. The investigators' proof-of-concept work has found that a single session of DCS-augmented behavior therapy reduced the severity of tics targeted in treatment on the Hopkins Motor/Vocal Tic Scale (HM/VTS) compared to placebo-augmented behavior therapy. This highlights the exciting potential of combining DCS with behavior therapy to improve reductions in tic severity. However, prior to a large-scale clinical trial, it is essential to determine the feasibility and efficacy of augmenting behavior therapy with DCS over multiple treatment sessions.",
        "tokens": "['D', '-', 'cycloserine', 'Augmented', 'Treatment', ':', 'Enhancing', 'Extinction', 'Learning', 'in', 'Youth', 'With', 'Tic', 'Disorders', '|', 'This', 'pilot', 'study', 'aims', 'evaluate', 'the', 'feasibility', 'and', 'initial', 'efficacy', 'of', 'behavior', 'therapy', 'augmented', 'by', 'd', '-', 'cycloserine', '(', 'DCS', ')', 'compared', 'to', 'behavior', 'therapy', 'augmented', 'by', 'placebo', '.', 'After', 'an', 'initial', 'assessment', 'to', 'determine', 'eligibility', ',', 'youth', 'with', 'TD', 'will', 'be', 'randomly', 'assigned', 'to', 'receive', 'four', 'sessions', 'of', 'behavior', 'therapy', 'augmented', 'by', 'either', 'DCS', 'or', 'placebo', '.', 'D', '-', 'cycloserine', 'is', 'an', 'FDA', '-', 'approved', 'antibiotic', 'medication', 'that', 'has', 'been', 'shown', 'to', 'enhance', 'extinction', 'learning', 'in', 'several', 'studies', '.', 'The', 'investigators', \"'\", 'proof', '-', 'of', '-', 'concept', 'work', 'has', 'found', 'that', 'a', 'single', 'session', 'of', 'DCS', '-', 'augmented', 'behavior', 'therapy', 'reduced', 'the', 'severity', 'of', 'tics', 'targeted', 'in', 'treatment', 'on', 'the', 'Hopkins', 'Motor', '/', 'Vocal', 'Tic', 'Scale', '(', 'HM', '/', 'VTS', ')', 'compared', 'to', 'placebo', '-', 'augmented', 'behavior', 'therapy', '.', 'This', 'highlights', 'the', 'exciting', 'potential', 'of', 'combining', 'DCS', 'with', 'behavior', 'therapy', 'to', 'improve', 'reductions', 'in', 'tic', 'severity', '.', 'However', ',', 'prior', 'to', 'a', 'large', '-', 'scale', 'clinical', 'trial', ',', 'it', 'is', 'essential', 'to', 'determine', 'the', 'feasibility', 'and', 'efficacy', 'of', 'augmenting', 'behavior', 'therapy', 'with', 'DCS', 'over', 'multiple', 'treatment', 'sessions', '.']",
        "token_bio_labels": "['B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 13,
                "text": "D-cycloserine",
                "type": "DRUG"
            },
            {
                "start": 79,
                "end": 92,
                "text": "Tic Disorders",
                "type": "CONDITION"
            },
            {
                "start": 166,
                "end": 182,
                "text": "behavior therapy",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 196,
                "end": 209,
                "text": "d-cycloserine",
                "type": "DRUG"
            },
            {
                "start": 211,
                "end": 214,
                "text": "DCS",
                "type": "DRUG"
            },
            {
                "start": 228,
                "end": 265,
                "text": "behavior therapy augmented by placebo",
                "type": "CONTROL"
            },
            {
                "start": 332,
                "end": 334,
                "text": "TD",
                "type": "CONDITION"
            },
            {
                "start": 389,
                "end": 405,
                "text": "behavior therapy",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 426,
                "end": 429,
                "text": "DCS",
                "type": "DRUG"
            },
            {
                "start": 433,
                "end": 440,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 442,
                "end": 455,
                "text": "D-cycloserine",
                "type": "DRUG"
            },
            {
                "start": 644,
                "end": 647,
                "text": "DCS",
                "type": "DRUG"
            },
            {
                "start": 658,
                "end": 674,
                "text": "behavior therapy",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 699,
                "end": 703,
                "text": "tics",
                "type": "CONDITION"
            },
            {
                "start": 784,
                "end": 818,
                "text": "placebo-augmented behavior therapy",
                "type": "CONTROL"
            },
            {
                "start": 872,
                "end": 875,
                "text": "DCS",
                "type": "DRUG"
            },
            {
                "start": 881,
                "end": 897,
                "text": "behavior therapy",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 923,
                "end": 926,
                "text": "tic",
                "type": "CONDITION"
            },
            {
                "start": 1057,
                "end": 1073,
                "text": "behavior therapy",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 1079,
                "end": 1082,
                "text": "DCS",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT04644367",
        "text": "The Effects of a Biomechanical Based Tai Chi Intervention Program on Postural Stability and Gait in People With Parkinson's Disease | Parkinson's disease (PD) is associated with changes in gait and posture that can lead to a higher frequency of falls and injuries in this population. Research has shown a positive effect of tai chi (TC) training on the movement capacity for those with PD, however the understanding of the impact of TC training on gait and postural stability in PD is lacking. This study aims to examine the impact of a biomechanical-based TC intervention on dynamic postural stability and how it relates to walking performance. It is hypothesized that the effects of the TC intervention will help to improve measures relating to postural stability, gait, and cognition.",
        "tokens": "['The', 'Effects', 'of', 'a', 'Biomechanical', 'Based', 'Tai', 'Chi', 'Intervention', 'Program', 'on', 'Postural', 'Stability', 'and', 'Gait', 'in', 'People', 'With', 'Parkinson', \"'s\", 'Disease', '|', 'Parkinson', \"'s\", 'disease', '(', 'PD', ')', 'is', 'associated', 'with', 'changes', 'in', 'gait', 'and', 'posture', 'that', 'can', 'lead', 'to', 'a', 'higher', 'frequency', 'of', 'falls', 'and', 'injuries', 'in', 'this', 'population', '.', 'Research', 'has', 'shown', 'a', 'positive', 'effect', 'of', 'tai', 'chi', '(', 'TC', ')', 'training', 'on', 'the', 'movement', 'capacity', 'for', 'those', 'with', 'PD', ',', 'however', 'the', 'understanding', 'of', 'the', 'impact', 'of', 'TC', 'training', 'on', 'gait', 'and', 'postural', 'stability', 'in', 'PD', 'is', 'lacking', '.', 'This', 'study', 'aims', 'to', 'examine', 'the', 'impact', 'of', 'a', 'biomechanical', '-', 'based', 'TC', 'intervention', 'on', 'dynamic', 'postural', 'stability', 'and', 'how', 'it', 'relates', 'to', 'walking', 'performance', '.', 'It', 'is', 'hypothesized', 'that', 'the', 'effects', 'of', 'the', 'TC', 'intervention', 'will', 'help', 'to', 'improve', 'measures', 'relating', 'to', 'postural', 'stability', ',', 'gait', ',', 'and', 'cognition', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 17,
                "end": 65,
                "text": "Biomechanical Based Tai Chi Intervention Program",
                "type": "PHYSICAL"
            },
            {
                "start": 112,
                "end": 131,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 134,
                "end": 153,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 155,
                "end": 157,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 324,
                "end": 331,
                "text": "tai chi",
                "type": "PHYSICAL"
            },
            {
                "start": 333,
                "end": 335,
                "text": "TC",
                "type": "PHYSICAL"
            },
            {
                "start": 386,
                "end": 388,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 433,
                "end": 444,
                "text": "TC training",
                "type": "PHYSICAL"
            },
            {
                "start": 479,
                "end": 481,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 537,
                "end": 572,
                "text": "biomechanical-based TC intervention",
                "type": "OTHER"
            },
            {
                "start": 689,
                "end": 704,
                "text": "TC intervention",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT00351299",
        "text": "Study of Dexmedetomidine as an Effective Sedative to Treat Acute ICU Delirium | The purpose of the research is to see if dexmedetomidine (a drug that has a calming effect - a sedative) is effective for the treatment of acute delirium",
        "tokens": "['Study', 'of', 'Dexmedetomidine', 'as', 'an', 'Effective', 'Sedative', 'to', 'Treat', 'Acute', 'ICU', 'Delirium', '|', 'The', 'purpose', 'of', 'the', 'research', 'is', 'to', 'see', 'if', 'dexmedetomidine', '(', 'a', 'drug', 'that', 'has', 'a', 'calming', 'effect', '-', 'a', 'sedative', ')', 'is', 'effective', 'for', 'the', 'treatment', 'of', 'acute', 'delirium']",
        "token_bio_labels": "['O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND']",
        "entities": [
            {
                "start": 9,
                "end": 24,
                "text": "Dexmedetomidine",
                "type": "DRUG"
            },
            {
                "start": 59,
                "end": 77,
                "text": "Acute ICU Delirium",
                "type": "CONDITION"
            },
            {
                "start": 121,
                "end": 136,
                "text": "dexmedetomidine",
                "type": "DRUG"
            },
            {
                "start": 219,
                "end": 233,
                "text": "acute delirium",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03410628",
        "text": "Non-invasive Neurostimulation of the Vagus Nerve With the gammaCore Device for the Relief of Pain and Allodynia Associated With Migraine | The purpose of this feasibility study is to gather preliminary information on the safety and effectiveness of patient self-administration of a noninvasive neurostimulation of the vagus nerve using the GammaCore device for the treatment of pain and allodynia symptoms associated with acute migraine in adults.",
        "tokens": "['Non', '-', 'invasive', 'Neurostimulation', 'of', 'the', 'Vagus', 'Nerve', 'With', 'the', 'gammaCore', 'Device', 'for', 'the', 'Relief', 'of', 'Pain', 'and', 'Allodynia', 'Associated', 'With', 'Migraine', '|', 'The', 'purpose', 'of', 'this', 'feasibility', 'study', 'is', 'to', 'gather', 'preliminary', 'information', 'on', 'the', 'safety', 'and', 'effectiveness', 'of', 'patient', 'self', '-', 'administration', 'of', 'a', 'noninvasive', 'neurostimulation', 'of', 'the', 'vagus', 'nerve', 'using', 'the', 'GammaCore', 'device', 'for', 'the', 'treatment', 'of', 'pain', 'and', 'allodynia', 'symptoms', 'associated', 'with', 'acute', 'migraine', 'in', 'adults', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 74,
                "text": "Non-invasive Neurostimulation of the Vagus Nerve With the gammaCore Device",
                "type": "OTHER"
            },
            {
                "start": 102,
                "end": 111,
                "text": "Allodynia",
                "type": "CONDITION"
            },
            {
                "start": 128,
                "end": 136,
                "text": "Migraine",
                "type": "CONDITION"
            },
            {
                "start": 282,
                "end": 356,
                "text": "noninvasive neurostimulation of the vagus nerve using the GammaCore device",
                "type": "OTHER"
            },
            {
                "start": 387,
                "end": 396,
                "text": "allodynia",
                "type": "CONDITION"
            },
            {
                "start": 422,
                "end": 436,
                "text": "acute migraine",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01444898",
        "text": "Effects of Exenatide on Obesity and Appetite in Overweight Patients With Prader-Willi Syndrome | Prader-Willi Syndrome (PWS) is one of the most common genetic causes of obesity. Obesity is a major source of morbidity and mortality in this population. It can lead to sleep apnea, cor pulmonale, diabetes mellitus, and atherosclerosis. PWS has distinct characteristics that set it apart from other forms of obesity including insatiable appetite and food-seeking behavior which can be disruptive to home and school activities, and can cause severe social and psychological turmoil within families. PWS is also associated with unique hormonal abnormalities, most notably hyperghrelinemia. Ghrelin is a gut hormone produced in the stomach that stimulates food intake during a fast. It is hypothesized that the extremely high ghrelin levels in patients with PWS may cause or contribute to their insatiable appetite. Exenatide, a medication used in the treatment of type 2 diabetes mellitus in adults, appears to suppress ghrelin levels and cause weight loss. It was designed to mimic glucagon-like peptide 1 (GLP-1), an incretin hormone that stimulates insulin secretion and delays gastric emptying, among other effects. In the present study, the investigators will investigate the effects of a 6 month trial of exenatide in overweight adolescents with PWS. The investigators will quantify the changes in weight and body composition, as well as subjective measures of appetite, and concentrations of appetite-associated hormones. The investigators hypothesize that exenatide will improve weight, body composition, appetite, and plasma ghrelin levels during the treatment period.",
        "tokens": "['Effects', 'of', 'Exenatide', 'on', 'Obesity', 'and', 'Appetite', 'in', 'Overweight', 'Patients', 'With', 'Prader', '-', 'Willi', 'Syndrome', '|', 'Prader', '-', 'Willi', 'Syndrome', '(', 'PWS', ')', 'is', 'one', 'of', 'the', 'most', 'common', 'genetic', 'causes', 'of', 'obesity', '.', 'Obesity', 'is', 'a', 'major', 'source', 'of', 'morbidity', 'and', 'mortality', 'in', 'this', 'population', '.', 'It', 'can', 'lead', 'to', 'sleep', 'apnea', ',', 'cor', 'pulmonale', ',', 'diabetes', 'mellitus', ',', 'and', 'atherosclerosis', '.', 'PWS', 'has', 'distinct', 'characteristics', 'that', 'set', 'it', 'apart', 'from', 'other', 'forms', 'of', 'obesity', 'including', 'insatiable', 'appetite', 'and', 'food', '-', 'seeking', 'behavior', 'which', 'can', 'be', 'disruptive', 'to', 'home', 'and', 'school', 'activities', ',', 'and', 'can', 'cause', 'severe', 'social', 'and', 'psychological', 'turmoil', 'within', 'families', '.', 'PWS', 'is', 'also', 'associated', 'with', 'unique', 'hormonal', 'abnormalities', ',', 'most', 'notably', 'hyperghrelinemia', '.', 'Ghrelin', 'is', 'a', 'gut', 'hormone', 'produced', 'in', 'the', 'stomach', 'that', 'stimulates', 'food', 'intake', 'during', 'a', 'fast', '.', 'It', 'is', 'hypothesized', 'that', 'the', 'extremely', 'high', 'ghrelin', 'levels', 'in', 'patients', 'with', 'PWS', 'may', 'cause', 'or', 'contribute', 'to', 'their', 'insatiable', 'appetite', '.', 'Exenatide', ',', 'a', 'medication', 'used', 'in', 'the', 'treatment', 'of', 'type', '2', 'diabetes', 'mellitus', 'in', 'adults', ',', 'appears', 'to', 'suppress', 'ghrelin', 'levels', 'and', 'cause', 'weight', 'loss', '.', 'It', 'was', 'designed', 'to', 'mimic', 'glucagon', '-', 'like', 'peptide', '1', '(', 'GLP-1', ')', ',', 'an', 'incretin', 'hormone', 'that', 'stimulates', 'insulin', 'secretion', 'and', 'delays', 'gastric', 'emptying', ',', 'among', 'other', 'effects', '.', 'In', 'the', 'present', 'study', ',', 'the', 'investigators', 'will', 'investigate', 'the', 'effects', 'of', 'a', '6', 'month', 'trial', 'of', 'exenatide', 'in', 'overweight', 'adolescents', 'with', 'PWS', '.', 'The', 'investigators', 'will', 'quantify', 'the', 'changes', 'in', 'weight', 'and', 'body', 'composition', ',', 'as', 'well', 'as', 'subjective', 'measures', 'of', 'appetite', ',', 'and', 'concentrations', 'of', 'appetite', '-', 'associated', 'hormones', '.', 'The', 'investigators', 'hypothesize', 'that', 'exenatide', 'will', 'improve', 'weight', ',', 'body', 'composition', ',', 'appetite', ',', 'and', 'plasma', 'ghrelin', 'levels', 'during', 'the', 'treatment', 'period', '.']",
        "token_bio_labels": "['O', 'O', 'B-DRUG', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 11,
                "end": 20,
                "text": "Exenatide",
                "type": "DRUG"
            },
            {
                "start": 24,
                "end": 31,
                "text": "Obesity",
                "type": "CONDITION"
            },
            {
                "start": 48,
                "end": 58,
                "text": "Overweight",
                "type": "CONDITION"
            },
            {
                "start": 73,
                "end": 94,
                "text": "Prader-Willi Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 97,
                "end": 118,
                "text": "Prader-Willi Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 120,
                "end": 123,
                "text": "PWS",
                "type": "CONDITION"
            },
            {
                "start": 169,
                "end": 176,
                "text": "obesity",
                "type": "CONDITION"
            },
            {
                "start": 178,
                "end": 185,
                "text": "Obesity",
                "type": "CONDITION"
            },
            {
                "start": 334,
                "end": 337,
                "text": "PWS",
                "type": "CONDITION"
            },
            {
                "start": 405,
                "end": 412,
                "text": "obesity",
                "type": "CONDITION"
            },
            {
                "start": 595,
                "end": 598,
                "text": "PWS",
                "type": "CONDITION"
            },
            {
                "start": 852,
                "end": 855,
                "text": "PWS",
                "type": "CONDITION"
            },
            {
                "start": 910,
                "end": 919,
                "text": "Exenatide",
                "type": "DRUG"
            },
            {
                "start": 1306,
                "end": 1315,
                "text": "exenatide",
                "type": "DRUG"
            },
            {
                "start": 1319,
                "end": 1329,
                "text": "overweight",
                "type": "CONDITION"
            },
            {
                "start": 1347,
                "end": 1350,
                "text": "PWS",
                "type": "CONDITION"
            },
            {
                "start": 1559,
                "end": 1568,
                "text": "exenatide",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT04085887",
        "text": "Phase 1/Phase 2, Open Label Study Evaluating the Safety, Dosing and Efficacy of Panitumumab IRDye800 as an Optical Imaging Agent to Detect Pediatric Neoplasms During Neurosurgical Procedures | The objective of the study is to assess safety of panitumumab-IRDye800 in pediatric patients undergoing brain surgery to remove suspected tumors.",
        "tokens": "['Phase', '1', '/', 'Phase', '2', ',', 'Open', 'Label', 'Study', 'Evaluating', 'the', 'Safety', ',', 'Dosing', 'and', 'Efficacy', 'of', 'Panitumumab', 'IRDye800', 'as', 'an', 'Optical', 'Imaging', 'Agent', 'to', 'Detect', 'Pediatric', 'Neoplasms', 'During', 'Neurosurgical', 'Procedures', '|', 'The', 'objective', 'of', 'the', 'study', 'is', 'to', 'assess', 'safety', 'of', 'panitumumab', '-', 'IRDye800', 'in', 'pediatric', 'patients', 'undergoing', 'brain', 'surgery', 'to', 'remove', 'suspected', 'tumors', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 80,
                "end": 100,
                "text": "Panitumumab IRDye800",
                "type": "DRUG"
            },
            {
                "start": 149,
                "end": 158,
                "text": "Neoplasms",
                "type": "CONDITION"
            },
            {
                "start": 166,
                "end": 190,
                "text": "Neurosurgical Procedures",
                "type": "CONDITION"
            },
            {
                "start": 243,
                "end": 263,
                "text": "panitumumab-IRDye800",
                "type": "DRUG"
            },
            {
                "start": 297,
                "end": 310,
                "text": "brain surgery",
                "type": "CONDITION"
            },
            {
                "start": 331,
                "end": 337,
                "text": "tumors",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04008355",
        "text": "A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 on Cerebrospinal Fluid Biomarkers in 36 Patients With Progressive Supranuclear Palsy | A phase 2 study to assess tolerability, safety, pharmacokinetics and effect of AZP2006 at different doses versus placebo on cerebrospinal fluid biomarkers in 36 patients with progressive supranuclear palsy. The patient study duration is 29 weeks including a washout period.",
        "tokens": "['A', 'Multi', '-', 'center', ',', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', ',', 'Parallel', 'Group', 'Study', 'to', 'Assess', 'Tolerability', ',', 'Safety', ',', 'Pharmacokinetics', 'and', 'Effect', 'of', 'AZP2006', 'on', 'Cerebrospinal', 'Fluid', 'Biomarkers', 'in', '36', 'Patients', 'With', 'Progressive', 'Supranuclear', 'Palsy', '|', 'A', 'phase', '2', 'study', 'to', 'assess', 'tolerability', ',', 'safety', ',', 'pharmacokinetics', 'and', 'effect', 'of', 'AZP2006', 'at', 'different', 'doses', 'versus', 'placebo', 'on', 'cerebrospinal', 'fluid', 'biomarkers', 'in', '36', 'patients', 'with', 'progressive', 'supranuclear', 'palsy', '.', 'The', 'patient', 'study', 'duration', 'is', '29', 'weeks', 'including', 'a', 'washout', 'period', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 42,
                "end": 49,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 146,
                "end": 153,
                "text": "AZP2006",
                "type": "DRUG"
            },
            {
                "start": 208,
                "end": 238,
                "text": "Progressive Supranuclear Palsy",
                "type": "CONDITION"
            },
            {
                "start": 320,
                "end": 327,
                "text": "AZP2006",
                "type": "DRUG"
            },
            {
                "start": 354,
                "end": 361,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 416,
                "end": 446,
                "text": "progressive supranuclear palsy",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04810871",
        "text": "Surgical Resection of Latent Brain Tumors Prior to Recurrence | This clinical trial evaluates the side effects and possible benefits of operating on brain tumors prior to the tumor coming back (recurrence). Understanding when surgery is most useful to patients with brain tumors is important. Some patients may undergo chemotherapy or radiation but still have visible tumor remaining after treatment. The purpose of this research is to compare outcomes of those who have surgery after chemotherapy or radiation, but prior to tumor recurrence, to those who have surgery at a different time, or no surgery at all.",
        "tokens": "['Surgical', 'Resection', 'of', 'Latent', 'Brain', 'Tumors', 'Prior', 'to', 'Recurrence', '|', 'This', 'clinical', 'trial', 'evaluates', 'the', 'side', 'effects', 'and', 'possible', 'benefits', 'of', 'operating', 'on', 'brain', 'tumors', 'prior', 'to', 'the', 'tumor', 'coming', 'back', '(', 'recurrence', ')', '.', 'Understanding', 'when', 'surgery', 'is', 'most', 'useful', 'to', 'patients', 'with', 'brain', 'tumors', 'is', 'important', '.', 'Some', 'patients', 'may', 'undergo', 'chemotherapy', 'or', 'radiation', 'but', 'still', 'have', 'visible', 'tumor', 'remaining', 'after', 'treatment', '.', 'The', 'purpose', 'of', 'this', 'research', 'is', 'to', 'compare', 'outcomes', 'of', 'those', 'who', 'have', 'surgery', 'after', 'chemotherapy', 'or', 'radiation', ',', 'but', 'prior', 'to', 'tumor', 'recurrence', ',', 'to', 'those', 'who', 'have', 'surgery', 'at', 'a', 'different', 'time', ',', 'or', 'no', 'surgery', 'at', 'all', '.']",
        "token_bio_labels": "['B-SURG', 'I-SURG', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 18,
                "text": "Surgical Resection",
                "type": "SURGICAL"
            },
            {
                "start": 22,
                "end": 61,
                "text": "Latent Brain Tumors Prior to Recurrence",
                "type": "CONDITION"
            },
            {
                "start": 149,
                "end": 161,
                "text": "brain tumors",
                "type": "CONDITION"
            },
            {
                "start": 175,
                "end": 180,
                "text": "tumor",
                "type": "CONDITION"
            },
            {
                "start": 266,
                "end": 278,
                "text": "brain tumors",
                "type": "CONDITION"
            },
            {
                "start": 368,
                "end": 373,
                "text": "tumor",
                "type": "CONDITION"
            },
            {
                "start": 471,
                "end": 510,
                "text": "surgery after chemotherapy or radiation",
                "type": "SURGICAL"
            },
            {
                "start": 516,
                "end": 541,
                "text": "prior to tumor recurrence",
                "type": "CONDITION"
            },
            {
                "start": 561,
                "end": 588,
                "text": "surgery at a different time",
                "type": "SURGICAL"
            },
            {
                "start": 593,
                "end": 610,
                "text": "no surgery at all",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT03213730",
        "text": "Perceptual-Cognitive Training After a Mild Traumatic Brain Injury: Towards a Sensitive Marker for Recovery | This study is part of a larger, multi-centered project done with the collaboration of University Of Victoria. This study holds three separate studies on the mild traumatic brain injured population and the use of perceptual-cognitive training (3D-MOT).",
        "tokens": "['Perceptual', '-', 'Cognitive', 'Training', 'After', 'a', 'Mild', 'Traumatic', 'Brain', 'Injury', ':', 'Towards', 'a', 'Sensitive', 'Marker', 'for', 'Recovery', '|', 'This', 'study', 'is', 'part', 'of', 'a', 'larger', ',', 'multi', '-', 'centered', 'project', 'done', 'with', 'the', 'collaboration', 'of', 'University', 'Of', 'Victoria', '.', 'This', 'study', 'holds', 'three', 'separate', 'studies', 'on', 'the', 'mild', 'traumatic', 'brain', 'injured', 'population', 'and', 'the', 'use', 'of', 'perceptual', '-', 'cognitive', 'training', '(', '3D', '-', 'MOT', ')', '.']",
        "token_bio_labels": "['B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 29,
                "text": "Perceptual-Cognitive Training",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 38,
                "end": 65,
                "text": "Mild Traumatic Brain Injury",
                "type": "CONDITION"
            },
            {
                "start": 266,
                "end": 294,
                "text": "mild traumatic brain injured",
                "type": "CONDITION"
            },
            {
                "start": 321,
                "end": 350,
                "text": "perceptual-cognitive training",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 352,
                "end": 358,
                "text": "3D-MOT",
                "type": "BEHAVIOURAL"
            }
        ]
    },
    {
        "nctid": "NCT04304274",
        "text": "Early and Late Postoperative Analgesia and Recovery Effects of Programmed Intermittent Bolus Infusion of Thoracic Paravertebral Block for Hepatectomy: A Prospective, Randomized, Double-blinded, Controlled Study | Hepatectomy induces moderate to severe postoperative pain. Patient-controlled intravenous analgesia has been used in many medical centers for post-hepatectomy analgesia, but the effects are limited and often cause undesirable adverse effects.\n\nRegional Block has been used for postoperative analgesia in many surgeries. Some studies suggest that regional analgesia has an opioid-sparing effect and can reduce the incidence of chronic pain. Also, the programmed intermittent bolus infusion is better than continuous infusion, with less analgesic consumption and fewer adverse effects.\n\nStudies on the early and late postoperative analgesia and recovery effects of paravertebral block for open hepatectomy are scarce. Therefore, the investigators aim to conduct a prospective, randomized, subject and assessor-blinded, parallel-group, placebo-controlled study to test the hypothesis that the programmed intermittent bolus infusion of right thoracic paravertebral block reduces postoperative intravenous analgesic use and pain scores and improved patients' satisfaction.",
        "tokens": "['Early', 'and', 'Late', 'Postoperative', 'Analgesia', 'and', 'Recovery', 'Effects', 'of', 'Programmed', 'Intermittent', 'Bolus', 'Infusion', 'of', 'Thoracic', 'Paravertebral', 'Block', 'for', 'Hepatectomy', ':', 'A', 'Prospective', ',', 'Randomized', ',', 'Double', '-', 'blinded', ',', 'Controlled', 'Study', '|', 'Hepatectomy', 'induces', 'moderate', 'to', 'severe', 'postoperative', 'pain', '.', 'Patient', '-', 'controlled', 'intravenous', 'analgesia', 'has', 'been', 'used', 'in', 'many', 'medical', 'centers', 'for', 'post', '-', 'hepatectomy', 'analgesia', ',', 'but', 'the', 'effects', 'are', 'limited', 'and', 'often', 'cause', 'undesirable', 'adverse', 'effects', '.', '\\n\\n', 'Regional', 'Block', 'has', 'been', 'used', 'for', 'postoperative', 'analgesia', 'in', 'many', 'surgeries', '.', 'Some', 'studies', 'suggest', 'that', 'regional', 'analgesia', 'has', 'an', 'opioid', '-', 'sparing', 'effect', 'and', 'can', 'reduce', 'the', 'incidence', 'of', 'chronic', 'pain', '.', 'Also', ',', 'the', 'programmed', 'intermittent', 'bolus', 'infusion', 'is', 'better', 'than', 'continuous', 'infusion', ',', 'with', 'less', 'analgesic', 'consumption', 'and', 'fewer', 'adverse', 'effects', '.', '\\n\\n', 'Studies', 'on', 'the', 'early', 'and', 'late', 'postoperative', 'analgesia', 'and', 'recovery', 'effects', 'of', 'paravertebral', 'block', 'for', 'open', 'hepatectomy', 'are', 'scarce', '.', 'Therefore', ',', 'the', 'investigators', 'aim', 'to', 'conduct', 'a', 'prospective', ',', 'randomized', ',', 'subject', 'and', 'assessor', '-', 'blinded', ',', 'parallel', '-', 'group', ',', 'placebo', '-', 'controlled', 'study', 'to', 'test', 'the', 'hypothesis', 'that', 'the', 'programmed', 'intermittent', 'bolus', 'infusion', 'of', 'right', 'thoracic', 'paravertebral', 'block', 'reduces', 'postoperative', 'intravenous', 'analgesic', 'use', 'and', 'pain', 'scores', 'and', 'improved', 'patients', \"'\", 'satisfaction', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 63,
                "end": 133,
                "text": "Programmed Intermittent Bolus Infusion of Thoracic Paravertebral Block",
                "type": "OTHER"
            },
            {
                "start": 138,
                "end": 149,
                "text": "Hepatectomy",
                "type": "CONDITION"
            },
            {
                "start": 213,
                "end": 224,
                "text": "Hepatectomy",
                "type": "CONDITION"
            },
            {
                "start": 266,
                "end": 270,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 457,
                "end": 471,
                "text": "Regional Block",
                "type": "OTHER"
            },
            {
                "start": 639,
                "end": 651,
                "text": "chronic pain",
                "type": "CONDITION"
            },
            {
                "start": 663,
                "end": 701,
                "text": "programmed intermittent bolus infusion",
                "type": "OTHER"
            },
            {
                "start": 876,
                "end": 895,
                "text": "paravertebral block",
                "type": "OTHER"
            },
            {
                "start": 905,
                "end": 916,
                "text": "hepatectomy",
                "type": "CONDITION"
            },
            {
                "start": 1046,
                "end": 1053,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 1103,
                "end": 1179,
                "text": "programmed intermittent bolus infusion of right thoracic paravertebral block",
                "type": "OTHER"
            },
            {
                "start": 1232,
                "end": 1236,
                "text": "pain",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05707091",
        "text": "Effects of Low Laser Therapy on Facial Motor Functions Function and Synkinesis in Patients With Bell's Palsy | To determine the effects of low-level laser therapy on facial motor functions and synkinesis in patients with bell's palsy",
        "tokens": "['Effects', 'of', 'Low', 'Laser', 'Therapy', 'on', 'Facial', 'Motor', 'Functions', 'Function', 'and', 'Synkinesis', 'in', 'Patients', 'With', 'Bell', \"'s\", 'Palsy', '|', 'To', 'determine', 'the', 'effects', 'of', 'low', '-', 'level', 'laser', 'therapy', 'on', 'facial', 'motor', 'functions', 'and', 'synkinesis', 'in', 'patients', 'with', 'bell', \"'s\", 'palsy']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND']",
        "entities": [
            {
                "start": 11,
                "end": 28,
                "text": "Low Laser Therapy",
                "type": "OTHER"
            },
            {
                "start": 96,
                "end": 108,
                "text": "Bell's Palsy",
                "type": "CONDITION"
            },
            {
                "start": 139,
                "end": 162,
                "text": "low-level laser therapy",
                "type": "OTHER"
            },
            {
                "start": 221,
                "end": 233,
                "text": "bell's palsy",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00716976",
        "text": "A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children | RATIONALE: Sodium thiosulfate may reduce or prevent hearing loss in young patients receiving cisplatin for cancer. It is not yet known whether sodium thiosulfate is more effective than no additional treatment in preventing hearing loss.\n\nPURPOSE: This randomized phase III trial is studying sodium thiosulfate to see how well it works in preventing hearing loss in young patients receiving cisplatin for newly diagnosed germ cell tumor, hepatoblastoma, medulloblastoma, neuroblastoma, osteosarcoma, or other malignancy.",
        "tokens": "['A', 'Randomized', 'Phase', 'III', 'Study', 'of', 'Sodium', 'Thiosulfate', 'for', 'the', 'Prevention', 'of', 'Cisplatin', '-', 'Induced', 'Ototoxicity', 'in', 'Children', '|', 'RATIONALE', ':', 'Sodium', 'thiosulfate', 'may', 'reduce', 'or', 'prevent', 'hearing', 'loss', 'in', 'young', 'patients', 'receiving', 'cisplatin', 'for', 'cancer', '.', 'It', 'is', 'not', 'yet', 'known', 'whether', 'sodium', 'thiosulfate', 'is', 'more', 'effective', 'than', 'no', 'additional', 'treatment', 'in', 'preventing', 'hearing', 'loss', '.', '\\n\\n', 'PURPOSE', ':', 'This', 'randomized', 'phase', 'III', 'trial', 'is', 'studying', 'sodium', 'thiosulfate', 'to', 'see', 'how', 'well', 'it', 'works', 'in', 'preventing', 'hearing', 'loss', 'in', 'young', 'patients', 'receiving', 'cisplatin', 'for', 'newly', 'diagnosed', 'germ', 'cell', 'tumor', ',', 'hepatoblastoma', ',', 'medulloblastoma', ',', 'neuroblastoma', ',', 'osteosarcoma', ',', 'or', 'other', 'malignancy', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 32,
                "end": 50,
                "text": "Sodium Thiosulfate",
                "type": "DRUG"
            },
            {
                "start": 73,
                "end": 102,
                "text": "Cisplatin-Induced Ototoxicity",
                "type": "CONDITION"
            },
            {
                "start": 128,
                "end": 146,
                "text": "Sodium thiosulfate",
                "type": "DRUG"
            },
            {
                "start": 169,
                "end": 181,
                "text": "hearing loss",
                "type": "CONDITION"
            },
            {
                "start": 210,
                "end": 219,
                "text": "cisplatin",
                "type": "CONDITION"
            },
            {
                "start": 224,
                "end": 230,
                "text": "cancer",
                "type": "CONDITION"
            },
            {
                "start": 260,
                "end": 278,
                "text": "sodium thiosulfate",
                "type": "DRUG"
            },
            {
                "start": 340,
                "end": 352,
                "text": "hearing loss",
                "type": "CONDITION"
            },
            {
                "start": 408,
                "end": 426,
                "text": "sodium thiosulfate",
                "type": "DRUG"
            },
            {
                "start": 466,
                "end": 478,
                "text": "hearing loss",
                "type": "CONDITION"
            },
            {
                "start": 507,
                "end": 516,
                "text": "cisplatin",
                "type": "CONDITION"
            },
            {
                "start": 537,
                "end": 552,
                "text": "germ cell tumor",
                "type": "CONDITION"
            },
            {
                "start": 554,
                "end": 568,
                "text": "hepatoblastoma",
                "type": "CONDITION"
            },
            {
                "start": 570,
                "end": 585,
                "text": "medulloblastoma",
                "type": "CONDITION"
            },
            {
                "start": 587,
                "end": 600,
                "text": "neuroblastoma",
                "type": "CONDITION"
            },
            {
                "start": 602,
                "end": 614,
                "text": "osteosarcoma",
                "type": "CONDITION"
            },
            {
                "start": 625,
                "end": 635,
                "text": "malignancy",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02517931",
        "text": "Sphenopalatine Ganglion Block for Treatment of Postdural Puncture Headache in the Emergency Department: A Prospective, Randomized, Double-Blind Placebo Controlled Study | This study evaluates sphenopalatine ganglion block (SPGB) for the treatment of postdural puncture headache (PDPH) in the emergency department (ED). Half of the patients will receive a true nerve block with lidocaine and bupivacaine. The other half will receive a placebo nerve block.",
        "tokens": "['Sphenopalatine', 'Ganglion', 'Block', 'for', 'Treatment', 'of', 'Postdural', 'Puncture', 'Headache', 'in', 'the', 'Emergency', 'Department', ':', 'A', 'Prospective', ',', 'Randomized', ',', 'Double', '-', 'Blind', 'Placebo', 'Controlled', 'Study', '|', 'This', 'study', 'evaluates', 'sphenopalatine', 'ganglion', 'block', '(', 'SPGB', ')', 'for', 'the', 'treatment', 'of', 'postdural', 'puncture', 'headache', '(', 'PDPH', ')', 'in', 'the', 'emergency', 'department', '(', 'ED', ')', '.', 'Half', 'of', 'the', 'patients', 'will', 'receive', 'a', 'true', 'nerve', 'block', 'with', 'lidocaine', 'and', 'bupivacaine', '.', 'The', 'other', 'half', 'will', 'receive', 'a', 'placebo', 'nerve', 'block', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 29,
                "text": "Sphenopalatine Ganglion Block",
                "type": "OTHER"
            },
            {
                "start": 47,
                "end": 74,
                "text": "Postdural Puncture Headache",
                "type": "CONDITION"
            },
            {
                "start": 144,
                "end": 151,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 192,
                "end": 221,
                "text": "sphenopalatine ganglion block",
                "type": "OTHER"
            },
            {
                "start": 223,
                "end": 227,
                "text": "SPGB",
                "type": "OTHER"
            },
            {
                "start": 250,
                "end": 277,
                "text": "postdural puncture headache",
                "type": "CONDITION"
            },
            {
                "start": 279,
                "end": 283,
                "text": "PDPH",
                "type": "CONDITION"
            },
            {
                "start": 377,
                "end": 386,
                "text": "lidocaine",
                "type": "DRUG"
            },
            {
                "start": 391,
                "end": 402,
                "text": "bupivacaine",
                "type": "DRUG"
            },
            {
                "start": 434,
                "end": 453,
                "text": "placebo nerve block",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT01757873",
        "text": "A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Z160 in Subjects With Postherpetic Neuralgia | This study will compare Z160 and placebo in patients with Postherpetic Neuralgia for safety and efficacy for a period of 6 weeks.",
        "tokens": "['A', 'Phase', '2', ',', 'Multicenter', ',', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', ',', 'Parallel', '-', 'Group', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', 'and', 'Safety', 'of', 'Z160', 'in', 'Subjects', 'With', 'Postherpetic', 'Neuralgia', '|', 'This', 'study', 'will', 'compare', 'Z160', 'and', 'placebo', 'in', 'patients', 'with', 'Postherpetic', 'Neuralgia', 'for', 'safety', 'and', 'efficacy', 'for', 'a', 'period', 'of', '6', 'weeks', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 50,
                "end": 57,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 130,
                "end": 134,
                "text": "Z160",
                "type": "DRUG"
            },
            {
                "start": 152,
                "end": 174,
                "text": "Postherpetic Neuralgia",
                "type": "CONDITION"
            },
            {
                "start": 201,
                "end": 205,
                "text": "Z160",
                "type": "DRUG"
            },
            {
                "start": 210,
                "end": 217,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 235,
                "end": 257,
                "text": "Postherpetic Neuralgia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05318079",
        "text": "Telehealth Virtual Reality Exergaming and Peer Networking Among People With Spinal Cord Injury | This pilot feasibility study aims to test whether youth and adults with spinal cord injury can use a group virtual reality gaming intervention to exercise. A second purpose is to examine whether there are potential benefits to cardiometabolic health and psychosocial health.",
        "tokens": "['Telehealth', 'Virtual', 'Reality', 'Exergaming', 'and', 'Peer', 'Networking', 'Among', 'People', 'With', 'Spinal', 'Cord', 'Injury', '|', 'This', 'pilot', 'feasibility', 'study', 'aims', 'to', 'test', 'whether', 'youth', 'and', 'adults', 'with', 'spinal', 'cord', 'injury', 'can', 'use', 'a', 'group', 'virtual', 'reality', 'gaming', 'intervention', 'to', 'exercise', '.', 'A', 'second', 'purpose', 'is', 'to', 'examine', 'whether', 'there', 'are', 'potential', 'benefits', 'to', 'cardiometabolic', 'health', 'and', 'psychosocial', 'health', '.']",
        "token_bio_labels": "['B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 37,
                "text": "Telehealth Virtual Reality Exergaming",
                "type": "PHYSICAL"
            },
            {
                "start": 42,
                "end": 57,
                "text": "Peer Networking",
                "type": "OTHER"
            },
            {
                "start": 76,
                "end": 94,
                "text": "Spinal Cord Injury",
                "type": "CONDITION"
            },
            {
                "start": 169,
                "end": 187,
                "text": "spinal cord injury",
                "type": "CONDITION"
            },
            {
                "start": 198,
                "end": 251,
                "text": "group virtual reality gaming intervention to exercise",
                "type": "PHYSICAL"
            }
        ]
    },
    {
        "nctid": "NCT02797418",
        "text": "\"Cognitus & Moi\": a New Cognitive Remediation Tool for Children With Intellectual Deficiency With Behavioral Disorders | Holders children with intellectual disabilities have great difficulty in adapting to social situations and relationships.Cognitive impairment associated with intellectual disability are important factors to understand their difficulties in processing social information. In the field of recognition of facial emotions in particular, basic cognitive processes such as visuospatial and attentional functions, are heavily involved.Cognitive remediation is a management tool widely used by practitioners to help patients who experience cognitive difficulties. Currently, no program can meet specific and validated the problems are children with intellectual disabilities manner in their daily functioning.",
        "tokens": "['\"', 'Cognitus', '&', 'Moi', '\"', ':', 'a', 'New', 'Cognitive', 'Remediation', 'Tool', 'for', 'Children', 'With', 'Intellectual', 'Deficiency', 'With', 'Behavioral', 'Disorders', '|', 'Holders', 'children', 'with', 'intellectual', 'disabilities', 'have', 'great', 'difficulty', 'in', 'adapting', 'to', 'social', 'situations', 'and', 'relationships', '.', 'Cognitive', 'impairment', 'associated', 'with', 'intellectual', 'disability', 'are', 'important', 'factors', 'to', 'understand', 'their', 'difficulties', 'in', 'processing', 'social', 'information', '.', 'In', 'the', 'field', 'of', 'recognition', 'of', 'facial', 'emotions', 'in', 'particular', ',', 'basic', 'cognitive', 'processes', 'such', 'as', 'visuospatial', 'and', 'attentional', 'functions', ',', 'are', 'heavily', 'involved', '.', 'Cognitive', 'remediation', 'is', 'a', 'management', 'tool', 'widely', 'used', 'by', 'practitioners', 'to', 'help', 'patients', 'who', 'experience', 'cognitive', 'difficulties', '.', 'Currently', ',', 'no', 'program', 'can', 'meet', 'specific', 'and', 'validated', 'the', 'problems', 'are', 'children', 'with', 'intellectual', 'disabilities', 'manner', 'in', 'their', 'daily', 'functioning', '.']",
        "token_bio_labels": "['O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 1,
                "end": 15,
                "text": "Cognitus & Moi",
                "type": "OTHER"
            },
            {
                "start": 24,
                "end": 50,
                "text": "Cognitive Remediation Tool",
                "type": "OTHER"
            },
            {
                "start": 69,
                "end": 92,
                "text": "Intellectual Deficiency",
                "type": "CONDITION"
            },
            {
                "start": 98,
                "end": 118,
                "text": "Behavioral Disorders",
                "type": "CONDITION"
            },
            {
                "start": 143,
                "end": 168,
                "text": "intellectual disabilities",
                "type": "CONDITION"
            },
            {
                "start": 242,
                "end": 262,
                "text": "Cognitive impairment",
                "type": "CONDITION"
            },
            {
                "start": 279,
                "end": 302,
                "text": "intellectual disability",
                "type": "CONDITION"
            },
            {
                "start": 549,
                "end": 570,
                "text": "Cognitive remediation",
                "type": "OTHER"
            },
            {
                "start": 653,
                "end": 675,
                "text": "cognitive difficulties",
                "type": "CONDITION"
            },
            {
                "start": 762,
                "end": 787,
                "text": "intellectual disabilities",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03459118",
        "text": "The Impact of Dementia on Care and Outcomes Associated With a Function Focused Care Intervention Among Residents in Assisted Living Settings. | This study will evaluate pain, management of pain, behavioral symptoms, and the quality of staff-resident interactions between residents with and without dementia, test the relationship of these variables to participation in function focused care at baseline, and consider if there is a differential impact of FFC-AL-EIT between those with and without dementia with regard to participation in function focused care, functional outcomes and physical activity over the 12 month study period. Findings from this study will provide new information on how to optimize function and physical activity among older adults with dementia in assisted living.",
        "tokens": "['The', 'Impact', 'of', 'Dementia', 'on', 'Care', 'and', 'Outcomes', 'Associated', 'With', 'a', 'Function', 'Focused', 'Care', 'Intervention', 'Among', 'Residents', 'in', 'Assisted', 'Living', 'Settings', '.', '|', 'This', 'study', 'will', 'evaluate', 'pain', ',', 'management', 'of', 'pain', ',', 'behavioral', 'symptoms', ',', 'and', 'the', 'quality', 'of', 'staff', '-', 'resident', 'interactions', 'between', 'residents', 'with', 'and', 'without', 'dementia', ',', 'test', 'the', 'relationship', 'of', 'these', 'variables', 'to', 'participation', 'in', 'function', 'focused', 'care', 'at', 'baseline', ',', 'and', 'consider', 'if', 'there', 'is', 'a', 'differential', 'impact', 'of', 'FFC', '-', 'AL', '-', 'EIT', 'between', 'those', 'with', 'and', 'without', 'dementia', 'with', 'regard', 'to', 'participation', 'in', 'function', 'focused', 'care', ',', 'functional', 'outcomes', 'and', 'physical', 'activity', 'over', 'the', '12', 'month', 'study', 'period', '.', 'Findings', 'from', 'this', 'study', 'will', 'provide', 'new', 'information', 'on', 'how', 'to', 'optimize', 'function', 'and', 'physical', 'activity', 'among', 'older', 'adults', 'with', 'dementia', 'in', 'assisted', 'living', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 14,
                "end": 22,
                "text": "Dementia",
                "type": "CONDITION"
            },
            {
                "start": 62,
                "end": 83,
                "text": "Function Focused Care",
                "type": "OTHER"
            },
            {
                "start": 169,
                "end": 173,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 189,
                "end": 193,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 298,
                "end": 306,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 454,
                "end": 464,
                "text": "FFC-AL-EIT",
                "type": "OTHER"
            },
            {
                "start": 496,
                "end": 504,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 762,
                "end": 770,
                "text": "dementia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02647242",
        "text": "Pilot Study on Feasibility and Safety of a Gait Auto-rehabilitation Program by Rhythmic Auditory Cueing Delivered by BeatHealth in Patients With Parkinson's Disease. | Physical activity has demonstrated its beneficial effect on functional capabilities and quality of life in patients with PD. However, the daily physical activity remains limited in these patients. Rhythmic auditory cueing improves spatio-temporal gait parameters in patients with PD. The first results of BeatHealth studies have allowed us to identify the best musical stimulation to improve these parameters and the motivation of the patients.\n\nThe originality of this study is to propose a gait auto-rehabilitation program using BeatHealth device with optimal auditory cueing during four weeks in ecological conditions in PD.\n\nObservance (utilization's time), safety (falls, pain, fatigability) and efficacy (gait parameters, balance, quality of life) will be evaluated.",
        "tokens": "['Pilot', 'Study', 'on', 'Feasibility', 'and', 'Safety', 'of', 'a', 'Gait', 'Auto', '-', 'rehabilitation', 'Program', 'by', 'Rhythmic', 'Auditory', 'Cueing', 'Delivered', 'by', 'BeatHealth', 'in', 'Patients', 'With', 'Parkinson', \"'s\", 'Disease', '.', '|', 'Physical', 'activity', 'has', 'demonstrated', 'its', 'beneficial', 'effect', 'on', 'functional', 'capabilities', 'and', 'quality', 'of', 'life', 'in', 'patients', 'with', 'PD', '.', 'However', ',', 'the', 'daily', 'physical', 'activity', 'remains', 'limited', 'in', 'these', 'patients', '.', 'Rhythmic', 'auditory', 'cueing', 'improves', 'spatio', '-', 'temporal', 'gait', 'parameters', 'in', 'patients', 'with', 'PD', '.', 'The', 'first', 'results', 'of', 'BeatHealth', 'studies', 'have', 'allowed', 'us', 'to', 'identify', 'the', 'best', 'musical', 'stimulation', 'to', 'improve', 'these', 'parameters', 'and', 'the', 'motivation', 'of', 'the', 'patients', '.', '\\n\\n', 'The', 'originality', 'of', 'this', 'study', 'is', 'to', 'propose', 'a', 'gait', 'auto', '-', 'rehabilitation', 'program', 'using', 'BeatHealth', 'device', 'with', 'optimal', 'auditory', 'cueing', 'during', 'four', 'weeks', 'in', 'ecological', 'conditions', 'in', 'PD', '.', '\\n\\n', 'Observance', '(', 'utilization', \"'s\", 'time', ')', ',', 'safety', '(', 'falls', ',', 'pain', ',', 'fatigability', ')', 'and', 'efficacy', '(', 'gait', 'parameters', ',', 'balance', ',', 'quality', 'of', 'life', ')', 'will', 'be', 'evaluated', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 43,
                "end": 75,
                "text": "Gait Auto-rehabilitation Program",
                "type": "PHYSICAL"
            },
            {
                "start": 79,
                "end": 103,
                "text": "Rhythmic Auditory Cueing",
                "type": "OTHER"
            },
            {
                "start": 117,
                "end": 127,
                "text": "BeatHealth",
                "type": "OTHER"
            },
            {
                "start": 145,
                "end": 164,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 289,
                "end": 291,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 365,
                "end": 389,
                "text": "Rhythmic auditory cueing",
                "type": "OTHER"
            },
            {
                "start": 448,
                "end": 450,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 473,
                "end": 483,
                "text": "BeatHealth",
                "type": "OTHER"
            },
            {
                "start": 660,
                "end": 692,
                "text": "gait auto-rehabilitation program",
                "type": "PHYSICAL"
            },
            {
                "start": 699,
                "end": 709,
                "text": "BeatHealth",
                "type": "OTHER"
            },
            {
                "start": 792,
                "end": 794,
                "text": "PD",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00486551",
        "text": "Anger Control Training for Youth With Tourette Syndrome | This is a clinical study of a cognitive-behavioral therapy known as anger control training in adolescents with Tourette Syndrome and explosive, disruptive behavior. ACT is compared to treatment as usual (TAU) in a randomized clinical trial.",
        "tokens": "['Anger', 'Control', 'Training', 'for', 'Youth', 'With', 'Tourette', 'Syndrome', '|', 'This', 'is', 'a', 'clinical', 'study', 'of', 'a', 'cognitive', '-', 'behavioral', 'therapy', 'known', 'as', 'anger', 'control', 'training', 'in', 'adolescents', 'with', 'Tourette', 'Syndrome', 'and', 'explosive', ',', 'disruptive', 'behavior', '.', 'ACT', 'is', 'compared', 'to', 'treatment', 'as', 'usual', '(', 'TAU', ')', 'in', 'a', 'randomized', 'clinical', 'trial', '.']",
        "token_bio_labels": "['B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-BEH', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 22,
                "text": "Anger Control Training",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 38,
                "end": 55,
                "text": "Tourette Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 88,
                "end": 116,
                "text": "cognitive-behavioral therapy",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 126,
                "end": 148,
                "text": "anger control training",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 169,
                "end": 186,
                "text": "Tourette Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 191,
                "end": 221,
                "text": "explosive, disruptive behavior",
                "type": "CONDITION"
            },
            {
                "start": 223,
                "end": 226,
                "text": "ACT",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 242,
                "end": 260,
                "text": "treatment as usual",
                "type": "CONTROL"
            },
            {
                "start": 262,
                "end": 265,
                "text": "TAU",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT00640965",
        "text": "Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Two-Arm, Multi-Center Phase II Trial to Assess the Safety, Tolerability, and Efficacy of DP-VPA (up to 900 mg) Once Daily for 10 Weeks in Adult Subjects With Migraine | The study will evaluate if DP-VPA, a derivative of valproate (a drug that is commonly used for the prevention of migraine attacks), can reduce the rate of migraine attacks.\n\nMigraine patients will take DP-VPA or placebo (an inactive look-alike drug) every morning and will have to report any migraine attacks they have during the study's 18-week follow up.",
        "tokens": "['Double', '-', 'Blind', ',', 'Randomized', ',', 'Placebo', '-', 'Controlled', ',', 'Parallel', '-', 'Group', ',', 'Two', '-', 'Arm', ',', 'Multi', '-', 'Center', 'Phase', 'II', 'Trial', 'to', 'Assess', 'the', 'Safety', ',', 'Tolerability', ',', 'and', 'Efficacy', 'of', 'DP', '-', 'VPA', '(', 'up', 'to', '900', 'mg', ')', 'Once', 'Daily', 'for', '10', 'Weeks', 'in', 'Adult', 'Subjects', 'With', 'Migraine', '|', 'The', 'study', 'will', 'evaluate', 'if', 'DP', '-', 'VPA', ',', 'a', 'derivative', 'of', 'valproate', '(', 'a', 'drug', 'that', 'is', 'commonly', 'used', 'for', 'the', 'prevention', 'of', 'migraine', 'attacks', ')', ',', 'can', 'reduce', 'the', 'rate', 'of', 'migraine', 'attacks', '.', '\\n\\n', 'Migraine', 'patients', 'will', 'take', 'DP', '-', 'VPA', 'or', 'placebo', '(', 'an', 'inactive', 'look', '-', 'alike', 'drug', ')', 'every', 'morning', 'and', 'will', 'have', 'to', 'report', 'any', 'migraine', 'attacks', 'they', 'have', 'during', 'the', 'study', \"'s\", '18', '-', 'week', 'follow', 'up', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 26,
                "end": 33,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 151,
                "end": 157,
                "text": "DP-VPA",
                "type": "DRUG"
            },
            {
                "start": 220,
                "end": 228,
                "text": "Migraine",
                "type": "CONDITION"
            },
            {
                "start": 258,
                "end": 264,
                "text": "DP-VPA",
                "type": "DRUG"
            },
            {
                "start": 282,
                "end": 291,
                "text": "valproate",
                "type": "DRUG"
            },
            {
                "start": 344,
                "end": 360,
                "text": "migraine attacks",
                "type": "CONDITION"
            },
            {
                "start": 386,
                "end": 402,
                "text": "migraine attacks",
                "type": "CONDITION"
            },
            {
                "start": 405,
                "end": 413,
                "text": "Migraine",
                "type": "CONDITION"
            },
            {
                "start": 433,
                "end": 439,
                "text": "DP-VPA",
                "type": "DRUG"
            },
            {
                "start": 443,
                "end": 450,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 523,
                "end": 539,
                "text": "migraine attacks",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01530620",
        "text": "Efficacy and Tolerability of Propiverine Hydrochloride Extended Release (ER) Compared to Immediate Release (IR) in Patients With Neurogenic Detrusor Overactivity. A Randomized, Double Blind, Parallel Group, Multicenter Clinical Trial | The purpose of this clinical study is to compare efficacy and safety of propiverine hydrochloride extended and immediate release formulations in patients suffering from neurogenic detrusor overactivity.",
        "tokens": "['Efficacy', 'and', 'Tolerability', 'of', 'Propiverine', 'Hydrochloride', 'Extended', 'Release', '(', 'ER', ')', 'Compared', 'to', 'Immediate', 'Release', '(', 'IR', ')', 'in', 'Patients', 'With', 'Neurogenic', 'Detrusor', 'Overactivity', '.', 'A', 'Randomized', ',', 'Double', 'Blind', ',', 'Parallel', 'Group', ',', 'Multicenter', 'Clinical', 'Trial', '|', 'The', 'purpose', 'of', 'this', 'clinical', 'study', 'is', 'to', 'compare', 'efficacy', 'and', 'safety', 'of', 'propiverine', 'hydrochloride', 'extended', 'and', 'immediate', 'release', 'formulations', 'in', 'patients', 'suffering', 'from', 'neurogenic', 'detrusor', 'overactivity', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 29,
                "end": 54,
                "text": "Propiverine Hydrochloride",
                "type": "DRUG"
            },
            {
                "start": 129,
                "end": 161,
                "text": "Neurogenic Detrusor Overactivity",
                "type": "CONDITION"
            },
            {
                "start": 308,
                "end": 333,
                "text": "propiverine hydrochloride",
                "type": "DRUG"
            },
            {
                "start": 405,
                "end": 437,
                "text": "neurogenic detrusor overactivity",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05080270",
        "text": "Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis | Fibroblasts have demonstrated potent immune modulatory and therapeutic activity in the experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis, as well as in other models of autoimmune and inflammatory diseases.\n\nThis study will assess primary safety and secondary efficacy endpoints of intravenous administration of 100 million tolerogenic fibroblasts to 5 patients with relapsing remitting MS resistant to interferon. While the safety of fibroblasts administered clinically is established, it is unknown whether these cells are effective in the treatment of multiple sclerosis (MS).\n\nOur hypothesis is that the tolerogenic fibroblasts will be well-tolerated and meet our primary objective. In addition, The investigators are optimistic that they will see signs of efficacy based on the following: Neurological assessment of the MS functional composite assessment which comprises of EDSS, the expanded EDSS (Rating Neurologic Impairment in Multiple Sclerosis, the Scripps neurological rating scale (NRS), paced auditory serial addition test (PASAT), the nine-hole peg test, and 25-foot walking time, short-form 36 (SF-36) quality of life questionnaire and gadolinium-enhanced MRI scans of the brain and cervical spinal cord.",
        "tokens": "['Feasibility', 'Study', 'of', 'Tolerogenic', 'Fibroblasts', 'in', 'Patients', 'With', 'Refractory', 'Multiple', 'Sclerosis', '|', 'Fibroblasts', 'have', 'demonstrated', 'potent', 'immune', 'modulatory', 'and', 'therapeutic', 'activity', 'in', 'the', 'experimental', 'autoimmune', 'encephalomyelitis', '(', 'EAE', ')', 'model', 'of', 'multiple', 'sclerosis', ',', 'as', 'well', 'as', 'in', 'other', 'models', 'of', 'autoimmune', 'and', 'inflammatory', 'diseases', '.', '\\n\\n', 'This', 'study', 'will', 'assess', 'primary', 'safety', 'and', 'secondary', 'efficacy', 'endpoints', 'of', 'intravenous', 'administration', 'of', '100', 'million', 'tolerogenic', 'fibroblasts', 'to', '5', 'patients', 'with', 'relapsing', 'remitting', 'MS', 'resistant', 'to', 'interferon', '.', 'While', 'the', 'safety', 'of', 'fibroblasts', 'administered', 'clinically', 'is', 'established', ',', 'it', 'is', 'unknown', 'whether', 'these', 'cells', 'are', 'effective', 'in', 'the', 'treatment', 'of', 'multiple', 'sclerosis', '(', 'MS', ')', '.', '\\n\\n', 'Our', 'hypothesis', 'is', 'that', 'the', 'tolerogenic', 'fibroblasts', 'will', 'be', 'well', '-', 'tolerated', 'and', 'meet', 'our', 'primary', 'objective', '.', 'In', 'addition', ',', 'The', 'investigators', 'are', 'optimistic', 'that', 'they', 'will', 'see', 'signs', 'of', 'efficacy', 'based', 'on', 'the', 'following', ':', 'Neurological', 'assessment', 'of', 'the', 'MS', 'functional', 'composite', 'assessment', 'which', 'comprises', 'of', 'EDSS', ',', 'the', 'expanded', 'EDSS', '(', 'Rating', 'Neurologic', 'Impairment', 'in', 'Multiple', 'Sclerosis', ',', 'the', 'Scripps', 'neurological', 'rating', 'scale', '(', 'NRS', ')', ',', 'paced', 'auditory', 'serial', 'addition', 'test', '(', 'PASAT', ')', ',', 'the', 'nine', '-', 'hole', 'peg', 'test', ',', 'and', '25', '-', 'foot', 'walking', 'time', ',', 'short', '-', 'form', '36', '(', 'SF-36', ')', 'quality', 'of', 'life', 'questionnaire', 'and', 'gadolinium', '-', 'enhanced', 'MRI', 'scans', 'of', 'the', 'brain', 'and', 'cervical', 'spinal', 'cord', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 21,
                "end": 44,
                "text": "Tolerogenic Fibroblasts",
                "type": "SURGICAL"
            },
            {
                "start": 62,
                "end": 91,
                "text": "Refractory Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 94,
                "end": 105,
                "text": "Fibroblasts",
                "type": "SURGICAL"
            },
            {
                "start": 238,
                "end": 256,
                "text": "multiple sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 443,
                "end": 466,
                "text": "tolerogenic fibroblasts",
                "type": "SURGICAL"
            },
            {
                "start": 486,
                "end": 508,
                "text": "relapsing remitting MS",
                "type": "CONDITION"
            },
            {
                "start": 554,
                "end": 565,
                "text": "fibroblasts",
                "type": "SURGICAL"
            },
            {
                "start": 674,
                "end": 692,
                "text": "multiple sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 694,
                "end": 696,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 727,
                "end": 750,
                "text": "tolerogenic fibroblasts",
                "type": "SURGICAL"
            },
            {
                "start": 944,
                "end": 946,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 1055,
                "end": 1073,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03841695",
        "text": "The Therapeutic Effect of the Rehabotics Medical Technology Corporation (RMTC) Finger-hand Robot on Upper-limb Rehabilitation of Stroke Patients | In the present study, the RMTC finger-hand robot and combined with the mechanism of neuroplasticity will be used on the upper-limb rehabilitation of stroke patients. The participants will be randomized assigned to treatment group (TG, robot assisted treatment) and control group (CG, conventional treatment). In the experimental group, task oriented bi-manual training will be applied using the unaffected hand to guide the affected hand by RMTC robot system. The investigators will estimate the motor function of distal part of upper-limb before and after treatments. The results will be compared with the convention rehabilitation treatment. The primary outcomes are Fugl-Meyer assessment (FMA); and the secondary outcome measurements are modified Ashworth scale (MAS),Action Reach Arm Test (ARAT), Box & block test\u3001Brunnstrom recovery Stage, and motor activity log (MAL).",
        "tokens": "['The', 'Therapeutic', 'Effect', 'of', 'the', 'Rehabotics', 'Medical', 'Technology', 'Corporation', '(', 'RMTC', ')', 'Finger', '-', 'hand', 'Robot', 'on', 'Upper', '-', 'limb', 'Rehabilitation', 'of', 'Stroke', 'Patients', '|', 'In', 'the', 'present', 'study', ',', 'the', 'RMTC', 'finger', '-', 'hand', 'robot', 'and', 'combined', 'with', 'the', 'mechanism', 'of', 'neuroplasticity', 'will', 'be', 'used', 'on', 'the', 'upper', '-', 'limb', 'rehabilitation', 'of', 'stroke', 'patients', '.', 'The', 'participants', 'will', 'be', 'randomized', 'assigned', 'to', 'treatment', 'group', '(', 'TG', ',', 'robot', 'assisted', 'treatment', ')', 'and', 'control', 'group', '(', 'CG', ',', 'conventional', 'treatment', ')', '.', 'In', 'the', 'experimental', 'group', ',', 'task', 'oriented', 'bi', '-', 'manual', 'training', 'will', 'be', 'applied', 'using', 'the', 'unaffected', 'hand', 'to', 'guide', 'the', 'affected', 'hand', 'by', 'RMTC', 'robot', 'system', '.', 'The', 'investigators', 'will', 'estimate', 'the', 'motor', 'function', 'of', 'distal', 'part', 'of', 'upper', '-', 'limb', 'before', 'and', 'after', 'treatments', '.', 'The', 'results', 'will', 'be', 'compared', 'with', 'the', 'convention', 'rehabilitation', 'treatment', '.', 'The', 'primary', 'outcomes', 'are', 'Fugl', '-', 'Meyer', 'assessment', '(', 'FMA', ')', ';', 'and', 'the', 'secondary', 'outcome', 'measurements', 'are', 'modified', 'Ashworth', 'scale', '(', 'MAS),Action', 'Reach', 'Arm', 'Test', '(', 'ARAT', ')', ',', 'Box', '&', 'block', 'test\u3001Brunnstrom', 'recovery', 'Stage', ',', 'and', 'motor', 'activity', 'log', '(', 'MAL', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 30,
                "end": 96,
                "text": "Rehabotics Medical Technology Corporation (RMTC) Finger-hand Robot",
                "type": "OTHER"
            },
            {
                "start": 100,
                "end": 125,
                "text": "Upper-limb Rehabilitation",
                "type": "PHYSICAL"
            },
            {
                "start": 129,
                "end": 135,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 173,
                "end": 195,
                "text": "RMTC finger-hand robot",
                "type": "OTHER"
            },
            {
                "start": 267,
                "end": 292,
                "text": "upper-limb rehabilitation",
                "type": "PHYSICAL"
            },
            {
                "start": 296,
                "end": 302,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 382,
                "end": 406,
                "text": "robot assisted treatment",
                "type": "OTHER"
            },
            {
                "start": 431,
                "end": 453,
                "text": "conventional treatment",
                "type": "CONTROL"
            },
            {
                "start": 483,
                "end": 515,
                "text": "task oriented bi-manual training",
                "type": "OTHER"
            },
            {
                "start": 588,
                "end": 605,
                "text": "RMTC robot system",
                "type": "OTHER"
            },
            {
                "start": 754,
                "end": 789,
                "text": "convention rehabilitation treatment",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT02645942",
        "text": "L-carnitine for Reducing Cardio-metabolic Risk in Patients With Obstructive Sleep Apnea - Double Blind Randomized Clinical Trial | The investigators designed this intervention to investigate the potential role of L-C in lipid and carbohydrates metabolism (primary outcome) with precision noninvasively measurement of: central blood pressure, pulse wave velocity and peripheral arterial stiffness (secondary outcome) in OSA patients.",
        "tokens": "['L', '-', 'carnitine', 'for', 'Reducing', 'Cardio', '-', 'metabolic', 'Risk', 'in', 'Patients', 'With', 'Obstructive', 'Sleep', 'Apnea', '-', 'Double', 'Blind', 'Randomized', 'Clinical', 'Trial', '|', 'The', 'investigators', 'designed', 'this', 'intervention', 'to', 'investigate', 'the', 'potential', 'role', 'of', 'L', '-', 'C', 'in', 'lipid', 'and', 'carbohydrates', 'metabolism', '(', 'primary', 'outcome', ')', 'with', 'precision', 'noninvasively', 'measurement', 'of', ':', 'central', 'blood', 'pressure', ',', 'pulse', 'wave', 'velocity', 'and', 'peripheral', 'arterial', 'stiffness', '(', 'secondary', 'outcome', ')', 'in', 'OSA', 'patients', '.']",
        "token_bio_labels": "['B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 11,
                "text": "L-carnitine",
                "type": "DRUG"
            },
            {
                "start": 64,
                "end": 87,
                "text": "Obstructive Sleep Apnea",
                "type": "CONDITION"
            },
            {
                "start": 213,
                "end": 216,
                "text": "L-C",
                "type": "DRUG"
            },
            {
                "start": 419,
                "end": 422,
                "text": "OSA",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02676375",
        "text": "Nicotine Receptor Density & Response to Nicotine Patch: Pt 2 Extended Treatment | The study investigators will enroll 45 treatment seeking, cigarette smokers with a Diagnostic and Statistical Manual (DSM-IV) diagnosis of schizophrenia who will be randomly assigned into three arms of treatment for smoking cessation treatment, receiving either 1. Control: \"standard therapy\" (n=15), including stepwise monotherapy of nicotine patch or bupropion sustained release, 2. Extended treatment with combination bupropion, nicotine patch, and nicotine lozenge for 6 months (n=15), or 3. Extended treatment with combination bupropion, nicotine patch, and nicotine lozenge for 6 months with home visits (n=15) and phone calls to the home or living facility. During all treatments, participants will receive weekly smoking cessation group counseling, as is standard for smoking cessation treatment. At the time of enrollment, participants will complete a one-study visit lead-in to complete baseline assessments, psychological and medical evaluation, and comprehensive assessment of drug use to determine study eligibility. Once determined to be eligible for the trial, participants will be randomly assigned to one of the treatment arms using a randomization procedure. The \"standard therapy\" treatment arm, or control group, will receive either nicotine patch taper starting at 21 milligrams (mg) daily, nicotine lozenge as needed, and/or bupropion sustained release at 150mg daily for 3 days, then 150 mg twice a day for a total of 12 weeks. The extended therapy arm will start the nicotine patch at 21mg daily with as needed nicotine lozenge for breakthrough cravings and initiation of bupropion sustained release at 150mg daily for 3 days a week prior to starting nicotine replacement, then 150 mg twice daily for 6 months (as tolerated). The third arm will be identical to the second arm except for the added home visit intervention.",
        "tokens": "['Nicotine', 'Receptor', 'Density', '&', 'Response', 'to', 'Nicotine', 'Patch', ':', 'Pt', '2', 'Extended', 'Treatment', '|', 'The', 'study', 'investigators', 'will', 'enroll', '45', 'treatment', 'seeking', ',', 'cigarette', 'smokers', 'with', 'a', 'Diagnostic', 'and', 'Statistical', 'Manual', '(', 'DSM', '-', 'IV', ')', 'diagnosis', 'of', 'schizophrenia', 'who', 'will', 'be', 'randomly', 'assigned', 'into', 'three', 'arms', 'of', 'treatment', 'for', 'smoking', 'cessation', 'treatment', ',', 'receiving', 'either', '1', '.', 'Control', ':', '\"', 'standard', 'therapy', '\"', '(', 'n=15', ')', ',', 'including', 'stepwise', 'monotherapy', 'of', 'nicotine', 'patch', 'or', 'bupropion', 'sustained', 'release', ',', '2', '.', 'Extended', 'treatment', 'with', 'combination', 'bupropion', ',', 'nicotine', 'patch', ',', 'and', 'nicotine', 'lozenge', 'for', '6', 'months', '(', 'n=15', ')', ',', 'or', '3', '.', 'Extended', 'treatment', 'with', 'combination', 'bupropion', ',', 'nicotine', 'patch', ',', 'and', 'nicotine', 'lozenge', 'for', '6', 'months', 'with', 'home', 'visits', '(', 'n=15', ')', 'and', 'phone', 'calls', 'to', 'the', 'home', 'or', 'living', 'facility', '.', 'During', 'all', 'treatments', ',', 'participants', 'will', 'receive', 'weekly', 'smoking', 'cessation', 'group', 'counseling', ',', 'as', 'is', 'standard', 'for', 'smoking', 'cessation', 'treatment', '.', 'At', 'the', 'time', 'of', 'enrollment', ',', 'participants', 'will', 'complete', 'a', 'one', '-', 'study', 'visit', 'lead', '-', 'in', 'to', 'complete', 'baseline', 'assessments', ',', 'psychological', 'and', 'medical', 'evaluation', ',', 'and', 'comprehensive', 'assessment', 'of', 'drug', 'use', 'to', 'determine', 'study', 'eligibility', '.', 'Once', 'determined', 'to', 'be', 'eligible', 'for', 'the', 'trial', ',', 'participants', 'will', 'be', 'randomly', 'assigned', 'to', 'one', 'of', 'the', 'treatment', 'arms', 'using', 'a', 'randomization', 'procedure', '.', 'The', '\"', 'standard', 'therapy', '\"', 'treatment', 'arm', ',', 'or', 'control', 'group', ',', 'will', 'receive', 'either', 'nicotine', 'patch', 'taper', 'starting', 'at', '21', 'milligrams', '(', 'mg', ')', 'daily', ',', 'nicotine', 'lozenge', 'as', 'needed', ',', 'and/or', 'bupropion', 'sustained', 'release', 'at', '150', 'mg', 'daily', 'for', '3', 'days', ',', 'then', '150', 'mg', 'twice', 'a', 'day', 'for', 'a', 'total', 'of', '12', 'weeks', '.', 'The', 'extended', 'therapy', 'arm', 'will', 'start', 'the', 'nicotine', 'patch', 'at', '21', 'mg', 'daily', 'with', 'as', 'needed', 'nicotine', 'lozenge', 'for', 'breakthrough', 'cravings', 'and', 'initiation', 'of', 'bupropion', 'sustained', 'release', 'at', '150', 'mg', 'daily', 'for', '3', 'days', 'a', 'week', 'prior', 'to', 'starting', 'nicotine', 'replacement', ',', 'then', '150', 'mg', 'twice', 'daily', 'for', '6', 'months', '(', 'as', 'tolerated', ')', '.', 'The', 'third', 'arm', 'will', 'be', 'identical', 'to', 'the', 'second', 'arm', 'except', 'for', 'the', 'added', 'home', 'visit', 'intervention', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O']",
        "entities": [
            {
                "start": 40,
                "end": 48,
                "text": "Nicotine",
                "type": "DRUG"
            },
            {
                "start": 140,
                "end": 157,
                "text": "cigarette smokers",
                "type": "CONDITION"
            },
            {
                "start": 221,
                "end": 234,
                "text": "schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 357,
                "end": 373,
                "text": "standard therapy",
                "type": "CONTROL"
            },
            {
                "start": 417,
                "end": 425,
                "text": "nicotine",
                "type": "DRUG"
            },
            {
                "start": 435,
                "end": 444,
                "text": "bupropion",
                "type": "DRUG"
            },
            {
                "start": 503,
                "end": 512,
                "text": "bupropion",
                "type": "DRUG"
            },
            {
                "start": 514,
                "end": 522,
                "text": "nicotine",
                "type": "DRUG"
            },
            {
                "start": 534,
                "end": 542,
                "text": "nicotine",
                "type": "DRUG"
            },
            {
                "start": 614,
                "end": 623,
                "text": "bupropion",
                "type": "DRUG"
            },
            {
                "start": 625,
                "end": 633,
                "text": "nicotine",
                "type": "DRUG"
            },
            {
                "start": 645,
                "end": 653,
                "text": "nicotine",
                "type": "DRUG"
            },
            {
                "start": 680,
                "end": 691,
                "text": "home visits",
                "type": "OTHER"
            },
            {
                "start": 703,
                "end": 714,
                "text": "phone calls",
                "type": "OTHER"
            },
            {
                "start": 803,
                "end": 837,
                "text": "smoking cessation group counseling",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 1264,
                "end": 1280,
                "text": "standard therapy",
                "type": "CONTROL"
            },
            {
                "start": 1335,
                "end": 1343,
                "text": "nicotine",
                "type": "DRUG"
            },
            {
                "start": 1394,
                "end": 1402,
                "text": "nicotine",
                "type": "DRUG"
            },
            {
                "start": 1429,
                "end": 1438,
                "text": "bupropion",
                "type": "DRUG"
            },
            {
                "start": 1573,
                "end": 1581,
                "text": "nicotine",
                "type": "DRUG"
            },
            {
                "start": 1617,
                "end": 1625,
                "text": "nicotine",
                "type": "DRUG"
            },
            {
                "start": 1678,
                "end": 1687,
                "text": "bupropion",
                "type": "DRUG"
            },
            {
                "start": 1757,
                "end": 1765,
                "text": "nicotine",
                "type": "DRUG"
            },
            {
                "start": 1903,
                "end": 1926,
                "text": "home visit intervention",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT03755349",
        "text": "COveRs to impRove EsthetiC ouTcome After Surgery for Chronic Subdural hemAtoma by buRr Hole Trepanation (CORRECT-SCAR) - a Single-blinded, Randomized Controlled Trial | The clinical-functional result after frontal and parietal burr-hole trepanation for the treatment of chronic subdural hematoma (cSDH) is effective with regards to control of the hematoma and regression of symptoms (headache, decreased vigilance and neurological deficits). However, in patients the treatment may leave visible depressions of the scalp, just above the trepanation sites, that typically develop gradually after weeks - months after the procedure. A considerable proportion of patients find this aesthetically, functionally and psychologically disturbing; the skin depressions may even cause pain or interfere with activities of daily living, such as combing, etc.\n\nAn effective method would exist to avoid this undesired treatment effect: Before the skin is closed, a permeable titanium burr-hole plate could be attached above the trepanation site in order to prevent the skin from sinking into the bony defect. However, this is rarely done today, likely because there is no evidence that this treatment modification is effective and safe. Moreover, as material is implanted, this causes additional costs.\n\nThe primary aim of this study is to evaluate whether the application of burr-hole plates on both the frontal and parietal burr-hole in the context of burr-hole trepanation for the treatment of cSDH can improve patient satisfaction with the aesthetic result of the surgery.\n\nIn addition, the study is intended to demonstrate that this additional measure will not result in poorer hematoma control, poorer clinical/neurological outcomes, or additional complications for the patient.\n\nIn a prospective, single-blind and controlled approach, we randomize 80 patients with uni- or bilateral cSDH into an intervention group (with burr-hole plates) or into a control group (without burr-hole plates).\n\nThe primary end result of the study is the patient's reported satisfaction with the aesthetic outcome of the surgical scar. Secondary results are pain, functionality, neurological status, health-related quality of life, residual hematoma volume, and complications (according to Clavien-Dindo scale; especially re-operation rate for recurring cSDH and infections).\n\nThe study corresponds to a modern approach, since today's patients not only expect favorable treatment results for their disease, but the therapy should also avoid permanent undesired side-effects, if possible.",
        "tokens": "['COveRs', 'to', 'impRove', 'EsthetiC', 'ouTcome', 'After', 'Surgery', 'for', 'Chronic', 'Subdural', 'hemAtoma', 'by', 'buRr', 'Hole', 'Trepanation', '(', 'CORRECT', '-', 'SCAR', ')', '-', 'a', 'Single', '-', 'blinded', ',', 'Randomized', 'Controlled', 'Trial', '|', 'The', 'clinical', '-', 'functional', 'result', 'after', 'frontal', 'and', 'parietal', 'burr', '-', 'hole', 'trepanation', 'for', 'the', 'treatment', 'of', 'chronic', 'subdural', 'hematoma', '(', 'cSDH', ')', 'is', 'effective', 'with', 'regards', 'to', 'control', 'of', 'the', 'hematoma', 'and', 'regression', 'of', 'symptoms', '(', 'headache', ',', 'decreased', 'vigilance', 'and', 'neurological', 'deficits', ')', '.', 'However', ',', 'in', 'patients', 'the', 'treatment', 'may', 'leave', 'visible', 'depressions', 'of', 'the', 'scalp', ',', 'just', 'above', 'the', 'trepanation', 'sites', ',', 'that', 'typically', 'develop', 'gradually', 'after', 'weeks', '-', 'months', 'after', 'the', 'procedure', '.', 'A', 'considerable', 'proportion', 'of', 'patients', 'find', 'this', 'aesthetically', ',', 'functionally', 'and', 'psychologically', 'disturbing', ';', 'the', 'skin', 'depressions', 'may', 'even', 'cause', 'pain', 'or', 'interfere', 'with', 'activities', 'of', 'daily', 'living', ',', 'such', 'as', 'combing', ',', 'etc', '.', '\\n\\n', 'An', 'effective', 'method', 'would', 'exist', 'to', 'avoid', 'this', 'undesired', 'treatment', 'effect', ':', 'Before', 'the', 'skin', 'is', 'closed', ',', 'a', 'permeable', 'titanium', 'burr', '-', 'hole', 'plate', 'could', 'be', 'attached', 'above', 'the', 'trepanation', 'site', 'in', 'order', 'to', 'prevent', 'the', 'skin', 'from', 'sinking', 'into', 'the', 'bony', 'defect', '.', 'However', ',', 'this', 'is', 'rarely', 'done', 'today', ',', 'likely', 'because', 'there', 'is', 'no', 'evidence', 'that', 'this', 'treatment', 'modification', 'is', 'effective', 'and', 'safe', '.', 'Moreover', ',', 'as', 'material', 'is', 'implanted', ',', 'this', 'causes', 'additional', 'costs', '.', '\\n\\n', 'The', 'primary', 'aim', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'whether', 'the', 'application', 'of', 'burr', '-', 'hole', 'plates', 'on', 'both', 'the', 'frontal', 'and', 'parietal', 'burr', '-', 'hole', 'in', 'the', 'context', 'of', 'burr', '-', 'hole', 'trepanation', 'for', 'the', 'treatment', 'of', 'cSDH', 'can', 'improve', 'patient', 'satisfaction', 'with', 'the', 'aesthetic', 'result', 'of', 'the', 'surgery', '.', '\\n\\n', 'In', 'addition', ',', 'the', 'study', 'is', 'intended', 'to', 'demonstrate', 'that', 'this', 'additional', 'measure', 'will', 'not', 'result', 'in', 'poorer', 'hematoma', 'control', ',', 'poorer', 'clinical', '/', 'neurological', 'outcomes', ',', 'or', 'additional', 'complications', 'for', 'the', 'patient', '.', '\\n\\n', 'In', 'a', 'prospective', ',', 'single', '-', 'blind', 'and', 'controlled', 'approach', ',', 'we', 'randomize', '80', 'patients', 'with', 'uni-', 'or', 'bilateral', 'cSDH', 'into', 'an', 'intervention', 'group', '(', 'with', 'burr', '-', 'hole', 'plates', ')', 'or', 'into', 'a', 'control', 'group', '(', 'without', 'burr', '-', 'hole', 'plates', ')', '.', '\\n\\n', 'The', 'primary', 'end', 'result', 'of', 'the', 'study', 'is', 'the', 'patient', \"'s\", 'reported', 'satisfaction', 'with', 'the', 'aesthetic', 'outcome', 'of', 'the', 'surgical', 'scar', '.', 'Secondary', 'results', 'are', 'pain', ',', 'functionality', ',', 'neurological', 'status', ',', 'health', '-', 'related', 'quality', 'of', 'life', ',', 'residual', 'hematoma', 'volume', ',', 'and', 'complications', '(', 'according', 'to', 'Clavien', '-', 'Dindo', 'scale', ';', 'especially', 're', '-', 'operation', 'rate', 'for', 'recurring', 'cSDH', 'and', 'infections', ')', '.', '\\n\\n', 'The', 'study', 'corresponds', 'to', 'a', 'modern', 'approach', ',', 'since', 'today', \"'s\", 'patients', 'not', 'only', 'expect', 'favorable', 'treatment', 'results', 'for', 'their', 'disease', ',', 'but', 'the', 'therapy', 'should', 'also', 'avoid', 'permanent', 'undesired', 'side', '-', 'effects', ',', 'if', 'possible', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 53,
                "end": 78,
                "text": "Chronic Subdural hemAtoma",
                "type": "CONDITION"
            },
            {
                "start": 82,
                "end": 103,
                "text": "buRr Hole Trepanation",
                "type": "CONDITION"
            },
            {
                "start": 206,
                "end": 248,
                "text": "frontal and parietal burr-hole trepanation",
                "type": "CONDITION"
            },
            {
                "start": 270,
                "end": 295,
                "text": "chronic subdural hematoma",
                "type": "CONDITION"
            },
            {
                "start": 297,
                "end": 301,
                "text": "cSDH",
                "type": "CONDITION"
            },
            {
                "start": 347,
                "end": 355,
                "text": "hematoma",
                "type": "CONDITION"
            },
            {
                "start": 536,
                "end": 547,
                "text": "trepanation",
                "type": "CONDITION"
            },
            {
                "start": 951,
                "end": 985,
                "text": "permeable titanium burr-hole plate",
                "type": "OTHER"
            },
            {
                "start": 1362,
                "end": 1421,
                "text": "burr-hole plates on both the frontal and parietal burr-hole",
                "type": "OTHER"
            },
            {
                "start": 1440,
                "end": 1461,
                "text": "burr-hole trepanation",
                "type": "CONDITION"
            },
            {
                "start": 1483,
                "end": 1487,
                "text": "cSDH",
                "type": "CONDITION"
            },
            {
                "start": 1858,
                "end": 1880,
                "text": "uni- or bilateral cSDH",
                "type": "CONDITION"
            },
            {
                "start": 1914,
                "end": 1930,
                "text": "burr-hole plates",
                "type": "OTHER"
            },
            {
                "start": 1957,
                "end": 1981,
                "text": "without burr-hole plates",
                "type": "CONTROL"
            },
            {
                "start": 2214,
                "end": 2222,
                "text": "hematoma",
                "type": "CONDITION"
            },
            {
                "start": 2327,
                "end": 2331,
                "text": "cSDH",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03311711",
        "text": "Preparation for End-of-Life Decision Making in Mild Dementia | The proposed study will adapt and pilot test an efficacious advance care planning interventions, Sharing Patient's Illness Representations to Increase Trust (SPIRIT), with patients with mild dementia and their surrogates to promote open, honest discussions while such discussions about end-of-life care are possible. Patient and surrogate decision maker dyads will participate in a single SPIRIT session and will then have a follow up phone call 2-3 days later. One year after the SPIRIT session some surrogates will be contacted to provide additional feedback about the intervention.",
        "tokens": "['Preparation', 'for', 'End', '-', 'of', '-', 'Life', 'Decision', 'Making', 'in', 'Mild', 'Dementia', '|', 'The', 'proposed', 'study', 'will', 'adapt', 'and', 'pilot', 'test', 'an', 'efficacious', 'advance', 'care', 'planning', 'interventions', ',', 'Sharing', 'Patient', \"'s\", 'Illness', 'Representations', 'to', 'Increase', 'Trust', '(', 'SPIRIT', ')', ',', 'with', 'patients', 'with', 'mild', 'dementia', 'and', 'their', 'surrogates', 'to', 'promote', 'open', ',', 'honest', 'discussions', 'while', 'such', 'discussions', 'about', 'end', '-', 'of', '-', 'life', 'care', 'are', 'possible', '.', 'Patient', 'and', 'surrogate', 'decision', 'maker', 'dyads', 'will', 'participate', 'in', 'a', 'single', 'SPIRIT', 'session', 'and', 'will', 'then', 'have', 'a', 'follow', 'up', 'phone', 'call', '2', '-', '3', 'days', 'later', '.', 'One', 'year', 'after', 'the', 'SPIRIT', 'session', 'some', 'surrogates', 'will', 'be', 'contacted', 'to', 'provide', 'additional', 'feedback', 'about', 'the', 'intervention', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 47,
                "end": 60,
                "text": "Mild Dementia",
                "type": "CONDITION"
            },
            {
                "start": 160,
                "end": 219,
                "text": "Sharing Patient's Illness Representations to Increase Trust",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 221,
                "end": 227,
                "text": "SPIRIT",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 249,
                "end": 262,
                "text": "mild dementia",
                "type": "CONDITION"
            },
            {
                "start": 452,
                "end": 458,
                "text": "SPIRIT",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 544,
                "end": 550,
                "text": "SPIRIT",
                "type": "BEHAVIOURAL"
            }
        ]
    },
    {
        "nctid": "NCT04740060",
        "text": "Major Research Instrumentation Program: Development of an Innovative Instrument on Robot-Aided Virtual Rehabilitation for Intelligent Physical Training of Individuals With Disabilities (iRAPID) | Investigate development of an Innovative Instrument on Robot-Aided and Virtual Reality Rehabilitation for Intelligent Physical Training (i.e. gait and stepping) of Individuals post-stroke.",
        "tokens": "['Major', 'Research', 'Instrumentation', 'Program', ':', 'Development', 'of', 'an', 'Innovative', 'Instrument', 'on', 'Robot', '-', 'Aided', 'Virtual', 'Rehabilitation', 'for', 'Intelligent', 'Physical', 'Training', 'of', 'Individuals', 'With', 'Disabilities', '(', 'iRAPID', ')', '|', 'Investigate', 'development', 'of', 'an', 'Innovative', 'Instrument', 'on', 'Robot', '-', 'Aided', 'and', 'Virtual', 'Reality', 'Rehabilitation', 'for', 'Intelligent', 'Physical', 'Training', '(', 'i.e.', 'gait', 'and', 'stepping', ')', 'of', 'Individuals', 'post', '-', 'stroke', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 83,
                "end": 117,
                "text": "Robot-Aided Virtual Rehabilitation",
                "type": "PHYSICAL"
            },
            {
                "start": 122,
                "end": 151,
                "text": "Intelligent Physical Training",
                "type": "PHYSICAL"
            },
            {
                "start": 251,
                "end": 297,
                "text": "Robot-Aided and Virtual Reality Rehabilitation",
                "type": "PHYSICAL"
            },
            {
                "start": 302,
                "end": 331,
                "text": "Intelligent Physical Training",
                "type": "PHYSICAL"
            },
            {
                "start": 372,
                "end": 383,
                "text": "post-stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02687633",
        "text": "Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex | The investigators are running an intervention study for young children with Tuberous Sclerosis Complex (TSC). The study will include free play-based behavioral intervention that may improve social and communication skills in children with TSC. Eligible families will have a child in the age range of 12-36 months, with a diagnosis of TSC. A parent must also be available to attend the weekly intervention sessions at UCLA.\n\nThe intervention will focus on teaching caregivers skills to improve the social and communication outcomes of their children. The content of the intervention will be individually tailored to the child's developmental level. The intervention involves pre-assessments, an intervention period of daily 60 minute sessions for 10 days, followed by weekly 60 minute sessions for 10 weeks, and post-assessments. The classroom can have up to 3 parent-child dyad and the curriculum focuses on improving social-communication and play skills.",
        "tokens": "['Early', 'Behavioral', 'Intervention', 'to', 'Improve', 'Social', 'Communication', 'Function', 'in', 'Infants', 'With', 'Tuberous', 'Sclerosis', 'Complex', '|', 'The', 'investigators', 'are', 'running', 'an', 'intervention', 'study', 'for', 'young', 'children', 'with', 'Tuberous', 'Sclerosis', 'Complex', '(', 'TSC', ')', '.', 'The', 'study', 'will', 'include', 'free', 'play', '-', 'based', 'behavioral', 'intervention', 'that', 'may', 'improve', 'social', 'and', 'communication', 'skills', 'in', 'children', 'with', 'TSC', '.', 'Eligible', 'families', 'will', 'have', 'a', 'child', 'in', 'the', 'age', 'range', 'of', '12', '-', '36', 'months', ',', 'with', 'a', 'diagnosis', 'of', 'TSC', '.', 'A', 'parent', 'must', 'also', 'be', 'available', 'to', 'attend', 'the', 'weekly', 'intervention', 'sessions', 'at', 'UCLA', '.', '\\n\\n', 'The', 'intervention', 'will', 'focus', 'on', 'teaching', 'caregivers', 'skills', 'to', 'improve', 'the', 'social', 'and', 'communication', 'outcomes', 'of', 'their', 'children', '.', 'The', 'content', 'of', 'the', 'intervention', 'will', 'be', 'individually', 'tailored', 'to', 'the', 'child', \"'s\", 'developmental', 'level', '.', 'The', 'intervention', 'involves', 'pre', '-', 'assessments', ',', 'an', 'intervention', 'period', 'of', 'daily', '60', 'minute', 'sessions', 'for', '10', 'days', ',', 'followed', 'by', 'weekly', '60', 'minute', 'sessions', 'for', '10', 'weeks', ',', 'and', 'post', '-', 'assessments', '.', 'The', 'classroom', 'can', 'have', 'up', 'to', '3', 'parent', '-', 'child', 'dyad', 'and', 'the', 'curriculum', 'focuses', 'on', 'improving', 'social', '-', 'communication', 'and', 'play', 'skills', '.']",
        "token_bio_labels": "['B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 29,
                "text": "Early Behavioral Intervention",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 87,
                "end": 113,
                "text": "Tuberous Sclerosis Complex",
                "type": "CONDITION"
            },
            {
                "start": 192,
                "end": 218,
                "text": "Tuberous Sclerosis Complex",
                "type": "CONDITION"
            },
            {
                "start": 220,
                "end": 223,
                "text": "TSC",
                "type": "CONDITION"
            },
            {
                "start": 249,
                "end": 288,
                "text": "free play-based behavioral intervention",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 355,
                "end": 358,
                "text": "TSC",
                "type": "CONDITION"
            },
            {
                "start": 450,
                "end": 453,
                "text": "TSC",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04106154",
        "text": "Impacting Children's Physical and Mental Health Through Kinesiology Support in Clinical Care | Over the past four decades, it has become clear that childhood physical activity carries with it a myriad of beneficial effects. It is closely linked to quality of life and the recognized benefits include, but are not limited to, optimal growth and development, a healthier self-concept, enhanced peer socialization, and decreased anxiety and depression. Long term, an active lifestyle decreases the risk of many important physical and mental morbidities. Thus, the observation that children living with medical conditions and disabilities (MC&D) today, although surviving longer thanks to advances in medical care, are much less active than their peers is a matter of significant concern. Research indicates that the 350,000 Ontario children with MC&D have lower levels of physical activity, higher screen time and more frequent sleep problems.\n\nWhile the reasons underlying this reality are complex, previous research has identified a substantial subset of children who are motivated to be active but lack the confidence to do so. Fear of pain, concern for MC&D exacerbation and a lack of confidence in individual physical movement capacity contribute to their hesitation. Clinical experience suggests that these children represent 50% to 70% of inactive patients. Research indicates that being motivated to make a change and having the confidence that the desired change can be achieved are the essential precursors upon which successful behaviour change initiatives are built. This randomized, controlled trial will explore whether group sessions with a Registered Kinesiologist lead to a direct bolstering of physical activity confidence, and in turn to increased and sustained physical activity in these children. Such an approach holds the promise of a nonpharmacologic, low cost and accessible means of enhancing health that shall be met with a high level of patient and family support while bringing a significant societal and medical return on investment.",
        "tokens": "['Impacting', 'Children', \"'s\", 'Physical', 'and', 'Mental', 'Health', 'Through', 'Kinesiology', 'Support', 'in', 'Clinical', 'Care', '|', 'Over', 'the', 'past', 'four', 'decades', ',', 'it', 'has', 'become', 'clear', 'that', 'childhood', 'physical', 'activity', 'carries', 'with', 'it', 'a', 'myriad', 'of', 'beneficial', 'effects', '.', 'It', 'is', 'closely', 'linked', 'to', 'quality', 'of', 'life', 'and', 'the', 'recognized', 'benefits', 'include', ',', 'but', 'are', 'not', 'limited', 'to', ',', 'optimal', 'growth', 'and', 'development', ',', 'a', 'healthier', 'self', '-', 'concept', ',', 'enhanced', 'peer', 'socialization', ',', 'and', 'decreased', 'anxiety', 'and', 'depression', '.', 'Long', 'term', ',', 'an', 'active', 'lifestyle', 'decreases', 'the', 'risk', 'of', 'many', 'important', 'physical', 'and', 'mental', 'morbidities', '.', 'Thus', ',', 'the', 'observation', 'that', 'children', 'living', 'with', 'medical', 'conditions', 'and', 'disabilities', '(', 'MC&D', ')', 'today', ',', 'although', 'surviving', 'longer', 'thanks', 'to', 'advances', 'in', 'medical', 'care', ',', 'are', 'much', 'less', 'active', 'than', 'their', 'peers', 'is', 'a', 'matter', 'of', 'significant', 'concern', '.', 'Research', 'indicates', 'that', 'the', '350,000', 'Ontario', 'children', 'with', 'MC&D', 'have', 'lower', 'levels', 'of', 'physical', 'activity', ',', 'higher', 'screen', 'time', 'and', 'more', 'frequent', 'sleep', 'problems', '.', '\\n\\n', 'While', 'the', 'reasons', 'underlying', 'this', 'reality', 'are', 'complex', ',', 'previous', 'research', 'has', 'identified', 'a', 'substantial', 'subset', 'of', 'children', 'who', 'are', 'motivated', 'to', 'be', 'active', 'but', 'lack', 'the', 'confidence', 'to', 'do', 'so', '.', 'Fear', 'of', 'pain', ',', 'concern', 'for', 'MC&D', 'exacerbation', 'and', 'a', 'lack', 'of', 'confidence', 'in', 'individual', 'physical', 'movement', 'capacity', 'contribute', 'to', 'their', 'hesitation', '.', 'Clinical', 'experience', 'suggests', 'that', 'these', 'children', 'represent', '50', '%', 'to', '70', '%', 'of', 'inactive', 'patients', '.', 'Research', 'indicates', 'that', 'being', 'motivated', 'to', 'make', 'a', 'change', 'and', 'having', 'the', 'confidence', 'that', 'the', 'desired', 'change', 'can', 'be', 'achieved', 'are', 'the', 'essential', 'precursors', 'upon', 'which', 'successful', 'behaviour', 'change', 'initiatives', 'are', 'built', '.', 'This', 'randomized', ',', 'controlled', 'trial', 'will', 'explore', 'whether', 'group', 'sessions', 'with', 'a', 'Registered', 'Kinesiologist', 'lead', 'to', 'a', 'direct', 'bolstering', 'of', 'physical', 'activity', 'confidence', ',', 'and', 'in', 'turn', 'to', 'increased', 'and', 'sustained', 'physical', 'activity', 'in', 'these', 'children', '.', 'Such', 'an', 'approach', 'holds', 'the', 'promise', 'of', 'a', 'nonpharmacologic', ',', 'low', 'cost', 'and', 'accessible', 'means', 'of', 'enhancing', 'health', 'that', 'shall', 'be', 'met', 'with', 'a', 'high', 'level', 'of', 'patient', 'and', 'family', 'support', 'while', 'bringing', 'a', 'significant', 'societal', 'and', 'medical', 'return', 'on', 'investment', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 56,
                "end": 75,
                "text": "Kinesiology Support",
                "type": "PHYSICAL"
            },
            {
                "start": 1631,
                "end": 1677,
                "text": "group sessions with a Registered Kinesiologist",
                "type": "PHYSICAL"
            }
        ]
    },
    {
        "nctid": "NCT02350127",
        "text": "Preventing Loss of Independence Through Exercise (PLIE) in Persons With Dementia | Nearly 1 in 10 older Veterans have dementia, which is a devastating condition that leads to a progressive loss of independence and functional status. Currently available dementia medications do not alter the disease course. Therefore, it is critically important to identify effective strategies for helping older Veterans living with dementia to enhance their functional status and quality of life. The investigators have developed a novel, integrative group movement program called Preventing Loss of Independence through Exercise (PLIE) that incorporates elements from Eastern and Western exercise modalities and is designed to build and maintain the capacity to perform basic functional movements while increasing mindful body awareness and enhancing social connection. Pilot study results suggested that PLIE is associated with meaningful improvements in physical function, cognitive function and quality of life as well as reduced caregiver burden. The goal of the current study is to perform a full-scale randomized, controlled trial to test the efficacy of PLIE in older Veterans with dementia.",
        "tokens": "['Preventing', 'Loss', 'of', 'Independence', 'Through', 'Exercise', '(', 'PLIE', ')', 'in', 'Persons', 'With', 'Dementia', '|', 'Nearly', '1', 'in', '10', 'older', 'Veterans', 'have', 'dementia', ',', 'which', 'is', 'a', 'devastating', 'condition', 'that', 'leads', 'to', 'a', 'progressive', 'loss', 'of', 'independence', 'and', 'functional', 'status', '.', 'Currently', 'available', 'dementia', 'medications', 'do', 'not', 'alter', 'the', 'disease', 'course', '.', 'Therefore', ',', 'it', 'is', 'critically', 'important', 'to', 'identify', 'effective', 'strategies', 'for', 'helping', 'older', 'Veterans', 'living', 'with', 'dementia', 'to', 'enhance', 'their', 'functional', 'status', 'and', 'quality', 'of', 'life', '.', 'The', 'investigators', 'have', 'developed', 'a', 'novel', ',', 'integrative', 'group', 'movement', 'program', 'called', 'Preventing', 'Loss', 'of', 'Independence', 'through', 'Exercise', '(', 'PLIE', ')', 'that', 'incorporates', 'elements', 'from', 'Eastern', 'and', 'Western', 'exercise', 'modalities', 'and', 'is', 'designed', 'to', 'build', 'and', 'maintain', 'the', 'capacity', 'to', 'perform', 'basic', 'functional', 'movements', 'while', 'increasing', 'mindful', 'body', 'awareness', 'and', 'enhancing', 'social', 'connection', '.', 'Pilot', 'study', 'results', 'suggested', 'that', 'PLIE', 'is', 'associated', 'with', 'meaningful', 'improvements', 'in', 'physical', 'function', ',', 'cognitive', 'function', 'and', 'quality', 'of', 'life', 'as', 'well', 'as', 'reduced', 'caregiver', 'burden', '.', 'The', 'goal', 'of', 'the', 'current', 'study', 'is', 'to', 'perform', 'a', 'full', '-', 'scale', 'randomized', ',', 'controlled', 'trial', 'to', 'test', 'the', 'efficacy', 'of', 'PLIE', 'in', 'older', 'Veterans', 'with', 'dementia', '.']",
        "token_bio_labels": "['B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 48,
                "text": "Preventing Loss of Independence Through Exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 50,
                "end": 54,
                "text": "PLIE",
                "type": "PHYSICAL"
            },
            {
                "start": 72,
                "end": 80,
                "text": "Dementia",
                "type": "CONDITION"
            },
            {
                "start": 118,
                "end": 126,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 253,
                "end": 261,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 417,
                "end": 425,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 524,
                "end": 558,
                "text": "integrative group movement program",
                "type": "PHYSICAL"
            },
            {
                "start": 566,
                "end": 614,
                "text": "Preventing Loss of Independence through Exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 616,
                "end": 620,
                "text": "PLIE",
                "type": "PHYSICAL"
            },
            {
                "start": 891,
                "end": 895,
                "text": "PLIE",
                "type": "PHYSICAL"
            },
            {
                "start": 1147,
                "end": 1151,
                "text": "PLIE",
                "type": "PHYSICAL"
            },
            {
                "start": 1175,
                "end": 1183,
                "text": "dementia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03124147",
        "text": "Optimizing Transcranial Direct Current Stimulation for Motor Recovery From Severe Post-stroke Hemiparesis | This study will compare the effectiveness of different polarities of transcranial direct current stimulation paired with intensive motor training in recovery of upper extremity function in individuals with severe post-stroke hemiparesis. The hypothesis is that more severely impaired individuals will derive greater benefit from anodal stimulation of the ipsilesional hemisphere or cathodal stimulation of the contralesional hemisphere than dual stimulation (anodal applied to the ipsilesional hemisphere and cathodal applied to the contralesional hemisphere.)",
        "tokens": "['Optimizing', 'Transcranial', 'Direct', 'Current', 'Stimulation', 'for', 'Motor', 'Recovery', 'From', 'Severe', 'Post', '-', 'stroke', 'Hemiparesis', '|', 'This', 'study', 'will', 'compare', 'the', 'effectiveness', 'of', 'different', 'polarities', 'of', 'transcranial', 'direct', 'current', 'stimulation', 'paired', 'with', 'intensive', 'motor', 'training', 'in', 'recovery', 'of', 'upper', 'extremity', 'function', 'in', 'individuals', 'with', 'severe', 'post', '-', 'stroke', 'hemiparesis', '.', 'The', 'hypothesis', 'is', 'that', 'more', 'severely', 'impaired', 'individuals', 'will', 'derive', 'greater', 'benefit', 'from', 'anodal', 'stimulation', 'of', 'the', 'ipsilesional', 'hemisphere', 'or', 'cathodal', 'stimulation', 'of', 'the', 'contralesional', 'hemisphere', 'than', 'dual', 'stimulation', '(', 'anodal', 'applied', 'to', 'the', 'ipsilesional', 'hemisphere', 'and', 'cathodal', 'applied', 'to', 'the', 'contralesional', 'hemisphere', '.', ')']",
        "token_bio_labels": "['O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 11,
                "end": 50,
                "text": "Transcranial Direct Current Stimulation",
                "type": "OTHER"
            },
            {
                "start": 75,
                "end": 105,
                "text": "Severe Post-stroke Hemiparesis",
                "type": "CONDITION"
            },
            {
                "start": 177,
                "end": 216,
                "text": "transcranial direct current stimulation",
                "type": "OTHER"
            },
            {
                "start": 229,
                "end": 253,
                "text": "intensive motor training",
                "type": "PHYSICAL"
            },
            {
                "start": 314,
                "end": 344,
                "text": "severe post-stroke hemiparesis",
                "type": "CONDITION"
            },
            {
                "start": 437,
                "end": 486,
                "text": "anodal stimulation of the ipsilesional hemisphere",
                "type": "OTHER"
            },
            {
                "start": 490,
                "end": 543,
                "text": "cathodal stimulation of the contralesional hemisphere",
                "type": "OTHER"
            },
            {
                "start": 549,
                "end": 565,
                "text": "dual stimulation",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT01829009",
        "text": "Resistance Exercise Effect on Physical Performance and Functional Status in Sarcopenic Older Women | Aging is characterized by a progressive loss of multiple physical and cognitive abilities. From these changes, the most important one is the loss of muscle mass, which has been called \"sarcopenia\". Resistance exercise is a therapeutic approach for sarcopenia, nevertheless there is no universal consensus. Therefore, this research is interested in determining the effect of a resistance exercise program on physical performance and/or functional status in sarcopenic older women. The main study hypothesis is that a program of resistance exercise will improve physical performance and functional status in sarcopenic older women compared against general recommendations.\n\nThis is a single-blind, controlled clinical trial, including women> 70 years, living in the community with sarcopenia. Those who agree to participate, will be randomly assigned to one of the following groups:\n\nResistance Exercise Group\nGeneral Recommendations Group (control) The study will last 24 weeks, with 4 measurements performed at baseline, week 6, 12 and 24. Multilevel models (random effects) will be constructed for the comparison between the two groups. Tests will be conducted with a P=0.05 and confidence intervals at 95%. This protocol has been approved by the local ethics committee.",
        "tokens": "['Resistance', 'Exercise', 'Effect', 'on', 'Physical', 'Performance', 'and', 'Functional', 'Status', 'in', 'Sarcopenic', 'Older', 'Women', '|', 'Aging', 'is', 'characterized', 'by', 'a', 'progressive', 'loss', 'of', 'multiple', 'physical', 'and', 'cognitive', 'abilities', '.', 'From', 'these', 'changes', ',', 'the', 'most', 'important', 'one', 'is', 'the', 'loss', 'of', 'muscle', 'mass', ',', 'which', 'has', 'been', 'called', '\"', 'sarcopenia', '\"', '.', 'Resistance', 'exercise', 'is', 'a', 'therapeutic', 'approach', 'for', 'sarcopenia', ',', 'nevertheless', 'there', 'is', 'no', 'universal', 'consensus', '.', 'Therefore', ',', 'this', 'research', 'is', 'interested', 'in', 'determining', 'the', 'effect', 'of', 'a', 'resistance', 'exercise', 'program', 'on', 'physical', 'performance', 'and/or', 'functional', 'status', 'in', 'sarcopenic', 'older', 'women', '.', 'The', 'main', 'study', 'hypothesis', 'is', 'that', 'a', 'program', 'of', 'resistance', 'exercise', 'will', 'improve', 'physical', 'performance', 'and', 'functional', 'status', 'in', 'sarcopenic', 'older', 'women', 'compared', 'against', 'general', 'recommendations', '.', '\\n\\n', 'This', 'is', 'a', 'single', '-', 'blind', ',', 'controlled', 'clinical', 'trial', ',', 'including', 'women', '>', '70', 'years', ',', 'living', 'in', 'the', 'community', 'with', 'sarcopenia', '.', 'Those', 'who', 'agree', 'to', 'participate', ',', 'will', 'be', 'randomly', 'assigned', 'to', 'one', 'of', 'the', 'following', 'groups', ':', '\\n\\n', 'Resistance', 'Exercise', 'Group', '\\n', 'General', 'Recommendations', 'Group', '(', 'control', ')', 'The', 'study', 'will', 'last', '24', 'weeks', ',', 'with', '4', 'measurements', 'performed', 'at', 'baseline', ',', 'week', '6', ',', '12', 'and', '24', '.', 'Multilevel', 'models', '(', 'random', 'effects', ')', 'will', 'be', 'constructed', 'for', 'the', 'comparison', 'between', 'the', 'two', 'groups', '.', 'Tests', 'will', 'be', 'conducted', 'with', 'a', 'P=0.05', 'and', 'confidence', 'intervals', 'at', '95', '%', '.', 'This', 'protocol', 'has', 'been', 'approved', 'by', 'the', 'local', 'ethics', 'committee', '.']",
        "token_bio_labels": "['B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 19,
                "text": "Resistance Exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 76,
                "end": 86,
                "text": "Sarcopenic",
                "type": "CONDITION"
            },
            {
                "start": 286,
                "end": 296,
                "text": "sarcopenia",
                "type": "CONDITION"
            },
            {
                "start": 299,
                "end": 318,
                "text": "Resistance exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 349,
                "end": 359,
                "text": "sarcopenia",
                "type": "CONDITION"
            },
            {
                "start": 477,
                "end": 504,
                "text": "resistance exercise program",
                "type": "PHYSICAL"
            },
            {
                "start": 557,
                "end": 567,
                "text": "sarcopenic",
                "type": "CONDITION"
            },
            {
                "start": 617,
                "end": 647,
                "text": "program of resistance exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 707,
                "end": 717,
                "text": "sarcopenic",
                "type": "CONDITION"
            },
            {
                "start": 747,
                "end": 770,
                "text": "general recommendations",
                "type": "CONTROL"
            },
            {
                "start": 880,
                "end": 890,
                "text": "sarcopenia",
                "type": "CONDITION"
            },
            {
                "start": 983,
                "end": 1002,
                "text": "Resistance Exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 1009,
                "end": 1032,
                "text": "General Recommendations",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT01881360",
        "text": "Comparison Between a Gluten-free Diet and a Hypocaloric Diet for the Treatment of Patients With Fibromyalgia and Celiac-type Symptoms | Fibromyalgia patients frequently suffer from symptoms similar to those of adult celiac disease, raising the possibility that some fibromyalgia patients experience oligosymptomatic celiac disease or non-celiac gluten intolerance. The objective of this study is to compare the effect of a gluten-free diet with a hypocaloric diet in patients with fibromyalgia and celiac-type symptoms.",
        "tokens": "['Comparison', 'Between', 'a', 'Gluten', '-', 'free', 'Diet', 'and', 'a', 'Hypocaloric', 'Diet', 'for', 'the', 'Treatment', 'of', 'Patients', 'With', 'Fibromyalgia', 'and', 'Celiac', '-', 'type', 'Symptoms', '|', 'Fibromyalgia', 'patients', 'frequently', 'suffer', 'from', 'symptoms', 'similar', 'to', 'those', 'of', 'adult', 'celiac', 'disease', ',', 'raising', 'the', 'possibility', 'that', 'some', 'fibromyalgia', 'patients', 'experience', 'oligosymptomatic', 'celiac', 'disease', 'or', 'non', '-', 'celiac', 'gluten', 'intolerance', '.', 'The', 'objective', 'of', 'this', 'study', 'is', 'to', 'compare', 'the', 'effect', 'of', 'a', 'gluten', '-', 'free', 'diet', 'with', 'a', 'hypocaloric', 'diet', 'in', 'patients', 'with', 'fibromyalgia', 'and', 'celiac', '-', 'type', 'symptoms', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 21,
                "end": 37,
                "text": "Gluten-free Diet",
                "type": "OTHER"
            },
            {
                "start": 44,
                "end": 60,
                "text": "Hypocaloric Diet",
                "type": "OTHER"
            },
            {
                "start": 96,
                "end": 108,
                "text": "Fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 113,
                "end": 133,
                "text": "Celiac-type Symptoms",
                "type": "CONDITION"
            },
            {
                "start": 136,
                "end": 148,
                "text": "Fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 216,
                "end": 230,
                "text": "celiac disease",
                "type": "CONDITION"
            },
            {
                "start": 266,
                "end": 278,
                "text": "fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 316,
                "end": 330,
                "text": "celiac disease",
                "type": "CONDITION"
            },
            {
                "start": 345,
                "end": 363,
                "text": "gluten intolerance",
                "type": "CONDITION"
            },
            {
                "start": 423,
                "end": 439,
                "text": "gluten-free diet",
                "type": "OTHER"
            },
            {
                "start": 447,
                "end": 463,
                "text": "hypocaloric diet",
                "type": "OTHER"
            },
            {
                "start": 481,
                "end": 493,
                "text": "fibromyalgia",
                "type": "CONDITION"
            },
            {
                "start": 498,
                "end": 518,
                "text": "celiac-type symptoms",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04092790",
        "text": "The Identification and Prevention of Sarcopenia in Older Patients in the Acute Hospital Setting | This study will assess whether the use of technology using the Virtual Gate Device (VGD) will prevent or minimize the development of hospital acquired Sarcopenia resulting from Immobilization.",
        "tokens": "['The', 'Identification', 'and', 'Prevention', 'of', 'Sarcopenia', 'in', 'Older', 'Patients', 'in', 'the', 'Acute', 'Hospital', 'Setting', '|', 'This', 'study', 'will', 'assess', 'whether', 'the', 'use', 'of', 'technology', 'using', 'the', 'Virtual', 'Gate', 'Device', '(', 'VGD', ')', 'will', 'prevent', 'or', 'minimize', 'the', 'development', 'of', 'hospital', 'acquired', 'Sarcopenia', 'resulting', 'from', 'Immobilization', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 37,
                "end": 47,
                "text": "Sarcopenia",
                "type": "CONDITION"
            },
            {
                "start": 161,
                "end": 180,
                "text": "Virtual Gate Device",
                "type": "OTHER"
            },
            {
                "start": 182,
                "end": 185,
                "text": "VGD",
                "type": "OTHER"
            },
            {
                "start": 249,
                "end": 259,
                "text": "Sarcopenia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00004659",
        "text": "Phase II Randomized Study of Stereotactic Radiosurgery Plus Fractionated Whole-Brain Radiotherapy Vs Fractionated Whole-Brain Radiotherapy Alone for Multiple Primary or Metastatic Brain Tumors | OBJECTIVES: I. Evaluate whether stereotactic radiosurgery provides local control at multiple sites in patients with primary or metastatic brain tumors, controlled systemic disease, and preserved neurologic function.\n\nII. Examine survival, clinical outcome, and local tumor imaging response in these patients.",
        "tokens": "['Phase', 'II', 'Randomized', 'Study', 'of', 'Stereotactic', 'Radiosurgery', 'Plus', 'Fractionated', 'Whole', '-', 'Brain', 'Radiotherapy', 'Vs', 'Fractionated', 'Whole', '-', 'Brain', 'Radiotherapy', 'Alone', 'for', 'Multiple', 'Primary', 'or', 'Metastatic', 'Brain', 'Tumors', '|', 'OBJECTIVES', ':', 'I.', 'Evaluate', 'whether', 'stereotactic', 'radiosurgery', 'provides', 'local', 'control', 'at', 'multiple', 'sites', 'in', 'patients', 'with', 'primary', 'or', 'metastatic', 'brain', 'tumors', ',', 'controlled', 'systemic', 'disease', ',', 'and', 'preserved', 'neurologic', 'function', '.', '\\n\\n', 'II', '.', 'Examine', 'survival', ',', 'clinical', 'outcome', ',', 'and', 'local', 'tumor', 'imaging', 'response', 'in', 'these', 'patients', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'B-RADIO', 'I-RADIO', 'I-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 29,
                "end": 54,
                "text": "Stereotactic Radiosurgery",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 60,
                "end": 97,
                "text": "Fractionated Whole-Brain Radiotherapy",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 101,
                "end": 144,
                "text": "Fractionated Whole-Brain Radiotherapy Alone",
                "type": "CONTROL"
            },
            {
                "start": 149,
                "end": 192,
                "text": "Multiple Primary or Metastatic Brain Tumors",
                "type": "CONDITION"
            },
            {
                "start": 227,
                "end": 252,
                "text": "stereotactic radiosurgery",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 311,
                "end": 345,
                "text": "primary or metastatic brain tumors",
                "type": "CONDITION"
            },
            {
                "start": 462,
                "end": 467,
                "text": "tumor",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02127294",
        "text": "Effectiveness and Safety of Transcatheter Patent Foramen Ovale Closure for Migraine | The purpose of the study is to evaluate effectiveness and safety of transcatheter patent foramen ovale closure for migraine.",
        "tokens": "['Effectiveness', 'and', 'Safety', 'of', 'Transcatheter', 'Patent', 'Foramen', 'Ovale', 'Closure', 'for', 'Migraine', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'effectiveness', 'and', 'safety', 'of', 'transcatheter', 'patent', 'foramen', 'ovale', 'closure', 'for', 'migraine', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 28,
                "end": 70,
                "text": "Transcatheter Patent Foramen Ovale Closure",
                "type": "SURGICAL"
            },
            {
                "start": 75,
                "end": 83,
                "text": "Migraine",
                "type": "CONDITION"
            },
            {
                "start": 154,
                "end": 196,
                "text": "transcatheter patent foramen ovale closure",
                "type": "SURGICAL"
            },
            {
                "start": 201,
                "end": 209,
                "text": "migraine",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03363763",
        "text": "Phase 2 Multi Center Prospective Rand. Double Blind Placebo Cont. Parallel Design Study to Evaluate Safety & Efficacy of Topical Sirolimus for Cutaneous Angiofibromas in Subjects W/ Tuberous Sclerosis Complex Followed by Opt. Open Label | The objective of this study is to evaluate the safety and efficacy of sirolimus (0.2% and 0.4% formulations) and its vehicle when applied topically once daily for 12 weeks for the treatment of cutaneous angiofibromas in pediatric subjects with tuberous sclerosis complex (TSC).",
        "tokens": "['Phase', '2', 'Multi', 'Center', 'Prospective', 'Rand', '.', 'Double', 'Blind', 'Placebo', 'Cont', '.', 'Parallel', 'Design', 'Study', 'to', 'Evaluate', 'Safety', '&', 'Efficacy', 'of', 'Topical', 'Sirolimus', 'for', 'Cutaneous', 'Angiofibromas', 'in', 'Subjects', 'W/', 'Tuberous', 'Sclerosis', 'Complex', 'Followed', 'by', 'Opt', '.', 'Open', 'Label', '|', 'The', 'objective', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'safety', 'and', 'efficacy', 'of', 'sirolimus', '(', '0.2', '%', 'and', '0.4', '%', 'formulations', ')', 'and', 'its', 'vehicle', 'when', 'applied', 'topically', 'once', 'daily', 'for', '12', 'weeks', 'for', 'the', 'treatment', 'of', 'cutaneous', 'angiofibromas', 'in', 'pediatric', 'subjects', 'with', 'tuberous', 'sclerosis', 'complex', '(', 'TSC', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 129,
                "end": 138,
                "text": "Sirolimus",
                "type": "DRUG"
            },
            {
                "start": 143,
                "end": 166,
                "text": "Cutaneous Angiofibromas",
                "type": "CONDITION"
            },
            {
                "start": 182,
                "end": 208,
                "text": "Tuberous Sclerosis Complex",
                "type": "CONDITION"
            },
            {
                "start": 309,
                "end": 318,
                "text": "sirolimus",
                "type": "DRUG"
            },
            {
                "start": 432,
                "end": 455,
                "text": "cutaneous angiofibromas",
                "type": "CONDITION"
            },
            {
                "start": 483,
                "end": 509,
                "text": "tuberous sclerosis complex",
                "type": "CONDITION"
            },
            {
                "start": 511,
                "end": 514,
                "text": "TSC",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00467415",
        "text": "Multi-Center Project: Supported Speed Treadmill Training Exercise Program (SSTTEP) for Marginally Ambulatory Children With Cerebral Palsy | The investigators are studying the effects of a 12-week exercise program, consisting of either:\n\nWalking on a treadmill with partial body weight\nFunctional exercise program\n\nThe investigators would like to know the effects these two exercise programs have on the quality of life, muscle strength and control, coordination, walking, and functional movement of children with cerebral palsy who are marginal ambulators. This is a randomized control trial with subjects randomly assigned to one of the 2 groups.Subjects in both groups will be seen twice a day for two weeks at our hospital for intervention and parent training, and then participate in a 10 week home-based program. During each subject's two-week clinic-based training, a parent or caregiver is trained in all home program exercises and/or equipment usage. This person must be able to safely perform the exercise program with the child. Each subject will also need to participate in three separate 5-hour long data collection sessions scheduled over the 4 month study period.",
        "tokens": "['Multi', '-', 'Center', 'Project', ':', 'Supported', 'Speed', 'Treadmill', 'Training', 'Exercise', 'Program', '(', 'SSTTEP', ')', 'for', 'Marginally', 'Ambulatory', 'Children', 'With', 'Cerebral', 'Palsy', '|', 'The', 'investigators', 'are', 'studying', 'the', 'effects', 'of', 'a', '12', '-', 'week', 'exercise', 'program', ',', 'consisting', 'of', 'either', ':', '\\n\\n', 'Walking', 'on', 'a', 'treadmill', 'with', 'partial', 'body', 'weight', '\\n', 'Functional', 'exercise', 'program', '\\n\\n', 'The', 'investigators', 'would', 'like', 'to', 'know', 'the', 'effects', 'these', 'two', 'exercise', 'programs', 'have', 'on', 'the', 'quality', 'of', 'life', ',', 'muscle', 'strength', 'and', 'control', ',', 'coordination', ',', 'walking', ',', 'and', 'functional', 'movement', 'of', 'children', 'with', 'cerebral', 'palsy', 'who', 'are', 'marginal', 'ambulators', '.', 'This', 'is', 'a', 'randomized', 'control', 'trial', 'with', 'subjects', 'randomly', 'assigned', 'to', 'one', 'of', 'the', '2', 'groups', '.', 'Subjects', 'in', 'both', 'groups', 'will', 'be', 'seen', 'twice', 'a', 'day', 'for', 'two', 'weeks', 'at', 'our', 'hospital', 'for', 'intervention', 'and', 'parent', 'training', ',', 'and', 'then', 'participate', 'in', 'a', '10', 'week', 'home', '-', 'based', 'program', '.', 'During', 'each', 'subject', \"'s\", 'two', '-', 'week', 'clinic', '-', 'based', 'training', ',', 'a', 'parent', 'or', 'caregiver', 'is', 'trained', 'in', 'all', 'home', 'program', 'exercises', 'and/or', 'equipment', 'usage', '.', 'This', 'person', 'must', 'be', 'able', 'to', 'safely', 'perform', 'the', 'exercise', 'program', 'with', 'the', 'child', '.', 'Each', 'subject', 'will', 'also', 'need', 'to', 'participate', 'in', 'three', 'separate', '5', '-', 'hour', 'long', 'data', 'collection', 'sessions', 'scheduled', 'over', 'the', '4', 'month', 'study', 'period', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 22,
                "end": 73,
                "text": "Supported Speed Treadmill Training Exercise Program",
                "type": "PHYSICAL"
            },
            {
                "start": 75,
                "end": 81,
                "text": "SSTTEP",
                "type": "PHYSICAL"
            },
            {
                "start": 123,
                "end": 137,
                "text": "Cerebral Palsy",
                "type": "CONDITION"
            },
            {
                "start": 196,
                "end": 212,
                "text": "exercise program",
                "type": "PHYSICAL"
            },
            {
                "start": 237,
                "end": 284,
                "text": "Walking on a treadmill with partial body weight",
                "type": "PHYSICAL"
            },
            {
                "start": 285,
                "end": 312,
                "text": "Functional exercise program",
                "type": "PHYSICAL"
            },
            {
                "start": 373,
                "end": 390,
                "text": "exercise programs",
                "type": "PHYSICAL"
            },
            {
                "start": 513,
                "end": 527,
                "text": "cerebral palsy",
                "type": "CONDITION"
            },
            {
                "start": 798,
                "end": 816,
                "text": "home-based program",
                "type": "PHYSICAL"
            },
            {
                "start": 912,
                "end": 934,
                "text": "home program exercises",
                "type": "PHYSICAL"
            },
            {
                "start": 1006,
                "end": 1014,
                "text": "exercise",
                "type": "PHYSICAL"
            }
        ]
    },
    {
        "nctid": "NCT00827918",
        "text": "A Phase IIa, Randomized, Multicenter, Double-Blind, Active Comparator- and Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of MK8998 in Acutely Psychotic Patients With Schizophrenia | A study to evaluate the safety and efficacy of treatment with MK-8998 as compared to placebo and olanzapine for acutely psychotic patients with schizophrenia. The primary hypothesis is that in participants undergoing an acute psychotic episode of schizophrenia, MK-8998 6 to 8 mg twice daily is superior to placebo in the treatment of symptoms of schizophrenia as measured by the mean change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score at Week 4.",
        "tokens": "['A', 'Phase', 'IIa', ',', 'Randomized', ',', 'Multicenter', ',', 'Double', '-', 'Blind', ',', 'Active', 'Comparator-', 'and', 'Placebo', '-', 'Controlled', ',', 'Clinical', 'Trial', 'to', 'Study', 'the', 'Safety', 'and', 'Efficacy', 'of', 'MK8998', 'in', 'Acutely', 'Psychotic', 'Patients', 'With', 'Schizophrenia', '|', 'A', 'study', 'to', 'evaluate', 'the', 'safety', 'and', 'efficacy', 'of', 'treatment', 'with', 'MK-8998', 'as', 'compared', 'to', 'placebo', 'and', 'olanzapine', 'for', 'acutely', 'psychotic', 'patients', 'with', 'schizophrenia', '.', 'The', 'primary', 'hypothesis', 'is', 'that', 'in', 'participants', 'undergoing', 'an', 'acute', 'psychotic', 'episode', 'of', 'schizophrenia', ',', 'MK-8998', '6', 'to', '8', 'mg', 'twice', 'daily', 'is', 'superior', 'to', 'placebo', 'in', 'the', 'treatment', 'of', 'symptoms', 'of', 'schizophrenia', 'as', 'measured', 'by', 'the', 'mean', 'change', 'from', 'baseline', 'in', 'the', 'Positive', 'and', 'Negative', 'Syndrome', 'Scale', '(', 'PANSS', ')', 'total', 'score', 'at', 'Week', '4', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-CTRL', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 75,
                "end": 82,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 146,
                "end": 152,
                "text": "MK8998",
                "type": "DRUG"
            },
            {
                "start": 156,
                "end": 173,
                "text": "Acutely Psychotic",
                "type": "CONDITION"
            },
            {
                "start": 188,
                "end": 201,
                "text": "Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 266,
                "end": 273,
                "text": "MK-8998",
                "type": "DRUG"
            },
            {
                "start": 289,
                "end": 296,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 301,
                "end": 311,
                "text": "olanzapine",
                "type": "DRUG"
            },
            {
                "start": 316,
                "end": 333,
                "text": "acutely psychotic",
                "type": "CONDITION"
            },
            {
                "start": 348,
                "end": 361,
                "text": "schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 424,
                "end": 439,
                "text": "acute psychotic",
                "type": "CONDITION"
            },
            {
                "start": 451,
                "end": 464,
                "text": "schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 466,
                "end": 473,
                "text": "MK-8998",
                "type": "DRUG"
            },
            {
                "start": 511,
                "end": 518,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 551,
                "end": 564,
                "text": "schizophrenia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04225221",
        "text": "Ovarian Hormones, Reward Response, and Binge Eating in Bulimia Nervosa: An Experimental Design | This pilot study experimentally manipulates ovarian hormones to examine the direct impact of estrogen (E2) and progesterone (P4) on binge eating symptom burden and the behavioral reward response in women with bulimia nervosa (n=15). This is completed by taking medications that change ovarian hormone levels. This line of research could lead to the development of pharmacological interventions developed to target specific areas of the brain, brain receptors, or pathways identified to be involved in the mechanism underlying ovarian hormone change and binge eating.",
        "tokens": "['Ovarian', 'Hormones', ',', 'Reward', 'Response', ',', 'and', 'Binge', 'Eating', 'in', 'Bulimia', 'Nervosa', ':', 'An', 'Experimental', 'Design', '|', 'This', 'pilot', 'study', 'experimentally', 'manipulates', 'ovarian', 'hormones', 'to', 'examine', 'the', 'direct', 'impact', 'of', 'estrogen', '(', 'E2', ')', 'and', 'progesterone', '(', 'P4', ')', 'on', 'binge', 'eating', 'symptom', 'burden', 'and', 'the', 'behavioral', 'reward', 'response', 'in', 'women', 'with', 'bulimia', 'nervosa', '(', 'n=15', ')', '.', 'This', 'is', 'completed', 'by', 'taking', 'medications', 'that', 'change', 'ovarian', 'hormone', 'levels', '.', 'This', 'line', 'of', 'research', 'could', 'lead', 'to', 'the', 'development', 'of', 'pharmacological', 'interventions', 'developed', 'to', 'target', 'specific', 'areas', 'of', 'the', 'brain', ',', 'brain', 'receptors', ',', 'or', 'pathways', 'identified', 'to', 'be', 'involved', 'in', 'the', 'mechanism', 'underlying', 'ovarian', 'hormone', 'change', 'and', 'binge', 'eating', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 16,
                "text": "Ovarian Hormones",
                "type": "OTHER"
            },
            {
                "start": 39,
                "end": 51,
                "text": "Binge Eating",
                "type": "CONDITION"
            },
            {
                "start": 55,
                "end": 70,
                "text": "Bulimia Nervosa",
                "type": "CONDITION"
            },
            {
                "start": 141,
                "end": 157,
                "text": "ovarian hormones",
                "type": "OTHER"
            },
            {
                "start": 229,
                "end": 241,
                "text": "binge eating",
                "type": "CONDITION"
            },
            {
                "start": 306,
                "end": 321,
                "text": "bulimia nervosa",
                "type": "CONDITION"
            },
            {
                "start": 382,
                "end": 397,
                "text": "ovarian hormone",
                "type": "OTHER"
            },
            {
                "start": 623,
                "end": 638,
                "text": "ovarian hormone",
                "type": "OTHER"
            },
            {
                "start": 650,
                "end": 662,
                "text": "binge eating",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00376207",
        "text": "Decreased insulin sensitivity is and independent risk factor for stroke despite glycemic control. It is known that physical exercise increases insulin sensitivity in healthy subjects. Wether stroke patients can increase insulin sensitivity via physical exercise is not known.\n\nChronic low-grade inflammation is associated with an increased risk of stroke. Physical exercise has shown to increase IL-6 directly after exercise in untrained subjects. When fitness is increased in each subject then the peak IL-6 concentration after exercise decreases and so does the basal level of IL-6. It is not known whether stroke patients can increase physical activity level to a degree where chronic inflammation are decreased.\n\nThis study is designed to evaluate if physical exercise after stroke will increases insulin sensitivity and reduce low-grade chronic inflammation.\n\nStroke patients have been randomized to intervention with physical exercise or control in the ExStroke pilot trial and followed for 2 years. Using the study population from the ExStroke pilot trail blood samples will be obtained at the last control. Insulin sensitivity can be measured from fasting glucose and insulin using the Homeostasis Model Assessment (HOMA). Interleukin-6, TNF-alfa and CRP is measured to estimate chronic inflammation.",
        "tokens": "['Decreased', 'insulin', 'sensitivity', 'is', 'and', 'independent', 'risk', 'factor', 'for', 'stroke', 'despite', 'glycemic', 'control', '.', 'It', 'is', 'known', 'that', 'physical', 'exercise', 'increases', 'insulin', 'sensitivity', 'in', 'healthy', 'subjects', '.', 'Wether', 'stroke', 'patients', 'can', 'increase', 'insulin', 'sensitivity', 'via', 'physical', 'exercise', 'is', 'not', 'known', '.', '\\n\\n', 'Chronic', 'low', '-', 'grade', 'inflammation', 'is', 'associated', 'with', 'an', 'increased', 'risk', 'of', 'stroke', '.', 'Physical', 'exercise', 'has', 'shown', 'to', 'increase', 'IL-6', 'directly', 'after', 'exercise', 'in', 'untrained', 'subjects', '.', 'When', 'fitness', 'is', 'increased', 'in', 'each', 'subject', 'then', 'the', 'peak', 'IL-6', 'concentration', 'after', 'exercise', 'decreases', 'and', 'so', 'does', 'the', 'basal', 'level', 'of', 'IL-6', '.', 'It', 'is', 'not', 'known', 'whether', 'stroke', 'patients', 'can', 'increase', 'physical', 'activity', 'level', 'to', 'a', 'degree', 'where', 'chronic', 'inflammation', 'are', 'decreased', '.', '\\n\\n', 'This', 'study', 'is', 'designed', 'to', 'evaluate', 'if', 'physical', 'exercise', 'after', 'stroke', 'will', 'increases', 'insulin', 'sensitivity', 'and', 'reduce', 'low', '-', 'grade', 'chronic', 'inflammation', '.', '\\n\\n', 'Stroke', 'patients', 'have', 'been', 'randomized', 'to', 'intervention', 'with', 'physical', 'exercise', 'or', 'control', 'in', 'the', 'ExStroke', 'pilot', 'trial', 'and', 'followed', 'for', '2', 'years', '.', 'Using', 'the', 'study', 'population', 'from', 'the', 'ExStroke', 'pilot', 'trail', 'blood', 'samples', 'will', 'be', 'obtained', 'at', 'the', 'last', 'control', '.', 'Insulin', 'sensitivity', 'can', 'be', 'measured', 'from', 'fasting', 'glucose', 'and', 'insulin', 'using', 'the', 'Homeostasis', 'Model', 'Assessment', '(', 'HOMA', ')', '.', 'Interleukin-6', ',', 'TNF', '-', 'alfa', 'and', 'CRP', 'is', 'measured', 'to', 'estimate', 'chronic', 'inflammation', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 65,
                "end": 71,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 115,
                "end": 132,
                "text": "physical exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 191,
                "end": 197,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 244,
                "end": 261,
                "text": "physical exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 277,
                "end": 307,
                "text": "Chronic low-grade inflammation",
                "type": "CONDITION"
            },
            {
                "start": 348,
                "end": 354,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 356,
                "end": 373,
                "text": "Physical exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 609,
                "end": 615,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 680,
                "end": 700,
                "text": "chronic inflammation",
                "type": "CONDITION"
            },
            {
                "start": 755,
                "end": 772,
                "text": "physical exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 779,
                "end": 785,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 832,
                "end": 862,
                "text": "low-grade chronic inflammation",
                "type": "CONDITION"
            },
            {
                "start": 865,
                "end": 871,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 923,
                "end": 940,
                "text": "physical exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 944,
                "end": 951,
                "text": "control",
                "type": "CONTROL"
            },
            {
                "start": 1287,
                "end": 1307,
                "text": "chronic inflammation",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03530982",
        "text": "Intensive Training of Functional Priorities Reported by Adolescents With Cerebral Palsy | Adolescents with cerebral palsy (CP) present important limitations for the performance of daily living activities. The aims of the study is to evaluate the feasibility and effects of an intensive goal training protocol for adolescents with CP. He hypothesize that adolescents submitted to the studied protocol will present improvements in performance and satisfaction of prioritized functional goals.",
        "tokens": "['Intensive', 'Training', 'of', 'Functional', 'Priorities', 'Reported', 'by', 'Adolescents', 'With', 'Cerebral', 'Palsy', '|', 'Adolescents', 'with', 'cerebral', 'palsy', '(', 'CP', ')', 'present', 'important', 'limitations', 'for', 'the', 'performance', 'of', 'daily', 'living', 'activities', '.', 'The', 'aims', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'the', 'feasibility', 'and', 'effects', 'of', 'an', 'intensive', 'goal', 'training', 'protocol', 'for', 'adolescents', 'with', 'CP', '.', 'He', 'hypothesize', 'that', 'adolescents', 'submitted', 'to', 'the', 'studied', 'protocol', 'will', 'present', 'improvements', 'in', 'performance', 'and', 'satisfaction', 'of', 'prioritized', 'functional', 'goals', '.']",
        "token_bio_labels": "['B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 43,
                "text": "Intensive Training of Functional Priorities",
                "type": "PHYSICAL"
            },
            {
                "start": 73,
                "end": 87,
                "text": "Cerebral Palsy",
                "type": "CONDITION"
            },
            {
                "start": 107,
                "end": 121,
                "text": "cerebral palsy",
                "type": "CONDITION"
            },
            {
                "start": 123,
                "end": 125,
                "text": "CP",
                "type": "CONDITION"
            },
            {
                "start": 276,
                "end": 299,
                "text": "intensive goal training",
                "type": "PHYSICAL"
            },
            {
                "start": 330,
                "end": 332,
                "text": "CP",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03615521",
        "text": "Diz Osteoartritinde Farkl\u0131 Proprioseptif N\u00f6rom\u00fcsk\u00fcler Fasilitasyon Tekniklerinin, A\u011fr\u0131, Propriosepsiyon, Postural Kontrol, Kas Kuvveti, Eklem Hareket A\u00e7\u0131kl\u0131\u011f\u0131 ve Diz Fonksiyonlar\u0131 \u00dczerine Olan Etkileri | The aim of this study is to investigate the effects of 6-week physiotherapy and rehabilitation programs involving different 'Proprioceptive Neuromuscular Facilitation' (PNF) techniques in patients with knee osteoarthritis on pain, proprioception, postural control, muscle strength, range of motion and knee functions",
        "tokens": "['Diz', 'Osteoartritinde', 'Farkl\u0131', 'Proprioseptif', 'N\u00f6rom\u00fcsk\u00fcler', 'Fasilitasyon', 'Tekniklerinin', ',', 'A\u011fr\u0131', ',', 'Propriosepsiyon', ',', 'Postural', 'Kontrol', ',', 'Kas', 'Kuvveti', ',', 'Eklem', 'Hareket', 'A\u00e7\u0131kl\u0131\u011f\u0131', 've', 'Diz', 'Fonksiyonlar\u0131', '\u00dczerine', 'Olan', 'Etkileri', '|', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'investigate', 'the', 'effects', 'of', '6', '-', 'week', 'physiotherapy', 'and', 'rehabilitation', 'programs', 'involving', 'different', \"'\", 'Proprioceptive', 'Neuromuscular', 'Facilitation', \"'\", '(', 'PNF', ')', 'techniques', 'in', 'patients', 'with', 'knee', 'osteoarthritis', 'on', 'pain', ',', 'proprioception', ',', 'postural', 'control', ',', 'muscle', 'strength', ',', 'range', 'of', 'motion', 'and', 'knee', 'functions']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 266,
                "end": 307,
                "text": "physiotherapy and rehabilitation programs",
                "type": "PHYSICAL"
            },
            {
                "start": 329,
                "end": 370,
                "text": "Proprioceptive Neuromuscular Facilitation",
                "type": "PHYSICAL"
            },
            {
                "start": 373,
                "end": 376,
                "text": "PNF",
                "type": "PHYSICAL"
            },
            {
                "start": 406,
                "end": 425,
                "text": "knee osteoarthritis",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05041582",
        "text": "Combining SSRIs and TDCS to Enhance Motor Recovery After Stroke | Post-stroke motor recovery is compelling but limited. Current rehabilitation has less impacts on the plateau that spontaneous biological recovery could be expected. The advances in non-invasive neuromodulation and neurophysiological characterization of critical motor recovery period enable breaking the proportional recovery limitation. Our pilot studies demonstrated the safety and responsiveness of combing dual transcranial direct current stimulation (tDCS) and motor training in subacute stroke patients. There is also strong evidence that selective serotonin reuptake inhibitors (SSRIs) can substantially increase the effects of tDCS and improve motor function after stroke, even in the absence of depression. This proposal aims to prove the potential of combining of tDCS and the commonly used SSRI citalopram to improve response to a daily motor training intervention in acute stroke patients (Co-STARS trial).",
        "tokens": "['Combining', 'SSRIs', 'and', 'TDCS', 'to', 'Enhance', 'Motor', 'Recovery', 'After', 'Stroke', '|', 'Post', '-', 'stroke', 'motor', 'recovery', 'is', 'compelling', 'but', 'limited', '.', 'Current', 'rehabilitation', 'has', 'less', 'impacts', 'on', 'the', 'plateau', 'that', 'spontaneous', 'biological', 'recovery', 'could', 'be', 'expected', '.', 'The', 'advances', 'in', 'non', '-', 'invasive', 'neuromodulation', 'and', 'neurophysiological', 'characterization', 'of', 'critical', 'motor', 'recovery', 'period', 'enable', 'breaking', 'the', 'proportional', 'recovery', 'limitation', '.', 'Our', 'pilot', 'studies', 'demonstrated', 'the', 'safety', 'and', 'responsiveness', 'of', 'combing', 'dual', 'transcranial', 'direct', 'current', 'stimulation', '(', 'tDCS', ')', 'and', 'motor', 'training', 'in', 'subacute', 'stroke', 'patients', '.', 'There', 'is', 'also', 'strong', 'evidence', 'that', 'selective', 'serotonin', 'reuptake', 'inhibitors', '(', 'SSRIs', ')', 'can', 'substantially', 'increase', 'the', 'effects', 'of', 'tDCS', 'and', 'improve', 'motor', 'function', 'after', 'stroke', ',', 'even', 'in', 'the', 'absence', 'of', 'depression', '.', 'This', 'proposal', 'aims', 'to', 'prove', 'the', 'potential', 'of', 'combining', 'of', 'tDCS', 'and', 'the', 'commonly', 'used', 'SSRI', 'citalopram', 'to', 'improve', 'response', 'to', 'a', 'daily', 'motor', 'training', 'intervention', 'in', 'acute', 'stroke', 'patients', '(', 'Co', '-', 'STARS', 'trial', ')', '.']",
        "token_bio_labels": "['O', 'B-DRUG', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-DRUG', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 15,
                "text": "SSRIs",
                "type": "DRUG"
            },
            {
                "start": 20,
                "end": 24,
                "text": "TDCS",
                "type": "OTHER"
            },
            {
                "start": 57,
                "end": 63,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 66,
                "end": 77,
                "text": "Post-stroke",
                "type": "CONDITION"
            },
            {
                "start": 247,
                "end": 275,
                "text": "non-invasive neuromodulation",
                "type": "OTHER"
            },
            {
                "start": 476,
                "end": 520,
                "text": "dual transcranial direct current stimulation",
                "type": "OTHER"
            },
            {
                "start": 522,
                "end": 526,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 532,
                "end": 546,
                "text": "motor training",
                "type": "PHYSICAL"
            },
            {
                "start": 550,
                "end": 565,
                "text": "subacute stroke",
                "type": "CONDITION"
            },
            {
                "start": 611,
                "end": 650,
                "text": "selective serotonin reuptake inhibitors",
                "type": "DRUG"
            },
            {
                "start": 652,
                "end": 657,
                "text": "SSRIs",
                "type": "DRUG"
            },
            {
                "start": 701,
                "end": 705,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 739,
                "end": 745,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 840,
                "end": 844,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 867,
                "end": 871,
                "text": "SSRI",
                "type": "DRUG"
            },
            {
                "start": 872,
                "end": 882,
                "text": "citalopram",
                "type": "DRUG"
            },
            {
                "start": 914,
                "end": 941,
                "text": "motor training intervention",
                "type": "PHYSICAL"
            },
            {
                "start": 945,
                "end": 957,
                "text": "acute stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02253732",
        "text": "Skeletal Muscle as a Mediator of Exercise Induced Effects on Metabolism & Cognitive Function: Role for Myokines & miRNAs | The purpose of this study is to determine specific changes in muscle secretory profile (myokines, miRNA) in association with neurodegenerative disease progression and metabolic dysfunction. Next the investigators would like to determine the shift in the muscle secretory activity induced by regular exercise intervention, which the investigators think could be translated into the beneficial changes in clinical phenotypes, determined by neuroimaging, cognitive function tests and metabolic phenotyping.",
        "tokens": "['Skeletal', 'Muscle', 'as', 'a', 'Mediator', 'of', 'Exercise', 'Induced', 'Effects', 'on', 'Metabolism', '&', 'Cognitive', 'Function', ':', 'Role', 'for', 'Myokines', '&', 'miRNAs', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'specific', 'changes', 'in', 'muscle', 'secretory', 'profile', '(', 'myokines', ',', 'miRNA', ')', 'in', 'association', 'with', 'neurodegenerative', 'disease', 'progression', 'and', 'metabolic', 'dysfunction', '.', 'Next', 'the', 'investigators', 'would', 'like', 'to', 'determine', 'the', 'shift', 'in', 'the', 'muscle', 'secretory', 'activity', 'induced', 'by', 'regular', 'exercise', 'intervention', ',', 'which', 'the', 'investigators', 'think', 'could', 'be', 'translated', 'into', 'the', 'beneficial', 'changes', 'in', 'clinical', 'phenotypes', ',', 'determined', 'by', 'neuroimaging', ',', 'cognitive', 'function', 'tests', 'and', 'metabolic', 'phenotyping', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 33,
                "end": 41,
                "text": "Exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 248,
                "end": 273,
                "text": "neurodegenerative disease",
                "type": "CONDITION"
            },
            {
                "start": 290,
                "end": 311,
                "text": "metabolic dysfunction",
                "type": "CONDITION"
            },
            {
                "start": 414,
                "end": 443,
                "text": "regular exercise intervention",
                "type": "PHYSICAL"
            }
        ]
    },
    {
        "nctid": "NCT03835182",
        "text": "Efficacy of Ultrasound Versus Short Wave Diathermy in the Treatment of Lumbar Disc Herniation: a Randomised Control Study | Chronic low back pain is a common problem which results in reduced functionality, quality of life and general well being. Conservative treatment includes patient education, exercise, maintaining a healthy body mass index and appropriate modifications to activities of daily living. Physical modalities are used to support the mainstay of treatment and include superficial heat, transcutaneous electrical nerve stimulation (TENS), ultrasound, short wave diathermy , traction, and complimentary therapies.\n\nIn the clinical practice of the investigators, diathermy, in the form of ultrasound and short wave, is used to heat deeper tissues, increase tissue elasticity and metabolic rate and reduce pain and muscle spasm. The medical literature to date states that further studies are required to compare the efficacy of different diathermy modalities in the treatment of lower back pain.\n\nThe aim of this study was to compare the efficacy of ultrasound to that of short wave diathermy and a treatment program which does not include diathermy in the treatment of a slipped disc.",
        "tokens": "['Efficacy', 'of', 'Ultrasound', 'Versus', 'Short', 'Wave', 'Diathermy', 'in', 'the', 'Treatment', 'of', 'Lumbar', 'Disc', 'Herniation', ':', 'a', 'Randomised', 'Control', 'Study', '|', 'Chronic', 'low', 'back', 'pain', 'is', 'a', 'common', 'problem', 'which', 'results', 'in', 'reduced', 'functionality', ',', 'quality', 'of', 'life', 'and', 'general', 'well', 'being', '.', 'Conservative', 'treatment', 'includes', 'patient', 'education', ',', 'exercise', ',', 'maintaining', 'a', 'healthy', 'body', 'mass', 'index', 'and', 'appropriate', 'modifications', 'to', 'activities', 'of', 'daily', 'living', '.', 'Physical', 'modalities', 'are', 'used', 'to', 'support', 'the', 'mainstay', 'of', 'treatment', 'and', 'include', 'superficial', 'heat', ',', 'transcutaneous', 'electrical', 'nerve', 'stimulation', '(', 'TENS', ')', ',', 'ultrasound', ',', 'short', 'wave', 'diathermy', ',', 'traction', ',', 'and', 'complimentary', 'therapies', '.', '\\n\\n', 'In', 'the', 'clinical', 'practice', 'of', 'the', 'investigators', ',', 'diathermy', ',', 'in', 'the', 'form', 'of', 'ultrasound', 'and', 'short', 'wave', ',', 'is', 'used', 'to', 'heat', 'deeper', 'tissues', ',', 'increase', 'tissue', 'elasticity', 'and', 'metabolic', 'rate', 'and', 'reduce', 'pain', 'and', 'muscle', 'spasm', '.', 'The', 'medical', 'literature', 'to', 'date', 'states', 'that', 'further', 'studies', 'are', 'required', 'to', 'compare', 'the', 'efficacy', 'of', 'different', 'diathermy', 'modalities', 'in', 'the', 'treatment', 'of', 'lower', 'back', 'pain', '.', '\\n\\n', 'The', 'aim', 'of', 'this', 'study', 'was', 'to', 'compare', 'the', 'efficacy', 'of', 'ultrasound', 'to', 'that', 'of', 'short', 'wave', 'diathermy', 'and', 'a', 'treatment', 'program', 'which', 'does', 'not', 'include', 'diathermy', 'in', 'the', 'treatment', 'of', 'a', 'slipped', 'disc', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 12,
                "end": 22,
                "text": "Ultrasound",
                "type": "OTHER"
            },
            {
                "start": 30,
                "end": 50,
                "text": "Short Wave Diathermy",
                "type": "OTHER"
            },
            {
                "start": 71,
                "end": 93,
                "text": "Lumbar Disc Herniation",
                "type": "CONDITION"
            },
            {
                "start": 124,
                "end": 145,
                "text": "Chronic low back pain",
                "type": "CONDITION"
            },
            {
                "start": 554,
                "end": 564,
                "text": "ultrasound",
                "type": "OTHER"
            },
            {
                "start": 566,
                "end": 586,
                "text": "short wave diathermy",
                "type": "OTHER"
            },
            {
                "start": 676,
                "end": 685,
                "text": "diathermy",
                "type": "OTHER"
            },
            {
                "start": 702,
                "end": 712,
                "text": "ultrasound",
                "type": "OTHER"
            },
            {
                "start": 717,
                "end": 727,
                "text": "short wave",
                "type": "OTHER"
            },
            {
                "start": 950,
                "end": 959,
                "text": "diathermy",
                "type": "OTHER"
            },
            {
                "start": 991,
                "end": 1006,
                "text": "lower back pain",
                "type": "CONDITION"
            },
            {
                "start": 1062,
                "end": 1072,
                "text": "ultrasound",
                "type": "OTHER"
            },
            {
                "start": 1084,
                "end": 1104,
                "text": "short wave diathermy",
                "type": "OTHER"
            },
            {
                "start": 1111,
                "end": 1161,
                "text": "treatment program which does not include diathermy",
                "type": "CONTROL"
            },
            {
                "start": 1184,
                "end": 1196,
                "text": "slipped disc",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00081497",
        "text": "Multi-Center, Open-Label Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease That Previously Participated in the AGAL-008-00 Study | People with Fabry Disease have an alteration in their genetic material (DNA) which causes a deficiency of the alpha-galactosidase A enzyme. Fabrazyme (agalsidase beta) is a drug that helps to break down and removes certain types of fatty substances called \"glycolipids\". These glycolipids are normally present within the body in most cells. In Fabry disease, glycolipids build up in various tissues such as the liver, kidney, skin, and blood vessels because a-galactosidase A is not present, or is present in small quantities. The build up of glycolipid (globatriaosylceramide or GL-3) levels in these tissues in particular is thought to cause the clinical symptoms that are common to Fabry disease. This study analyzed the safety and efficacy of Fabrazyme in the treatment of patients with Fabry disease that previously participated in the AGAL-008-00 (NCT0074984) study.",
        "tokens": "['Multi', '-', 'Center', ',', 'Open', '-', 'Label', 'Study', 'of', 'the', 'Safety', 'and', 'Efficacy', 'of', 'Fabrazyme', 'in', 'Patients', 'With', 'Fabry', 'Disease', 'That', 'Previously', 'Participated', 'in', 'the', 'AGAL-008', '-', '00', 'Study', '|', 'People', 'with', 'Fabry', 'Disease', 'have', 'an', 'alteration', 'in', 'their', 'genetic', 'material', '(', 'DNA', ')', 'which', 'causes', 'a', 'deficiency', 'of', 'the', 'alpha', '-', 'galactosidase', 'A', 'enzyme', '.', 'Fabrazyme', '(', 'agalsidase', 'beta', ')', 'is', 'a', 'drug', 'that', 'helps', 'to', 'break', 'down', 'and', 'removes', 'certain', 'types', 'of', 'fatty', 'substances', 'called', '\"', 'glycolipids', '\"', '.', 'These', 'glycolipids', 'are', 'normally', 'present', 'within', 'the', 'body', 'in', 'most', 'cells', '.', 'In', 'Fabry', 'disease', ',', 'glycolipids', 'build', 'up', 'in', 'various', 'tissues', 'such', 'as', 'the', 'liver', ',', 'kidney', ',', 'skin', ',', 'and', 'blood', 'vessels', 'because', 'a', '-', 'galactosidase', 'A', 'is', 'not', 'present', ',', 'or', 'is', 'present', 'in', 'small', 'quantities', '.', 'The', 'build', 'up', 'of', 'glycolipid', '(', 'globatriaosylceramide', 'or', 'GL-3', ')', 'levels', 'in', 'these', 'tissues', 'in', 'particular', 'is', 'thought', 'to', 'cause', 'the', 'clinical', 'symptoms', 'that', 'are', 'common', 'to', 'Fabry', 'disease', '.', 'This', 'study', 'analyzed', 'the', 'safety', 'and', 'efficacy', 'of', 'Fabrazyme', 'in', 'the', 'treatment', 'of', 'patients', 'with', 'Fabry', 'disease', 'that', 'previously', 'participated', 'in', 'the', 'AGAL-008', '-', '00', '(', 'NCT0074984', ')', 'study', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 61,
                "end": 70,
                "text": "Fabrazyme",
                "type": "DRUG"
            },
            {
                "start": 88,
                "end": 101,
                "text": "Fabry Disease",
                "type": "CONDITION"
            },
            {
                "start": 170,
                "end": 183,
                "text": "Fabry Disease",
                "type": "CONDITION"
            },
            {
                "start": 298,
                "end": 307,
                "text": "Fabrazyme",
                "type": "DRUG"
            },
            {
                "start": 309,
                "end": 324,
                "text": "agalsidase beta",
                "type": "DRUG"
            },
            {
                "start": 502,
                "end": 515,
                "text": "Fabry disease",
                "type": "CONDITION"
            },
            {
                "start": 843,
                "end": 856,
                "text": "Fabry disease",
                "type": "CONDITION"
            },
            {
                "start": 905,
                "end": 914,
                "text": "Fabrazyme",
                "type": "DRUG"
            },
            {
                "start": 949,
                "end": 962,
                "text": "Fabry disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02180867",
        "text": "Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754) | This randomized phase II/III trial studies how well pazopanib, when combined with chemotherapy and radiation therapy or radiation therapy alone, work in the treatment of patients with newly diagnosed non-rhabdomyosarcoma soft tissue sarcomas that can eventually be removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as ifosfamide and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether these therapies can be safely combined and if they work better when given together in treating patients with non-rhabdomyosarcoma soft tissue sarcomas.",
        "tokens": "['Pazopanib', 'Neoadjuvant', 'Trial', 'in', 'Non', '-', 'Rhabdomyosarcoma', 'Soft', 'Tissue', 'Sarcomas', '(', 'PAZNTIS', '):', 'A', 'Phase', 'II', '/', 'III', 'Randomized', 'Trial', 'of', 'Preoperative', 'Chemoradiation', 'or', 'Preoperative', 'Radiation', 'Plus', 'or', 'Minus', 'Pazopanib', '(', 'NSC', '#', '737754', ')', '|', 'This', 'randomized', 'phase', 'II', '/', 'III', 'trial', 'studies', 'how', 'well', 'pazopanib', ',', 'when', 'combined', 'with', 'chemotherapy', 'and', 'radiation', 'therapy', 'or', 'radiation', 'therapy', 'alone', ',', 'work', 'in', 'the', 'treatment', 'of', 'patients', 'with', 'newly', 'diagnosed', 'non', '-', 'rhabdomyosarcoma', 'soft', 'tissue', 'sarcomas', 'that', 'can', 'eventually', 'be', 'removed', 'by', 'surgery', '.', 'Radiation', 'therapy', 'uses', 'high', 'energy', 'x', '-', 'rays', 'to', 'kill', 'tumor', 'cells', '.', 'Drugs', 'used', 'in', 'chemotherapy', ',', 'such', 'as', 'ifosfamide', 'and', 'doxorubicin', ',', 'work', 'in', 'different', 'ways', 'to', 'stop', 'the', 'growth', 'of', 'tumor', 'cells', ',', 'either', 'by', 'killing', 'the', 'cells', ',', 'by', 'stopping', 'them', 'from', 'dividing', ',', 'or', 'by', 'stopping', 'them', 'from', 'spreading', '.', 'Pazopanib', 'may', 'stop', 'the', 'growth', 'of', 'tumor', 'cells', 'by', 'blocking', 'some', 'of', 'the', 'enzymes', 'needed', 'for', 'cell', 'growth', '.', 'It', 'is', 'not', 'yet', 'known', 'whether', 'these', 'therapies', 'can', 'be', 'safely', 'combined', 'and', 'if', 'they', 'work', 'better', 'when', 'given', 'together', 'in', 'treating', 'patients', 'with', 'non', '-', 'rhabdomyosarcoma', 'soft', 'tissue', 'sarcomas', '.']",
        "token_bio_labels": "['B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-RADIO', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-RADIO', 'I-RADIO', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 9,
                "text": "Pazopanib",
                "type": "DRUG"
            },
            {
                "start": 31,
                "end": 72,
                "text": "Non-Rhabdomyosarcoma Soft Tissue Sarcomas",
                "type": "CONDITION"
            },
            {
                "start": 132,
                "end": 146,
                "text": "Chemoradiation",
                "type": "OTHER"
            },
            {
                "start": 163,
                "end": 172,
                "text": "Radiation",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 187,
                "end": 196,
                "text": "Pazopanib",
                "type": "DRUG"
            },
            {
                "start": 198,
                "end": 209,
                "text": "NSC# 737754",
                "type": "DRUG"
            },
            {
                "start": 265,
                "end": 274,
                "text": "pazopanib",
                "type": "DRUG"
            },
            {
                "start": 295,
                "end": 307,
                "text": "chemotherapy",
                "type": "OTHER"
            },
            {
                "start": 312,
                "end": 329,
                "text": "radiation therapy",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 333,
                "end": 356,
                "text": "radiation therapy alone",
                "type": "CONTROL"
            },
            {
                "start": 413,
                "end": 454,
                "text": "non-rhabdomyosarcoma soft tissue sarcomas",
                "type": "CONDITION"
            },
            {
                "start": 498,
                "end": 515,
                "text": "Radiation therapy",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 548,
                "end": 553,
                "text": "tumor",
                "type": "CONDITION"
            },
            {
                "start": 670,
                "end": 675,
                "text": "tumor",
                "type": "CONDITION"
            },
            {
                "start": 780,
                "end": 789,
                "text": "Pazopanib",
                "type": "DRUG"
            },
            {
                "start": 813,
                "end": 818,
                "text": "tumor",
                "type": "CONDITION"
            },
            {
                "start": 1018,
                "end": 1059,
                "text": "non-rhabdomyosarcoma soft tissue sarcomas",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05222386",
        "text": "Building Online Community to Improve Patient and Caregiver Outcomes in Parkinson Disease, Lewy Body Dementia and Related Disorders | The purpose of this study is to learn more about the effectiveness of palliative care training for community physicians and telemedicine support services for patients and carepartners with Parkinson's disease and Lewy Body Dementia (LBD) or related conditions and their care partners. Palliative care is a treatment approach focused on improving quality of life by relieving suffering in the areas of physical symptoms such as pain, psychiatric symptoms such as depression, psychosocial issues and spiritual needs. Telemedicine is the use of technology that allows participants to interact with a health care provider without being physically near the provider.",
        "tokens": "['Building', 'Online', 'Community', 'to', 'Improve', 'Patient', 'and', 'Caregiver', 'Outcomes', 'in', 'Parkinson', 'Disease', ',', 'Lewy', 'Body', 'Dementia', 'and', 'Related', 'Disorders', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'learn', 'more', 'about', 'the', 'effectiveness', 'of', 'palliative', 'care', 'training', 'for', 'community', 'physicians', 'and', 'telemedicine', 'support', 'services', 'for', 'patients', 'and', 'carepartners', 'with', 'Parkinson', \"'s\", 'disease', 'and', 'Lewy', 'Body', 'Dementia', '(', 'LBD', ')', 'or', 'related', 'conditions', 'and', 'their', 'care', 'partners', '.', 'Palliative', 'care', 'is', 'a', 'treatment', 'approach', 'focused', 'on', 'improving', 'quality', 'of', 'life', 'by', 'relieving', 'suffering', 'in', 'the', 'areas', 'of', 'physical', 'symptoms', 'such', 'as', 'pain', ',', 'psychiatric', 'symptoms', 'such', 'as', 'depression', ',', 'psychosocial', 'issues', 'and', 'spiritual', 'needs', '.', 'Telemedicine', 'is', 'the', 'use', 'of', 'technology', 'that', 'allows', 'participants', 'to', 'interact', 'with', 'a', 'health', 'care', 'provider', 'without', 'being', 'physically', 'near', 'the', 'provider', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 71,
                "end": 88,
                "text": "Parkinson Disease",
                "type": "CONDITION"
            },
            {
                "start": 90,
                "end": 108,
                "text": "Lewy Body Dementia",
                "type": "CONDITION"
            },
            {
                "start": 203,
                "end": 252,
                "text": "palliative care training for community physicians",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 257,
                "end": 286,
                "text": "telemedicine support services",
                "type": "OTHER"
            },
            {
                "start": 322,
                "end": 341,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 346,
                "end": 364,
                "text": "Lewy Body Dementia",
                "type": "CONDITION"
            },
            {
                "start": 366,
                "end": 369,
                "text": "LBD",
                "type": "CONDITION"
            },
            {
                "start": 418,
                "end": 433,
                "text": "Palliative care",
                "type": "OTHER"
            },
            {
                "start": 648,
                "end": 660,
                "text": "Telemedicine",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT01748656",
        "text": "Comparison of Two Noninvasive Positive Pressure Ventilation Devices Using Target Volume Modes in Obesity Hypoventilation Syndrome (OHS): A Pilot Randomized Crossover Controlled Trial | Patients with OHS are efficiently managed with long term home-based nocturnal noninvasive positive pressure ventilation (NIPPV). Several NIPPV devices offer the feature of automatically adjusting pressure support (and/or respiratory back-up rate) on the basis of a pre-determined \"ideal tidal volume\" or \"ideal ventilation\". However algorithms used to achieve these ideal targets are different among different commercialized devices and the relative efficacy from an algorithm compared to another remains unknown. The main objective is this study is to compare two commercialized NIPPV that have this option",
        "tokens": "['Comparison', 'of', 'Two', 'Noninvasive', 'Positive', 'Pressure', 'Ventilation', 'Devices', 'Using', 'Target', 'Volume', 'Modes', 'in', 'Obesity', 'Hypoventilation', 'Syndrome', '(', 'OHS', '):', 'A', 'Pilot', 'Randomized', 'Crossover', 'Controlled', 'Trial', '|', 'Patients', 'with', 'OHS', 'are', 'efficiently', 'managed', 'with', 'long', 'term', 'home', '-', 'based', 'nocturnal', 'noninvasive', 'positive', 'pressure', 'ventilation', '(', 'NIPPV', ')', '.', 'Several', 'NIPPV', 'devices', 'offer', 'the', 'feature', 'of', 'automatically', 'adjusting', 'pressure', 'support', '(', 'and/or', 'respiratory', 'back', '-', 'up', 'rate', ')', 'on', 'the', 'basis', 'of', 'a', 'pre', '-', 'determined', '\"', 'ideal', 'tidal', 'volume', '\"', 'or', '\"', 'ideal', 'ventilation', '\"', '.', 'However', 'algorithms', 'used', 'to', 'achieve', 'these', 'ideal', 'targets', 'are', 'different', 'among', 'different', 'commercialized', 'devices', 'and', 'the', 'relative', 'efficacy', 'from', 'an', 'algorithm', 'compared', 'to', 'another', 'remains', 'unknown', '.', 'The', 'main', 'objective', 'is', 'this', 'study', 'is', 'to', 'compare', 'two', 'commercialized', 'NIPPV', 'that', 'have', 'this', 'option']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 18,
                "end": 67,
                "text": "Noninvasive Positive Pressure Ventilation Devices",
                "type": "OTHER"
            },
            {
                "start": 97,
                "end": 129,
                "text": "Obesity Hypoventilation Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 131,
                "end": 134,
                "text": "OHS",
                "type": "CONDITION"
            },
            {
                "start": 199,
                "end": 202,
                "text": "OHS",
                "type": "CONDITION"
            },
            {
                "start": 253,
                "end": 304,
                "text": "nocturnal noninvasive positive pressure ventilation",
                "type": "OTHER"
            },
            {
                "start": 306,
                "end": 311,
                "text": "NIPPV",
                "type": "OTHER"
            },
            {
                "start": 322,
                "end": 335,
                "text": "NIPPV devices",
                "type": "OTHER"
            },
            {
                "start": 765,
                "end": 770,
                "text": "NIPPV",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT03177967",
        "text": "\"Get up\" - The Sleep Study in Oppegard (St\u00e5 Opp - S\u00f8vnstudien i Oppeg\u00e5rd) | A randomized, controlled study to examine the effect of group treatment for insomnia (CBT-I) in an outpatient clinic compared with waiting list and treatment-as-usual (sleep-hygiene based educational course)",
        "tokens": "['\"', 'Get', 'up', '\"', '-', 'The', 'Sleep', 'Study', 'in', 'Oppegard', '(', 'St\u00e5', 'Opp', '-', 'S\u00f8vnstudien', 'i', 'Oppeg\u00e5rd', ')', '|', 'A', 'randomized', ',', 'controlled', 'study', 'to', 'examine', 'the', 'effect', 'of', 'group', 'treatment', 'for', 'insomnia', '(', 'CBT', '-', 'I', ')', 'in', 'an', 'outpatient', 'clinic', 'compared', 'with', 'waiting', 'list', 'and', 'treatment', '-', 'as', '-', 'usual', '(', 'sleep', '-', 'hygiene', 'based', 'educational', 'course', ')']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O']",
        "entities": [
            {
                "start": 132,
                "end": 147,
                "text": "group treatment",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 152,
                "end": 160,
                "text": "insomnia",
                "type": "CONDITION"
            },
            {
                "start": 207,
                "end": 219,
                "text": "waiting list",
                "type": "CONTROL"
            },
            {
                "start": 224,
                "end": 242,
                "text": "treatment-as-usual",
                "type": "CONTROL"
            },
            {
                "start": 244,
                "end": 282,
                "text": "sleep-hygiene based educational course",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT04603352",
        "text": "Impact of an Orthotic Garment on Gross Motor Skill Acquisition for Infants With Down Syndrome | Infants with Down syndrome (DS) develop slower than their typically developing peers. Physical therapist (PT) supervised home programs have the potential to optimize gross motor development in a financially feasible way. An inexpensive orthotic garment (Hip Helpers\u00ae) is commonly employed by PTs as a home program supplement, but its effectiveness has not yet been investigated. The garment is worn as pliable shorts over a child's lower extremities to keep upper legs together, promoting a narrow base of support. This encourages activation of upright postural muscles to improve gross motor skill development. The purpose of this randomized controlled study is to investigate the impact of a home program using the Hip Helpers\u00ae orthotic garment on gross motor skill acquisition in infants with DS. We hypothesize that the addition of a structured home program using Hip Helpers\u00ae, supervised by a PT and implemented by parents, will increase the rate at which infants with DS acquire gross motor skills. Thirty-four participants, consisting of children who are at least three-months-old and are not yet able maintain sitting independently, will be randomly assigned to a control (n=17) or intervention group (n=17). PTs at pediatric therapy agencies will initiate the home program and administer the Gross Motor Function Measure-88 (GMFM-88) at regular intervals to monitor gross motor skill acquisition until the child is able to take three independent steps. Groups will be compared on the length of time elapsed between the acquisition of identified gross motor skills using independent t-tests. GMFM-88 scores will be compared between the two groups at different ages to identify trends using independent t-tests. The contribution of this project will be significant by informing physical therapists about the effectiveness of an inexpensive orthotic garment used in a supervised home program on gross motor outcomes in infants with DS.",
        "tokens": "['Impact', 'of', 'an', 'Orthotic', 'Garment', 'on', 'Gross', 'Motor', 'Skill', 'Acquisition', 'for', 'Infants', 'With', 'Down', 'Syndrome', '|', 'Infants', 'with', 'Down', 'syndrome', '(', 'DS', ')', 'develop', 'slower', 'than', 'their', 'typically', 'developing', 'peers', '.', 'Physical', 'therapist', '(', 'PT', ')', 'supervised', 'home', 'programs', 'have', 'the', 'potential', 'to', 'optimize', 'gross', 'motor', 'development', 'in', 'a', 'financially', 'feasible', 'way', '.', 'An', 'inexpensive', 'orthotic', 'garment', '(', 'Hip', 'Helpers', '\u00ae', ')', 'is', 'commonly', 'employed', 'by', 'PTs', 'as', 'a', 'home', 'program', 'supplement', ',', 'but', 'its', 'effectiveness', 'has', 'not', 'yet', 'been', 'investigated', '.', 'The', 'garment', 'is', 'worn', 'as', 'pliable', 'shorts', 'over', 'a', 'child', \"'s\", 'lower', 'extremities', 'to', 'keep', 'upper', 'legs', 'together', ',', 'promoting', 'a', 'narrow', 'base', 'of', 'support', '.', 'This', 'encourages', 'activation', 'of', 'upright', 'postural', 'muscles', 'to', 'improve', 'gross', 'motor', 'skill', 'development', '.', 'The', 'purpose', 'of', 'this', 'randomized', 'controlled', 'study', 'is', 'to', 'investigate', 'the', 'impact', 'of', 'a', 'home', 'program', 'using', 'the', 'Hip', 'Helpers', '\u00ae', 'orthotic', 'garment', 'on', 'gross', 'motor', 'skill', 'acquisition', 'in', 'infants', 'with', 'DS', '.', 'We', 'hypothesize', 'that', 'the', 'addition', 'of', 'a', 'structured', 'home', 'program', 'using', 'Hip', 'Helpers', '\u00ae', ',', 'supervised', 'by', 'a', 'PT', 'and', 'implemented', 'by', 'parents', ',', 'will', 'increase', 'the', 'rate', 'at', 'which', 'infants', 'with', 'DS', 'acquire', 'gross', 'motor', 'skills', '.', 'Thirty', '-', 'four', 'participants', ',', 'consisting', 'of', 'children', 'who', 'are', 'at', 'least', 'three', '-', 'months', '-', 'old', 'and', 'are', 'not', 'yet', 'able', 'maintain', 'sitting', 'independently', ',', 'will', 'be', 'randomly', 'assigned', 'to', 'a', 'control', '(', 'n=17', ')', 'or', 'intervention', 'group', '(', 'n=17', ')', '.', 'PTs', 'at', 'pediatric', 'therapy', 'agencies', 'will', 'initiate', 'the', 'home', 'program', 'and', 'administer', 'the', 'Gross', 'Motor', 'Function', 'Measure-88', '(', 'GMFM-88', ')', 'at', 'regular', 'intervals', 'to', 'monitor', 'gross', 'motor', 'skill', 'acquisition', 'until', 'the', 'child', 'is', 'able', 'to', 'take', 'three', 'independent', 'steps', '.', 'Groups', 'will', 'be', 'compared', 'on', 'the', 'length', 'of', 'time', 'elapsed', 'between', 'the', 'acquisition', 'of', 'identified', 'gross', 'motor', 'skills', 'using', 'independent', 't', '-', 'tests', '.', 'GMFM-88', 'scores', 'will', 'be', 'compared', 'between', 'the', 'two', 'groups', 'at', 'different', 'ages', 'to', 'identify', 'trends', 'using', 'independent', 't', '-', 'tests', '.', 'The', 'contribution', 'of', 'this', 'project', 'will', 'be', 'significant', 'by', 'informing', 'physical', 'therapists', 'about', 'the', 'effectiveness', 'of', 'an', 'inexpensive', 'orthotic', 'garment', 'used', 'in', 'a', 'supervised', 'home', 'program', 'on', 'gross', 'motor', 'outcomes', 'in', 'infants', 'with', 'DS', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 13,
                "end": 29,
                "text": "Orthotic Garment",
                "type": "OTHER"
            },
            {
                "start": 80,
                "end": 93,
                "text": "Down Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 109,
                "end": 122,
                "text": "Down syndrome",
                "type": "CONDITION"
            },
            {
                "start": 124,
                "end": 126,
                "text": "DS",
                "type": "CONDITION"
            },
            {
                "start": 182,
                "end": 230,
                "text": "Physical therapist (PT) supervised home programs",
                "type": "PHYSICAL"
            },
            {
                "start": 332,
                "end": 348,
                "text": "orthotic garment",
                "type": "OTHER"
            },
            {
                "start": 350,
                "end": 361,
                "text": "Hip Helpers",
                "type": "OTHER"
            },
            {
                "start": 397,
                "end": 409,
                "text": "home program",
                "type": "PHYSICAL"
            },
            {
                "start": 790,
                "end": 802,
                "text": "home program",
                "type": "PHYSICAL"
            },
            {
                "start": 813,
                "end": 842,
                "text": "Hip Helpers\u00ae orthotic garment",
                "type": "OTHER"
            },
            {
                "start": 892,
                "end": 894,
                "text": "DS",
                "type": "CONDITION"
            },
            {
                "start": 945,
                "end": 957,
                "text": "home program",
                "type": "PHYSICAL"
            },
            {
                "start": 964,
                "end": 975,
                "text": "Hip Helpers",
                "type": "OTHER"
            },
            {
                "start": 1070,
                "end": 1072,
                "text": "DS",
                "type": "CONDITION"
            },
            {
                "start": 1268,
                "end": 1275,
                "text": "control",
                "type": "CONTROL"
            },
            {
                "start": 1365,
                "end": 1377,
                "text": "home program",
                "type": "PHYSICAL"
            },
            {
                "start": 1943,
                "end": 1959,
                "text": "orthotic garment",
                "type": "OTHER"
            },
            {
                "start": 1981,
                "end": 1993,
                "text": "home program",
                "type": "PHYSICAL"
            },
            {
                "start": 2034,
                "end": 2036,
                "text": "DS",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04355299",
        "text": "Effectiveness of a Short-term Mixed Exercise Program for Treating Sarcopenia in Hospitalized Patients Aged 80 Years and Older | Most previous clinical trials that addressed exercise for sarcopenic elderly subjects focused on community-dwelling older adults who were relatively healthy. There is a notable paucity of high-quality research investigating the effects and feasibility of exercise for hospitalized or institutionalized older people, who are generally frailer and more severe in functional impairment than those living in the community. Moreover, most reported exercise programs were of long-term duration, which typically lasted 3 to 6 months with two sessions per week. It remains unclear whether short-term exercise would be effective for treating sarcopenia. Therefore, the investigators aimed to assess the effectiveness of short-term exercise for treating sarcopenia in hospitalized older patients aged 80 years and over.",
        "tokens": "['Effectiveness', 'of', 'a', 'Short', '-', 'term', 'Mixed', 'Exercise', 'Program', 'for', 'Treating', 'Sarcopenia', 'in', 'Hospitalized', 'Patients', 'Aged', '80', 'Years', 'and', 'Older', '|', 'Most', 'previous', 'clinical', 'trials', 'that', 'addressed', 'exercise', 'for', 'sarcopenic', 'elderly', 'subjects', 'focused', 'on', 'community', '-', 'dwelling', 'older', 'adults', 'who', 'were', 'relatively', 'healthy', '.', 'There', 'is', 'a', 'notable', 'paucity', 'of', 'high', '-', 'quality', 'research', 'investigating', 'the', 'effects', 'and', 'feasibility', 'of', 'exercise', 'for', 'hospitalized', 'or', 'institutionalized', 'older', 'people', ',', 'who', 'are', 'generally', 'frailer', 'and', 'more', 'severe', 'in', 'functional', 'impairment', 'than', 'those', 'living', 'in', 'the', 'community', '.', 'Moreover', ',', 'most', 'reported', 'exercise', 'programs', 'were', 'of', 'long', '-', 'term', 'duration', ',', 'which', 'typically', 'lasted', '3', 'to', '6', 'months', 'with', 'two', 'sessions', 'per', 'week', '.', 'It', 'remains', 'unclear', 'whether', 'short', '-', 'term', 'exercise', 'would', 'be', 'effective', 'for', 'treating', 'sarcopenia', '.', 'Therefore', ',', 'the', 'investigators', 'aimed', 'to', 'assess', 'the', 'effectiveness', 'of', 'short', '-', 'term', 'exercise', 'for', 'treating', 'sarcopenia', 'in', 'hospitalized', 'older', 'patients', 'aged', '80', 'years', 'and', 'over', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 19,
                "end": 52,
                "text": "Short-term Mixed Exercise Program",
                "type": "PHYSICAL"
            },
            {
                "start": 66,
                "end": 76,
                "text": "Sarcopenia",
                "type": "CONDITION"
            },
            {
                "start": 186,
                "end": 196,
                "text": "sarcopenic",
                "type": "CONDITION"
            },
            {
                "start": 383,
                "end": 391,
                "text": "exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 571,
                "end": 588,
                "text": "exercise programs",
                "type": "PHYSICAL"
            },
            {
                "start": 709,
                "end": 728,
                "text": "short-term exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 761,
                "end": 771,
                "text": "sarcopenia",
                "type": "CONDITION"
            },
            {
                "start": 839,
                "end": 858,
                "text": "short-term exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 872,
                "end": 882,
                "text": "sarcopenia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02119078",
        "text": "Acute Care for Elders (ACE) Program at OHSU Hospital | The purpose of this investigation is to assess the effectiveness of a multi-disciplinary Acute Care for Elders (ACE) program dedicated to the care of patients age 70 and older admitted to Oregon Health & Science University's hospital medicine service. The ACE program will aim to improve the quality of care of older patients in the investigators hospital by implementing focused interventions and recommendations specific to geriatric needs and syndromes, including: reduced fall rate, decreased incidence and duration of delirium, early recognition and treatment of impaired mobility and function, careful minimization of medication use, prevention of unnecessary catheter and restraint use, decreased hospital readmission rates, improved transitional care following hospital discharge, and high levels of patient and referring physician satisfaction. Additionally, the ACE program aims to improve resident and student competence in treating geriatric syndromes, and to improve staff and learner satisfaction with caring for older adults. ACE programs have been well studied at other institutions, so the investigators will be implementing a program that is already standard of care, and studying the elements that are unique to OHSU.\n\nThis will be a quality improvement project. Study participants will be a convenience sample of OHSU faculty, staff, residents and students who are employed by or on rotation with General Medicine Team 1 of the Medicine Teaching Service. Faculty, staff, and learners (ACE team members) will receive the ACE training. Study personnel will conduct prospective and retrospective chart review of patients admitted to the ACE service to determine outcomes as noted above.",
        "tokens": "['Acute', 'Care', 'for', 'Elders', '(', 'ACE', ')', 'Program', 'at', 'OHSU', 'Hospital', '|', 'The', 'purpose', 'of', 'this', 'investigation', 'is', 'to', 'assess', 'the', 'effectiveness', 'of', 'a', 'multi', '-', 'disciplinary', 'Acute', 'Care', 'for', 'Elders', '(', 'ACE', ')', 'program', 'dedicated', 'to', 'the', 'care', 'of', 'patients', 'age', '70', 'and', 'older', 'admitted', 'to', 'Oregon', 'Health', '&', 'Science', 'University', \"'s\", 'hospital', 'medicine', 'service', '.', 'The', 'ACE', 'program', 'will', 'aim', 'to', 'improve', 'the', 'quality', 'of', 'care', 'of', 'older', 'patients', 'in', 'the', 'investigators', 'hospital', 'by', 'implementing', 'focused', 'interventions', 'and', 'recommendations', 'specific', 'to', 'geriatric', 'needs', 'and', 'syndromes', ',', 'including', ':', 'reduced', 'fall', 'rate', ',', 'decreased', 'incidence', 'and', 'duration', 'of', 'delirium', ',', 'early', 'recognition', 'and', 'treatment', 'of', 'impaired', 'mobility', 'and', 'function', ',', 'careful', 'minimization', 'of', 'medication', 'use', ',', 'prevention', 'of', 'unnecessary', 'catheter', 'and', 'restraint', 'use', ',', 'decreased', 'hospital', 'readmission', 'rates', ',', 'improved', 'transitional', 'care', 'following', 'hospital', 'discharge', ',', 'and', 'high', 'levels', 'of', 'patient', 'and', 'referring', 'physician', 'satisfaction', '.', 'Additionally', ',', 'the', 'ACE', 'program', 'aims', 'to', 'improve', 'resident', 'and', 'student', 'competence', 'in', 'treating', 'geriatric', 'syndromes', ',', 'and', 'to', 'improve', 'staff', 'and', 'learner', 'satisfaction', 'with', 'caring', 'for', 'older', 'adults', '.', 'ACE', 'programs', 'have', 'been', 'well', 'studied', 'at', 'other', 'institutions', ',', 'so', 'the', 'investigators', 'will', 'be', 'implementing', 'a', 'program', 'that', 'is', 'already', 'standard', 'of', 'care', ',', 'and', 'studying', 'the', 'elements', 'that', 'are', 'unique', 'to', 'OHSU', '.', '\\n\\n', 'This', 'will', 'be', 'a', 'quality', 'improvement', 'project', '.', 'Study', 'participants', 'will', 'be', 'a', 'convenience', 'sample', 'of', 'OHSU', 'faculty', ',', 'staff', ',', 'residents', 'and', 'students', 'who', 'are', 'employed', 'by', 'or', 'on', 'rotation', 'with', 'General', 'Medicine', 'Team', '1', 'of', 'the', 'Medicine', 'Teaching', 'Service', '.', 'Faculty', ',', 'staff', ',', 'and', 'learners', '(', 'ACE', 'team', 'members', ')', 'will', 'receive', 'the', 'ACE', 'training', '.', 'Study', 'personnel', 'will', 'conduct', 'prospective', 'and', 'retrospective', 'chart', 'review', 'of', 'patients', 'admitted', 'to', 'the', 'ACE', 'service', 'to', 'determine', 'outcomes', 'as', 'noted', 'above', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 35,
                "text": "Acute Care for Elders (ACE) Program",
                "type": "OTHER"
            },
            {
                "start": 144,
                "end": 179,
                "text": "Acute Care for Elders (ACE) program",
                "type": "OTHER"
            },
            {
                "start": 311,
                "end": 322,
                "text": "ACE program",
                "type": "OTHER"
            },
            {
                "start": 927,
                "end": 938,
                "text": "ACE program",
                "type": "OTHER"
            },
            {
                "start": 1096,
                "end": 1108,
                "text": "ACE programs",
                "type": "OTHER"
            },
            {
                "start": 1560,
                "end": 1563,
                "text": "ACE",
                "type": "OTHER"
            },
            {
                "start": 1595,
                "end": 1607,
                "text": "ACE training",
                "type": "OTHER"
            },
            {
                "start": 1709,
                "end": 1720,
                "text": "ACE service",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT05682963",
        "text": "Effect of Square- Stepping Exercises on Mobility, Balance and Knee Joint Position Sense in Individuals With Multiple Sclerosis | Square stepping exercises can promote correct foot placement, fast and coordinated step patterns, and sensory-motor interaction. The aim of this study is to examine the effect of square stepping exercises on mobility, balance and knee joint position sense in individuals with multiple sclerosis.",
        "tokens": "['Effect', 'of', 'Square-', 'Stepping', 'Exercises', 'on', 'Mobility', ',', 'Balance', 'and', 'Knee', 'Joint', 'Position', 'Sense', 'in', 'Individuals', 'With', 'Multiple', 'Sclerosis', '|', 'Square', 'stepping', 'exercises', 'can', 'promote', 'correct', 'foot', 'placement', ',', 'fast', 'and', 'coordinated', 'step', 'patterns', ',', 'and', 'sensory', '-', 'motor', 'interaction', '.', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'examine', 'the', 'effect', 'of', 'square', 'stepping', 'exercises', 'on', 'mobility', ',', 'balance', 'and', 'knee', 'joint', 'position', 'sense', 'in', 'individuals', 'with', 'multiple', 'sclerosis', '.']",
        "token_bio_labels": "['O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 36,
                "text": "Square- Stepping Exercises",
                "type": "PHYSICAL"
            },
            {
                "start": 108,
                "end": 126,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 129,
                "end": 154,
                "text": "Square stepping exercises",
                "type": "PHYSICAL"
            },
            {
                "start": 308,
                "end": 333,
                "text": "square stepping exercises",
                "type": "PHYSICAL"
            },
            {
                "start": 405,
                "end": 423,
                "text": "multiple sclerosis",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00099242",
        "text": "Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease | The goal of this research study is to evaluate the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease.",
        "tokens": "['Efficacy', 'and', 'Safety', 'of', 'the', 'Rivastigmine', 'Transdermal', 'Patch', 'in', 'Patients', 'With', 'Probable', 'Alzheimer', \"'s\", 'Disease', '|', 'The', 'goal', 'of', 'this', 'research', 'study', 'is', 'to', 'evaluate', 'the', 'safety', 'and', 'efficacy', 'of', 'the', 'rivastigmine', 'transdermal', 'patch', 'in', 'patients', 'with', 'probable', 'Alzheimer', \"'s\", 'Disease', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 27,
                "end": 39,
                "text": "Rivastigmine",
                "type": "DRUG"
            },
            {
                "start": 84,
                "end": 103,
                "text": "Alzheimer's Disease",
                "type": "CONDITION"
            },
            {
                "start": 184,
                "end": 196,
                "text": "rivastigmine",
                "type": "DRUG"
            },
            {
                "start": 241,
                "end": 260,
                "text": "Alzheimer's Disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01000350",
        "text": "Intravenous Saline on Exercise Tolerance in Orthostatic Intolerance | The investigators will test whether an intravenous infusion of saline (salt water) will improve the exercise capacity in patients with postural tachycardia syndrome (POTS).",
        "tokens": "['Intravenous', 'Saline', 'on', 'Exercise', 'Tolerance', 'in', 'Orthostatic', 'Intolerance', '|', 'The', 'investigators', 'will', 'test', 'whether', 'an', 'intravenous', 'infusion', 'of', 'saline', '(', 'salt', 'water', ')', 'will', 'improve', 'the', 'exercise', 'capacity', 'in', 'patients', 'with', 'postural', 'tachycardia', 'syndrome', '(', 'POTS', ')', '.']",
        "token_bio_labels": "['O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 12,
                "end": 18,
                "text": "Saline",
                "type": "DRUG"
            },
            {
                "start": 44,
                "end": 67,
                "text": "Orthostatic Intolerance",
                "type": "CONDITION"
            },
            {
                "start": 133,
                "end": 139,
                "text": "saline",
                "type": "DRUG"
            },
            {
                "start": 141,
                "end": 151,
                "text": "salt water",
                "type": "DRUG"
            },
            {
                "start": 205,
                "end": 234,
                "text": "postural tachycardia syndrome",
                "type": "CONDITION"
            },
            {
                "start": 236,
                "end": 240,
                "text": "POTS",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00864708",
        "text": "Enhancing Function Using the RF Microstimulator Gait System Following Stroke 2008 | The purpose of the study is to investigate new Technology for recovery of ankle walking function after stroke.",
        "tokens": "['Enhancing', 'Function', 'Using', 'the', 'RF', 'Microstimulator', 'Gait', 'System', 'Following', 'Stroke', '2008', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'investigate', 'new', 'Technology', 'for', 'recovery', 'of', 'ankle', 'walking', 'function', 'after', 'stroke', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 29,
                "end": 59,
                "text": "RF Microstimulator Gait System",
                "type": "OTHER"
            },
            {
                "start": 70,
                "end": 76,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 131,
                "end": 154,
                "text": "Technology for recovery",
                "type": "OTHER"
            },
            {
                "start": 187,
                "end": 193,
                "text": "stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05799690",
        "text": "Multiparametric Biomarkers to Predict the Response to Different Protocols of Motor-cognitive Rehabilitation in Parkinson's Disease Subjects With Postural Instability and Gait Disorders | The aim of the study is to compare the effects of 2 different dosages and modalities of motor-cognitive rehabilitation in Parkinson's disease with postural instability and gait disorders (PD-PIGD) on clinical features, neuroimaging and blood-based biomarkers at short-term (2 months) and long-term (7 months) follow-up. Fifty subjects with PD-PIGD will be randomized in 2 training groups: DUAL-TASK+AOT-MI and the DUAL-TASK groups. The DUAL-TASK+AOT-MI group will perform a dual-task gait/balance training consisting of action observation training (AOT) and motor imagery (MI) combined with practicing the observed-imagined exercises; DUAL-TASK group will perform the same exercises combined with watching landscape videos. The training will last 6 weeks, 3 times/week, 1 hour per session.\n\nBefore and after training (W6), all the patients will undergo neurological, gait/balance, cognitive/behavioral, magnetic resonance imaging (MRI) and serum biomarkers evaluations. Neurological, gait/balance, cognitive/behavioral assessments and serum biomarkers will be also repeated at the 14-week follow-up (W14) to assess maintenance of results.\n\nPatients of both DUAL-TASK+AOT-MI and DUAL-TASK groups will be further randomized to repeat the training (6 weeks, 3 times/week, 1 hour each session) starting at W14 (DUAL-TASK+AOT-MI_DOUBLE and DUAL-TASK_DOUBLE groups). After six weeks (W20) all the subjects repeating the training will be evaluated (neurological, gait/balance, cognitive/behavioral assessments). At 28-week follow-up (W28), the whole sample of patients will be assessed with neurological, gait/balance, cognitive/behavioral, MRI and serum biomarkers evaluations. All MRI scans will be acquired at least 12 hours after last dopaminergic therapy administration to mitigate the pharmacological effects on neural activity. Twenty age- and sex-matched healthy controls will be recruited to perform gait/balance and cognitive/behavioral assessments, blood sample and brain MRI acquisition at baseline. The secondary aims of the study are to define the neuroimaging and blood-based biomarkers of PD-PIGD patients presenting different clinical features (e.g. presence of mild cognitive impairment, freezing of gait, falls and mood disturbances) and to evaluate the role of blood-based and neuroimaging biomarkers, together with clinical characteristics, in predicting the response to different dosages of rehabilitation in PD-PIGD throughout the development of a machine-learning algorithm.",
        "tokens": "['Multiparametric', 'Biomarkers', 'to', 'Predict', 'the', 'Response', 'to', 'Different', 'Protocols', 'of', 'Motor', '-', 'cognitive', 'Rehabilitation', 'in', 'Parkinson', \"'s\", 'Disease', 'Subjects', 'With', 'Postural', 'Instability', 'and', 'Gait', 'Disorders', '|', 'The', 'aim', 'of', 'the', 'study', 'is', 'to', 'compare', 'the', 'effects', 'of', '2', 'different', 'dosages', 'and', 'modalities', 'of', 'motor', '-', 'cognitive', 'rehabilitation', 'in', 'Parkinson', \"'s\", 'disease', 'with', 'postural', 'instability', 'and', 'gait', 'disorders', '(', 'PD', '-', 'PIGD', ')', 'on', 'clinical', 'features', ',', 'neuroimaging', 'and', 'blood', '-', 'based', 'biomarkers', 'at', 'short', '-', 'term', '(', '2', 'months', ')', 'and', 'long', '-', 'term', '(', '7', 'months', ')', 'follow', '-', 'up', '.', 'Fifty', 'subjects', 'with', 'PD', '-', 'PIGD', 'will', 'be', 'randomized', 'in', '2', 'training', 'groups', ':', 'DUAL', '-', 'TASK+AOT', '-', 'MI', 'and', 'the', 'DUAL', '-', 'TASK', 'groups', '.', 'The', 'DUAL', '-', 'TASK+AOT', '-', 'MI', 'group', 'will', 'perform', 'a', 'dual', '-', 'task', 'gait', '/', 'balance', 'training', 'consisting', 'of', 'action', 'observation', 'training', '(', 'AOT', ')', 'and', 'motor', 'imagery', '(', 'MI', ')', 'combined', 'with', 'practicing', 'the', 'observed', '-', 'imagined', 'exercises', ';', 'DUAL', '-', 'TASK', 'group', 'will', 'perform', 'the', 'same', 'exercises', 'combined', 'with', 'watching', 'landscape', 'videos', '.', 'The', 'training', 'will', 'last', '6', 'weeks', ',', '3', 'times', '/', 'week', ',', '1', 'hour', 'per', 'session', '.', '\\n\\n', 'Before', 'and', 'after', 'training', '(', 'W6', ')', ',', 'all', 'the', 'patients', 'will', 'undergo', 'neurological', ',', 'gait', '/', 'balance', ',', 'cognitive', '/', 'behavioral', ',', 'magnetic', 'resonance', 'imaging', '(', 'MRI', ')', 'and', 'serum', 'biomarkers', 'evaluations', '.', 'Neurological', ',', 'gait', '/', 'balance', ',', 'cognitive', '/', 'behavioral', 'assessments', 'and', 'serum', 'biomarkers', 'will', 'be', 'also', 'repeated', 'at', 'the', '14', '-', 'week', 'follow', '-', 'up', '(', 'W14', ')', 'to', 'assess', 'maintenance', 'of', 'results', '.', '\\n\\n', 'Patients', 'of', 'both', 'DUAL', '-', 'TASK+AOT', '-', 'MI', 'and', 'DUAL', '-', 'TASK', 'groups', 'will', 'be', 'further', 'randomized', 'to', 'repeat', 'the', 'training', '(', '6', 'weeks', ',', '3', 'times', '/', 'week', ',', '1', 'hour', 'each', 'session', ')', 'starting', 'at', 'W14', '(', 'DUAL', '-', 'TASK+AOT', '-', 'MI_DOUBLE', 'and', 'DUAL', '-', 'TASK_DOUBLE', 'groups', ')', '.', 'After', 'six', 'weeks', '(', 'W20', ')', 'all', 'the', 'subjects', 'repeating', 'the', 'training', 'will', 'be', 'evaluated', '(', 'neurological', ',', 'gait', '/', 'balance', ',', 'cognitive', '/', 'behavioral', 'assessments', ')', '.', 'At', '28', '-', 'week', 'follow', '-', 'up', '(', 'W28', ')', ',', 'the', 'whole', 'sample', 'of', 'patients', 'will', 'be', 'assessed', 'with', 'neurological', ',', 'gait', '/', 'balance', ',', 'cognitive', '/', 'behavioral', ',', 'MRI', 'and', 'serum', 'biomarkers', 'evaluations', '.', 'All', 'MRI', 'scans', 'will', 'be', 'acquired', 'at', 'least', '12', 'hours', 'after', 'last', 'dopaminergic', 'therapy', 'administration', 'to', 'mitigate', 'the', 'pharmacological', 'effects', 'on', 'neural', 'activity', '.', 'Twenty', 'age-', 'and', 'sex', '-', 'matched', 'healthy', 'controls', 'will', 'be', 'recruited', 'to', 'perform', 'gait', '/', 'balance', 'and', 'cognitive', '/', 'behavioral', 'assessments', ',', 'blood', 'sample', 'and', 'brain', 'MRI', 'acquisition', 'at', 'baseline', '.', 'The', 'secondary', 'aims', 'of', 'the', 'study', 'are', 'to', 'define', 'the', 'neuroimaging', 'and', 'blood', '-', 'based', 'biomarkers', 'of', 'PD', '-', 'PIGD', 'patients', 'presenting', 'different', 'clinical', 'features', '(', 'e.g.', 'presence', 'of', 'mild', 'cognitive', 'impairment', ',', 'freezing', 'of', 'gait', ',', 'falls', 'and', 'mood', 'disturbances', ')', 'and', 'to', 'evaluate', 'the', 'role', 'of', 'blood', '-', 'based', 'and', 'neuroimaging', 'biomarkers', ',', 'together', 'with', 'clinical', 'characteristics', ',', 'in', 'predicting', 'the', 'response', 'to', 'different', 'dosages', 'of', 'rehabilitation', 'in', 'PD', '-', 'PIGD', 'throughout', 'the', 'development', 'of', 'a', 'machine', '-', 'learning', 'algorithm', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 77,
                "end": 107,
                "text": "Motor-cognitive Rehabilitation",
                "type": "OTHER"
            },
            {
                "start": 111,
                "end": 130,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 145,
                "end": 165,
                "text": "Postural Instability",
                "type": "CONDITION"
            },
            {
                "start": 170,
                "end": 184,
                "text": "Gait Disorders",
                "type": "CONDITION"
            },
            {
                "start": 275,
                "end": 305,
                "text": "motor-cognitive rehabilitation",
                "type": "OTHER"
            },
            {
                "start": 309,
                "end": 328,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 334,
                "end": 354,
                "text": "postural instability",
                "type": "CONDITION"
            },
            {
                "start": 359,
                "end": 373,
                "text": "gait disorders",
                "type": "CONDITION"
            },
            {
                "start": 375,
                "end": 382,
                "text": "PD-PIGD",
                "type": "CONDITION"
            },
            {
                "start": 527,
                "end": 534,
                "text": "PD-PIGD",
                "type": "CONDITION"
            },
            {
                "start": 576,
                "end": 592,
                "text": "DUAL-TASK+AOT-MI",
                "type": "OTHER"
            },
            {
                "start": 601,
                "end": 610,
                "text": "DUAL-TASK",
                "type": "OTHER"
            },
            {
                "start": 623,
                "end": 639,
                "text": "DUAL-TASK+AOT-MI",
                "type": "OTHER"
            },
            {
                "start": 661,
                "end": 692,
                "text": "dual-task gait/balance training",
                "type": "PHYSICAL"
            },
            {
                "start": 707,
                "end": 734,
                "text": "action observation training",
                "type": "OTHER"
            },
            {
                "start": 736,
                "end": 739,
                "text": "AOT",
                "type": "OTHER"
            },
            {
                "start": 745,
                "end": 758,
                "text": "motor imagery",
                "type": "OTHER"
            },
            {
                "start": 760,
                "end": 762,
                "text": "MI",
                "type": "OTHER"
            },
            {
                "start": 822,
                "end": 831,
                "text": "DUAL-TASK",
                "type": "OTHER"
            },
            {
                "start": 884,
                "end": 909,
                "text": "watching landscape videos",
                "type": "OTHER"
            },
            {
                "start": 1344,
                "end": 1360,
                "text": "DUAL-TASK+AOT-MI",
                "type": "OTHER"
            },
            {
                "start": 1365,
                "end": 1374,
                "text": "DUAL-TASK",
                "type": "OTHER"
            },
            {
                "start": 2285,
                "end": 2292,
                "text": "PD-PIGD",
                "type": "CONDITION"
            },
            {
                "start": 2359,
                "end": 2384,
                "text": "mild cognitive impairment",
                "type": "CONDITION"
            },
            {
                "start": 2386,
                "end": 2402,
                "text": "freezing of gait",
                "type": "CONDITION"
            },
            {
                "start": 2404,
                "end": 2409,
                "text": "falls",
                "type": "CONDITION"
            },
            {
                "start": 2414,
                "end": 2431,
                "text": "mood disturbances",
                "type": "CONDITION"
            },
            {
                "start": 2611,
                "end": 2618,
                "text": "PD-PIGD",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02705547",
        "text": "Open-label Biomarker Study of Rosuvastatin (Crestor) for the Treatment of Patients With Friedreich Ataxia | This study is an exploratory open-label clinical trial of Rosuvastatin in patients with Friedreich ataxia (FRDA). This is an outpatient trial with the goal of enrolling 10 evaluable adults with genetically confirmed FRDA who are between the ages of 18-65. Subjects will receive 10mg of oral Rosuvastatin daily for three months.",
        "tokens": "['Open', '-', 'label', 'Biomarker', 'Study', 'of', 'Rosuvastatin', '(', 'Crestor', ')', 'for', 'the', 'Treatment', 'of', 'Patients', 'With', 'Friedreich', 'Ataxia', '|', 'This', 'study', 'is', 'an', 'exploratory', 'open', '-', 'label', 'clinical', 'trial', 'of', 'Rosuvastatin', 'in', 'patients', 'with', 'Friedreich', 'ataxia', '(', 'FRDA', ')', '.', 'This', 'is', 'an', 'outpatient', 'trial', 'with', 'the', 'goal', 'of', 'enrolling', '10', 'evaluable', 'adults', 'with', 'genetically', 'confirmed', 'FRDA', 'who', 'are', 'between', 'the', 'ages', 'of', '18', '-', '65', '.', 'Subjects', 'will', 'receive', '10', 'mg', 'of', 'oral', 'Rosuvastatin', 'daily', 'for', 'three', 'months', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 30,
                "end": 42,
                "text": "Rosuvastatin",
                "type": "DRUG"
            },
            {
                "start": 44,
                "end": 51,
                "text": "Crestor",
                "type": "DRUG"
            },
            {
                "start": 88,
                "end": 105,
                "text": "Friedreich Ataxia",
                "type": "CONDITION"
            },
            {
                "start": 166,
                "end": 178,
                "text": "Rosuvastatin",
                "type": "DRUG"
            },
            {
                "start": 196,
                "end": 213,
                "text": "Friedreich ataxia",
                "type": "CONDITION"
            },
            {
                "start": 215,
                "end": 219,
                "text": "FRDA",
                "type": "CONDITION"
            },
            {
                "start": 324,
                "end": 328,
                "text": "FRDA",
                "type": "CONDITION"
            },
            {
                "start": 399,
                "end": 411,
                "text": "Rosuvastatin",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT03451955",
        "text": "The Effect of a Gluten Free Diet on the Permeability of the Blood Brain Barrier in Patients With Clinically Isolated Syndrome Measured by Dynamic Contrast Enhanced Magnetic Resonance Imaging | Disruption of the blood brain barrier (BBB) is associated with inflammatory conditions of the central nervous system (CNS). This clinical trial aims to investigate whether following a gluten-free diet (GFD) for six months can contribute to normalizing BBB permeability in patients with newly diagnosed clinically isolated syndrome (CIS) and multiple sclerosis (MS). Furthermore, the study seeks to identify possible effects of a GFD on markers of systemic as well as CNS inflammation. Lastly, gut permeability is measured in order to examine whether there are any correlations between the permeability of the gut and the BBB as well as the inflammatory state in the intestine and CNS. From a patient's view, potential positive effects of a GFD will be manifested through an alleviation of symptoms, improved quality of life and reduced risk of CIS progressing to MS. Evaluating a possible role of gluten in MS pathogenesis can contribute to directing future research and optimizing treatment protocols.",
        "tokens": "['The', 'Effect', 'of', 'a', 'Gluten', 'Free', 'Diet', 'on', 'the', 'Permeability', 'of', 'the', 'Blood', 'Brain', 'Barrier', 'in', 'Patients', 'With', 'Clinically', 'Isolated', 'Syndrome', 'Measured', 'by', 'Dynamic', 'Contrast', 'Enhanced', 'Magnetic', 'Resonance', 'Imaging', '|', 'Disruption', 'of', 'the', 'blood', 'brain', 'barrier', '(', 'BBB', ')', 'is', 'associated', 'with', 'inflammatory', 'conditions', 'of', 'the', 'central', 'nervous', 'system', '(', 'CNS', ')', '.', 'This', 'clinical', 'trial', 'aims', 'to', 'investigate', 'whether', 'following', 'a', 'gluten', '-', 'free', 'diet', '(', 'GFD', ')', 'for', 'six', 'months', 'can', 'contribute', 'to', 'normalizing', 'BBB', 'permeability', 'in', 'patients', 'with', 'newly', 'diagnosed', 'clinically', 'isolated', 'syndrome', '(', 'CIS', ')', 'and', 'multiple', 'sclerosis', '(', 'MS', ')', '.', 'Furthermore', ',', 'the', 'study', 'seeks', 'to', 'identify', 'possible', 'effects', 'of', 'a', 'GFD', 'on', 'markers', 'of', 'systemic', 'as', 'well', 'as', 'CNS', 'inflammation', '.', 'Lastly', ',', 'gut', 'permeability', 'is', 'measured', 'in', 'order', 'to', 'examine', 'whether', 'there', 'are', 'any', 'correlations', 'between', 'the', 'permeability', 'of', 'the', 'gut', 'and', 'the', 'BBB', 'as', 'well', 'as', 'the', 'inflammatory', 'state', 'in', 'the', 'intestine', 'and', 'CNS', '.', 'From', 'a', 'patient', \"'s\", 'view', ',', 'potential', 'positive', 'effects', 'of', 'a', 'GFD', 'will', 'be', 'manifested', 'through', 'an', 'alleviation', 'of', 'symptoms', ',', 'improved', 'quality', 'of', 'life', 'and', 'reduced', 'risk', 'of', 'CIS', 'progressing', 'to', 'MS', '.', 'Evaluating', 'a', 'possible', 'role', 'of', 'gluten', 'in', 'MS', 'pathogenesis', 'can', 'contribute', 'to', 'directing', 'future', 'research', 'and', 'optimizing', 'treatment', 'protocols', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 16,
                "end": 32,
                "text": "Gluten Free Diet",
                "type": "OTHER"
            },
            {
                "start": 97,
                "end": 125,
                "text": "Clinically Isolated Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 377,
                "end": 393,
                "text": "gluten-free diet",
                "type": "OTHER"
            },
            {
                "start": 395,
                "end": 398,
                "text": "GFD",
                "type": "OTHER"
            },
            {
                "start": 479,
                "end": 523,
                "text": "newly diagnosed clinically isolated syndrome",
                "type": "CONDITION"
            },
            {
                "start": 525,
                "end": 528,
                "text": "CIS",
                "type": "CONDITION"
            },
            {
                "start": 534,
                "end": 552,
                "text": "multiple sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 554,
                "end": 556,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 622,
                "end": 625,
                "text": "GFD",
                "type": "OTHER"
            },
            {
                "start": 933,
                "end": 936,
                "text": "GFD",
                "type": "OTHER"
            },
            {
                "start": 1037,
                "end": 1040,
                "text": "CIS",
                "type": "CONDITION"
            },
            {
                "start": 1056,
                "end": 1058,
                "text": "MS",
                "type": "CONDITION"
            },
            {
                "start": 1100,
                "end": 1102,
                "text": "MS",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00407667",
        "text": "Transcranial Direct Current Stimulation (tDCS) of the Lesioned or Non-lesioned Hemisphere Plus Computer-assisted Arm Trainer: a Randomized, Placebo-controlled Double-blind Multi-centre Study in Patients With Severe Arm Paresis Early After Stroke | Transcranial galvanic stimulation (tDCS) seems to promote motor recovery after stroke by stimulating (anodal) or inhibiting (cathodal) neural circuits in the brain. In the treatment of severe arm paresis after stroke, robot-assisted arm training (AT) proved to be effective, but nevertheless only a few patients could use their affected hand functionally in daily life after robot training. Therefore the present study intends to combine both approaches, tDCS + AT, applied at the same time every day for six weeks. The study has three treatment arms, two groups will receive the tDCS, either anodal of the lesioned or cathodal of the non-lesioned hemisphere. The anodal stimulation is expected to facilitate the activity of the arm motor area of the lesioned side directly, while the cathodal stimulation of the non-lesioned hemisphere is expected to facilitate the lesioned side indirectly by decreasing inhibitory inputs. The third group will receive a sham-stimulation. All patients will work with the AT simultaneously to the tDCS, respectively sham-tDCS.",
        "tokens": "['Transcranial', 'Direct', 'Current', 'Stimulation', '(', 'tDCS', ')', 'of', 'the', 'Lesioned', 'or', 'Non', '-', 'lesioned', 'Hemisphere', 'Plus', 'Computer', '-', 'assisted', 'Arm', 'Trainer', ':', 'a', 'Randomized', ',', 'Placebo', '-', 'controlled', 'Double', '-', 'blind', 'Multi', '-', 'centre', 'Study', 'in', 'Patients', 'With', 'Severe', 'Arm', 'Paresis', 'Early', 'After', 'Stroke', '|', 'Transcranial', 'galvanic', 'stimulation', '(', 'tDCS', ')', 'seems', 'to', 'promote', 'motor', 'recovery', 'after', 'stroke', 'by', 'stimulating', '(', 'anodal', ')', 'or', 'inhibiting', '(', 'cathodal', ')', 'neural', 'circuits', 'in', 'the', 'brain', '.', 'In', 'the', 'treatment', 'of', 'severe', 'arm', 'paresis', 'after', 'stroke', ',', 'robot', '-', 'assisted', 'arm', 'training', '(', 'AT', ')', 'proved', 'to', 'be', 'effective', ',', 'but', 'nevertheless', 'only', 'a', 'few', 'patients', 'could', 'use', 'their', 'affected', 'hand', 'functionally', 'in', 'daily', 'life', 'after', 'robot', 'training', '.', 'Therefore', 'the', 'present', 'study', 'intends', 'to', 'combine', 'both', 'approaches', ',', 'tDCS', '+', 'AT', ',', 'applied', 'at', 'the', 'same', 'time', 'every', 'day', 'for', 'six', 'weeks', '.', 'The', 'study', 'has', 'three', 'treatment', 'arms', ',', 'two', 'groups', 'will', 'receive', 'the', 'tDCS', ',', 'either', 'anodal', 'of', 'the', 'lesioned', 'or', 'cathodal', 'of', 'the', 'non', '-', 'lesioned', 'hemisphere', '.', 'The', 'anodal', 'stimulation', 'is', 'expected', 'to', 'facilitate', 'the', 'activity', 'of', 'the', 'arm', 'motor', 'area', 'of', 'the', 'lesioned', 'side', 'directly', ',', 'while', 'the', 'cathodal', 'stimulation', 'of', 'the', 'non', '-', 'lesioned', 'hemisphere', 'is', 'expected', 'to', 'facilitate', 'the', 'lesioned', 'side', 'indirectly', 'by', 'decreasing', 'inhibitory', 'inputs', '.', 'The', 'third', 'group', 'will', 'receive', 'a', 'sham', '-', 'stimulation', '.', 'All', 'patients', 'will', 'work', 'with', 'the', 'AT', 'simultaneously', 'to', 'the', 'tDCS', ',', 'respectively', 'sham', '-', 'tDCS', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'B-COND', 'I-COND', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 39,
                "text": "Transcranial Direct Current Stimulation",
                "type": "OTHER"
            },
            {
                "start": 41,
                "end": 45,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 95,
                "end": 124,
                "text": "Computer-assisted Arm Trainer",
                "type": "PHYSICAL"
            },
            {
                "start": 140,
                "end": 147,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 208,
                "end": 226,
                "text": "Severe Arm Paresis",
                "type": "CONDITION"
            },
            {
                "start": 227,
                "end": 245,
                "text": "Early After Stroke",
                "type": "CONDITION"
            },
            {
                "start": 248,
                "end": 281,
                "text": "Transcranial galvanic stimulation",
                "type": "OTHER"
            },
            {
                "start": 283,
                "end": 287,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 327,
                "end": 333,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 433,
                "end": 451,
                "text": "severe arm paresis",
                "type": "CONDITION"
            },
            {
                "start": 452,
                "end": 464,
                "text": "after stroke",
                "type": "CONDITION"
            },
            {
                "start": 466,
                "end": 493,
                "text": "robot-assisted arm training",
                "type": "PHYSICAL"
            },
            {
                "start": 495,
                "end": 497,
                "text": "AT",
                "type": "PHYSICAL"
            },
            {
                "start": 623,
                "end": 637,
                "text": "robot training",
                "type": "PHYSICAL"
            },
            {
                "start": 703,
                "end": 707,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 710,
                "end": 712,
                "text": "AT",
                "type": "PHYSICAL"
            },
            {
                "start": 828,
                "end": 832,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 1204,
                "end": 1220,
                "text": "sham-stimulation",
                "type": "CONTROL"
            },
            {
                "start": 1254,
                "end": 1256,
                "text": "AT",
                "type": "PHYSICAL"
            },
            {
                "start": 1279,
                "end": 1283,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 1298,
                "end": 1307,
                "text": "sham-tDCS",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT05307354",
        "text": "The Effectiveness of Tibial Nerve Mobilization in Patients With Tarsal Tunnel Syndrome | This randomized, clinical, single-blinded, controlledstudywasinitiallyplannedtoinclude 35 patients diagnosed with tarsal tunnel who applied to K\u00fctahya Health Sciences University, Evliya \u00c7elebi Training and Research Hospital, Physical Medicine and Rehabilitation outpatient clinic.Patients aged 20-55 years who were diagnosed with tarsal tunnel syndrome by electromyography (EMG) in the last 6 months were included in the study. The patients were randomized into two groups using the computer-assisted randomization method. Tibial nerve mobilization and foot-ankle range of motion exercises will be given to the study group, and only foot-ankle joint range of motion exercises will be given to the control group. All the patients were evaluated with the Visual Analog Scale (VAS), Foot Functional Index (FFI), Neuropathic Pain QuestionnaireN (NPQ) and Tibial Nerve ultrasonography before the intervention and at the fourth week of intervention.",
        "tokens": "['The', 'Effectiveness', 'of', 'Tibial', 'Nerve', 'Mobilization', 'in', 'Patients', 'With', 'Tarsal', 'Tunnel', 'Syndrome', '|', 'This', 'randomized', ',', 'clinical', ',', 'single', '-', 'blinded', ',', 'controlledstudywasinitiallyplannedtoinclude', '35', 'patients', 'diagnosed', 'with', 'tarsal', 'tunnel', 'who', 'applied', 'to', 'K\u00fctahya', 'Health', 'Sciences', 'University', ',', 'Evliya', '\u00c7elebi', 'Training', 'and', 'Research', 'Hospital', ',', 'Physical', 'Medicine', 'and', 'Rehabilitation', 'outpatient', 'clinic', '.', 'Patients', 'aged', '20', '-', '55', 'years', 'who', 'were', 'diagnosed', 'with', 'tarsal', 'tunnel', 'syndrome', 'by', 'electromyography', '(', 'EMG', ')', 'in', 'the', 'last', '6', 'months', 'were', 'included', 'in', 'the', 'study', '.', 'The', 'patients', 'were', 'randomized', 'into', 'two', 'groups', 'using', 'the', 'computer', '-', 'assisted', 'randomization', 'method', '.', 'Tibial', 'nerve', 'mobilization', 'and', 'foot', '-', 'ankle', 'range', 'of', 'motion', 'exercises', 'will', 'be', 'given', 'to', 'the', 'study', 'group', ',', 'and', 'only', 'foot', '-', 'ankle', 'joint', 'range', 'of', 'motion', 'exercises', 'will', 'be', 'given', 'to', 'the', 'control', 'group', '.', 'All', 'the', 'patients', 'were', 'evaluated', 'with', 'the', 'Visual', 'Analog', 'Scale', '(', 'VAS', ')', ',', 'Foot', 'Functional', 'Index', '(', 'FFI', ')', ',', 'Neuropathic', 'Pain', 'QuestionnaireN', '(', 'NPQ', ')', 'and', 'Tibial', 'Nerve', 'ultrasonography', 'before', 'the', 'intervention', 'and', 'at', 'the', 'fourth', 'week', 'of', 'intervention', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 21,
                "end": 46,
                "text": "Tibial Nerve Mobilization",
                "type": "PHYSICAL"
            },
            {
                "start": 64,
                "end": 86,
                "text": "Tarsal Tunnel Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 203,
                "end": 216,
                "text": "tarsal tunnel",
                "type": "CONDITION"
            },
            {
                "start": 419,
                "end": 441,
                "text": "tarsal tunnel syndrome",
                "type": "CONDITION"
            },
            {
                "start": 612,
                "end": 637,
                "text": "Tibial nerve mobilization",
                "type": "PHYSICAL"
            },
            {
                "start": 642,
                "end": 678,
                "text": "foot-ankle range of motion exercises",
                "type": "PHYSICAL"
            },
            {
                "start": 717,
                "end": 764,
                "text": "only foot-ankle joint range of motion exercises",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT03944447",
        "text": "Outcomes Mandate National Integration With Cannabis as Medicine | This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.",
        "tokens": "['Outcomes', 'Mandate', 'National', 'Integration', 'With', 'Cannabis', 'as', 'Medicine', '|', 'This', 'will', 'be', 'a', 'multistate', ',', 'multicenter', 'clinical', 'study', 'to', 'determine', 'the', 'efficacy', 'and', 'safety', 'of', 'medical', 'cannabis', 'for', 'a', 'wide', 'variety', 'of', 'chronic', 'medical', 'conditions', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 43,
                "end": 51,
                "text": "Cannabis",
                "type": "OTHER"
            },
            {
                "start": 160,
                "end": 176,
                "text": "medical cannabis",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT04468750",
        "text": "The Effect of Kinesiotaping on Glenohumeral Shoulder Subluxation in Post-stroke Patients | To evaluate the effectiveness of the kinesiotaping on pain, recovery of movement and daily life activities in Turkish hemiplegic patients.",
        "tokens": "['The', 'Effect', 'of', 'Kinesiotaping', 'on', 'Glenohumeral', 'Shoulder', 'Subluxation', 'in', 'Post', '-', 'stroke', 'Patients', '|', 'To', 'evaluate', 'the', 'effectiveness', 'of', 'the', 'kinesiotaping', 'on', 'pain', ',', 'recovery', 'of', 'movement', 'and', 'daily', 'life', 'activities', 'in', 'Turkish', 'hemiplegic', 'patients', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 14,
                "end": 27,
                "text": "Kinesiotaping",
                "type": "OTHER"
            },
            {
                "start": 31,
                "end": 64,
                "text": "Glenohumeral Shoulder Subluxation",
                "type": "CONDITION"
            },
            {
                "start": 73,
                "end": 79,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 128,
                "end": 141,
                "text": "kinesiotaping",
                "type": "OTHER"
            },
            {
                "start": 145,
                "end": 149,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 209,
                "end": 219,
                "text": "hemiplegic",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03746392",
        "text": "Using the Electronic Health Record to Identify and Promote Goals-of-Care Communication | This two-year pilot study will test whether a one-page \"Jumpstart Form\" will affect goals-of-care discussions in the hospital. This form will be provided to clinicians and will include patient-specific information about preferences for goals-of-care communication and for care, as well as tips to improve this communication. Jumpstart forms will also be provided to patients or, if they are unable to communicate, their surrogates/family members. The information on the form will be obtained from questionnaires. The form is tailored to help patients and surrogates talk with clinicians about goals of care. This study is based on a successful application of Jumpstart Form in the outpatient clinic setting.",
        "tokens": "['Using', 'the', 'Electronic', 'Health', 'Record', 'to', 'Identify', 'and', 'Promote', 'Goals', '-', 'of', '-', 'Care', 'Communication', '|', 'This', 'two', '-', 'year', 'pilot', 'study', 'will', 'test', 'whether', 'a', 'one', '-', 'page', '\"', 'Jumpstart', 'Form', '\"', 'will', 'affect', 'goals', '-', 'of', '-', 'care', 'discussions', 'in', 'the', 'hospital', '.', 'This', 'form', 'will', 'be', 'provided', 'to', 'clinicians', 'and', 'will', 'include', 'patient', '-', 'specific', 'information', 'about', 'preferences', 'for', 'goals', '-', 'of', '-', 'care', 'communication', 'and', 'for', 'care', ',', 'as', 'well', 'as', 'tips', 'to', 'improve', 'this', 'communication', '.', 'Jumpstart', 'forms', 'will', 'also', 'be', 'provided', 'to', 'patients', 'or', ',', 'if', 'they', 'are', 'unable', 'to', 'communicate', ',', 'their', 'surrogates', '/', 'family', 'members', '.', 'The', 'information', 'on', 'the', 'form', 'will', 'be', 'obtained', 'from', 'questionnaires', '.', 'The', 'form', 'is', 'tailored', 'to', 'help', 'patients', 'and', 'surrogates', 'talk', 'with', 'clinicians', 'about', 'goals', 'of', 'care', '.', 'This', 'study', 'is', 'based', 'on', 'a', 'successful', 'application', 'of', 'Jumpstart', 'Form', 'in', 'the', 'outpatient', 'clinic', 'setting', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 145,
                "end": 159,
                "text": "Jumpstart Form",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 414,
                "end": 429,
                "text": "Jumpstart forms",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 748,
                "end": 762,
                "text": "Jumpstart Form",
                "type": "BEHAVIOURAL"
            }
        ]
    },
    {
        "nctid": "NCT05681663",
        "text": "The Effectiveness of Different Pressure of Extracorporeal Shock Wave Therapy for Management of Carpal Tunnel Syndrome: a Randomized Controlled Trial | Peripheral nerve entrapment neuropathies are the most common mononeuropathies in clinical practice. Carpal Tunnel Syndrome (CTS), n. It occurs as a result of compression of the medianus as it passes through the carpal tunnel, a narrow osteofibrous canal. CTS is the most common entrapment neuropathy of the upper extremity, affecting approximately 3% of the general adult population.\n\nThis study, which was designed as a randomized controlled study, will include 36 patients with CTS, aged between 18-65, who applied to K\u0131r\u015fehir Ahi Evran University Training and Research Hospital. In our study, both groups will be given 10 minutes of paraffin, 20 minutes of TENS, and 10 repetitions of tendon gliding exercise, 3 days a week for a total of 3 weeks (9 sessions). EESDT will be applied once a week in both groups (one group at 4 bar and the other at 1.5 bar pressure). Measurements will be made before treatment, after treatment, and at 12 weeks post-treatment.\n\nIn the literature, different pressure parameters were used in studies examining the efficacy of ESDT in the treatment of CTS. Although ESDT has been shown to have a curative effect on CTS, there is no consensus on which pressure parameter is more effective. Therefore, in this study, the effectiveness of ESDT applied at different pressure parameters in the treatment of CTS will be examined.",
        "tokens": "['The', 'Effectiveness', 'of', 'Different', 'Pressure', 'of', 'Extracorporeal', 'Shock', 'Wave', 'Therapy', 'for', 'Management', 'of', 'Carpal', 'Tunnel', 'Syndrome', ':', 'a', 'Randomized', 'Controlled', 'Trial', '|', 'Peripheral', 'nerve', 'entrapment', 'neuropathies', 'are', 'the', 'most', 'common', 'mononeuropathies', 'in', 'clinical', 'practice', '.', 'Carpal', 'Tunnel', 'Syndrome', '(', 'CTS', ')', ',', 'n.', 'It', 'occurs', 'as', 'a', 'result', 'of', 'compression', 'of', 'the', 'medianus', 'as', 'it', 'passes', 'through', 'the', 'carpal', 'tunnel', ',', 'a', 'narrow', 'osteofibrous', 'canal', '.', 'CTS', 'is', 'the', 'most', 'common', 'entrapment', 'neuropathy', 'of', 'the', 'upper', 'extremity', ',', 'affecting', 'approximately', '3', '%', 'of', 'the', 'general', 'adult', 'population', '.', '\\n\\n', 'This', 'study', ',', 'which', 'was', 'designed', 'as', 'a', 'randomized', 'controlled', 'study', ',', 'will', 'include', '36', 'patients', 'with', 'CTS', ',', 'aged', 'between', '18', '-', '65', ',', 'who', 'applied', 'to', 'K\u0131r\u015fehir', 'Ahi', 'Evran', 'University', 'Training', 'and', 'Research', 'Hospital', '.', 'In', 'our', 'study', ',', 'both', 'groups', 'will', 'be', 'given', '10', 'minutes', 'of', 'paraffin', ',', '20', 'minutes', 'of', 'TENS', ',', 'and', '10', 'repetitions', 'of', 'tendon', 'gliding', 'exercise', ',', '3', 'days', 'a', 'week', 'for', 'a', 'total', 'of', '3', 'weeks', '(', '9', 'sessions', ')', '.', 'EESDT', 'will', 'be', 'applied', 'once', 'a', 'week', 'in', 'both', 'groups', '(', 'one', 'group', 'at', '4', 'bar', 'and', 'the', 'other', 'at', '1.5', 'bar', 'pressure', ')', '.', 'Measurements', 'will', 'be', 'made', 'before', 'treatment', ',', 'after', 'treatment', ',', 'and', 'at', '12', 'weeks', 'post', '-', 'treatment', '.', '\\n\\n', 'In', 'the', 'literature', ',', 'different', 'pressure', 'parameters', 'were', 'used', 'in', 'studies', 'examining', 'the', 'efficacy', 'of', 'ESDT', 'in', 'the', 'treatment', 'of', 'CTS', '.', 'Although', 'ESDT', 'has', 'been', 'shown', 'to', 'have', 'a', 'curative', 'effect', 'on', 'CTS', ',', 'there', 'is', 'no', 'consensus', 'on', 'which', 'pressure', 'parameter', 'is', 'more', 'effective', '.', 'Therefore', ',', 'in', 'this', 'study', ',', 'the', 'effectiveness', 'of', 'ESDT', 'applied', 'at', 'different', 'pressure', 'parameters', 'in', 'the', 'treatment', 'of', 'CTS', 'will', 'be', 'examined', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 43,
                "end": 76,
                "text": "Extracorporeal Shock Wave Therapy",
                "type": "OTHER"
            },
            {
                "start": 95,
                "end": 117,
                "text": "Carpal Tunnel Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 251,
                "end": 273,
                "text": "Carpal Tunnel Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 275,
                "end": 278,
                "text": "CTS",
                "type": "CONDITION"
            },
            {
                "start": 406,
                "end": 409,
                "text": "CTS",
                "type": "CONDITION"
            },
            {
                "start": 631,
                "end": 634,
                "text": "CTS",
                "type": "CONDITION"
            },
            {
                "start": 787,
                "end": 795,
                "text": "paraffin",
                "type": "OTHER"
            },
            {
                "start": 811,
                "end": 815,
                "text": "TENS",
                "type": "OTHER"
            },
            {
                "start": 839,
                "end": 862,
                "text": "tendon gliding exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 915,
                "end": 920,
                "text": "EESDT",
                "type": "OTHER"
            },
            {
                "start": 1210,
                "end": 1214,
                "text": "ESDT",
                "type": "OTHER"
            },
            {
                "start": 1235,
                "end": 1238,
                "text": "CTS",
                "type": "CONDITION"
            },
            {
                "start": 1249,
                "end": 1253,
                "text": "ESDT",
                "type": "OTHER"
            },
            {
                "start": 1298,
                "end": 1301,
                "text": "CTS",
                "type": "CONDITION"
            },
            {
                "start": 1419,
                "end": 1423,
                "text": "ESDT",
                "type": "OTHER"
            },
            {
                "start": 1485,
                "end": 1488,
                "text": "CTS",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03684577",
        "text": "Efficacy of Hypnotherapy Compared to a Wait-list Control Group in the Treatment of Agoraphobia | The purpose of the study is to compare the efficacy of Hypnotherapy for the treatment of Agoraphobia compared to a wait-list control group.",
        "tokens": "['Efficacy', 'of', 'Hypnotherapy', 'Compared', 'to', 'a', 'Wait', '-', 'list', 'Control', 'Group', 'in', 'the', 'Treatment', 'of', 'Agoraphobia', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'compare', 'the', 'efficacy', 'of', 'Hypnotherapy', 'for', 'the', 'treatment', 'of', 'Agoraphobia', 'compared', 'to', 'a', 'wait', '-', 'list', 'control', 'group', '.']",
        "token_bio_labels": "['O', 'O', 'B-BEH', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O']",
        "entities": [
            {
                "start": 12,
                "end": 24,
                "text": "Hypnotherapy",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 39,
                "end": 56,
                "text": "Wait-list Control",
                "type": "CONTROL"
            },
            {
                "start": 83,
                "end": 94,
                "text": "Agoraphobia",
                "type": "CONDITION"
            },
            {
                "start": 152,
                "end": 164,
                "text": "Hypnotherapy",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 186,
                "end": 197,
                "text": "Agoraphobia",
                "type": "CONDITION"
            },
            {
                "start": 212,
                "end": 229,
                "text": "wait-list control",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT00976040",
        "text": "A Randomized Clinical Trial of Immediate Versus Standard Antiretroviral Therapy for HIV-infected Adults Presenting With Cryptococcal Meningitis | The goal of this randomized clinical trial is to compare early versus standard timing of initiation of antiretroviral therapy (ART) with respect to clearance of Cryptococcus neoformans from cerebrospinal fluid (CSF) among HIV-infected adults with Cryptococcal Meningitis.\n\nThe investigators hypothesize that early ART mediates more rapid clearance of C. neoformans from CSF, as manifested by a greater rate of decrease in C. neoformans colony forming units (CFUs) during the first 28 days after initiating antifungal treatment.\n\nSecondary hypotheses are that recovery of pathogen specific cellular immunity directed at C. neoformans, as manifested by increases in the number and function of C. neoformans-specific peripheral blood mononuclear cells is associated with 1) ART and 2) pathogen clearance. In addition, patients randomized to the intervention arm will have more rapid clearance of antigen levels in CSF and serum and will have a lower incidence of grade 3 and 4 Adverse events.",
        "tokens": "['A', 'Randomized', 'Clinical', 'Trial', 'of', 'Immediate', 'Versus', 'Standard', 'Antiretroviral', 'Therapy', 'for', 'HIV', '-', 'infected', 'Adults', 'Presenting', 'With', 'Cryptococcal', 'Meningitis', '|', 'The', 'goal', 'of', 'this', 'randomized', 'clinical', 'trial', 'is', 'to', 'compare', 'early', 'versus', 'standard', 'timing', 'of', 'initiation', 'of', 'antiretroviral', 'therapy', '(', 'ART', ')', 'with', 'respect', 'to', 'clearance', 'of', 'Cryptococcus', 'neoformans', 'from', 'cerebrospinal', 'fluid', '(', 'CSF', ')', 'among', 'HIV', '-', 'infected', 'adults', 'with', 'Cryptococcal', 'Meningitis', '.', '\\n\\n', 'The', 'investigators', 'hypothesize', 'that', 'early', 'ART', 'mediates', 'more', 'rapid', 'clearance', 'of', 'C.', 'neoformans', 'from', 'CSF', ',', 'as', 'manifested', 'by', 'a', 'greater', 'rate', 'of', 'decrease', 'in', 'C.', 'neoformans', 'colony', 'forming', 'units', '(', 'CFUs', ')', 'during', 'the', 'first', '28', 'days', 'after', 'initiating', 'antifungal', 'treatment', '.', '\\n\\n', 'Secondary', 'hypotheses', 'are', 'that', 'recovery', 'of', 'pathogen', 'specific', 'cellular', 'immunity', 'directed', 'at', 'C.', 'neoformans', ',', 'as', 'manifested', 'by', 'increases', 'in', 'the', 'number', 'and', 'function', 'of', 'C.', 'neoformans', '-', 'specific', 'peripheral', 'blood', 'mononuclear', 'cells', 'is', 'associated', 'with', '1', ')', 'ART', 'and', '2', ')', 'pathogen', 'clearance', '.', 'In', 'addition', ',', 'patients', 'randomized', 'to', 'the', 'intervention', 'arm', 'will', 'have', 'more', 'rapid', 'clearance', 'of', 'antigen', 'levels', 'in', 'CSF', 'and', 'serum', 'and', 'will', 'have', 'a', 'lower', 'incidence', 'of', 'grade', '3', 'and', '4', 'Adverse', 'events', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 31,
                "end": 79,
                "text": "Immediate Versus Standard Antiretroviral Therapy",
                "type": "OTHER"
            },
            {
                "start": 84,
                "end": 87,
                "text": "HIV",
                "type": "CONDITION"
            },
            {
                "start": 120,
                "end": 143,
                "text": "Cryptococcal Meningitis",
                "type": "CONDITION"
            },
            {
                "start": 203,
                "end": 271,
                "text": "early versus standard timing of initiation of antiretroviral therapy",
                "type": "OTHER"
            },
            {
                "start": 273,
                "end": 276,
                "text": "ART",
                "type": "OTHER"
            },
            {
                "start": 368,
                "end": 371,
                "text": "HIV",
                "type": "CONDITION"
            },
            {
                "start": 393,
                "end": 416,
                "text": "Cryptococcal Meningitis",
                "type": "CONDITION"
            },
            {
                "start": 454,
                "end": 463,
                "text": "early ART",
                "type": "OTHER"
            },
            {
                "start": 917,
                "end": 920,
                "text": "ART",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT03273816",
        "text": "Evaluation of the Benefit Provided by Sessions of Sophrology on the Intraoperative Management of Parkinsonian Patients in the Context of Deep Brain Stimulation Surgery. | Deep brain stimulation surgery, which consists of intracerebral implantation of electrodes, is considered one of the most effective techniques for controlling the motor fluctuations of Parkinson's disease. The particularity of this surgery is the necessity of the awakening of the patient for the correct positioning of the electrodes, it is therefore a difficult test for the patient.\n\nMedical sophrology is an ideal strategy to optimize the comfort of the patient during the operation thanks to its anxiolytic and analgesic virtues while guaranteeing the maintenance of a good patient vigilance favoring the cooperation with the operating room team. Indeed, sophrology is a body-mediated set of techniques, at the crossroads between hypnosis and yoga, which makes it possible to find a balance between emotions, thoughts and behaviors. It has already been applied in other fields such as oncology, pain management, preparation for childbirth, and for 5 years at the CHU of Rennes for preparation for the intervention of deep brain stimulation.",
        "tokens": "['Evaluation', 'of', 'the', 'Benefit', 'Provided', 'by', 'Sessions', 'of', 'Sophrology', 'on', 'the', 'Intraoperative', 'Management', 'of', 'Parkinsonian', 'Patients', 'in', 'the', 'Context', 'of', 'Deep', 'Brain', 'Stimulation', 'Surgery', '.', '|', 'Deep', 'brain', 'stimulation', 'surgery', ',', 'which', 'consists', 'of', 'intracerebral', 'implantation', 'of', 'electrodes', ',', 'is', 'considered', 'one', 'of', 'the', 'most', 'effective', 'techniques', 'for', 'controlling', 'the', 'motor', 'fluctuations', 'of', 'Parkinson', \"'s\", 'disease', '.', 'The', 'particularity', 'of', 'this', 'surgery', 'is', 'the', 'necessity', 'of', 'the', 'awakening', 'of', 'the', 'patient', 'for', 'the', 'correct', 'positioning', 'of', 'the', 'electrodes', ',', 'it', 'is', 'therefore', 'a', 'difficult', 'test', 'for', 'the', 'patient', '.', '\\n\\n', 'Medical', 'sophrology', 'is', 'an', 'ideal', 'strategy', 'to', 'optimize', 'the', 'comfort', 'of', 'the', 'patient', 'during', 'the', 'operation', 'thanks', 'to', 'its', 'anxiolytic', 'and', 'analgesic', 'virtues', 'while', 'guaranteeing', 'the', 'maintenance', 'of', 'a', 'good', 'patient', 'vigilance', 'favoring', 'the', 'cooperation', 'with', 'the', 'operating', 'room', 'team', '.', 'Indeed', ',', 'sophrology', 'is', 'a', 'body', '-', 'mediated', 'set', 'of', 'techniques', ',', 'at', 'the', 'crossroads', 'between', 'hypnosis', 'and', 'yoga', ',', 'which', 'makes', 'it', 'possible', 'to', 'find', 'a', 'balance', 'between', 'emotions', ',', 'thoughts', 'and', 'behaviors', '.', 'It', 'has', 'already', 'been', 'applied', 'in', 'other', 'fields', 'such', 'as', 'oncology', ',', 'pain', 'management', ',', 'preparation', 'for', 'childbirth', ',', 'and', 'for', '5', 'years', 'at', 'the', 'CHU', 'of', 'Rennes', 'for', 'preparation', 'for', 'the', 'intervention', 'of', 'deep', 'brain', 'stimulation', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O']",
        "entities": [
            {
                "start": 50,
                "end": 60,
                "text": "Sophrology",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 97,
                "end": 109,
                "text": "Parkinsonian",
                "type": "CONDITION"
            },
            {
                "start": 137,
                "end": 159,
                "text": "Deep Brain Stimulation",
                "type": "OTHER"
            },
            {
                "start": 171,
                "end": 193,
                "text": "Deep brain stimulation",
                "type": "OTHER"
            },
            {
                "start": 356,
                "end": 375,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 566,
                "end": 576,
                "text": "sophrology",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 831,
                "end": 841,
                "text": "sophrology",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 1193,
                "end": 1215,
                "text": "deep brain stimulation",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT00221767",
        "text": "Prospective Comparative Multicenter Study on the Medico-economical Impact of the Brindley Technique in the Management of Neurogenic Bladder in Patients With Injured Spinal Cord | Bladder dysfunction is a major problem in patients with complete spinal cord lesions. For patients presenting incontinence or risk for kidney, two major conventional alternatives are possible : conservative therapies (muscarinic receptor antagonists, vanilloids drugs and botulinum toxin in association with catheterization) and surgical techniques intervening in the nervous and urinary system.\n\nAmong these last alternatives, the Brindley technique (anterior sacral root stimulation with posterior rhizotomy) is the only technique allowing for the restauration of bladder function, continence, and micturition. The purpose of the study is to compare the Brindley technique with the first conventional approach in France from a medical and economical point of view.",
        "tokens": "['Prospective', 'Comparative', 'Multicenter', 'Study', 'on', 'the', 'Medico', '-', 'economical', 'Impact', 'of', 'the', 'Brindley', 'Technique', 'in', 'the', 'Management', 'of', 'Neurogenic', 'Bladder', 'in', 'Patients', 'With', 'Injured', 'Spinal', 'Cord', '|', 'Bladder', 'dysfunction', 'is', 'a', 'major', 'problem', 'in', 'patients', 'with', 'complete', 'spinal', 'cord', 'lesions', '.', 'For', 'patients', 'presenting', 'incontinence', 'or', 'risk', 'for', 'kidney', ',', 'two', 'major', 'conventional', 'alternatives', 'are', 'possible', ':', 'conservative', 'therapies', '(', 'muscarinic', 'receptor', 'antagonists', ',', 'vanilloids', 'drugs', 'and', 'botulinum', 'toxin', 'in', 'association', 'with', 'catheterization', ')', 'and', 'surgical', 'techniques', 'intervening', 'in', 'the', 'nervous', 'and', 'urinary', 'system', '.', '\\n\\n', 'Among', 'these', 'last', 'alternatives', ',', 'the', 'Brindley', 'technique', '(', 'anterior', 'sacral', 'root', 'stimulation', 'with', 'posterior', 'rhizotomy', ')', 'is', 'the', 'only', 'technique', 'allowing', 'for', 'the', 'restauration', 'of', 'bladder', 'function', ',', 'continence', ',', 'and', 'micturition', '.', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'compare', 'the', 'Brindley', 'technique', 'with', 'the', 'first', 'conventional', 'approach', 'in', 'France', 'from', 'a', 'medical', 'and', 'economical', 'point', 'of', 'view', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 81,
                "end": 99,
                "text": "Brindley Technique",
                "type": "SURGICAL"
            },
            {
                "start": 121,
                "end": 139,
                "text": "Neurogenic Bladder",
                "type": "CONDITION"
            },
            {
                "start": 157,
                "end": 176,
                "text": "Injured Spinal Cord",
                "type": "CONDITION"
            },
            {
                "start": 179,
                "end": 198,
                "text": "Bladder dysfunction",
                "type": "CONDITION"
            },
            {
                "start": 235,
                "end": 263,
                "text": "complete spinal cord lesions",
                "type": "CONDITION"
            },
            {
                "start": 611,
                "end": 629,
                "text": "Brindley technique",
                "type": "SURGICAL"
            },
            {
                "start": 631,
                "end": 688,
                "text": "anterior sacral root stimulation with posterior rhizotomy",
                "type": "SURGICAL"
            },
            {
                "start": 835,
                "end": 853,
                "text": "Brindley technique",
                "type": "SURGICAL"
            }
        ]
    },
    {
        "nctid": "NCT04576507",
        "text": "Effects of Repeated Cannabis Administration on Experimental Pain and Abuse Liability in Humans | Chronic pain is a significant public health concern in the U.S., for which prescription opioids have historically been the standard treatment. This has resulted in striking rates of opioid use disorders and fatal overdoses. Identifying non-opioid medications for the management of chronic pain with minimal abuse liability is a public health necessity, and cannabinoids are a promising drug class for this purpose. More than 80% of medicinal cannabis users report pain as their primary medical indication. These patients tend to seek products that are low in delta-9-tetrahydrocannabinol (THC; the primary psychoactive, and thus intoxicating, component of cannabis), and high in cannabidiol (CBD), a cannabinoid that purportedly has therapeutic benefit for pain but does not produce intoxicating effects [1]. However, there are few well-controlled human laboratory studies assessing the efficacy of high-CBD cannabis for pain in the context of abuse, and even less is known regarding the effects of daily repeated use of cannabis on pain and its relationship to abuse liability.\n\nThe proposed randomized, within-subjects, placebo-controlled 16-day crossover inpatient human laboratory pilot study (N = 16 healthy cannabis users; 8 men, 8 women) will address important gaps in our understanding of the potential therapeutic utility of cannabis for pain: 1) If repeated cannabis use can result in hyperalgesia; 2) If tolerance to the analgesic and abuse-related effects of cannabis develops and is reversible. Two distinct modalities of experimental pain will be assessed: The Cold Pressor Test (CPT) and Quantitative Sensory Testing Thermal Temporal Summation (QST-TTS), and participants will smoke cannabis 3x/day. Throughout the study, experimental pain and abuse-related effects will be assessed, as will sleep and subjective mood assessments.",
        "tokens": "['Effects', 'of', 'Repeated', 'Cannabis', 'Administration', 'on', 'Experimental', 'Pain', 'and', 'Abuse', 'Liability', 'in', 'Humans', '|', 'Chronic', 'pain', 'is', 'a', 'significant', 'public', 'health', 'concern', 'in', 'the', 'U.S.', ',', 'for', 'which', 'prescription', 'opioids', 'have', 'historically', 'been', 'the', 'standard', 'treatment', '.', 'This', 'has', 'resulted', 'in', 'striking', 'rates', 'of', 'opioid', 'use', 'disorders', 'and', 'fatal', 'overdoses', '.', 'Identifying', 'non', '-', 'opioid', 'medications', 'for', 'the', 'management', 'of', 'chronic', 'pain', 'with', 'minimal', 'abuse', 'liability', 'is', 'a', 'public', 'health', 'necessity', ',', 'and', 'cannabinoids', 'are', 'a', 'promising', 'drug', 'class', 'for', 'this', 'purpose', '.', 'More', 'than', '80', '%', 'of', 'medicinal', 'cannabis', 'users', 'report', 'pain', 'as', 'their', 'primary', 'medical', 'indication', '.', 'These', 'patients', 'tend', 'to', 'seek', 'products', 'that', 'are', 'low', 'in', 'delta-9', '-', 'tetrahydrocannabinol', '(', 'THC', ';', 'the', 'primary', 'psychoactive', ',', 'and', 'thus', 'intoxicating', ',', 'component', 'of', 'cannabis', ')', ',', 'and', 'high', 'in', 'cannabidiol', '(', 'CBD', ')', ',', 'a', 'cannabinoid', 'that', 'purportedly', 'has', 'therapeutic', 'benefit', 'for', 'pain', 'but', 'does', 'not', 'produce', 'intoxicating', 'effects', '[', '1', ']', '.', 'However', ',', 'there', 'are', 'few', 'well', '-', 'controlled', 'human', 'laboratory', 'studies', 'assessing', 'the', 'efficacy', 'of', 'high', '-', 'CBD', 'cannabis', 'for', 'pain', 'in', 'the', 'context', 'of', 'abuse', ',', 'and', 'even', 'less', 'is', 'known', 'regarding', 'the', 'effects', 'of', 'daily', 'repeated', 'use', 'of', 'cannabis', 'on', 'pain', 'and', 'its', 'relationship', 'to', 'abuse', 'liability', '.', '\\n\\n', 'The', 'proposed', 'randomized', ',', 'within', '-', 'subjects', ',', 'placebo', '-', 'controlled', '16', '-', 'day', 'crossover', 'inpatient', 'human', 'laboratory', 'pilot', 'study', '(', 'N', '=', '16', 'healthy', 'cannabis', 'users', ';', '8', 'men', ',', '8', 'women', ')', 'will', 'address', 'important', 'gaps', 'in', 'our', 'understanding', 'of', 'the', 'potential', 'therapeutic', 'utility', 'of', 'cannabis', 'for', 'pain', ':', '1', ')', 'If', 'repeated', 'cannabis', 'use', 'can', 'result', 'in', 'hyperalgesia', ';', '2', ')', 'If', 'tolerance', 'to', 'the', 'analgesic', 'and', 'abuse', '-', 'related', 'effects', 'of', 'cannabis', 'develops', 'and', 'is', 'reversible', '.', 'Two', 'distinct', 'modalities', 'of', 'experimental', 'pain', 'will', 'be', 'assessed', ':', 'The', 'Cold', 'Pressor', 'Test', '(', 'CPT', ')', 'and', 'Quantitative', 'Sensory', 'Testing', 'Thermal', 'Temporal', 'Summation', '(', 'QST', '-', 'TTS', ')', ',', 'and', 'participants', 'will', 'smoke', 'cannabis', '3x', '/', 'day', '.', 'Throughout', 'the', 'study', ',', 'experimental', 'pain', 'and', 'abuse', '-', 'related', 'effects', 'will', 'be', 'assessed', ',', 'as', 'will', 'sleep', 'and', 'subjective', 'mood', 'assessments', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 20,
                "end": 28,
                "text": "Cannabis",
                "type": "OTHER"
            },
            {
                "start": 60,
                "end": 64,
                "text": "Pain",
                "type": "CONDITION"
            },
            {
                "start": 97,
                "end": 109,
                "text": "Chronic pain",
                "type": "CONDITION"
            },
            {
                "start": 378,
                "end": 390,
                "text": "chronic pain",
                "type": "CONDITION"
            },
            {
                "start": 454,
                "end": 466,
                "text": "cannabinoids",
                "type": "DRUG"
            },
            {
                "start": 529,
                "end": 547,
                "text": "medicinal cannabis",
                "type": "OTHER"
            },
            {
                "start": 656,
                "end": 684,
                "text": "delta-9-tetrahydrocannabinol",
                "type": "DRUG"
            },
            {
                "start": 686,
                "end": 689,
                "text": "THC",
                "type": "DRUG"
            },
            {
                "start": 776,
                "end": 787,
                "text": "cannabidiol",
                "type": "DRUG"
            },
            {
                "start": 789,
                "end": 792,
                "text": "CBD",
                "type": "DRUG"
            },
            {
                "start": 797,
                "end": 808,
                "text": "cannabinoid",
                "type": "DRUG"
            },
            {
                "start": 854,
                "end": 858,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 996,
                "end": 1013,
                "text": "high-CBD cannabis",
                "type": "OTHER"
            },
            {
                "start": 1018,
                "end": 1022,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 1118,
                "end": 1126,
                "text": "cannabis",
                "type": "OTHER"
            },
            {
                "start": 1130,
                "end": 1134,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 1219,
                "end": 1226,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 1310,
                "end": 1318,
                "text": "cannabis",
                "type": "OTHER"
            },
            {
                "start": 1431,
                "end": 1439,
                "text": "cannabis",
                "type": "OTHER"
            },
            {
                "start": 1444,
                "end": 1448,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 1465,
                "end": 1473,
                "text": "cannabis",
                "type": "OTHER"
            },
            {
                "start": 1568,
                "end": 1576,
                "text": "cannabis",
                "type": "OTHER"
            },
            {
                "start": 1645,
                "end": 1649,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 1795,
                "end": 1803,
                "text": "cannabis",
                "type": "OTHER"
            },
            {
                "start": 1847,
                "end": 1851,
                "text": "pain",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01166828",
        "text": "Pressure Ulcer Prevention for SCI Using a Tele Home Program | NRI research focuses on nursing interventions that are patient-centered, culturally congruent, cost-effective and outcome-driven. High priority populations of interest are veterans with Spinal Cord Injuries (SCI). The development of innovative tele home techniques for preventing pressure ulcers in veterans with SCI is of high importance in the VA. Our findings may provide clinicians with improved methods for skin and wound assessment and more effective and efficient PUP strategies for Hispanic and non Hispanic veterans. The new model for primary care, the patient-centered Medical Home provides an exciting change in the VA that can benefit from the proposed project.",
        "tokens": "['Pressure', 'Ulcer', 'Prevention', 'for', 'SCI', 'Using', 'a', 'Tele', 'Home', 'Program', '|', 'NRI', 'research', 'focuses', 'on', 'nursing', 'interventions', 'that', 'are', 'patient', '-', 'centered', ',', 'culturally', 'congruent', ',', 'cost', '-', 'effective', 'and', 'outcome', '-', 'driven', '.', 'High', 'priority', 'populations', 'of', 'interest', 'are', 'veterans', 'with', 'Spinal', 'Cord', 'Injuries', '(', 'SCI', ')', '.', 'The', 'development', 'of', 'innovative', 'tele', 'home', 'techniques', 'for', 'preventing', 'pressure', 'ulcers', 'in', 'veterans', 'with', 'SCI', 'is', 'of', 'high', 'importance', 'in', 'the', 'VA', '.', 'Our', 'findings', 'may', 'provide', 'clinicians', 'with', 'improved', 'methods', 'for', 'skin', 'and', 'wound', 'assessment', 'and', 'more', 'effective', 'and', 'efficient', 'PUP', 'strategies', 'for', 'Hispanic', 'and', 'non', 'Hispanic', 'veterans', '.', 'The', 'new', 'model', 'for', 'primary', 'care', ',', 'the', 'patient', '-', 'centered', 'Medical', 'Home', 'provides', 'an', 'exciting', 'change', 'in', 'the', 'VA', 'that', 'can', 'benefit', 'from', 'the', 'proposed', 'project', '.']",
        "token_bio_labels": "['B-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 14,
                "text": "Pressure Ulcer",
                "type": "CONDITION"
            },
            {
                "start": 30,
                "end": 33,
                "text": "SCI",
                "type": "CONDITION"
            },
            {
                "start": 42,
                "end": 59,
                "text": "Tele Home Program",
                "type": "OTHER"
            },
            {
                "start": 248,
                "end": 268,
                "text": "Spinal Cord Injuries",
                "type": "CONDITION"
            },
            {
                "start": 270,
                "end": 273,
                "text": "SCI",
                "type": "CONDITION"
            },
            {
                "start": 306,
                "end": 326,
                "text": "tele home techniques",
                "type": "OTHER"
            },
            {
                "start": 342,
                "end": 357,
                "text": "pressure ulcers",
                "type": "CONDITION"
            },
            {
                "start": 375,
                "end": 378,
                "text": "SCI",
                "type": "CONDITION"
            },
            {
                "start": 624,
                "end": 653,
                "text": "patient-centered Medical Home",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT03170791",
        "text": "Feasibility and Acceptability of Transcutaneous Vagal Nerve Stimulation in Recovery of Upper Limb Function Post Stroke | This study will find out whether electrical stimulation of a nerve called the \"vagus\" nerve is acceptable for patients undergoing physiotherapy for arm weakness after a stroke. 20 patients will be recruited if they had a stroke between 4 and 48 months previously and have been left with reduced function in the affected arm. Patients will receive 3 sessions of physiotherapy per week for 6 weeks. Each session will last 1 hour during which the patient will be asked to perform specific movements e.g. shuffling cards, reaching for a shelf. With each arm movement the therapist will turn on a stimulator which is worn clipped to the patients ear. This will deliver a short burst of electricity creating a mild tingling sensation.\n\nAt the end of the session, the stimulator will be removed and the patient will be asked to rate the level of any discomfort or fatigue they experienced as well as any other side effects. The therapist will also record whether the stimulator device interfered with the therapy in any way. A heart tracing will be performed at each visit to check the heart rhythm. At the start and end of the 6 week course of physiotherapy, patients arm weakness and level of arm function will be assessed, as well as their general levels of fatigue, mood and quality of life. These will be reassessed at 1 month and 6 months after the course of physiotherapy has ended. The investigators will also interview patients to establish how they found the treatment itself. If the vagal nerve stimulation combined with physiotherapy is acceptable to patients and therapists and there are no safety concerns, the investigators will plan a larger trial of this treatment in stroke patients.",
        "tokens": "['Feasibility', 'and', 'Acceptability', 'of', 'Transcutaneous', 'Vagal', 'Nerve', 'Stimulation', 'in', 'Recovery', 'of', 'Upper', 'Limb', 'Function', 'Post', 'Stroke', '|', 'This', 'study', 'will', 'find', 'out', 'whether', 'electrical', 'stimulation', 'of', 'a', 'nerve', 'called', 'the', '\"', 'vagus', '\"', 'nerve', 'is', 'acceptable', 'for', 'patients', 'undergoing', 'physiotherapy', 'for', 'arm', 'weakness', 'after', 'a', 'stroke', '.', '20', 'patients', 'will', 'be', 'recruited', 'if', 'they', 'had', 'a', 'stroke', 'between', '4', 'and', '48', 'months', 'previously', 'and', 'have', 'been', 'left', 'with', 'reduced', 'function', 'in', 'the', 'affected', 'arm', '.', 'Patients', 'will', 'receive', '3', 'sessions', 'of', 'physiotherapy', 'per', 'week', 'for', '6', 'weeks', '.', 'Each', 'session', 'will', 'last', '1', 'hour', 'during', 'which', 'the', 'patient', 'will', 'be', 'asked', 'to', 'perform', 'specific', 'movements', 'e.g.', 'shuffling', 'cards', ',', 'reaching', 'for', 'a', 'shelf', '.', 'With', 'each', 'arm', 'movement', 'the', 'therapist', 'will', 'turn', 'on', 'a', 'stimulator', 'which', 'is', 'worn', 'clipped', 'to', 'the', 'patients', 'ear', '.', 'This', 'will', 'deliver', 'a', 'short', 'burst', 'of', 'electricity', 'creating', 'a', 'mild', 'tingling', 'sensation', '.', '\\n\\n', 'At', 'the', 'end', 'of', 'the', 'session', ',', 'the', 'stimulator', 'will', 'be', 'removed', 'and', 'the', 'patient', 'will', 'be', 'asked', 'to', 'rate', 'the', 'level', 'of', 'any', 'discomfort', 'or', 'fatigue', 'they', 'experienced', 'as', 'well', 'as', 'any', 'other', 'side', 'effects', '.', 'The', 'therapist', 'will', 'also', 'record', 'whether', 'the', 'stimulator', 'device', 'interfered', 'with', 'the', 'therapy', 'in', 'any', 'way', '.', 'A', 'heart', 'tracing', 'will', 'be', 'performed', 'at', 'each', 'visit', 'to', 'check', 'the', 'heart', 'rhythm', '.', 'At', 'the', 'start', 'and', 'end', 'of', 'the', '6', 'week', 'course', 'of', 'physiotherapy', ',', 'patients', 'arm', 'weakness', 'and', 'level', 'of', 'arm', 'function', 'will', 'be', 'assessed', ',', 'as', 'well', 'as', 'their', 'general', 'levels', 'of', 'fatigue', ',', 'mood', 'and', 'quality', 'of', 'life', '.', 'These', 'will', 'be', 'reassessed', 'at', '1', 'month', 'and', '6', 'months', 'after', 'the', 'course', 'of', 'physiotherapy', 'has', 'ended', '.', 'The', 'investigators', 'will', 'also', 'interview', 'patients', 'to', 'establish', 'how', 'they', 'found', 'the', 'treatment', 'itself', '.', 'If', 'the', 'vagal', 'nerve', 'stimulation', 'combined', 'with', 'physiotherapy', 'is', 'acceptable', 'to', 'patients', 'and', 'therapists', 'and', 'there', 'are', 'no', 'safety', 'concerns', ',', 'the', 'investigators', 'will', 'plan', 'a', 'larger', 'trial', 'of', 'this', 'treatment', 'in', 'stroke', 'patients', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 33,
                "end": 71,
                "text": "Transcutaneous Vagal Nerve Stimulation",
                "type": "OTHER"
            },
            {
                "start": 107,
                "end": 118,
                "text": "Post Stroke",
                "type": "CONDITION"
            },
            {
                "start": 290,
                "end": 296,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 342,
                "end": 348,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 408,
                "end": 444,
                "text": "reduced function in the affected arm",
                "type": "CONDITION"
            },
            {
                "start": 482,
                "end": 495,
                "text": "physiotherapy",
                "type": "PHYSICAL"
            },
            {
                "start": 1081,
                "end": 1098,
                "text": "stimulator device",
                "type": "OTHER"
            },
            {
                "start": 1259,
                "end": 1272,
                "text": "physiotherapy",
                "type": "PHYSICAL"
            },
            {
                "start": 1283,
                "end": 1295,
                "text": "arm weakness",
                "type": "CONDITION"
            },
            {
                "start": 1479,
                "end": 1492,
                "text": "physiotherapy",
                "type": "PHYSICAL"
            },
            {
                "start": 1608,
                "end": 1631,
                "text": "vagal nerve stimulation",
                "type": "OTHER"
            },
            {
                "start": 1646,
                "end": 1659,
                "text": "physiotherapy",
                "type": "PHYSICAL"
            },
            {
                "start": 1799,
                "end": 1805,
                "text": "stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03816345",
        "text": "A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO) | This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.",
        "tokens": "['A', 'Phase', 'Ib', 'Study', 'of', 'Nivolumab', 'in', 'Patients', 'With', 'Autoimmune', 'Disorders', 'and', 'Advanced', 'Malignancies', '(', 'AIM', '-', 'NIVO', ')', '|', 'This', 'phase', 'Ib', 'trial', 'studies', 'the', 'side', 'effects', 'of', 'nivolumab', 'and', 'to', 'see', 'how', 'well', 'it', 'works', 'in', 'treating', 'patients', 'with', 'autoimmune', 'disorders', 'and', 'cancer', 'that', 'has', 'spread', 'to', 'other', 'places', 'in', 'the', 'body', 'or', 'can', 'not', 'removed', 'by', 'surgery', '.', 'Immunotherapy', 'with', 'monoclonal', 'antibodies', ',', 'such', 'as', 'nivolumab', ',', 'may', 'help', 'the', 'body', \"'s\", 'immune', 'system', 'attack', 'the', 'cancer', ',', 'and', 'may', 'interfere', 'with', 'the', 'ability', 'of', 'tumor', 'cells', 'to', 'grow', 'and', 'spread', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 20,
                "end": 29,
                "text": "Nivolumab",
                "type": "DRUG"
            },
            {
                "start": 47,
                "end": 67,
                "text": "Autoimmune Disorders",
                "type": "CONDITION"
            },
            {
                "start": 72,
                "end": 93,
                "text": "Advanced Malignancies",
                "type": "CONDITION"
            },
            {
                "start": 155,
                "end": 164,
                "text": "nivolumab",
                "type": "DRUG"
            },
            {
                "start": 220,
                "end": 240,
                "text": "autoimmune disorders",
                "type": "CONDITION"
            },
            {
                "start": 245,
                "end": 251,
                "text": "cancer",
                "type": "CONDITION"
            },
            {
                "start": 376,
                "end": 385,
                "text": "nivolumab",
                "type": "DRUG"
            },
            {
                "start": 432,
                "end": 438,
                "text": "cancer",
                "type": "CONDITION"
            },
            {
                "start": 478,
                "end": 483,
                "text": "tumor",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01074944",
        "text": "A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once Daily Versus Twice Daily Dosing of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638 | The primary objective of this study was to evaluate the efficacy and safety of once daily (QD) versus twice daily (BID) dosing of eliglustat tartrate (Genz-112638) in participants with Gaucher disease type 1 who had demonstrated clinical stability on BID dosing of eliglustat tartrate (Genz-112638). The secondary objective was to evaluate the pharmacokinetics (PK) of Genz-99067 when eliglustat tartrate (Genz-112638) was administered QD and BID in participants with Gaucher disease type 1 who had demonstrated clinical stability on BID dosing of eliglustat tartrate (Genz-112638).",
        "tokens": "['A', 'Phase', '3', ',', 'Randomized', ',', 'Multi', '-', 'Center', ',', 'Multi', '-', 'National', ',', 'Double', '-', 'Blind', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', ',', 'Safety', 'and', 'Pharmacokinetics', 'of', 'Once', 'Daily', 'Versus', 'Twice', 'Daily', 'Dosing', 'of', 'Genz-112638', 'in', 'Patients', 'With', 'Gaucher', 'Disease', 'Type', '1', 'Who', 'Have', 'Demonstrated', 'Clinical', 'Stability', 'on', 'a', 'Twice', 'Daily', 'Dose', 'of', 'Genz-112638', '|', 'The', 'primary', 'objective', 'of', 'this', 'study', 'was', 'to', 'evaluate', 'the', 'efficacy', 'and', 'safety', 'of', 'once', 'daily', '(', 'QD', ')', 'versus', 'twice', 'daily', '(', 'BID', ')', 'dosing', 'of', 'eliglustat', 'tartrate', '(', 'Genz-112638', ')', 'in', 'participants', 'with', 'Gaucher', 'disease', 'type', '1', 'who', 'had', 'demonstrated', 'clinical', 'stability', 'on', 'BID', 'dosing', 'of', 'eliglustat', 'tartrate', '(', 'Genz-112638', ')', '.', 'The', 'secondary', 'objective', 'was', 'to', 'evaluate', 'the', 'pharmacokinetics', '(', 'PK', ')', 'of', 'Genz-99067', 'when', 'eliglustat', 'tartrate', '(', 'Genz-112638', ')', 'was', 'administered', 'QD', 'and', 'BID', 'in', 'participants', 'with', 'Gaucher', 'disease', 'type', '1', 'who', 'had', 'demonstrated', 'clinical', 'stability', 'on', 'BID', 'dosing', 'of', 'eliglustat', 'tartrate', '(', 'Genz-112638', ')', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O']",
        "entities": [
            {
                "start": 169,
                "end": 180,
                "text": "Genz-112638",
                "type": "DRUG"
            },
            {
                "start": 198,
                "end": 220,
                "text": "Gaucher Disease Type 1",
                "type": "CONDITION"
            },
            {
                "start": 287,
                "end": 298,
                "text": "Genz-112638",
                "type": "DRUG"
            },
            {
                "start": 431,
                "end": 450,
                "text": "eliglustat tartrate",
                "type": "DRUG"
            },
            {
                "start": 452,
                "end": 463,
                "text": "Genz-112638",
                "type": "DRUG"
            },
            {
                "start": 486,
                "end": 508,
                "text": "Gaucher disease type 1",
                "type": "CONDITION"
            },
            {
                "start": 566,
                "end": 585,
                "text": "eliglustat tartrate",
                "type": "DRUG"
            },
            {
                "start": 587,
                "end": 598,
                "text": "Genz-112638",
                "type": "DRUG"
            },
            {
                "start": 670,
                "end": 680,
                "text": "Genz-99067",
                "type": "DRUG"
            },
            {
                "start": 686,
                "end": 705,
                "text": "eliglustat tartrate",
                "type": "DRUG"
            },
            {
                "start": 707,
                "end": 718,
                "text": "Genz-112638",
                "type": "DRUG"
            },
            {
                "start": 769,
                "end": 791,
                "text": "Gaucher disease type 1",
                "type": "CONDITION"
            },
            {
                "start": 849,
                "end": 868,
                "text": "eliglustat tartrate",
                "type": "DRUG"
            },
            {
                "start": 870,
                "end": 881,
                "text": "Genz-112638",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT04976725",
        "text": "Comparison of the Effectiveness of Craniosacral Therapy and Myofacial Relaxation Techniques in People Diagnosed With Migraine | Headache is a neurological condition that is very common all over the world and is observed at some time in life in more than 90% of society. Migraine headache, known for thousands of years, is one of the oldest diseases of humanity. The word 'hemicrania', meaning 'half of a head', is used due to unilateral pain. Approaches to treating migraine include medication, relaxation, biofeedback, living a regular life, adequate sleep, exercise, and stress management. Neck pain is especially common in migraine patients. Exercise, manual practices, electrop novelties are used to reduce musculoskeletal problems, thus reducing the effects of migraine. Myofascial relaxation techniques, which are included in the manipulative techniques in the literature, are relaxation methods performed on myofascial trigger points.Osteopathic manual therapy (OMT) , which has recently entered the literature, 19. osteopathy, developed by Andrew Taylor STILL at the end of the century, is a treatment system characterized by focusing on integrity and using it by hand to heal diseases.The study of cranial OMM kraniyum first anatomical and physiological mechanisms for the prevention and treatment of disease as a whole is concerned with the relationship of the body, including diagnostic and therapeutic methods.It is used in the treatment of somatic dysfunction of the head and other body parts. An important component of cranial Omm is the primary respiratory mechanism, which occurs as movement of the head bones, sacrum, dural membranes, central nervous system and cerebrospinal fluid. The primary respiratory mechanism is synchronous with the cranial rhythmic impulse, a 2-phase rhythmic cycle that represents a dynamic metabolic exchange with each stage of the body. This cycle is indicated as loops between 7 and 14 per minute.Fascial mobilization therapy increases energy use in segments implemented by mechanical changes.Accordingly, it helps to reduce the spasm of these layers extending fascially, to dissolve adhesions, and to increase the range of motion of the joint.\n\nH0: Osteopathic Manipulative Therapy has no effect on migraine symptoms. H1: Osteopathic Manipulative Therapy has an effect on migraine symptoms. H2: myofascial relaxation techniques have no effect on migraine symptoms. H3: methods of Osteopathic Manipulative Therapy have an effect on migraine symptoms.\n\nH4: myofascial relaxation techniques and osteopathic manipulative treatment methods have no superiority over each other.\n\nH5: myofascial relaxation techniques and osteopathic manipulative treatment methods have superiority over each other.",
        "tokens": "['Comparison', 'of', 'the', 'Effectiveness', 'of', 'Craniosacral', 'Therapy', 'and', 'Myofacial', 'Relaxation', 'Techniques', 'in', 'People', 'Diagnosed', 'With', 'Migraine', '|', 'Headache', 'is', 'a', 'neurological', 'condition', 'that', 'is', 'very', 'common', 'all', 'over', 'the', 'world', 'and', 'is', 'observed', 'at', 'some', 'time', 'in', 'life', 'in', 'more', 'than', '90', '%', 'of', 'society', '.', 'Migraine', 'headache', ',', 'known', 'for', 'thousands', 'of', 'years', ',', 'is', 'one', 'of', 'the', 'oldest', 'diseases', 'of', 'humanity', '.', 'The', 'word', \"'\", 'hemicrania', \"'\", ',', 'meaning', \"'\", 'half', 'of', 'a', 'head', \"'\", ',', 'is', 'used', 'due', 'to', 'unilateral', 'pain', '.', 'Approaches', 'to', 'treating', 'migraine', 'include', 'medication', ',', 'relaxation', ',', 'biofeedback', ',', 'living', 'a', 'regular', 'life', ',', 'adequate', 'sleep', ',', 'exercise', ',', 'and', 'stress', 'management', '.', 'Neck', 'pain', 'is', 'especially', 'common', 'in', 'migraine', 'patients', '.', 'Exercise', ',', 'manual', 'practices', ',', 'electrop', 'novelties', 'are', 'used', 'to', 'reduce', 'musculoskeletal', 'problems', ',', 'thus', 'reducing', 'the', 'effects', 'of', 'migraine', '.', 'Myofascial', 'relaxation', 'techniques', ',', 'which', 'are', 'included', 'in', 'the', 'manipulative', 'techniques', 'in', 'the', 'literature', ',', 'are', 'relaxation', 'methods', 'performed', 'on', 'myofascial', 'trigger', 'points', '.', 'Osteopathic', 'manual', 'therapy', '(', 'OMT', ')', ',', 'which', 'has', 'recently', 'entered', 'the', 'literature', ',', '19', '.', 'osteopathy', ',', 'developed', 'by', 'Andrew', 'Taylor', 'STILL', 'at', 'the', 'end', 'of', 'the', 'century', ',', 'is', 'a', 'treatment', 'system', 'characterized', 'by', 'focusing', 'on', 'integrity', 'and', 'using', 'it', 'by', 'hand', 'to', 'heal', 'diseases', '.', 'The', 'study', 'of', 'cranial', 'OMM', 'kraniyum', 'first', 'anatomical', 'and', 'physiological', 'mechanisms', 'for', 'the', 'prevention', 'and', 'treatment', 'of', 'disease', 'as', 'a', 'whole', 'is', 'concerned', 'with', 'the', 'relationship', 'of', 'the', 'body', ',', 'including', 'diagnostic', 'and', 'therapeutic', 'methods', '.', 'It', 'is', 'used', 'in', 'the', 'treatment', 'of', 'somatic', 'dysfunction', 'of', 'the', 'head', 'and', 'other', 'body', 'parts', '.', 'An', 'important', 'component', 'of', 'cranial', 'Omm', 'is', 'the', 'primary', 'respiratory', 'mechanism', ',', 'which', 'occurs', 'as', 'movement', 'of', 'the', 'head', 'bones', ',', 'sacrum', ',', 'dural', 'membranes', ',', 'central', 'nervous', 'system', 'and', 'cerebrospinal', 'fluid', '.', 'The', 'primary', 'respiratory', 'mechanism', 'is', 'synchronous', 'with', 'the', 'cranial', 'rhythmic', 'impulse', ',', 'a', '2', '-', 'phase', 'rhythmic', 'cycle', 'that', 'represents', 'a', 'dynamic', 'metabolic', 'exchange', 'with', 'each', 'stage', 'of', 'the', 'body', '.', 'This', 'cycle', 'is', 'indicated', 'as', 'loops', 'between', '7', 'and', '14', 'per', 'minute', '.', 'Fascial', 'mobilization', 'therapy', 'increases', 'energy', 'use', 'in', 'segments', 'implemented', 'by', 'mechanical', 'changes', '.', 'Accordingly', ',', 'it', 'helps', 'to', 'reduce', 'the', 'spasm', 'of', 'these', 'layers', 'extending', 'fascially', ',', 'to', 'dissolve', 'adhesions', ',', 'and', 'to', 'increase', 'the', 'range', 'of', 'motion', 'of', 'the', 'joint', '.', '\\n\\n', 'H0', ':', 'Osteopathic', 'Manipulative', 'Therapy', 'has', 'no', 'effect', 'on', 'migraine', 'symptoms', '.', 'H1', ':', 'Osteopathic', 'Manipulative', 'Therapy', 'has', 'an', 'effect', 'on', 'migraine', 'symptoms', '.', 'H2', ':', 'myofascial', 'relaxation', 'techniques', 'have', 'no', 'effect', 'on', 'migraine', 'symptoms', '.', 'H3', ':', 'methods', 'of', 'Osteopathic', 'Manipulative', 'Therapy', 'have', 'an', 'effect', 'on', 'migraine', 'symptoms', '.', '\\n\\n', 'H4', ':', 'myofascial', 'relaxation', 'techniques', 'and', 'osteopathic', 'manipulative', 'treatment', 'methods', 'have', 'no', 'superiority', 'over', 'each', 'other', '.', '\\n\\n', 'H5', ':', 'myofascial', 'relaxation', 'techniques', 'and', 'osteopathic', 'manipulative', 'treatment', 'methods', 'have', 'superiority', 'over', 'each', 'other', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 35,
                "end": 55,
                "text": "Craniosacral Therapy",
                "type": "OTHER"
            },
            {
                "start": 60,
                "end": 91,
                "text": "Myofacial Relaxation Techniques",
                "type": "OTHER"
            },
            {
                "start": 117,
                "end": 125,
                "text": "Migraine",
                "type": "CONDITION"
            },
            {
                "start": 128,
                "end": 136,
                "text": "Headache",
                "type": "CONDITION"
            },
            {
                "start": 270,
                "end": 278,
                "text": "Migraine",
                "type": "CONDITION"
            },
            {
                "start": 372,
                "end": 382,
                "text": "hemicrania",
                "type": "CONDITION"
            },
            {
                "start": 437,
                "end": 441,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 466,
                "end": 474,
                "text": "migraine",
                "type": "CONDITION"
            },
            {
                "start": 592,
                "end": 601,
                "text": "Neck pain",
                "type": "CONDITION"
            },
            {
                "start": 626,
                "end": 634,
                "text": "migraine",
                "type": "CONDITION"
            },
            {
                "start": 766,
                "end": 774,
                "text": "migraine",
                "type": "CONDITION"
            },
            {
                "start": 776,
                "end": 808,
                "text": "Myofascial relaxation techniques",
                "type": "OTHER"
            },
            {
                "start": 941,
                "end": 967,
                "text": "Osteopathic manual therapy",
                "type": "OTHER"
            },
            {
                "start": 969,
                "end": 972,
                "text": "OMT",
                "type": "OTHER"
            },
            {
                "start": 1207,
                "end": 1227,
                "text": "cranial OMM kraniyum",
                "type": "OTHER"
            },
            {
                "start": 1533,
                "end": 1544,
                "text": "cranial Omm",
                "type": "OTHER"
            },
            {
                "start": 1944,
                "end": 1972,
                "text": "Fascial mobilization therapy",
                "type": "OTHER"
            },
            {
                "start": 2197,
                "end": 2229,
                "text": "Osteopathic Manipulative Therapy",
                "type": "OTHER"
            },
            {
                "start": 2247,
                "end": 2255,
                "text": "migraine",
                "type": "CONDITION"
            },
            {
                "start": 2270,
                "end": 2302,
                "text": "Osteopathic Manipulative Therapy",
                "type": "OTHER"
            },
            {
                "start": 2320,
                "end": 2328,
                "text": "migraine",
                "type": "CONDITION"
            },
            {
                "start": 2343,
                "end": 2375,
                "text": "myofascial relaxation techniques",
                "type": "OTHER"
            },
            {
                "start": 2394,
                "end": 2402,
                "text": "migraine",
                "type": "CONDITION"
            },
            {
                "start": 2428,
                "end": 2460,
                "text": "Osteopathic Manipulative Therapy",
                "type": "OTHER"
            },
            {
                "start": 2479,
                "end": 2487,
                "text": "migraine",
                "type": "CONDITION"
            },
            {
                "start": 2503,
                "end": 2535,
                "text": "myofascial relaxation techniques",
                "type": "OTHER"
            },
            {
                "start": 2540,
                "end": 2574,
                "text": "osteopathic manipulative treatment",
                "type": "OTHER"
            },
            {
                "start": 2625,
                "end": 2657,
                "text": "myofascial relaxation techniques",
                "type": "OTHER"
            },
            {
                "start": 2662,
                "end": 2696,
                "text": "osteopathic manipulative treatment",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT03714217",
        "text": "Weight Management in Spinal Cord Injury - Intervention and Monitoring Via Tele-Nutrition | The purpose of the study is to provide tele-nutrition counseling after a spinal cord injury (SCI). During the three months of participation, subjects will be given an iPad and the iPad will be used to record meals using a photo journal application, YouAte. In addition, subjects will receive dietary advice two times a month with a registered dietitian (RD). The dietitian role in the study will be to educate healthy weight management and accommodate any cultural and behavioral habits. The objective of this study is to show that the proposed tele-nutrition program will be effective with weight management through 3-month tele-nutrition counseling via iPad FaceTime. The hypotheses are 1) that weight and waist circumference will not increase after 3 months of tele-nutrition program, 2) quality of life will improve, and 3) quality of diet will improve.",
        "tokens": "['Weight', 'Management', 'in', 'Spinal', 'Cord', 'Injury', '-', 'Intervention', 'and', 'Monitoring', 'Via', 'Tele', '-', 'Nutrition', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'provide', 'tele', '-', 'nutrition', 'counseling', 'after', 'a', 'spinal', 'cord', 'injury', '(', 'SCI', ')', '.', 'During', 'the', 'three', 'months', 'of', 'participation', ',', 'subjects', 'will', 'be', 'given', 'an', 'iPad', 'and', 'the', 'iPad', 'will', 'be', 'used', 'to', 'record', 'meals', 'using', 'a', 'photo', 'journal', 'application', ',', 'YouAte', '.', 'In', 'addition', ',', 'subjects', 'will', 'receive', 'dietary', 'advice', 'two', 'times', 'a', 'month', 'with', 'a', 'registered', 'dietitian', '(', 'RD', ')', '.', 'The', 'dietitian', 'role', 'in', 'the', 'study', 'will', 'be', 'to', 'educate', 'healthy', 'weight', 'management', 'and', 'accommodate', 'any', 'cultural', 'and', 'behavioral', 'habits', '.', 'The', 'objective', 'of', 'this', 'study', 'is', 'to', 'show', 'that', 'the', 'proposed', 'tele', '-', 'nutrition', 'program', 'will', 'be', 'effective', 'with', 'weight', 'management', 'through', '3', '-', 'month', 'tele', '-', 'nutrition', 'counseling', 'via', 'iPad', 'FaceTime', '.', 'The', 'hypotheses', 'are', '1', ')', 'that', 'weight', 'and', 'waist', 'circumference', 'will', 'not', 'increase', 'after', '3', 'months', 'of', 'tele', '-', 'nutrition', 'program', ',', '2', ')', 'quality', 'of', 'life', 'will', 'improve', ',', 'and', '3', ')', 'quality', 'of', 'diet', 'will', 'improve', '.']",
        "token_bio_labels": "['B-BEH', 'I-BEH', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 17,
                "text": "Weight Management",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 21,
                "end": 39,
                "text": "Spinal Cord Injury",
                "type": "CONDITION"
            },
            {
                "start": 74,
                "end": 88,
                "text": "Tele-Nutrition",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 130,
                "end": 155,
                "text": "tele-nutrition counseling",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 164,
                "end": 182,
                "text": "spinal cord injury",
                "type": "CONDITION"
            },
            {
                "start": 184,
                "end": 187,
                "text": "SCI",
                "type": "CONDITION"
            },
            {
                "start": 340,
                "end": 346,
                "text": "YouAte",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 383,
                "end": 397,
                "text": "dietary advice",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 509,
                "end": 526,
                "text": "weight management",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 636,
                "end": 658,
                "text": "tele-nutrition program",
                "type": "BEHAVIOURAL"
            }
        ]
    },
    {
        "nctid": "NCT04566081",
        "text": "Digital Interventions in Neuro-Rehabilitation (DINR): A Digital Neuro Intervention (DNI) for Word Retrieval (Anomia) | iTALKBetter will provide an app-based therapy for people with word retrieval difficulties who have had a stroke.\n\nThis study aims to test the therapy application for people with naming difficulties through a small scale randomized controlled trial.",
        "tokens": "['Digital', 'Interventions', 'in', 'Neuro', '-', 'Rehabilitation', '(', 'DINR', '):', 'A', 'Digital', 'Neuro', 'Intervention', '(', 'DNI', ')', 'for', 'Word', 'Retrieval', '(', 'Anomia', ')', '|', 'iTALKBetter', 'will', 'provide', 'an', 'app', '-', 'based', 'therapy', 'for', 'people', 'with', 'word', 'retrieval', 'difficulties', 'who', 'have', 'had', 'a', 'stroke', '.', '\\n\\n', 'This', 'study', 'aims', 'to', 'test', 'the', 'therapy', 'application', 'for', 'people', 'with', 'naming', 'difficulties', 'through', 'a', 'small', 'scale', 'randomized', 'controlled', 'trial', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 45,
                "text": "Digital Interventions in Neuro-Rehabilitation",
                "type": "OTHER"
            },
            {
                "start": 47,
                "end": 51,
                "text": "DINR",
                "type": "OTHER"
            },
            {
                "start": 56,
                "end": 82,
                "text": "Digital Neuro Intervention",
                "type": "OTHER"
            },
            {
                "start": 84,
                "end": 87,
                "text": "DNI",
                "type": "OTHER"
            },
            {
                "start": 109,
                "end": 115,
                "text": "Anomia",
                "type": "CONDITION"
            },
            {
                "start": 119,
                "end": 130,
                "text": "iTALKBetter",
                "type": "OTHER"
            },
            {
                "start": 147,
                "end": 164,
                "text": "app-based therapy",
                "type": "OTHER"
            },
            {
                "start": 181,
                "end": 208,
                "text": "word retrieval difficulties",
                "type": "CONDITION"
            },
            {
                "start": 224,
                "end": 230,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 297,
                "end": 316,
                "text": "naming difficulties",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02850159",
        "text": "Effect of Simultaneous Dual Stimulation on Freezing of Gait in Parkinson's Disease | The purpose of this study is to investigate the effect of dual-mode non-invasive brain stimulation (NIBS) with high-frequency repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex of the lower leg and anodal transcranial direct current stimulation (tDCS) over the left dorsolateral prefrontal cortex compared with rTMS alone in patients with Parkinson's disease (PD) with freezing of gait (FOG).",
        "tokens": "['Effect', 'of', 'Simultaneous', 'Dual', 'Stimulation', 'on', 'Freezing', 'of', 'Gait', 'in', 'Parkinson', \"'s\", 'Disease', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'investigate', 'the', 'effect', 'of', 'dual', '-', 'mode', 'non', '-', 'invasive', 'brain', 'stimulation', '(', 'NIBS', ')', 'with', 'high', '-', 'frequency', 'repetitive', 'transcranial', 'magnetic', 'stimulation', '(', 'rTMS', ')', 'over', 'the', 'primary', 'motor', 'cortex', 'of', 'the', 'lower', 'leg', 'and', 'anodal', 'transcranial', 'direct', 'current', 'stimulation', '(', 'tDCS', ')', 'over', 'the', 'left', 'dorsolateral', 'prefrontal', 'cortex', 'compared', 'with', 'rTMS', 'alone', 'in', 'patients', 'with', 'Parkinson', \"'s\", 'disease', '(', 'PD', ')', 'with', 'freezing', 'of', 'gait', '(', 'FOG', ')', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 39,
                "text": "Simultaneous Dual Stimulation",
                "type": "OTHER"
            },
            {
                "start": 63,
                "end": 82,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 143,
                "end": 183,
                "text": "dual-mode non-invasive brain stimulation",
                "type": "OTHER"
            },
            {
                "start": 185,
                "end": 189,
                "text": "NIBS",
                "type": "OTHER"
            },
            {
                "start": 196,
                "end": 255,
                "text": "high-frequency repetitive transcranial magnetic stimulation",
                "type": "OTHER"
            },
            {
                "start": 257,
                "end": 261,
                "text": "rTMS",
                "type": "OTHER"
            },
            {
                "start": 321,
                "end": 360,
                "text": "transcranial direct current stimulation",
                "type": "OTHER"
            },
            {
                "start": 362,
                "end": 366,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 427,
                "end": 437,
                "text": "rTMS alone",
                "type": "CONTROL"
            },
            {
                "start": 455,
                "end": 474,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 476,
                "end": 478,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 485,
                "end": 501,
                "text": "freezing of gait",
                "type": "CONDITION"
            },
            {
                "start": 503,
                "end": 506,
                "text": "FOG",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03419793",
        "text": "Effect of Segmental Muscle Vibration on Upper Extremity Functional Ability Post Stroke | Background and objective: Upper extremity functional impairments are common consequences post stroke. The aim of this study was to investigate the influence of Segmental muscle vibration (SMV) application along with supervised physical therapy (SPT) on improving activities of daily living (ADL) and motor recovery on the hemiparetic upper extremity in patients with stroke.\n\nMethods: A sample of 37 patients post stroke (29 males) was randomly assigned to either supervised physical therapy (SPT) control group (n=18) or supervised physical therapy and segmental muscle vibration (SPT-SMV) experimental group (n=19). All patients received 3 sessions per week of SPT for 8 weeks. The SPT-SMV experimental group received SMV at the end of each SPT session. Outcome measures used were Barthel Index (BI), Modified Ashworth Scale (MAS), Manual Muscle Testing (MMT), and goniometry for Range of Motion (ROM) assessment.",
        "tokens": "['Effect', 'of', 'Segmental', 'Muscle', 'Vibration', 'on', 'Upper', 'Extremity', 'Functional', 'Ability', 'Post', 'Stroke', '|', 'Background', 'and', 'objective', ':', 'Upper', 'extremity', 'functional', 'impairments', 'are', 'common', 'consequences', 'post', 'stroke', '.', 'The', 'aim', 'of', 'this', 'study', 'was', 'to', 'investigate', 'the', 'influence', 'of', 'Segmental', 'muscle', 'vibration', '(', 'SMV', ')', 'application', 'along', 'with', 'supervised', 'physical', 'therapy', '(', 'SPT', ')', 'on', 'improving', 'activities', 'of', 'daily', 'living', '(', 'ADL', ')', 'and', 'motor', 'recovery', 'on', 'the', 'hemiparetic', 'upper', 'extremity', 'in', 'patients', 'with', 'stroke', '.', '\\n\\n', 'Methods', ':', 'A', 'sample', 'of', '37', 'patients', 'post', 'stroke', '(', '29', 'males', ')', 'was', 'randomly', 'assigned', 'to', 'either', 'supervised', 'physical', 'therapy', '(', 'SPT', ')', 'control', 'group', '(', 'n=18', ')', 'or', 'supervised', 'physical', 'therapy', 'and', 'segmental', 'muscle', 'vibration', '(', 'SPT', '-', 'SMV', ')', 'experimental', 'group', '(', 'n=19', ')', '.', 'All', 'patients', 'received', '3', 'sessions', 'per', 'week', 'of', 'SPT', 'for', '8', 'weeks', '.', 'The', 'SPT', '-', 'SMV', 'experimental', 'group', 'received', 'SMV', 'at', 'the', 'end', 'of', 'each', 'SPT', 'session', '.', 'Outcome', 'measures', 'used', 'were', 'Barthel', 'Index', '(', 'BI', ')', ',', 'Modified', 'Ashworth', 'Scale', '(', 'MAS', ')', ',', 'Manual', 'Muscle', 'Testing', '(', 'MMT', ')', ',', 'and', 'goniometry', 'for', 'Range', 'of', 'Motion', '(', 'ROM', ')', 'assessment', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 36,
                "text": "Segmental Muscle Vibration",
                "type": "OTHER"
            },
            {
                "start": 75,
                "end": 86,
                "text": "Post Stroke",
                "type": "CONDITION"
            },
            {
                "start": 115,
                "end": 153,
                "text": "Upper extremity functional impairments",
                "type": "CONDITION"
            },
            {
                "start": 178,
                "end": 189,
                "text": "post stroke",
                "type": "CONDITION"
            },
            {
                "start": 249,
                "end": 275,
                "text": "Segmental muscle vibration",
                "type": "OTHER"
            },
            {
                "start": 277,
                "end": 280,
                "text": "SMV",
                "type": "OTHER"
            },
            {
                "start": 305,
                "end": 332,
                "text": "supervised physical therapy",
                "type": "PHYSICAL"
            },
            {
                "start": 334,
                "end": 337,
                "text": "SPT",
                "type": "PHYSICAL"
            },
            {
                "start": 456,
                "end": 462,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 498,
                "end": 509,
                "text": "post stroke",
                "type": "CONDITION"
            },
            {
                "start": 553,
                "end": 580,
                "text": "supervised physical therapy",
                "type": "PHYSICAL"
            },
            {
                "start": 582,
                "end": 585,
                "text": "SPT",
                "type": "PHYSICAL"
            },
            {
                "start": 611,
                "end": 638,
                "text": "supervised physical therapy",
                "type": "PHYSICAL"
            },
            {
                "start": 643,
                "end": 669,
                "text": "segmental muscle vibration",
                "type": "OTHER"
            },
            {
                "start": 671,
                "end": 678,
                "text": "SPT-SMV",
                "type": "OTHER"
            },
            {
                "start": 752,
                "end": 755,
                "text": "SPT",
                "type": "PHYSICAL"
            },
            {
                "start": 773,
                "end": 780,
                "text": "SPT-SMV",
                "type": "OTHER"
            },
            {
                "start": 809,
                "end": 812,
                "text": "SMV",
                "type": "OTHER"
            },
            {
                "start": 832,
                "end": 835,
                "text": "SPT",
                "type": "PHYSICAL"
            }
        ]
    },
    {
        "nctid": "NCT02697721",
        "text": "Optimization of \"Powerful Tools for Caregivers\" of Dementia Patients | The purpose of this study is to examine if a psycho-educational intervention for caregivers of patients with dementia will decrease caregiver burden, increase caregiver physical activity, and decrease the reporting of behavioral and psychological symptoms of the person with dementia.",
        "tokens": "['Optimization', 'of', '\"', 'Powerful', 'Tools', 'for', 'Caregivers', '\"', 'of', 'Dementia', 'Patients', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'examine', 'if', 'a', 'psycho', '-', 'educational', 'intervention', 'for', 'caregivers', 'of', 'patients', 'with', 'dementia', 'will', 'decrease', 'caregiver', 'burden', ',', 'increase', 'caregiver', 'physical', 'activity', ',', 'and', 'decrease', 'the', 'reporting', 'of', 'behavioral', 'and', 'psychological', 'symptoms', 'of', 'the', 'person', 'with', 'dementia', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 17,
                "end": 46,
                "text": "Powerful Tools for Caregivers",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 51,
                "end": 59,
                "text": "Dementia",
                "type": "CONDITION"
            },
            {
                "start": 116,
                "end": 162,
                "text": "psycho-educational intervention for caregivers",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 180,
                "end": 188,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 346,
                "end": 354,
                "text": "dementia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05626855",
        "text": "An Open-Label, Multicenter, Extension Trial to Evaluate the Long-Term Safety and Efficacy of Apitegromab in Patients With Type 2 and Type 3 Spinal Muscular Atrophy Who Completed Previous Investigational Trials of Apitegromab | The ONYX study is an Open-Label, Multicenter, Extension study that will evaluate the long-term safety and efficacy of Apitegromab in Patients with Type 2 and Type 3 SMA who have completed TOPAZ or SAPPHIRE.",
        "tokens": "['An', 'Open', '-', 'Label', ',', 'Multicenter', ',', 'Extension', 'Trial', 'to', 'Evaluate', 'the', 'Long', '-', 'Term', 'Safety', 'and', 'Efficacy', 'of', 'Apitegromab', 'in', 'Patients', 'With', 'Type', '2', 'and', 'Type', '3', 'Spinal', 'Muscular', 'Atrophy', 'Who', 'Completed', 'Previous', 'Investigational', 'Trials', 'of', 'Apitegromab', '|', 'The', 'ONYX', 'study', 'is', 'an', 'Open', '-', 'Label', ',', 'Multicenter', ',', 'Extension', 'study', 'that', 'will', 'evaluate', 'the', 'long', '-', 'term', 'safety', 'and', 'efficacy', 'of', 'Apitegromab', 'in', 'Patients', 'with', 'Type', '2', 'and', 'Type', '3', 'SMA', 'who', 'have', 'completed', 'TOPAZ', 'or', 'SAPPHIRE', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 93,
                "end": 104,
                "text": "Apitegromab",
                "type": "DRUG"
            },
            {
                "start": 122,
                "end": 163,
                "text": "Type 2 and Type 3 Spinal Muscular Atrophy",
                "type": "CONDITION"
            },
            {
                "start": 213,
                "end": 224,
                "text": "Apitegromab",
                "type": "DRUG"
            },
            {
                "start": 345,
                "end": 356,
                "text": "Apitegromab",
                "type": "DRUG"
            },
            {
                "start": 374,
                "end": 395,
                "text": "Type 2 and Type 3 SMA",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02241434",
        "text": "The Role of Autologous Bone Marrow Mononuclear Cell Therapy in Duchenne Muscular Dystrophy | The purpose of this study was to study the effect of stem cell therapy in patients with Duchenne Muscular Dystrophy.",
        "tokens": "['The', 'Role', 'of', 'Autologous', 'Bone', 'Marrow', 'Mononuclear', 'Cell', 'Therapy', 'in', 'Duchenne', 'Muscular', 'Dystrophy', '|', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'study', 'the', 'effect', 'of', 'stem', 'cell', 'therapy', 'in', 'patients', 'with', 'Duchenne', 'Muscular', 'Dystrophy', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 12,
                "end": 59,
                "text": "Autologous Bone Marrow Mononuclear Cell Therapy",
                "type": "SURGICAL"
            },
            {
                "start": 63,
                "end": 90,
                "text": "Duchenne Muscular Dystrophy",
                "type": "CONDITION"
            },
            {
                "start": 146,
                "end": 163,
                "text": "stem cell therapy",
                "type": "SURGICAL"
            },
            {
                "start": 181,
                "end": 208,
                "text": "Duchenne Muscular Dystrophy",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02425527",
        "text": "Digital Gaming Used to Improve the Cognitive Functioning and Well-being of People With Traumatic Brain Injury: a Feasibility Study | The purpose of this feasibility study is to determine whether digital games are effective and acceptable in the treatment for patients with traumatic brain injury.",
        "tokens": "['Digital', 'Gaming', 'Used', 'to', 'Improve', 'the', 'Cognitive', 'Functioning', 'and', 'Well', '-', 'being', 'of', 'People', 'With', 'Traumatic', 'Brain', 'Injury', ':', 'a', 'Feasibility', 'Study', '|', 'The', 'purpose', 'of', 'this', 'feasibility', 'study', 'is', 'to', 'determine', 'whether', 'digital', 'games', 'are', 'effective', 'and', 'acceptable', 'in', 'the', 'treatment', 'for', 'patients', 'with', 'traumatic', 'brain', 'injury', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 14,
                "text": "Digital Gaming",
                "type": "OTHER"
            },
            {
                "start": 87,
                "end": 109,
                "text": "Traumatic Brain Injury",
                "type": "CONDITION"
            },
            {
                "start": 195,
                "end": 208,
                "text": "digital games",
                "type": "OTHER"
            },
            {
                "start": 273,
                "end": 295,
                "text": "traumatic brain injury",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04706910",
        "text": "18F-DOPA II - PET Imaging Optimization | A single centre non-randomized, non-blinded phase III prospective cohort study of 18F-DOPA PET/CT imaging in specific patient populations:\n\nPediatric patients (less than 18 years old) with congenital hyperinsulinism.\nPediatric patients (less than 18 years old) with neuroblastoma.\nPediatric (less than 18 years old) or Adult patients (18 or older) with known or clinically suspected neuroendocrine tumor.\nAdult patients (18 or older) with a clinical suspicion of Parkinson's disease or Lewy body dementia.\nPediatric (less than 18 years old) or Adult patients (18 or older) with brain tumors.\n\nImage optimization (the primary study objective) and gallbladder activity pattern (the secondary objective) will be evaluated.",
        "tokens": "['18F', '-', 'DOPA', 'II', '-', 'PET', 'Imaging', 'Optimization', '|', 'A', 'single', 'centre', 'non', '-', 'randomized', ',', 'non', '-', 'blinded', 'phase', 'III', 'prospective', 'cohort', 'study', 'of', '18F', '-', 'DOPA', 'PET', '/', 'CT', 'imaging', 'in', 'specific', 'patient', 'populations', ':', '\\n\\n', 'Pediatric', 'patients', '(', 'less', 'than', '18', 'years', 'old', ')', 'with', 'congenital', 'hyperinsulinism', '.', '\\n', 'Pediatric', 'patients', '(', 'less', 'than', '18', 'years', 'old', ')', 'with', 'neuroblastoma', '.', '\\n', 'Pediatric', '(', 'less', 'than', '18', 'years', 'old', ')', 'or', 'Adult', 'patients', '(', '18', 'or', 'older', ')', 'with', 'known', 'or', 'clinically', 'suspected', 'neuroendocrine', 'tumor', '.', '\\n', 'Adult', 'patients', '(', '18', 'or', 'older', ')', 'with', 'a', 'clinical', 'suspicion', 'of', 'Parkinson', \"'s\", 'disease', 'or', 'Lewy', 'body', 'dementia', '.', '\\n', 'Pediatric', '(', 'less', 'than', '18', 'years', 'old', ')', 'or', 'Adult', 'patients', '(', '18', 'or', 'older', ')', 'with', 'brain', 'tumors', '.', '\\n\\n', 'Image', 'optimization', '(', 'the', 'primary', 'study', 'objective', ')', 'and', 'gallbladder', 'activity', 'pattern', '(', 'the', 'secondary', 'objective', ')', 'will', 'be', 'evaluated', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 230,
                "end": 256,
                "text": "congenital hyperinsulinism",
                "type": "CONDITION"
            },
            {
                "start": 307,
                "end": 320,
                "text": "neuroblastoma",
                "type": "CONDITION"
            },
            {
                "start": 424,
                "end": 444,
                "text": "neuroendocrine tumor",
                "type": "CONDITION"
            },
            {
                "start": 527,
                "end": 545,
                "text": "Lewy body dementia",
                "type": "CONDITION"
            },
            {
                "start": 619,
                "end": 631,
                "text": "brain tumors",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04243889",
        "text": "Fetoscopic Spina Bifida Repair Using a Cryopreserved Human Umbilical Cord Allograft (NEOX Cord 1K\u00ae) as a Meningeal Patch | To fetoscopically use cryopreserved human umbilical cord allografts, named NEOX Cord 1K\u00ae, as a spinal cord cover of spina bifida defects. This procedure will be performed to create a watertight seal covering over the spinal cord in order to decrease the incidence rates of postnatal morbidities. For larger skin defects, NEOX Cord 1K\u00ae may be used as a skin cover.",
        "tokens": "['Fetoscopic', 'Spina', 'Bifida', 'Repair', 'Using', 'a', 'Cryopreserved', 'Human', 'Umbilical', 'Cord', 'Allograft', '(', 'NEOX', 'Cord', '1', 'K', '\u00ae', ')', 'as', 'a', 'Meningeal', 'Patch', '|', 'To', 'fetoscopically', 'use', 'cryopreserved', 'human', 'umbilical', 'cord', 'allografts', ',', 'named', 'NEOX', 'Cord', '1', 'K', '\u00ae', ',', 'as', 'a', 'spinal', 'cord', 'cover', 'of', 'spina', 'bifida', 'defects', '.', 'This', 'procedure', 'will', 'be', 'performed', 'to', 'create', 'a', 'watertight', 'seal', 'covering', 'over', 'the', 'spinal', 'cord', 'in', 'order', 'to', 'decrease', 'the', 'incidence', 'rates', 'of', 'postnatal', 'morbidities', '.', 'For', 'larger', 'skin', 'defects', ',', 'NEOX', 'Cord', '1', 'K', '\u00ae', 'may', 'be', 'used', 'as', 'a', 'skin', 'cover', '.']",
        "token_bio_labels": "['B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 30,
                "text": "Fetoscopic Spina Bifida Repair",
                "type": "SURGICAL"
            },
            {
                "start": 39,
                "end": 83,
                "text": "Cryopreserved Human Umbilical Cord Allograft",
                "type": "SURGICAL"
            },
            {
                "start": 85,
                "end": 97,
                "text": "NEOX Cord 1K",
                "type": "SURGICAL"
            },
            {
                "start": 145,
                "end": 191,
                "text": "cryopreserved human umbilical cord allografts,",
                "type": "SURGICAL"
            },
            {
                "start": 198,
                "end": 210,
                "text": "NEOX Cord 1K",
                "type": "SURGICAL"
            },
            {
                "start": 239,
                "end": 251,
                "text": "spina bifida",
                "type": "CONDITION"
            },
            {
                "start": 430,
                "end": 442,
                "text": "skin defects",
                "type": "CONDITION"
            },
            {
                "start": 444,
                "end": 456,
                "text": "NEOX Cord 1K",
                "type": "SURGICAL"
            }
        ]
    },
    {
        "nctid": "NCT04500795",
        "text": "Prospective Study on the Use of Middle Meningeal Artery Embolization for Chronic Subdural Haematoma | Subdural haematoma is a common neurosurgical condition that results in different levels of neurological deficits in patients. It can be further classified into acute and chronic, which have different pathophysiology. Acute haematoma is a common result of traumatic injuries involving the tearing of the bridging veins, while chronic subdural haematoma can be both a result of traumatic injuries or recurrence following surgical management of the acute counterpart. For symptomatic patients, they are often surgically managed by haematoma drainage via burr-hole drainage and craniotomy. Recurrent bleeding following close monitor or surgical evacuation of haematoma is however very high. Recent studies approximate the recurrence rate of 2%-33.3%. Recent evidence suggests the angiogenesis of middle meningeal arteries (MMA) in response to inflammation and healing process contributes to the development of chronic subdural haematoma, and its high recurrence chance. Several studies have looked into the use of middle meningeal artery embolization to halt the bleeding of a chronic subdural haematoma, and have found promising results in terms of haematoma reduction and prevention of surgical rescues.",
        "tokens": "['Prospective', 'Study', 'on', 'the', 'Use', 'of', 'Middle', 'Meningeal', 'Artery', 'Embolization', 'for', 'Chronic', 'Subdural', 'Haematoma', '|', 'Subdural', 'haematoma', 'is', 'a', 'common', 'neurosurgical', 'condition', 'that', 'results', 'in', 'different', 'levels', 'of', 'neurological', 'deficits', 'in', 'patients', '.', 'It', 'can', 'be', 'further', 'classified', 'into', 'acute', 'and', 'chronic', ',', 'which', 'have', 'different', 'pathophysiology', '.', 'Acute', 'haematoma', 'is', 'a', 'common', 'result', 'of', 'traumatic', 'injuries', 'involving', 'the', 'tearing', 'of', 'the', 'bridging', 'veins', ',', 'while', 'chronic', 'subdural', 'haematoma', 'can', 'be', 'both', 'a', 'result', 'of', 'traumatic', 'injuries', 'or', 'recurrence', 'following', 'surgical', 'management', 'of', 'the', 'acute', 'counterpart', '.', 'For', 'symptomatic', 'patients', ',', 'they', 'are', 'often', 'surgically', 'managed', 'by', 'haematoma', 'drainage', 'via', 'burr', '-', 'hole', 'drainage', 'and', 'craniotomy', '.', 'Recurrent', 'bleeding', 'following', 'close', 'monitor', 'or', 'surgical', 'evacuation', 'of', 'haematoma', 'is', 'however', 'very', 'high', '.', 'Recent', 'studies', 'approximate', 'the', 'recurrence', 'rate', 'of', '2%-33.3', '%', '.', 'Recent', 'evidence', 'suggests', 'the', 'angiogenesis', 'of', 'middle', 'meningeal', 'arteries', '(', 'MMA', ')', 'in', 'response', 'to', 'inflammation', 'and', 'healing', 'process', 'contributes', 'to', 'the', 'development', 'of', 'chronic', 'subdural', 'haematoma', ',', 'and', 'its', 'high', 'recurrence', 'chance', '.', 'Several', 'studies', 'have', 'looked', 'into', 'the', 'use', 'of', 'middle', 'meningeal', 'artery', 'embolization', 'to', 'halt', 'the', 'bleeding', 'of', 'a', 'chronic', 'subdural', 'haematoma', ',', 'and', 'have', 'found', 'promising', 'results', 'in', 'terms', 'of', 'haematoma', 'reduction', 'and', 'prevention', 'of', 'surgical', 'rescues', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 32,
                "end": 68,
                "text": "Middle Meningeal Artery Embolization",
                "type": "SURGICAL"
            },
            {
                "start": 73,
                "end": 99,
                "text": "Chronic Subdural Haematoma",
                "type": "CONDITION"
            },
            {
                "start": 102,
                "end": 120,
                "text": "Subdural haematoma",
                "type": "CONDITION"
            },
            {
                "start": 319,
                "end": 334,
                "text": "Acute haematoma",
                "type": "CONDITION"
            },
            {
                "start": 427,
                "end": 453,
                "text": "chronic subdural haematoma",
                "type": "CONDITION"
            },
            {
                "start": 630,
                "end": 639,
                "text": "haematoma",
                "type": "CONDITION"
            },
            {
                "start": 757,
                "end": 766,
                "text": "haematoma",
                "type": "CONDITION"
            },
            {
                "start": 1008,
                "end": 1034,
                "text": "chronic subdural haematoma",
                "type": "CONDITION"
            },
            {
                "start": 1112,
                "end": 1148,
                "text": "middle meningeal artery embolization",
                "type": "SURGICAL"
            },
            {
                "start": 1175,
                "end": 1201,
                "text": "chronic subdural haematoma",
                "type": "CONDITION"
            },
            {
                "start": 1248,
                "end": 1257,
                "text": "haematoma",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00597545",
        "text": "Effect of Augmentation of Cerebral Blood Flow on Neuropsychometric Performance After Carotid Endarterectomy in Type II Diabetic Patients | The purpose of this study is to determine if we can reduce the incidence of cognitive dysfunction - difficulty in performing certain pencil-paper, memory, finger dexterity and thinking type of tasks called neuropsychometric tests - in patients with adult onset diabetes mellitus (DM) undergoing surgery on the carotid artery (CEA).\n\nWe hypothesize that cognitive dysfunction can be decreased in patients with type II DM by augmenting cerebral blood flow with a shunt during carotid endarterectomy compared to patients with Type II DM who are treated with \"conventional\" management in which a shunt is placed only if the electroencephalogram (EEG) indicates cerebral ischemia.",
        "tokens": "['Effect', 'of', 'Augmentation', 'of', 'Cerebral', 'Blood', 'Flow', 'on', 'Neuropsychometric', 'Performance', 'After', 'Carotid', 'Endarterectomy', 'in', 'Type', 'II', 'Diabetic', 'Patients', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'if', 'we', 'can', 'reduce', 'the', 'incidence', 'of', 'cognitive', 'dysfunction', '-', 'difficulty', 'in', 'performing', 'certain', 'pencil', '-', 'paper', ',', 'memory', ',', 'finger', 'dexterity', 'and', 'thinking', 'type', 'of', 'tasks', 'called', 'neuropsychometric', 'tests', '-', 'in', 'patients', 'with', 'adult', 'onset', 'diabetes', 'mellitus', '(', 'DM', ')', 'undergoing', 'surgery', 'on', 'the', 'carotid', 'artery', '(', 'CEA', ')', '.', '\\n\\n', 'We', 'hypothesize', 'that', 'cognitive', 'dysfunction', 'can', 'be', 'decreased', 'in', 'patients', 'with', 'type', 'II', 'DM', 'by', 'augmenting', 'cerebral', 'blood', 'flow', 'with', 'a', 'shunt', 'during', 'carotid', 'endarterectomy', 'compared', 'to', 'patients', 'with', 'Type', 'II', 'DM', 'who', 'are', 'treated', 'with', '\"', 'conventional', '\"', 'management', 'in', 'which', 'a', 'shunt', 'is', 'placed', 'only', 'if', 'the', 'electroencephalogram', '(', 'EEG', ')', 'indicates', 'cerebral', 'ischemia', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 45,
                "text": "Augmentation of Cerebral Blood Flow",
                "type": "OTHER"
            },
            {
                "start": 85,
                "end": 107,
                "text": "Carotid Endarterectomy",
                "type": "CONDITION"
            },
            {
                "start": 111,
                "end": 127,
                "text": "Type II Diabetic",
                "type": "CONDITION"
            },
            {
                "start": 215,
                "end": 236,
                "text": "cognitive dysfunction",
                "type": "CONDITION"
            },
            {
                "start": 400,
                "end": 417,
                "text": "diabetes mellitus",
                "type": "CONDITION"
            },
            {
                "start": 419,
                "end": 421,
                "text": "DM",
                "type": "CONDITION"
            },
            {
                "start": 434,
                "end": 463,
                "text": "surgery on the carotid artery",
                "type": "CONDITION"
            },
            {
                "start": 465,
                "end": 468,
                "text": "CEA",
                "type": "CONDITION"
            },
            {
                "start": 492,
                "end": 513,
                "text": "cognitive dysfunction",
                "type": "CONDITION"
            },
            {
                "start": 548,
                "end": 558,
                "text": "type II DM",
                "type": "CONDITION"
            },
            {
                "start": 600,
                "end": 605,
                "text": "shunt",
                "type": "OTHER"
            },
            {
                "start": 613,
                "end": 635,
                "text": "carotid endarterectomy",
                "type": "CONDITION"
            },
            {
                "start": 662,
                "end": 672,
                "text": "Type II DM",
                "type": "CONDITION"
            },
            {
                "start": 694,
                "end": 719,
                "text": "\"conventional\" management",
                "type": "CONTROL"
            },
            {
                "start": 731,
                "end": 736,
                "text": "shunt",
                "type": "OTHER"
            },
            {
                "start": 796,
                "end": 813,
                "text": "cerebral ischemia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02856035",
        "text": "Novel Brain Signal Feedback Paradigm to Enhance Motor Learning After Stroke | Stroke (795,000/year in the US and 30 million existing stroke survivors in the world) damages brain neural structures that control coordinated upper limb movement. To most effectively target the brain damage, interventions should be directed so as to restore brain control serving coordination of peripheral neuromuscular function. Currently, there is a lack of a transformative intervention strategy, and only limited efficacy is seen in response to neural rehabilitation that is only peripherally-directed (limbs e.g.) or only directed at the brain. This study will employ a novel neural feedback approach with a closed-loop, real-time paradigm to engage and retrain existing brain function after stroke. Real-time functional magnetic resonance imaging (rtfMIR) provides neural feedback with the advantage of precisely identifying the location of brain activity for multiple cognitive and emotional tasks. However, the rtfMRI is costly and precludes motor learning that requires sitting and engaging the upper limb in complex motor tasks during imaging acquisition. In contrast, real-time functional near-infrared spectroscopy (rtfNIRS), although not as spatially precise as rtfMRI, offers a low-cost, portable solution to provide brain neural feedback during motor learning. This proposal will utilize both technologies in a hybrid, sequential motor learning protocol. Moreover, the study protocol will also simultaneously involve both central effective signals (through neural feedback) and peripheral affective signals by employing neutrally-triggered functional electrical stimulation (FES)-assisted coordination practice, which produces peripherally-induced affective signals from muscle and joint receptors. This novel combination intervention protocol will engage the central nervous system, motor effective pathway training along with induction of affective signal production (FES-assisted practice), all of which will be implemented within the framework of evidence-based motor learning principles.",
        "tokens": "['Novel', 'Brain', 'Signal', 'Feedback', 'Paradigm', 'to', 'Enhance', 'Motor', 'Learning', 'After', 'Stroke', '|', 'Stroke', '(', '795,000', '/', 'year', 'in', 'the', 'US', 'and', '30', 'million', 'existing', 'stroke', 'survivors', 'in', 'the', 'world', ')', 'damages', 'brain', 'neural', 'structures', 'that', 'control', 'coordinated', 'upper', 'limb', 'movement', '.', 'To', 'most', 'effectively', 'target', 'the', 'brain', 'damage', ',', 'interventions', 'should', 'be', 'directed', 'so', 'as', 'to', 'restore', 'brain', 'control', 'serving', 'coordination', 'of', 'peripheral', 'neuromuscular', 'function', '.', 'Currently', ',', 'there', 'is', 'a', 'lack', 'of', 'a', 'transformative', 'intervention', 'strategy', ',', 'and', 'only', 'limited', 'efficacy', 'is', 'seen', 'in', 'response', 'to', 'neural', 'rehabilitation', 'that', 'is', 'only', 'peripherally', '-', 'directed', '(', 'limbs', 'e.g.', ')', 'or', 'only', 'directed', 'at', 'the', 'brain', '.', 'This', 'study', 'will', 'employ', 'a', 'novel', 'neural', 'feedback', 'approach', 'with', 'a', 'closed', '-', 'loop', ',', 'real', '-', 'time', 'paradigm', 'to', 'engage', 'and', 'retrain', 'existing', 'brain', 'function', 'after', 'stroke', '.', 'Real', '-', 'time', 'functional', 'magnetic', 'resonance', 'imaging', '(', 'rtfMIR', ')', 'provides', 'neural', 'feedback', 'with', 'the', 'advantage', 'of', 'precisely', 'identifying', 'the', 'location', 'of', 'brain', 'activity', 'for', 'multiple', 'cognitive', 'and', 'emotional', 'tasks', '.', 'However', ',', 'the', 'rtfMRI', 'is', 'costly', 'and', 'precludes', 'motor', 'learning', 'that', 'requires', 'sitting', 'and', 'engaging', 'the', 'upper', 'limb', 'in', 'complex', 'motor', 'tasks', 'during', 'imaging', 'acquisition', '.', 'In', 'contrast', ',', 'real', '-', 'time', 'functional', 'near', '-', 'infrared', 'spectroscopy', '(', 'rtfNIRS', ')', ',', 'although', 'not', 'as', 'spatially', 'precise', 'as', 'rtfMRI', ',', 'offers', 'a', 'low', '-', 'cost', ',', 'portable', 'solution', 'to', 'provide', 'brain', 'neural', 'feedback', 'during', 'motor', 'learning', '.', 'This', 'proposal', 'will', 'utilize', 'both', 'technologies', 'in', 'a', 'hybrid', ',', 'sequential', 'motor', 'learning', 'protocol', '.', 'Moreover', ',', 'the', 'study', 'protocol', 'will', 'also', 'simultaneously', 'involve', 'both', 'central', 'effective', 'signals', '(', 'through', 'neural', 'feedback', ')', 'and', 'peripheral', 'affective', 'signals', 'by', 'employing', 'neutrally', '-', 'triggered', 'functional', 'electrical', 'stimulation', '(', 'FES)-assisted', 'coordination', 'practice', ',', 'which', 'produces', 'peripherally', '-', 'induced', 'affective', 'signals', 'from', 'muscle', 'and', 'joint', 'receptors', '.', 'This', 'novel', 'combination', 'intervention', 'protocol', 'will', 'engage', 'the', 'central', 'nervous', 'system', ',', 'motor', 'effective', 'pathway', 'training', 'along', 'with', 'induction', 'of', 'affective', 'signal', 'production', '(', 'FES', '-', 'assisted', 'practice', ')', ',', 'all', 'of', 'which', 'will', 'be', 'implemented', 'within', 'the', 'framework', 'of', 'evidence', '-', 'based', 'motor', 'learning', 'principles', '.']",
        "token_bio_labels": "['O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 6,
                "end": 36,
                "text": "Brain Signal Feedback Paradigm",
                "type": "OTHER"
            },
            {
                "start": 69,
                "end": 75,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 78,
                "end": 84,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 133,
                "end": 139,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 661,
                "end": 724,
                "text": "neural feedback approach with a closed-loop, real-time paradigm",
                "type": "OTHER"
            },
            {
                "start": 777,
                "end": 783,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 851,
                "end": 866,
                "text": "neural feedback",
                "type": "OTHER"
            },
            {
                "start": 1317,
                "end": 1332,
                "text": "neural feedback",
                "type": "OTHER"
            },
            {
                "start": 1406,
                "end": 1448,
                "text": "hybrid, sequential motor learning protocol",
                "type": "OTHER"
            },
            {
                "start": 1552,
                "end": 1567,
                "text": "neural feedback",
                "type": "OTHER"
            },
            {
                "start": 1615,
                "end": 1705,
                "text": "neutrally-triggered functional electrical stimulation (FES)-assisted coordination practice",
                "type": "OTHER"
            },
            {
                "start": 1879,
                "end": 1911,
                "text": "motor effective pathway training",
                "type": "OTHER"
            },
            {
                "start": 1965,
                "end": 1986,
                "text": "FES-assisted practice",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT00131729",
        "text": "Electronic Recording of Compliance With Occlusion Therapy for Amblyopia: 1 Effects of Patient Education on Compliance 2 Predictors for Non-Compliance | The purpose of this study was to determine whether compliance with occlusion therapy for amblyopia could be improved and, secondly, if risk factors for non-compliance could be identified.",
        "tokens": "['Electronic', 'Recording', 'of', 'Compliance', 'With', 'Occlusion', 'Therapy', 'for', 'Amblyopia', ':', '1', 'Effects', 'of', 'Patient', 'Education', 'on', 'Compliance', '2', 'Predictors', 'for', 'Non', '-', 'Compliance', '|', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'determine', 'whether', 'compliance', 'with', 'occlusion', 'therapy', 'for', 'amblyopia', 'could', 'be', 'improved', 'and', ',', 'secondly', ',', 'if', 'risk', 'factors', 'for', 'non', '-', 'compliance', 'could', 'be', 'identified', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 62,
                "end": 71,
                "text": "Amblyopia",
                "type": "CONDITION"
            },
            {
                "start": 86,
                "end": 103,
                "text": "Patient Education",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 241,
                "end": 250,
                "text": "amblyopia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02388152",
        "text": "Interventional, Open-label, Multiple-immunization Extension Study on the Safety, Tolerability and Immunogenicity of Lu AF20513/Adjuvant in Patients With Alzheimer's Disease | The purpose of this study is to determine if multiple immunizations with Lu AF20513 is tolerable and safe in patients with mild Alzheimer's disease.",
        "tokens": "['Interventional', ',', 'Open', '-', 'label', ',', 'Multiple', '-', 'immunization', 'Extension', 'Study', 'on', 'the', 'Safety', ',', 'Tolerability', 'and', 'Immunogenicity', 'of', 'Lu', 'AF20513', '/', 'Adjuvant', 'in', 'Patients', 'With', 'Alzheimer', \"'s\", 'Disease', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'if', 'multiple', 'immunizations', 'with', 'Lu', 'AF20513', 'is', 'tolerable', 'and', 'safe', 'in', 'patients', 'with', 'mild', 'Alzheimer', \"'s\", 'disease', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 116,
                "end": 126,
                "text": "Lu AF20513",
                "type": "DRUG"
            },
            {
                "start": 127,
                "end": 135,
                "text": "Adjuvant",
                "type": "CONTROL"
            },
            {
                "start": 153,
                "end": 172,
                "text": "Alzheimer's Disease",
                "type": "CONDITION"
            },
            {
                "start": 248,
                "end": 258,
                "text": "Lu AF20513",
                "type": "DRUG"
            },
            {
                "start": 298,
                "end": 322,
                "text": "mild Alzheimer's disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04524377",
        "text": "Evaluation of the Influence of Deep Brain Stimulation on the Spinal Deformities Associated With Parkinson's Disease | The intention of the study is to investigate whether Deep Brain Stimulation (DBS) will improve postural deformities of patients with Parkinson's disease.",
        "tokens": "['Evaluation', 'of', 'the', 'Influence', 'of', 'Deep', 'Brain', 'Stimulation', 'on', 'the', 'Spinal', 'Deformities', 'Associated', 'With', 'Parkinson', \"'s\", 'Disease', '|', 'The', 'intention', 'of', 'the', 'study', 'is', 'to', 'investigate', 'whether', 'Deep', 'Brain', 'Stimulation', '(', 'DBS', ')', 'will', 'improve', 'postural', 'deformities', 'of', 'patients', 'with', 'Parkinson', \"'s\", 'disease', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 31,
                "end": 53,
                "text": "Deep Brain Stimulation",
                "type": "OTHER"
            },
            {
                "start": 61,
                "end": 79,
                "text": "Spinal Deformities",
                "type": "CONDITION"
            },
            {
                "start": 96,
                "end": 115,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 171,
                "end": 193,
                "text": "Deep Brain Stimulation",
                "type": "OTHER"
            },
            {
                "start": 195,
                "end": 198,
                "text": "DBS",
                "type": "OTHER"
            },
            {
                "start": 213,
                "end": 233,
                "text": "postural deformities",
                "type": "CONDITION"
            },
            {
                "start": 251,
                "end": 270,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04442594",
        "text": "REMINISCENCES : Reminiscence Triggered by Virtual Reality for Older Adults With Mood Disorders | Presentation & Pre-screening of the control group / reminiscence group Patient/resident pre-screening team meeting for the study Explanation and proposal of the study to patients and their families Signature of resident/patient and family consents Audit of inclusion and non-inclusion criteria Inclusion Medical advice for VR Clinical interview with the family or legal guardian for an accurate life history + an anamnesis interview (psychologist or doctor) with the patient or resident.\n\nCreation of video contents Creation of personalized video contents Clinical scales review Evaluation of the number of psychotropic molecules prescribed (coordinating doctor, general practitioner, geriatrician)\n\nPre-test phase with the patient for the use of the VR headset\nRandomisation\nSession procedure As previously mentioned, the virtual reality sessions will take place in a quiet setting twice a week in the living or hosting residence. The sessions will be hold over a period of time of 6 weeks.\n\nEach subject of the reminiscence group will have two personalised virtual surroundings (after data being collected from team and/or families).\n\nThe virtual environment will change every 3 weeks in order to avoid the phenomenon of habituation.\n\nThe subjects of the control group will be exposed to two generic virtual settings (beach, mountain etc.) with a different virtual environment every 3 weeks.\n\nDuring the session, note will be taken on the subject's speech. The session will also be filmed and/or recorded with a prior signed agreement by the patient or his representative.\n\n- Last session (S6) Review of clinical scales (re-testing) Re-evaluation of drug prescriptions",
        "tokens": "['REMINISCENCES', ':', 'Reminiscence', 'Triggered', 'by', 'Virtual', 'Reality', 'for', 'Older', 'Adults', 'With', 'Mood', 'Disorders', '|', 'Presentation', '&', 'Pre', '-', 'screening', 'of', 'the', 'control', 'group', '/', 'reminiscence', 'group', 'Patient', '/', 'resident', 'pre', '-', 'screening', 'team', 'meeting', 'for', 'the', 'study', 'Explanation', 'and', 'proposal', 'of', 'the', 'study', 'to', 'patients', 'and', 'their', 'families', 'Signature', 'of', 'resident', '/', 'patient', 'and', 'family', 'consents', 'Audit', 'of', 'inclusion', 'and', 'non', '-', 'inclusion', 'criteria', 'Inclusion', 'Medical', 'advice', 'for', 'VR', 'Clinical', 'interview', 'with', 'the', 'family', 'or', 'legal', 'guardian', 'for', 'an', 'accurate', 'life', 'history', '+', 'an', 'anamnesis', 'interview', '(', 'psychologist', 'or', 'doctor', ')', 'with', 'the', 'patient', 'or', 'resident', '.', '\\n\\n', 'Creation', 'of', 'video', 'contents', 'Creation', 'of', 'personalized', 'video', 'contents', 'Clinical', 'scales', 'review', 'Evaluation', 'of', 'the', 'number', 'of', 'psychotropic', 'molecules', 'prescribed', '(', 'coordinating', 'doctor', ',', 'general', 'practitioner', ',', 'geriatrician', ')', '\\n\\n', 'Pre', '-', 'test', 'phase', 'with', 'the', 'patient', 'for', 'the', 'use', 'of', 'the', 'VR', 'headset', '\\n', 'Randomisation', '\\n', 'Session', 'procedure', 'As', 'previously', 'mentioned', ',', 'the', 'virtual', 'reality', 'sessions', 'will', 'take', 'place', 'in', 'a', 'quiet', 'setting', 'twice', 'a', 'week', 'in', 'the', 'living', 'or', 'hosting', 'residence', '.', 'The', 'sessions', 'will', 'be', 'hold', 'over', 'a', 'period', 'of', 'time', 'of', '6', 'weeks', '.', '\\n\\n', 'Each', 'subject', 'of', 'the', 'reminiscence', 'group', 'will', 'have', 'two', 'personalised', 'virtual', 'surroundings', '(', 'after', 'data', 'being', 'collected', 'from', 'team', 'and/or', 'families', ')', '.', '\\n\\n', 'The', 'virtual', 'environment', 'will', 'change', 'every', '3', 'weeks', 'in', 'order', 'to', 'avoid', 'the', 'phenomenon', 'of', 'habituation', '.', '\\n\\n', 'The', 'subjects', 'of', 'the', 'control', 'group', 'will', 'be', 'exposed', 'to', 'two', 'generic', 'virtual', 'settings', '(', 'beach', ',', 'mountain', 'etc', '.', ')', 'with', 'a', 'different', 'virtual', 'environment', 'every', '3', 'weeks', '.', '\\n\\n', 'During', 'the', 'session', ',', 'note', 'will', 'be', 'taken', 'on', 'the', 'subject', \"'s\", 'speech', '.', 'The', 'session', 'will', 'also', 'be', 'filmed', 'and/or', 'recorded', 'with', 'a', 'prior', 'signed', 'agreement', 'by', 'the', 'patient', 'or', 'his', 'representative', '.', '\\n\\n', '-', 'Last', 'session', '(', 'S6', ')', 'Review', 'of', 'clinical', 'scales', '(', 're', '-', 'testing', ')', 'Re', '-', 'evaluation', 'of', 'drug', 'prescriptions']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 42,
                "end": 57,
                "text": "Virtual Reality",
                "type": "OTHER"
            },
            {
                "start": 80,
                "end": 94,
                "text": "Mood Disorders",
                "type": "CONDITION"
            },
            {
                "start": 848,
                "end": 858,
                "text": "VR headset",
                "type": "OTHER"
            },
            {
                "start": 920,
                "end": 935,
                "text": "virtual reality",
                "type": "OTHER"
            },
            {
                "start": 1143,
                "end": 1176,
                "text": "personalised virtual surroundings",
                "type": "OTHER"
            },
            {
                "start": 1238,
                "end": 1257,
                "text": "virtual environment",
                "type": "OTHER"
            },
            {
                "start": 1391,
                "end": 1415,
                "text": "generic virtual settings",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT02810392",
        "text": "Intranasal Insulin and Post-stroke Cognition: A Pilot Study | Almost two-thirds of survivors have cognitive impairment (CI), manifested as memory, language, and judgement problems. Post-stroke CI at 2 weeks is a significant predictor of long-term functional outcome, and more generally, cognitive impairments have a major impact on functional outcome and ability to participate in rehabilitation. CI is associated with increased systemic inflammation. Intranasally-administered insulin is a promising new therapy for enhancing memory in patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD), shown in multiple randomized controlled studies. Likely mechanisms of benefit are intranasal insulin's ability to restore normal cerebral insulin signaling. Based on the overlap in cerebral insulin resistance that occurs in both AD and post-stroke CI, we have designed an innovative proof-of-concept, feasibility trial designed to provide pilot data as to whether post-stroke survivor CI and caregiver burden is improved with intranasal insulin early after stroke. We will explore the impact of intranasal insulin on inflammatory biomarkers, since inflammation is a major underlying cause of CI, as shown by others and in our preliminary studies of VCAM-1. Specific Aims are: 1. Determine if patients with ischemic stroke randomized to intranasal insulin 20 IU BID for 3 weeks have improved cognition, compared to patients who receive intranasal saline. Primary outcome is a composite of (a) memory and executive function z scores. 2. To assess the impact of intranasal insulin vs saline on change in inflammatory biomarker levels (VCAM-1, TNF-alpha, TNFR-I and II) before and after the treatment period. 3. To measure differences in burden among caregivers of participants in the intranasal insulin vs intranasal saline groups. We will prospectively randomize 40 subjects to intranasal insulin (40 IU) vs saline treatment. Following baseline cognitive testing 2 weeks post stroke, subjects will receive the assigned treatment for 3 weeks, followed by a 3-week washout period, with cognitive testing performed after the treatment and washout periods and again at 20 weeks. The proposed study will provide data on a promising method for treating cognitive function in stroke patients. If effective, our pilot data will set the stage for larger phase III clinical trials.",
        "tokens": "['Intranasal', 'Insulin', 'and', 'Post', '-', 'stroke', 'Cognition', ':', 'A', 'Pilot', 'Study', '|', 'Almost', 'two', '-', 'thirds', 'of', 'survivors', 'have', 'cognitive', 'impairment', '(', 'CI', ')', ',', 'manifested', 'as', 'memory', ',', 'language', ',', 'and', 'judgement', 'problems', '.', 'Post', '-', 'stroke', 'CI', 'at', '2', 'weeks', 'is', 'a', 'significant', 'predictor', 'of', 'long', '-', 'term', 'functional', 'outcome', ',', 'and', 'more', 'generally', ',', 'cognitive', 'impairments', 'have', 'a', 'major', 'impact', 'on', 'functional', 'outcome', 'and', 'ability', 'to', 'participate', 'in', 'rehabilitation', '.', 'CI', 'is', 'associated', 'with', 'increased', 'systemic', 'inflammation', '.', 'Intranasally', '-', 'administered', 'insulin', 'is', 'a', 'promising', 'new', 'therapy', 'for', 'enhancing', 'memory', 'in', 'patients', 'with', 'mild', 'cognitive', 'impairment', '(', 'MCI', ')', 'and', 'Alzheimer', \"'s\", 'disease', '(', 'AD', ')', ',', 'shown', 'in', 'multiple', 'randomized', 'controlled', 'studies', '.', 'Likely', 'mechanisms', 'of', 'benefit', 'are', 'intranasal', 'insulin', \"'s\", 'ability', 'to', 'restore', 'normal', 'cerebral', 'insulin', 'signaling', '.', 'Based', 'on', 'the', 'overlap', 'in', 'cerebral', 'insulin', 'resistance', 'that', 'occurs', 'in', 'both', 'AD', 'and', 'post', '-', 'stroke', 'CI', ',', 'we', 'have', 'designed', 'an', 'innovative', 'proof', '-', 'of', '-', 'concept', ',', 'feasibility', 'trial', 'designed', 'to', 'provide', 'pilot', 'data', 'as', 'to', 'whether', 'post', '-', 'stroke', 'survivor', 'CI', 'and', 'caregiver', 'burden', 'is', 'improved', 'with', 'intranasal', 'insulin', 'early', 'after', 'stroke', '.', 'We', 'will', 'explore', 'the', 'impact', 'of', 'intranasal', 'insulin', 'on', 'inflammatory', 'biomarkers', ',', 'since', 'inflammation', 'is', 'a', 'major', 'underlying', 'cause', 'of', 'CI', ',', 'as', 'shown', 'by', 'others', 'and', 'in', 'our', 'preliminary', 'studies', 'of', 'VCAM-1', '.', 'Specific', 'Aims', 'are', ':', '1', '.', 'Determine', 'if', 'patients', 'with', 'ischemic', 'stroke', 'randomized', 'to', 'intranasal', 'insulin', '20', 'IU', 'BID', 'for', '3', 'weeks', 'have', 'improved', 'cognition', ',', 'compared', 'to', 'patients', 'who', 'receive', 'intranasal', 'saline', '.', 'Primary', 'outcome', 'is', 'a', 'composite', 'of', '(', 'a', ')', 'memory', 'and', 'executive', 'function', 'z', 'scores', '.', '2', '.', 'To', 'assess', 'the', 'impact', 'of', 'intranasal', 'insulin', 'vs', 'saline', 'on', 'change', 'in', 'inflammatory', 'biomarker', 'levels', '(', 'VCAM-1', ',', 'TNF', '-', 'alpha', ',', 'TNFR', '-', 'I', 'and', 'II', ')', 'before', 'and', 'after', 'the', 'treatment', 'period', '.', '3', '.', 'To', 'measure', 'differences', 'in', 'burden', 'among', 'caregivers', 'of', 'participants', 'in', 'the', 'intranasal', 'insulin', 'vs', 'intranasal', 'saline', 'groups', '.', 'We', 'will', 'prospectively', 'randomize', '40', 'subjects', 'to', 'intranasal', 'insulin', '(', '40', 'IU', ')', 'vs', 'saline', 'treatment', '.', 'Following', 'baseline', 'cognitive', 'testing', '2', 'weeks', 'post', 'stroke', ',', 'subjects', 'will', 'receive', 'the', 'assigned', 'treatment', 'for', '3', 'weeks', ',', 'followed', 'by', 'a', '3', '-', 'week', 'washout', 'period', ',', 'with', 'cognitive', 'testing', 'performed', 'after', 'the', 'treatment', 'and', 'washout', 'periods', 'and', 'again', 'at', '20', 'weeks', '.', 'The', 'proposed', 'study', 'will', 'provide', 'data', 'on', 'a', 'promising', 'method', 'for', 'treating', 'cognitive', 'function', 'in', 'stroke', 'patients', '.', 'If', 'effective', ',', 'our', 'pilot', 'data', 'will', 'set', 'the', 'stage', 'for', 'larger', 'phase', 'III', 'clinical', 'trials', '.']",
        "token_bio_labels": "['O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 11,
                "end": 18,
                "text": "Insulin",
                "type": "DRUG"
            },
            {
                "start": 23,
                "end": 34,
                "text": "Post-stroke",
                "type": "CONDITION"
            },
            {
                "start": 98,
                "end": 118,
                "text": "cognitive impairment",
                "type": "CONDITION"
            },
            {
                "start": 120,
                "end": 122,
                "text": "CI",
                "type": "CONDITION"
            },
            {
                "start": 181,
                "end": 192,
                "text": "Post-stroke",
                "type": "CONDITION"
            },
            {
                "start": 193,
                "end": 195,
                "text": "CI",
                "type": "CONDITION"
            },
            {
                "start": 287,
                "end": 308,
                "text": "cognitive impairments",
                "type": "CONDITION"
            },
            {
                "start": 397,
                "end": 399,
                "text": "CI",
                "type": "CONDITION"
            },
            {
                "start": 478,
                "end": 485,
                "text": "insulin",
                "type": "DRUG"
            },
            {
                "start": 551,
                "end": 576,
                "text": "mild cognitive impairment",
                "type": "CONDITION"
            },
            {
                "start": 578,
                "end": 581,
                "text": "MCI",
                "type": "CONDITION"
            },
            {
                "start": 587,
                "end": 606,
                "text": "Alzheimer's disease",
                "type": "CONDITION"
            },
            {
                "start": 608,
                "end": 610,
                "text": "AD",
                "type": "CONDITION"
            },
            {
                "start": 706,
                "end": 713,
                "text": "insulin",
                "type": "DRUG"
            },
            {
                "start": 751,
                "end": 758,
                "text": "insulin",
                "type": "DRUG"
            },
            {
                "start": 803,
                "end": 810,
                "text": "insulin",
                "type": "DRUG"
            },
            {
                "start": 842,
                "end": 844,
                "text": "AD",
                "type": "CONDITION"
            },
            {
                "start": 849,
                "end": 860,
                "text": "post-stroke",
                "type": "CONDITION"
            },
            {
                "start": 861,
                "end": 863,
                "text": "CI",
                "type": "CONDITION"
            },
            {
                "start": 977,
                "end": 988,
                "text": "post-stroke",
                "type": "CONDITION"
            },
            {
                "start": 998,
                "end": 1000,
                "text": "CI",
                "type": "CONDITION"
            },
            {
                "start": 1050,
                "end": 1057,
                "text": "insulin",
                "type": "DRUG"
            },
            {
                "start": 1070,
                "end": 1076,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 1119,
                "end": 1126,
                "text": "insulin",
                "type": "DRUG"
            },
            {
                "start": 1205,
                "end": 1207,
                "text": "CI",
                "type": "CONDITION"
            },
            {
                "start": 1319,
                "end": 1334,
                "text": "ischemic stroke",
                "type": "CONDITION"
            },
            {
                "start": 1360,
                "end": 1367,
                "text": "insulin",
                "type": "DRUG"
            },
            {
                "start": 1459,
                "end": 1465,
                "text": "saline",
                "type": "CONTROL"
            },
            {
                "start": 1583,
                "end": 1590,
                "text": "insulin",
                "type": "DRUG"
            },
            {
                "start": 1594,
                "end": 1600,
                "text": "saline",
                "type": "CONTROL"
            },
            {
                "start": 1805,
                "end": 1812,
                "text": "insulin",
                "type": "DRUG"
            },
            {
                "start": 1827,
                "end": 1833,
                "text": "saline",
                "type": "CONTROL"
            },
            {
                "start": 1900,
                "end": 1907,
                "text": "insulin",
                "type": "DRUG"
            },
            {
                "start": 1919,
                "end": 1925,
                "text": "saline",
                "type": "CONTROL"
            },
            {
                "start": 1982,
                "end": 1993,
                "text": "post stroke",
                "type": "CONDITION"
            },
            {
                "start": 2280,
                "end": 2286,
                "text": "stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04052568",
        "text": "Effects of Psilocybin in Anorexia Nervosa | This open-label pilot study seeks to investigate the safety and efficacy of psilocybin in persons with chronic anorexia nervosa (AN). Psilocybin has previously been demonstrated to decrease depression and anxiety and increase long-term positive behavior change in other populations. The investigators seek to determine whether similar changes can be safely produced in people with AN when psilocybin is administered in a supportive setting with close follow-up. The investigators' primary hypotheses are that psilocybin is safe to administer in people with AN, that it will reduce measures of anxiety and depression, and that it will lead to increased quality of life. The investigators will also assess a number of exploratory measures related to eating disorder pathophysiology.",
        "tokens": "['Effects', 'of', 'Psilocybin', 'in', 'Anorexia', 'Nervosa', '|', 'This', 'open', '-', 'label', 'pilot', 'study', 'seeks', 'to', 'investigate', 'the', 'safety', 'and', 'efficacy', 'of', 'psilocybin', 'in', 'persons', 'with', 'chronic', 'anorexia', 'nervosa', '(', 'AN', ')', '.', 'Psilocybin', 'has', 'previously', 'been', 'demonstrated', 'to', 'decrease', 'depression', 'and', 'anxiety', 'and', 'increase', 'long', '-', 'term', 'positive', 'behavior', 'change', 'in', 'other', 'populations', '.', 'The', 'investigators', 'seek', 'to', 'determine', 'whether', 'similar', 'changes', 'can', 'be', 'safely', 'produced', 'in', 'people', 'with', 'AN', 'when', 'psilocybin', 'is', 'administered', 'in', 'a', 'supportive', 'setting', 'with', 'close', 'follow', '-', 'up', '.', 'The', 'investigators', \"'\", 'primary', 'hypotheses', 'are', 'that', 'psilocybin', 'is', 'safe', 'to', 'administer', 'in', 'people', 'with', 'AN', ',', 'that', 'it', 'will', 'reduce', 'measures', 'of', 'anxiety', 'and', 'depression', ',', 'and', 'that', 'it', 'will', 'lead', 'to', 'increased', 'quality', 'of', 'life', '.', 'The', 'investigators', 'will', 'also', 'assess', 'a', 'number', 'of', 'exploratory', 'measures', 'related', 'to', 'eating', 'disorder', 'pathophysiology', '.']",
        "token_bio_labels": "['O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O']",
        "entities": [
            {
                "start": 11,
                "end": 21,
                "text": "Psilocybin",
                "type": "DRUG"
            },
            {
                "start": 25,
                "end": 41,
                "text": "Anorexia Nervosa",
                "type": "CONDITION"
            },
            {
                "start": 120,
                "end": 130,
                "text": "psilocybin",
                "type": "DRUG"
            },
            {
                "start": 147,
                "end": 171,
                "text": "chronic anorexia nervosa",
                "type": "CONDITION"
            },
            {
                "start": 173,
                "end": 175,
                "text": "AN",
                "type": "CONDITION"
            },
            {
                "start": 178,
                "end": 188,
                "text": "Psilocybin",
                "type": "DRUG"
            },
            {
                "start": 234,
                "end": 244,
                "text": "depression",
                "type": "CONDITION"
            },
            {
                "start": 249,
                "end": 256,
                "text": "anxiety",
                "type": "CONDITION"
            },
            {
                "start": 425,
                "end": 427,
                "text": "AN",
                "type": "CONDITION"
            },
            {
                "start": 433,
                "end": 443,
                "text": "psilocybin",
                "type": "DRUG"
            },
            {
                "start": 553,
                "end": 563,
                "text": "psilocybin",
                "type": "DRUG"
            },
            {
                "start": 601,
                "end": 603,
                "text": "AN",
                "type": "CONDITION"
            },
            {
                "start": 637,
                "end": 644,
                "text": "anxiety",
                "type": "CONDITION"
            },
            {
                "start": 649,
                "end": 659,
                "text": "depression",
                "type": "CONDITION"
            },
            {
                "start": 792,
                "end": 807,
                "text": "eating disorder",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01255163",
        "text": "A Pilot Study of Exendin-4 in Alzheimer s Disease | Background:\n\nExendin-4 (or Exenatide) is a medication currently used to treat diabetes that has shown promising results in animal and cellular models of Alzheimer's disease. It is possible that Exendin-4 may be a treatment for Alzheimer's disease, which involves the gradual deterioration and death of neurons. Researchers are interested in studying the safety and comparing the effects of Exendin-4 with placebo on cognitive performance, clinical progression of dementia, various chemicals measured in blood and cerebrospinal fluid, and brain MRI, in individuals with early-stage Alzheimer's disease or mild cognitive impairment.\n\nObjectives:\n\nTo determine the safety and tolerability of twice daily administration of Exendin-4, as well as to acquire preliminary evidence for effects on cognitive performance, clinical progression of dementia, various chemicals measured in blood and cerebrospinal fluid, and brain MRI, in individuals with early-stage Alzheimer's disease or mild cognitive impairment.\n\nEligibility:\n\nIndividuals at least 60 years of age who have objective evidence of early-stage Alzheimer's disease or mild cognitive impairment in screening testing.\n\nDesign:\n\nParticipants will be screened.\nFollowing the telephone screening, two in-person screening visits to determine eligibility.\nThe screening visit will involve a medical history and neurological examination, tests of memory and cognition, a lumbar puncture, collection of blood and saliva samples, and brain Magnetic Resonance Imagine (MRI) studies. Participants will be required to appoint a Durable Power of Attorney for research and medical care during this protocol.\nEligible participants will be divided into two groups (double-blind randomization). One group will receive Exendin-4 SC twice daily, and the other will receive a placebo. Participants will keep a medication diary and will be scheduled for additional study visits 1 and 2 weeks after the start of the treatment.\nParticipants will have regular followup visits with blood tests, cognitive tests, imaging studies, and other examinations 6, 12, and 18 months after the start of the treatment. Another lumbar puncture may be performed optionally at the 18-month followup visit.",
        "tokens": "['A', 'Pilot', 'Study', 'of', 'Exendin-4', 'in', 'Alzheimer', 's', 'Disease', '|', 'Background', ':', '\\n\\n', 'Exendin-4', '(', 'or', 'Exenatide', ')', 'is', 'a', 'medication', 'currently', 'used', 'to', 'treat', 'diabetes', 'that', 'has', 'shown', 'promising', 'results', 'in', 'animal', 'and', 'cellular', 'models', 'of', 'Alzheimer', \"'s\", 'disease', '.', 'It', 'is', 'possible', 'that', 'Exendin-4', 'may', 'be', 'a', 'treatment', 'for', 'Alzheimer', \"'s\", 'disease', ',', 'which', 'involves', 'the', 'gradual', 'deterioration', 'and', 'death', 'of', 'neurons', '.', 'Researchers', 'are', 'interested', 'in', 'studying', 'the', 'safety', 'and', 'comparing', 'the', 'effects', 'of', 'Exendin-4', 'with', 'placebo', 'on', 'cognitive', 'performance', ',', 'clinical', 'progression', 'of', 'dementia', ',', 'various', 'chemicals', 'measured', 'in', 'blood', 'and', 'cerebrospinal', 'fluid', ',', 'and', 'brain', 'MRI', ',', 'in', 'individuals', 'with', 'early', '-', 'stage', 'Alzheimer', \"'s\", 'disease', 'or', 'mild', 'cognitive', 'impairment', '.', '\\n\\n', 'Objectives', ':', '\\n\\n', 'To', 'determine', 'the', 'safety', 'and', 'tolerability', 'of', 'twice', 'daily', 'administration', 'of', 'Exendin-4', ',', 'as', 'well', 'as', 'to', 'acquire', 'preliminary', 'evidence', 'for', 'effects', 'on', 'cognitive', 'performance', ',', 'clinical', 'progression', 'of', 'dementia', ',', 'various', 'chemicals', 'measured', 'in', 'blood', 'and', 'cerebrospinal', 'fluid', ',', 'and', 'brain', 'MRI', ',', 'in', 'individuals', 'with', 'early', '-', 'stage', 'Alzheimer', \"'s\", 'disease', 'or', 'mild', 'cognitive', 'impairment', '.', '\\n\\n', 'Eligibility', ':', '\\n\\n', 'Individuals', 'at', 'least', '60', 'years', 'of', 'age', 'who', 'have', 'objective', 'evidence', 'of', 'early', '-', 'stage', 'Alzheimer', \"'s\", 'disease', 'or', 'mild', 'cognitive', 'impairment', 'in', 'screening', 'testing', '.', '\\n\\n', 'Design', ':', '\\n\\n', 'Participants', 'will', 'be', 'screened', '.', '\\n', 'Following', 'the', 'telephone', 'screening', ',', 'two', 'in', '-', 'person', 'screening', 'visits', 'to', 'determine', 'eligibility', '.', '\\n', 'The', 'screening', 'visit', 'will', 'involve', 'a', 'medical', 'history', 'and', 'neurological', 'examination', ',', 'tests', 'of', 'memory', 'and', 'cognition', ',', 'a', 'lumbar', 'puncture', ',', 'collection', 'of', 'blood', 'and', 'saliva', 'samples', ',', 'and', 'brain', 'Magnetic', 'Resonance', 'Imagine', '(', 'MRI', ')', 'studies', '.', 'Participants', 'will', 'be', 'required', 'to', 'appoint', 'a', 'Durable', 'Power', 'of', 'Attorney', 'for', 'research', 'and', 'medical', 'care', 'during', 'this', 'protocol', '.', '\\n', 'Eligible', 'participants', 'will', 'be', 'divided', 'into', 'two', 'groups', '(', 'double', '-', 'blind', 'randomization', ')', '.', 'One', 'group', 'will', 'receive', 'Exendin-4', 'SC', 'twice', 'daily', ',', 'and', 'the', 'other', 'will', 'receive', 'a', 'placebo', '.', 'Participants', 'will', 'keep', 'a', 'medication', 'diary', 'and', 'will', 'be', 'scheduled', 'for', 'additional', 'study', 'visits', '1', 'and', '2', 'weeks', 'after', 'the', 'start', 'of', 'the', 'treatment', '.', '\\n', 'Participants', 'will', 'have', 'regular', 'followup', 'visits', 'with', 'blood', 'tests', ',', 'cognitive', 'tests', ',', 'imaging', 'studies', ',', 'and', 'other', 'examinations', '6', ',', '12', ',', 'and', '18', 'months', 'after', 'the', 'start', 'of', 'the', 'treatment', '.', 'Another', 'lumbar', 'puncture', 'may', 'be', 'performed', 'optionally', 'at', 'the', '18', '-', 'month', 'followup', 'visit', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 17,
                "end": 26,
                "text": "Exendin-4",
                "type": "DRUG"
            },
            {
                "start": 30,
                "end": 49,
                "text": "Alzheimer s Disease",
                "type": "CONDITION"
            },
            {
                "start": 65,
                "end": 74,
                "text": "Exendin-4",
                "type": "DRUG"
            },
            {
                "start": 79,
                "end": 88,
                "text": "Exenatide",
                "type": "DRUG"
            },
            {
                "start": 205,
                "end": 224,
                "text": "Alzheimer's disease",
                "type": "CONDITION"
            },
            {
                "start": 246,
                "end": 255,
                "text": "Exendin-4",
                "type": "DRUG"
            },
            {
                "start": 279,
                "end": 298,
                "text": "Alzheimer's disease",
                "type": "CONDITION"
            },
            {
                "start": 442,
                "end": 451,
                "text": "Exendin-4",
                "type": "DRUG"
            },
            {
                "start": 515,
                "end": 523,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 621,
                "end": 652,
                "text": "early-stage Alzheimer's disease",
                "type": "CONDITION"
            },
            {
                "start": 656,
                "end": 681,
                "text": "mild cognitive impairment",
                "type": "CONDITION"
            },
            {
                "start": 771,
                "end": 780,
                "text": "Exendin-4",
                "type": "DRUG"
            },
            {
                "start": 887,
                "end": 895,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 993,
                "end": 1024,
                "text": "early-stage Alzheimer's disease",
                "type": "CONDITION"
            },
            {
                "start": 1028,
                "end": 1053,
                "text": "mild cognitive impairment",
                "type": "CONDITION"
            },
            {
                "start": 1138,
                "end": 1169,
                "text": "early-stage Alzheimer's disease",
                "type": "CONDITION"
            },
            {
                "start": 1173,
                "end": 1198,
                "text": "mild cognitive impairment",
                "type": "CONDITION"
            },
            {
                "start": 1805,
                "end": 1814,
                "text": "Exendin-4",
                "type": "DRUG"
            },
            {
                "start": 1860,
                "end": 1867,
                "text": "placebo",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT03271736",
        "text": "Effects of Rhythmic Auditory Cueing on Stepping in Place in Patients With Parkinson's Disease | Patients with Parkinson's disease have internal rhythm dysfunction, which may affect the rhythmic movements such as walking. Poor regularity of the rhythmic movement may lead to freezing of gait. This study will apply rhythmic auditory cues on the stepping-in-place training and the investigators will examine if the behavior and neuroelectrophysiology would change after auditory cueing training. The investigators hypothesize the variation of rhythmic movements such as walking and stepping-in-place will be reduced, and the cortical excitability would be modulated after training.",
        "tokens": "['Effects', 'of', 'Rhythmic', 'Auditory', 'Cueing', 'on', 'Stepping', 'in', 'Place', 'in', 'Patients', 'With', 'Parkinson', \"'s\", 'Disease', '|', 'Patients', 'with', 'Parkinson', \"'s\", 'disease', 'have', 'internal', 'rhythm', 'dysfunction', ',', 'which', 'may', 'affect', 'the', 'rhythmic', 'movements', 'such', 'as', 'walking', '.', 'Poor', 'regularity', 'of', 'the', 'rhythmic', 'movement', 'may', 'lead', 'to', 'freezing', 'of', 'gait', '.', 'This', 'study', 'will', 'apply', 'rhythmic', 'auditory', 'cues', 'on', 'the', 'stepping', '-', 'in', '-', 'place', 'training', 'and', 'the', 'investigators', 'will', 'examine', 'if', 'the', 'behavior', 'and', 'neuroelectrophysiology', 'would', 'change', 'after', 'auditory', 'cueing', 'training', '.', 'The', 'investigators', 'hypothesize', 'the', 'variation', 'of', 'rhythmic', 'movements', 'such', 'as', 'walking', 'and', 'stepping', '-', 'in', '-', 'place', 'will', 'be', 'reduced', ',', 'and', 'the', 'cortical', 'excitability', 'would', 'be', 'modulated', 'after', 'training', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 11,
                "end": 35,
                "text": "Rhythmic Auditory Cueing",
                "type": "OTHER"
            },
            {
                "start": 74,
                "end": 93,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 110,
                "end": 129,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 135,
                "end": 162,
                "text": "internal rhythm dysfunction",
                "type": "CONDITION"
            },
            {
                "start": 274,
                "end": 290,
                "text": "freezing of gait",
                "type": "CONDITION"
            },
            {
                "start": 314,
                "end": 336,
                "text": "rhythmic auditory cues",
                "type": "OTHER"
            },
            {
                "start": 344,
                "end": 370,
                "text": "stepping-in-place training",
                "type": "PHYSICAL"
            },
            {
                "start": 468,
                "end": 492,
                "text": "auditory cueing training",
                "type": "OTHER"
            },
            {
                "start": 541,
                "end": 559,
                "text": "rhythmic movements",
                "type": "PHYSICAL"
            }
        ]
    },
    {
        "nctid": "NCT05833009",
        "text": "Study on the Optimal Scheme of Acupuncture Treatment for Schizophrenia-related Central Obesity | This clinical trial aims to test the effect of acupuncture in patients with schizophrenia-related central obesity. The main question it aims to answer is:\n\n\u2022 The effect, safety, and maintenance of acupuncture on schizophrenia-related central obesity.\n\nParticipants will receive acupuncture treatment on purpose acupoints, acupuncture on acupoint peripheries, or fake acupuncture treatment on purpose acupoints for 20 weeks. And they need three follow-up visits during the treatment period and two follow-up visits after treatment.\n\nResearchers will compare the waist circumstance of these three groups to see if the purpose acupoints are valid for schizophrenia-related central obesity.",
        "tokens": "['Study', 'on', 'the', 'Optimal', 'Scheme', 'of', 'Acupuncture', 'Treatment', 'for', 'Schizophrenia', '-', 'related', 'Central', 'Obesity', '|', 'This', 'clinical', 'trial', 'aims', 'to', 'test', 'the', 'effect', 'of', 'acupuncture', 'in', 'patients', 'with', 'schizophrenia', '-', 'related', 'central', 'obesity', '.', 'The', 'main', 'question', 'it', 'aims', 'to', 'answer', 'is', ':', '\\n\\n', '\u2022', 'The', 'effect', ',', 'safety', ',', 'and', 'maintenance', 'of', 'acupuncture', 'on', 'schizophrenia', '-', 'related', 'central', 'obesity', '.', '\\n\\n', 'Participants', 'will', 'receive', 'acupuncture', 'treatment', 'on', 'purpose', 'acupoints', ',', 'acupuncture', 'on', 'acupoint', 'peripheries', ',', 'or', 'fake', 'acupuncture', 'treatment', 'on', 'purpose', 'acupoints', 'for', '20', 'weeks', '.', 'And', 'they', 'need', 'three', 'follow', '-', 'up', 'visits', 'during', 'the', 'treatment', 'period', 'and', 'two', 'follow', '-', 'up', 'visits', 'after', 'treatment', '.', '\\n\\n', 'Researchers', 'will', 'compare', 'the', 'waist', 'circumstance', 'of', 'these', 'three', 'groups', 'to', 'see', 'if', 'the', 'purpose', 'acupoints', 'are', 'valid', 'for', 'schizophrenia', '-', 'related', 'central', 'obesity', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 31,
                "end": 52,
                "text": "Acupuncture Treatment",
                "type": "PHYSICAL"
            },
            {
                "start": 57,
                "end": 70,
                "text": "Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 79,
                "end": 94,
                "text": "Central Obesity",
                "type": "CONDITION"
            },
            {
                "start": 144,
                "end": 155,
                "text": "acupuncture",
                "type": "PHYSICAL"
            },
            {
                "start": 173,
                "end": 186,
                "text": "schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 195,
                "end": 210,
                "text": "central obesity",
                "type": "CONDITION"
            },
            {
                "start": 294,
                "end": 305,
                "text": "acupuncture",
                "type": "PHYSICAL"
            },
            {
                "start": 309,
                "end": 322,
                "text": "schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 331,
                "end": 346,
                "text": "central obesity",
                "type": "CONDITION"
            },
            {
                "start": 375,
                "end": 386,
                "text": "acupuncture",
                "type": "PHYSICAL"
            },
            {
                "start": 459,
                "end": 475,
                "text": "fake acupuncture",
                "type": "CONTROL"
            },
            {
                "start": 745,
                "end": 758,
                "text": "schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 767,
                "end": 782,
                "text": "central obesity",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01703988",
        "text": "An Open-Label, Dose Escalation Study to Assess the Safety, Tolerability and Dose-Range Finding of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Spinal Muscular Atrophy | This study will test the safety, tolerability, and pharmacokinetics of escalating doses of nusinersen (ISIS 396443) administered into the spinal fluid either two or three times over the duration of the trial, in participants with spinal muscular atrophy (SMA).\n\nFour dose levels will be evaluated sequentially. Each dose level will be studied in a cohort of approximately 8 participants, where all participants will receive active drug.",
        "tokens": "['An', 'Open', '-', 'Label', ',', 'Dose', 'Escalation', 'Study', 'to', 'Assess', 'the', 'Safety', ',', 'Tolerability', 'and', 'Dose', '-', 'Range', 'Finding', 'of', 'Multiple', 'Doses', 'of', 'ISIS', '396443', 'Delivered', 'Intrathecally', 'to', 'Patients', 'With', 'Spinal', 'Muscular', 'Atrophy', '|', 'This', 'study', 'will', 'test', 'the', 'safety', ',', 'tolerability', ',', 'and', 'pharmacokinetics', 'of', 'escalating', 'doses', 'of', 'nusinersen', '(', 'ISIS', '396443', ')', 'administered', 'into', 'the', 'spinal', 'fluid', 'either', 'two', 'or', 'three', 'times', 'over', 'the', 'duration', 'of', 'the', 'trial', ',', 'in', 'participants', 'with', 'spinal', 'muscular', 'atrophy', '(', 'SMA', ')', '.', '\\n\\n', 'Four', 'dose', 'levels', 'will', 'be', 'evaluated', 'sequentially', '.', 'Each', 'dose', 'level', 'will', 'be', 'studied', 'in', 'a', 'cohort', 'of', 'approximately', '8', 'participants', ',', 'where', 'all', 'participants', 'will', 'receive', 'active', 'drug', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 116,
                "end": 127,
                "text": "ISIS 396443",
                "type": "DRUG"
            },
            {
                "start": 169,
                "end": 192,
                "text": "Spinal Muscular Atrophy",
                "type": "CONDITION"
            },
            {
                "start": 286,
                "end": 296,
                "text": "nusinersen",
                "type": "DRUG"
            },
            {
                "start": 298,
                "end": 309,
                "text": "ISIS 396443",
                "type": "DRUG"
            },
            {
                "start": 425,
                "end": 448,
                "text": "spinal muscular atrophy",
                "type": "CONDITION"
            },
            {
                "start": 450,
                "end": 453,
                "text": "SMA",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02998021",
        "text": "Effect of Vibration Exercise on Upper Limb Strength, Function, and Pain | The primary purpose of this study is to explore the benefits of vibration dumbbell resistance training over standard dumbbell resistance training for improving upper limb strength, function and pain among manual wheelchair users with paraplegia.",
        "tokens": "['Effect', 'of', 'Vibration', 'Exercise', 'on', 'Upper', 'Limb', 'Strength', ',', 'Function', ',', 'and', 'Pain', '|', 'The', 'primary', 'purpose', 'of', 'this', 'study', 'is', 'to', 'explore', 'the', 'benefits', 'of', 'vibration', 'dumbbell', 'resistance', 'training', 'over', 'standard', 'dumbbell', 'resistance', 'training', 'for', 'improving', 'upper', 'limb', 'strength', ',', 'function', 'and', 'pain', 'among', 'manual', 'wheelchair', 'users', 'with', 'paraplegia', '.']",
        "token_bio_labels": "['O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 28,
                "text": "Vibration Exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 67,
                "end": 71,
                "text": "Pain",
                "type": "CONDITION"
            },
            {
                "start": 138,
                "end": 176,
                "text": "vibration dumbbell resistance training",
                "type": "PHYSICAL"
            },
            {
                "start": 182,
                "end": 219,
                "text": "standard dumbbell resistance training",
                "type": "CONTROL"
            },
            {
                "start": 268,
                "end": 272,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 308,
                "end": 318,
                "text": "paraplegia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03004014",
        "text": "Comparison Between Natural Sleep Endoscopy and Drug-induced Sleep Endoscopy Among Obstructive Sleep Apnea Subjects Referred for Surgical Treatment | Drug induced sleep endoscopy (DISE) has been performed worldwide since 1991 to determine the site and configuration of upper airway obstruction in patients with obstructive sleep apnea (OSA). However, there are no studies comparing DISE to sleep endoscopy during natural sleep. Objectives: To compare DISE to natural sleep endoscopy in OSA patients referred for surgical treatment.\n\nMethods: OSA patients referred to surgical treatment (lateral pharyngoplasty) will be enrolled in this study. Natural sleep endoscopy will be performed at the sleep lab during the night. Propofol induced sleep will be performed at the operating room before surgery. The VOTE (velum, oropharyngeal lateral walls, tongue base and epiglottis) classification will be used to compare site and configuration of collapse between studies. Peak inspiratory flow will also be compared between studies.",
        "tokens": "['Comparison', 'Between', 'Natural', 'Sleep', 'Endoscopy', 'and', 'Drug', '-', 'induced', 'Sleep', 'Endoscopy', 'Among', 'Obstructive', 'Sleep', 'Apnea', 'Subjects', 'Referred', 'for', 'Surgical', 'Treatment', '|', 'Drug', 'induced', 'sleep', 'endoscopy', '(', 'DISE', ')', 'has', 'been', 'performed', 'worldwide', 'since', '1991', 'to', 'determine', 'the', 'site', 'and', 'configuration', 'of', 'upper', 'airway', 'obstruction', 'in', 'patients', 'with', 'obstructive', 'sleep', 'apnea', '(', 'OSA', ')', '.', 'However', ',', 'there', 'are', 'no', 'studies', 'comparing', 'DISE', 'to', 'sleep', 'endoscopy', 'during', 'natural', 'sleep', '.', 'Objectives', ':', 'To', 'compare', 'DISE', 'to', 'natural', 'sleep', 'endoscopy', 'in', 'OSA', 'patients', 'referred', 'for', 'surgical', 'treatment', '.', '\\n\\n', 'Methods', ':', 'OSA', 'patients', 'referred', 'to', 'surgical', 'treatment', '(', 'lateral', 'pharyngoplasty', ')', 'will', 'be', 'enrolled', 'in', 'this', 'study', '.', 'Natural', 'sleep', 'endoscopy', 'will', 'be', 'performed', 'at', 'the', 'sleep', 'lab', 'during', 'the', 'night', '.', 'Propofol', 'induced', 'sleep', 'will', 'be', 'performed', 'at', 'the', 'operating', 'room', 'before', 'surgery', '.', 'The', 'VOTE', '(', 'velum', ',', 'oropharyngeal', 'lateral', 'walls', ',', 'tongue', 'base', 'and', 'epiglottis', ')', 'classification', 'will', 'be', 'used', 'to', 'compare', 'site', 'and', 'configuration', 'of', 'collapse', 'between', 'studies', '.', 'Peak', 'inspiratory', 'flow', 'will', 'also', 'be', 'compared', 'between', 'studies', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 82,
                "end": 105,
                "text": "Obstructive Sleep Apnea",
                "type": "CONDITION"
            },
            {
                "start": 310,
                "end": 333,
                "text": "obstructive sleep apnea",
                "type": "CONDITION"
            },
            {
                "start": 335,
                "end": 338,
                "text": "OSA",
                "type": "CONDITION"
            },
            {
                "start": 485,
                "end": 488,
                "text": "OSA",
                "type": "CONDITION"
            },
            {
                "start": 541,
                "end": 544,
                "text": "OSA",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04971733",
        "text": "An Open-Label Phase 1b/2 Study to Assess Safety and Target Engagement of E2814 in Subjects With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease | The primary objective of the study is to assess the safety and tolerability of intravenous (IV) infusions of E2814 in participants with dominantly inherited Alzheimer's disease (DIAD), and to evaluate target engagement (TE) of E2814 on microtubule binding region (MTBR)-tau species in cerebrospinal fluid (CSF) in participants with DIAD.",
        "tokens": "['An', 'Open', '-', 'Label', 'Phase', '1b/2', 'Study', 'to', 'Assess', 'Safety', 'and', 'Target', 'Engagement', 'of', 'E2814', 'in', 'Subjects', 'With', 'Mild', 'to', 'Moderate', 'Cognitive', 'Impairment', 'Due', 'to', 'Dominantly', 'Inherited', 'Alzheimer', \"'s\", 'Disease', '|', 'The', 'primary', 'objective', 'of', 'the', 'study', 'is', 'to', 'assess', 'the', 'safety', 'and', 'tolerability', 'of', 'intravenous', '(', 'IV', ')', 'infusions', 'of', 'E2814', 'in', 'participants', 'with', 'dominantly', 'inherited', 'Alzheimer', \"'s\", 'disease', '(', 'DIAD', ')', ',', 'and', 'to', 'evaluate', 'target', 'engagement', '(', 'TE', ')', 'of', 'E2814', 'on', 'microtubule', 'binding', 'region', '(', 'MTBR)-tau', 'species', 'in', 'cerebrospinal', 'fluid', '(', 'CSF', ')', 'in', 'participants', 'with', 'DIAD', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 73,
                "end": 78,
                "text": "E2814",
                "type": "DRUG"
            },
            {
                "start": 96,
                "end": 133,
                "text": "Mild to Moderate Cognitive Impairment",
                "type": "CONDITION"
            },
            {
                "start": 141,
                "end": 181,
                "text": "Dominantly Inherited Alzheimer's Disease",
                "type": "CONDITION"
            },
            {
                "start": 293,
                "end": 298,
                "text": "E2814",
                "type": "DRUG"
            },
            {
                "start": 320,
                "end": 360,
                "text": "dominantly inherited Alzheimer's disease",
                "type": "CONDITION"
            },
            {
                "start": 362,
                "end": 366,
                "text": "DIAD",
                "type": "CONDITION"
            },
            {
                "start": 411,
                "end": 416,
                "text": "E2814",
                "type": "DRUG"
            },
            {
                "start": 516,
                "end": 520,
                "text": "DIAD",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04635540",
        "text": "A Pilot Study Assessing the Benefits of a Dementia Caregiver Educational Brochure on Decreased Empathy and Emotion Recognition in Patients With Neurodegenerative Disease | This study evaluates an educational brochure tailored to caregivers of people with Alzheimer's disease, Parkinson's disease dementia, Lewy body disease, frontotemporal dementia, and vascular disease dementia. The goal of the brochure is educating caregivers about the decreased ability to detect emotion and decreased empathy that can be seen in dementia, increasing caregiver competence in providing care, and teaching caregivers ways to manage over time that lessens burden and improves quality of life.",
        "tokens": "['A', 'Pilot', 'Study', 'Assessing', 'the', 'Benefits', 'of', 'a', 'Dementia', 'Caregiver', 'Educational', 'Brochure', 'on', 'Decreased', 'Empathy', 'and', 'Emotion', 'Recognition', 'in', 'Patients', 'With', 'Neurodegenerative', 'Disease', '|', 'This', 'study', 'evaluates', 'an', 'educational', 'brochure', 'tailored', 'to', 'caregivers', 'of', 'people', 'with', 'Alzheimer', \"'s\", 'disease', ',', 'Parkinson', \"'s\", 'disease', 'dementia', ',', 'Lewy', 'body', 'disease', ',', 'frontotemporal', 'dementia', ',', 'and', 'vascular', 'disease', 'dementia', '.', 'The', 'goal', 'of', 'the', 'brochure', 'is', 'educating', 'caregivers', 'about', 'the', 'decreased', 'ability', 'to', 'detect', 'emotion', 'and', 'decreased', 'empathy', 'that', 'can', 'be', 'seen', 'in', 'dementia', ',', 'increasing', 'caregiver', 'competence', 'in', 'providing', 'care', ',', 'and', 'teaching', 'caregivers', 'ways', 'to', 'manage', 'over', 'time', 'that', 'lessens', 'burden', 'and', 'improves', 'quality', 'of', 'life', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 42,
                "end": 81,
                "text": "Dementia Caregiver Educational Brochure",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 144,
                "end": 169,
                "text": "Neurodegenerative Disease",
                "type": "CONDITION"
            },
            {
                "start": 196,
                "end": 239,
                "text": "educational brochure tailored to caregivers",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 255,
                "end": 274,
                "text": "Alzheimer's disease",
                "type": "CONDITION"
            },
            {
                "start": 276,
                "end": 304,
                "text": "Parkinson's disease dementia",
                "type": "CONDITION"
            },
            {
                "start": 306,
                "end": 323,
                "text": "Lewy body disease",
                "type": "CONDITION"
            },
            {
                "start": 325,
                "end": 348,
                "text": "frontotemporal dementia",
                "type": "CONDITION"
            },
            {
                "start": 354,
                "end": 379,
                "text": "vascular disease dementia",
                "type": "CONDITION"
            },
            {
                "start": 397,
                "end": 405,
                "text": "brochure",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 518,
                "end": 526,
                "text": "dementia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04210063",
        "text": "Effect of Inspiratory Muscle Training (IMT) on Breathing, Balance, and Blood Pressure Maintenance in Spinal Cord Injury (SCI) | The purpose of this study is to help understand how training breathing muscles will impact balance, blood pressure, and quality of life of participants with spinal cord injury.",
        "tokens": "['Effect', 'of', 'Inspiratory', 'Muscle', 'Training', '(', 'IMT', ')', 'on', 'Breathing', ',', 'Balance', ',', 'and', 'Blood', 'Pressure', 'Maintenance', 'in', 'Spinal', 'Cord', 'Injury', '(', 'SCI', ')', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'help', 'understand', 'how', 'training', 'breathing', 'muscles', 'will', 'impact', 'balance', ',', 'blood', 'pressure', ',', 'and', 'quality', 'of', 'life', 'of', 'participants', 'with', 'spinal', 'cord', 'injury', '.']",
        "token_bio_labels": "['O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 37,
                "text": "Inspiratory Muscle Training",
                "type": "PHYSICAL"
            },
            {
                "start": 39,
                "end": 42,
                "text": "IMT",
                "type": "PHYSICAL"
            },
            {
                "start": 101,
                "end": 119,
                "text": "Spinal Cord Injury",
                "type": "CONDITION"
            },
            {
                "start": 121,
                "end": 124,
                "text": "SCI",
                "type": "CONDITION"
            },
            {
                "start": 180,
                "end": 206,
                "text": "training breathing muscles",
                "type": "PHYSICAL"
            },
            {
                "start": 285,
                "end": 303,
                "text": "spinal cord injury",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04577573",
        "text": "Cognitive-based Rehabilitation Platform of Hand Grasp After Spinal Cord Injury Using Virtual Reality and Instrumented Wearables | Rehabilitation of functional movements after spinal cord injury (SCI) requires commitment and engagement to the processes of physical therapy. Outcomes may be improved by techniques that strengthen cognitive connections between users and physical therapy exercises.\n\nThe investigators will investigate combinations of virtual reality and innovative wearable technology to accelerate rehabilitation of hand grasp and reach. These devices use multi-sensory feedback to enhance the sense of agency, or feelings of control, and better train movements during physical rehabilitation exercises. The investigators will measure the effect of these devices on improving the speed, efficiency, and accuracy of performed movements in Veterans with SCI.",
        "tokens": "['Cognitive', '-', 'based', 'Rehabilitation', 'Platform', 'of', 'Hand', 'Grasp', 'After', 'Spinal', 'Cord', 'Injury', 'Using', 'Virtual', 'Reality', 'and', 'Instrumented', 'Wearables', '|', 'Rehabilitation', 'of', 'functional', 'movements', 'after', 'spinal', 'cord', 'injury', '(', 'SCI', ')', 'requires', 'commitment', 'and', 'engagement', 'to', 'the', 'processes', 'of', 'physical', 'therapy', '.', 'Outcomes', 'may', 'be', 'improved', 'by', 'techniques', 'that', 'strengthen', 'cognitive', 'connections', 'between', 'users', 'and', 'physical', 'therapy', 'exercises', '.', '\\n\\n', 'The', 'investigators', 'will', 'investigate', 'combinations', 'of', 'virtual', 'reality', 'and', 'innovative', 'wearable', 'technology', 'to', 'accelerate', 'rehabilitation', 'of', 'hand', 'grasp', 'and', 'reach', '.', 'These', 'devices', 'use', 'multi', '-', 'sensory', 'feedback', 'to', 'enhance', 'the', 'sense', 'of', 'agency', ',', 'or', 'feelings', 'of', 'control', ',', 'and', 'better', 'train', 'movements', 'during', 'physical', 'rehabilitation', 'exercises', '.', 'The', 'investigators', 'will', 'measure', 'the', 'effect', 'of', 'these', 'devices', 'on', 'improving', 'the', 'speed', ',', 'efficiency', ',', 'and', 'accuracy', 'of', 'performed', 'movements', 'in', 'Veterans', 'with', 'SCI', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 39,
                "text": "Cognitive-based Rehabilitation Platform",
                "type": "OTHER"
            },
            {
                "start": 60,
                "end": 78,
                "text": "Spinal Cord Injury",
                "type": "CONDITION"
            },
            {
                "start": 85,
                "end": 100,
                "text": "Virtual Reality",
                "type": "OTHER"
            },
            {
                "start": 105,
                "end": 127,
                "text": "Instrumented Wearables",
                "type": "OTHER"
            },
            {
                "start": 175,
                "end": 193,
                "text": "spinal cord injury",
                "type": "CONDITION"
            },
            {
                "start": 195,
                "end": 198,
                "text": "SCI",
                "type": "CONDITION"
            },
            {
                "start": 255,
                "end": 271,
                "text": "physical therapy",
                "type": "PHYSICAL"
            },
            {
                "start": 368,
                "end": 394,
                "text": "physical therapy exercises",
                "type": "PHYSICAL"
            },
            {
                "start": 448,
                "end": 463,
                "text": "virtual reality",
                "type": "OTHER"
            },
            {
                "start": 468,
                "end": 498,
                "text": "innovative wearable technology",
                "type": "OTHER"
            },
            {
                "start": 571,
                "end": 593,
                "text": "multi-sensory feedback",
                "type": "OTHER"
            },
            {
                "start": 684,
                "end": 717,
                "text": "physical rehabilitation exercises",
                "type": "PHYSICAL"
            },
            {
                "start": 867,
                "end": 870,
                "text": "SCI",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05640661",
        "text": "Effects of Terminal Visual Feedback Therapy After Immersive Virtual Reality in Patients With Chronic Shoulder Pain : Mixed-Methods Randomized Clinical Trial | The goal of this clinical trial is effect of terminal visual feedback therapy following the use of immersive virtual reality(VRi) effects on pain,kinesiophobia, fear of pain, disability, self-efficacy, grip strength and range of motion in motion in people with chronic shoulder pain compare with just VRi. The main question[s] it aims to answer are:\n\nCan terminal visual feedback therapy following the use of immersive virtual reality software decrease movement-evoked pain in patients with chronic shoulder pain compared with just VRi?\nCan terminal visual feedback therapy following the use of immersive virtual reality software increase shoulder flexion range of motion in patients with chronic shoulder pain compared with just VRi?\n\nParticipants will use a visual feedback therapy following the use of immersive virtual reality software compared with just specific VRi software",
        "tokens": "['Effects', 'of', 'Terminal', 'Visual', 'Feedback', 'Therapy', 'After', 'Immersive', 'Virtual', 'Reality', 'in', 'Patients', 'With', 'Chronic', 'Shoulder', 'Pain', ':', 'Mixed', '-', 'Methods', 'Randomized', 'Clinical', 'Trial', '|', 'The', 'goal', 'of', 'this', 'clinical', 'trial', 'is', 'effect', 'of', 'terminal', 'visual', 'feedback', 'therapy', 'following', 'the', 'use', 'of', 'immersive', 'virtual', 'reality(VRi', ')', 'effects', 'on', 'pain', ',', 'kinesiophobia', ',', 'fear', 'of', 'pain', ',', 'disability', ',', 'self', '-', 'efficacy', ',', 'grip', 'strength', 'and', 'range', 'of', 'motion', 'in', 'motion', 'in', 'people', 'with', 'chronic', 'shoulder', 'pain', 'compare', 'with', 'just', 'VRi', '.', 'The', 'main', 'question[s', ']', 'it', 'aims', 'to', 'answer', 'are', ':', '\\n\\n', 'Can', 'terminal', 'visual', 'feedback', 'therapy', 'following', 'the', 'use', 'of', 'immersive', 'virtual', 'reality', 'software', 'decrease', 'movement', '-', 'evoked', 'pain', 'in', 'patients', 'with', 'chronic', 'shoulder', 'pain', 'compared', 'with', 'just', 'VRi', '?', '\\n', 'Can', 'terminal', 'visual', 'feedback', 'therapy', 'following', 'the', 'use', 'of', 'immersive', 'virtual', 'reality', 'software', 'increase', 'shoulder', 'flexion', 'range', 'of', 'motion', 'in', 'patients', 'with', 'chronic', 'shoulder', 'pain', 'compared', 'with', 'just', 'VRi', '?', '\\n\\n', 'Participants', 'will', 'use', 'a', 'visual', 'feedback', 'therapy', 'following', 'the', 'use', 'of', 'immersive', 'virtual', 'reality', 'software', 'compared', 'with', 'just', 'specific', 'VRi', 'software']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O']",
        "entities": [
            {
                "start": 11,
                "end": 43,
                "text": "Terminal Visual Feedback Therapy",
                "type": "OTHER"
            },
            {
                "start": 50,
                "end": 75,
                "text": "Immersive Virtual Reality",
                "type": "OTHER"
            },
            {
                "start": 93,
                "end": 114,
                "text": "Chronic Shoulder Pain",
                "type": "CONDITION"
            },
            {
                "start": 204,
                "end": 236,
                "text": "terminal visual feedback therapy",
                "type": "OTHER"
            },
            {
                "start": 300,
                "end": 304,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 320,
                "end": 332,
                "text": "fear of pain",
                "type": "CONDITION"
            },
            {
                "start": 420,
                "end": 441,
                "text": "chronic shoulder pain",
                "type": "CONDITION"
            },
            {
                "start": 460,
                "end": 463,
                "text": "VRi",
                "type": "CONTROL"
            },
            {
                "start": 514,
                "end": 546,
                "text": "terminal visual feedback therapy",
                "type": "OTHER"
            },
            {
                "start": 568,
                "end": 593,
                "text": "immersive virtual reality",
                "type": "OTHER"
            },
            {
                "start": 650,
                "end": 671,
                "text": "chronic shoulder pain",
                "type": "CONDITION"
            },
            {
                "start": 691,
                "end": 694,
                "text": "VRi",
                "type": "CONTROL"
            },
            {
                "start": 700,
                "end": 724,
                "text": "terminal visual feedback",
                "type": "OTHER"
            },
            {
                "start": 754,
                "end": 779,
                "text": "immersive virtual reality",
                "type": "OTHER"
            },
            {
                "start": 848,
                "end": 869,
                "text": "chronic shoulder pain",
                "type": "CONDITION"
            },
            {
                "start": 889,
                "end": 892,
                "text": "VRi",
                "type": "CONTROL"
            },
            {
                "start": 919,
                "end": 942,
                "text": "visual feedback therapy",
                "type": "OTHER"
            },
            {
                "start": 964,
                "end": 989,
                "text": "immersive virtual reality",
                "type": "OTHER"
            },
            {
                "start": 1027,
                "end": 1030,
                "text": "VRi",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT04763109",
        "text": "Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence | This is a single arm pilot trial of a novel whole-body Magnetic Resonance Imaging paired with artificial intelligence intervention, to evaluate feasibility defined as scan-rescan reliability, and to estimate the positive predictive value of changes in Magnetic Resonance Imaging scans from baseline to 12-month visit using an Artificial Intelligence algorithm, among 15 pediatric patients with neurofibromatosis type 1 at Cedars-Sinai Medical Center.",
        "tokens": "['Identification', 'of', 'Pre', '-', 'Malignant', 'Lesions', 'In', 'Pediatric', 'Patients', 'With', 'Neurofibromatosis', 'Type', '1', 'Using', 'Novel', 'Magnetic', 'Resonance', 'Imaging', 'Techniques', 'Paired', 'With', 'Artificial', 'Intelligence', '|', 'This', 'is', 'a', 'single', 'arm', 'pilot', 'trial', 'of', 'a', 'novel', 'whole', '-', 'body', 'Magnetic', 'Resonance', 'Imaging', 'paired', 'with', 'artificial', 'intelligence', 'intervention', ',', 'to', 'evaluate', 'feasibility', 'defined', 'as', 'scan', '-', 'rescan', 'reliability', ',', 'and', 'to', 'estimate', 'the', 'positive', 'predictive', 'value', 'of', 'changes', 'in', 'Magnetic', 'Resonance', 'Imaging', 'scans', 'from', 'baseline', 'to', '12', '-', 'month', 'visit', 'using', 'an', 'Artificial', 'Intelligence', 'algorithm', ',', 'among', '15', 'pediatric', 'patients', 'with', 'neurofibromatosis', 'type', '1', 'at', 'Cedars', '-', 'Sinai', 'Medical', 'Center', '.']",
        "token_bio_labels": "['O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 18,
                "end": 39,
                "text": "Pre-Malignant Lesions",
                "type": "CONDITION"
            },
            {
                "start": 67,
                "end": 91,
                "text": "Neurofibromatosis Type 1",
                "type": "CONDITION"
            },
            {
                "start": 574,
                "end": 598,
                "text": "neurofibromatosis type 1",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01044693",
        "text": "Effect of Nebivolol on Blood Pressure in a Model of Hypertension Sensitive to Potentiation of Nitric Oxide Bioactivity | The purpose of this study is to evaluate the effect of the antihypertensive drug, nebivolol (Bystolic), compared to metoprolol (Lopressor) and sildenafil (Viagra) on blood pressure in patients with autonomic failure and supine hypertension.",
        "tokens": "['Effect', 'of', 'Nebivolol', 'on', 'Blood', 'Pressure', 'in', 'a', 'Model', 'of', 'Hypertension', 'Sensitive', 'to', 'Potentiation', 'of', 'Nitric', 'Oxide', 'Bioactivity', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'effect', 'of', 'the', 'antihypertensive', 'drug', ',', 'nebivolol', '(', 'Bystolic', ')', ',', 'compared', 'to', 'metoprolol', '(', 'Lopressor', ')', 'and', 'sildenafil', '(', 'Viagra', ')', 'on', 'blood', 'pressure', 'in', 'patients', 'with', 'autonomic', 'failure', 'and', 'supine', 'hypertension', '.']",
        "token_bio_labels": "['O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 19,
                "text": "Nebivolol",
                "type": "DRUG"
            },
            {
                "start": 52,
                "end": 64,
                "text": "Hypertension",
                "type": "CONDITION"
            },
            {
                "start": 203,
                "end": 212,
                "text": "nebivolol",
                "type": "DRUG"
            },
            {
                "start": 214,
                "end": 222,
                "text": "Bystolic",
                "type": "DRUG"
            },
            {
                "start": 237,
                "end": 247,
                "text": "metoprolol",
                "type": "DRUG"
            },
            {
                "start": 249,
                "end": 258,
                "text": "Lopressor",
                "type": "DRUG"
            },
            {
                "start": 264,
                "end": 274,
                "text": "sildenafil",
                "type": "DRUG"
            },
            {
                "start": 276,
                "end": 282,
                "text": "Viagra",
                "type": "DRUG"
            },
            {
                "start": 319,
                "end": 336,
                "text": "autonomic failure",
                "type": "CONDITION"
            },
            {
                "start": 341,
                "end": 360,
                "text": "supine hypertension",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01263392",
        "text": "A Comparison of the Incidence of Symptomatic Urinary Tract Infections in Children With Spina Bifida Using Hydrophilic or Non-hydrophilic Polyvinyl Chloride Catheters for Clean Intermittent Catheterization: a Randomized Cross Over Trial | The primary aim of this study was to determine if using the SpeediCath hydrophilic catheter would reduce the incidence of symptomatic urinary tract infections (UTI)in children with spina bifida who perform clean intermittent catheterization for bladder management. The hypothesis was that the incidence of symptomatic urinary tract infections would be significantly reduced (by 25%) in users of the SpeediCath hydrophilic catheter when compared to users of a reused polyvinyl chloride (PVC) catheter. Subjects were randomly assigned to either starting the study with PVC catheter for 6 months followed by the hydrophilic catheter for 6 months or visa versa. Each subject kept a weekly diary recording urinary tract infections symptoms, hematuria determined by urine dipstick, physician visits, days of missed school and other activities. At the end of each 6 months subjects completed a questionnaire recording their comfort and satisfaction in using the PVC or hydrophilic coated catheter. 70 subjects were randomized and 46 had complete data. There were no differences in febrile UTI, antibiotic use, healthcare visits or school days missed. The incidence of self reported UTI was lower in the PVC group than the hydrophilic group. 40% of subjects indicated that the hydrophilic coated catheter was slippery and difficult to handle compared to 10% for the PVC catheter. However overall satisfaction was no different between products. The study results are consistent with the current Cochrane Review that there is a lack of evidence to state that the incidence of UTI is affected by multiuse or hydrophilic catheter use.",
        "tokens": "['A', 'Comparison', 'of', 'the', 'Incidence', 'of', 'Symptomatic', 'Urinary', 'Tract', 'Infections', 'in', 'Children', 'With', 'Spina', 'Bifida', 'Using', 'Hydrophilic', 'or', 'Non', '-', 'hydrophilic', 'Polyvinyl', 'Chloride', 'Catheters', 'for', 'Clean', 'Intermittent', 'Catheterization', ':', 'a', 'Randomized', 'Cross', 'Over', 'Trial', '|', 'The', 'primary', 'aim', 'of', 'this', 'study', 'was', 'to', 'determine', 'if', 'using', 'the', 'SpeediCath', 'hydrophilic', 'catheter', 'would', 'reduce', 'the', 'incidence', 'of', 'symptomatic', 'urinary', 'tract', 'infections', '(', 'UTI)in', 'children', 'with', 'spina', 'bifida', 'who', 'perform', 'clean', 'intermittent', 'catheterization', 'for', 'bladder', 'management', '.', 'The', 'hypothesis', 'was', 'that', 'the', 'incidence', 'of', 'symptomatic', 'urinary', 'tract', 'infections', 'would', 'be', 'significantly', 'reduced', '(', 'by', '25', '%', ')', 'in', 'users', 'of', 'the', 'SpeediCath', 'hydrophilic', 'catheter', 'when', 'compared', 'to', 'users', 'of', 'a', 'reused', 'polyvinyl', 'chloride', '(', 'PVC', ')', 'catheter', '.', 'Subjects', 'were', 'randomly', 'assigned', 'to', 'either', 'starting', 'the', 'study', 'with', 'PVC', 'catheter', 'for', '6', 'months', 'followed', 'by', 'the', 'hydrophilic', 'catheter', 'for', '6', 'months', 'or', 'visa', 'versa', '.', 'Each', 'subject', 'kept', 'a', 'weekly', 'diary', 'recording', 'urinary', 'tract', 'infections', 'symptoms', ',', 'hematuria', 'determined', 'by', 'urine', 'dipstick', ',', 'physician', 'visits', ',', 'days', 'of', 'missed', 'school', 'and', 'other', 'activities', '.', 'At', 'the', 'end', 'of', 'each', '6', 'months', 'subjects', 'completed', 'a', 'questionnaire', 'recording', 'their', 'comfort', 'and', 'satisfaction', 'in', 'using', 'the', 'PVC', 'or', 'hydrophilic', 'coated', 'catheter', '.', '70', 'subjects', 'were', 'randomized', 'and', '46', 'had', 'complete', 'data', '.', 'There', 'were', 'no', 'differences', 'in', 'febrile', 'UTI', ',', 'antibiotic', 'use', ',', 'healthcare', 'visits', 'or', 'school', 'days', 'missed', '.', 'The', 'incidence', 'of', 'self', 'reported', 'UTI', 'was', 'lower', 'in', 'the', 'PVC', 'group', 'than', 'the', 'hydrophilic', 'group', '.', '40', '%', 'of', 'subjects', 'indicated', 'that', 'the', 'hydrophilic', 'coated', 'catheter', 'was', 'slippery', 'and', 'difficult', 'to', 'handle', 'compared', 'to', '10', '%', 'for', 'the', 'PVC', 'catheter', '.', 'However', 'overall', 'satisfaction', 'was', 'no', 'different', 'between', 'products', '.', 'The', 'study', 'results', 'are', 'consistent', 'with', 'the', 'current', 'Cochrane', 'Review', 'that', 'there', 'is', 'a', 'lack', 'of', 'evidence', 'to', 'state', 'that', 'the', 'incidence', 'of', 'UTI', 'is', 'affected', 'by', 'multiuse', 'or', 'hydrophilic', 'catheter', 'use', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O']",
        "entities": [
            {
                "start": 33,
                "end": 69,
                "text": "Symptomatic Urinary Tract Infections",
                "type": "CONDITION"
            },
            {
                "start": 87,
                "end": 99,
                "text": "Spina Bifida",
                "type": "CONDITION"
            },
            {
                "start": 106,
                "end": 165,
                "text": "Hydrophilic or Non-hydrophilic Polyvinyl Chloride Catheters",
                "type": "OTHER"
            },
            {
                "start": 170,
                "end": 204,
                "text": "Clean Intermittent Catheterization",
                "type": "CONDITION"
            },
            {
                "start": 298,
                "end": 329,
                "text": "SpeediCath hydrophilic catheter",
                "type": "OTHER"
            },
            {
                "start": 360,
                "end": 396,
                "text": "symptomatic urinary tract infections",
                "type": "CONDITION"
            },
            {
                "start": 419,
                "end": 431,
                "text": "spina bifida",
                "type": "CONDITION"
            },
            {
                "start": 544,
                "end": 580,
                "text": "symptomatic urinary tract infections",
                "type": "CONDITION"
            },
            {
                "start": 637,
                "end": 668,
                "text": "SpeediCath hydrophilic catheter",
                "type": "OTHER"
            },
            {
                "start": 704,
                "end": 737,
                "text": "polyvinyl chloride (PVC) catheter",
                "type": "CONTROL"
            },
            {
                "start": 805,
                "end": 817,
                "text": "PVC catheter",
                "type": "CONTROL"
            },
            {
                "start": 847,
                "end": 867,
                "text": "hydrophilic catheter",
                "type": "OTHER"
            },
            {
                "start": 1193,
                "end": 1227,
                "text": "PVC or hydrophilic coated catheter",
                "type": "OTHER"
            },
            {
                "start": 1320,
                "end": 1323,
                "text": "UTI",
                "type": "CONDITION"
            },
            {
                "start": 1413,
                "end": 1416,
                "text": "UTI",
                "type": "CONDITION"
            },
            {
                "start": 1507,
                "end": 1534,
                "text": "hydrophilic coated catheter",
                "type": "OTHER"
            },
            {
                "start": 1596,
                "end": 1608,
                "text": "PVC catheter",
                "type": "CONTROL"
            },
            {
                "start": 1804,
                "end": 1807,
                "text": "UTI",
                "type": "CONDITION"
            },
            {
                "start": 1823,
                "end": 1859,
                "text": "multiuse or hydrophilic catheter use",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT02157805",
        "text": "Effect of Technological Processes on Nutritional Quality of Meat Proteins | This project aims to assess the impact of technological processes of meat, as cooking conditions, on amino acid bioavailability and protein metabolism. The hypothesis is that, even if meat is considered as a good provider of fast proteins and so could be useful to prevent sarcopenia in aged people, the manner it is cooked can change its digestion rate and amino acids bioavailability for muscle synthesis.",
        "tokens": "['Effect', 'of', 'Technological', 'Processes', 'on', 'Nutritional', 'Quality', 'of', 'Meat', 'Proteins', '|', 'This', 'project', 'aims', 'to', 'assess', 'the', 'impact', 'of', 'technological', 'processes', 'of', 'meat', ',', 'as', 'cooking', 'conditions', ',', 'on', 'amino', 'acid', 'bioavailability', 'and', 'protein', 'metabolism', '.', 'The', 'hypothesis', 'is', 'that', ',', 'even', 'if', 'meat', 'is', 'considered', 'as', 'a', 'good', 'provider', 'of', 'fast', 'proteins', 'and', 'so', 'could', 'be', 'useful', 'to', 'prevent', 'sarcopenia', 'in', 'aged', 'people', ',', 'the', 'manner', 'it', 'is', 'cooked', 'can', 'change', 'its', 'digestion', 'rate', 'and', 'amino', 'acids', 'bioavailability', 'for', 'muscle', 'synthesis', '.']",
        "token_bio_labels": "['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 10,
                "end": 73,
                "text": "Technological Processes on Nutritional Quality of Meat Proteins",
                "type": "OTHER"
            },
            {
                "start": 118,
                "end": 149,
                "text": "technological processes of meat",
                "type": "OTHER"
            },
            {
                "start": 349,
                "end": 359,
                "text": "sarcopenia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03320954",
        "text": "Language Assessment and Treatment Following Acquired Brain Injury | People with acquired brain injury (ABI) often experience persistent language challenges that are subtle in nature and not readily observable to others. These challenges can have substantial negative effects on vocational and social endeavors despite their subtlety. Even though these challenges are prevalent in the ABI population, limited methods exist for quantifying and remediating them. The two purposes of Phase I of this research are to (a) explore methods of using event related potential (ERP) recordings to quantify language processing differences between people with and without ABI and (b) correlate behavioral observations from language tests with ERP findings. The purpose of Phase II is to explore the use of game-based, group activities as an intervention for people with ABI who experience word-retrieval challenges. The purpose of Phase III is to collect post-intervention data for comparison with Phase I data and provide evidence about the effectiveness of the intervention program.",
        "tokens": "['Language', 'Assessment', 'and', 'Treatment', 'Following', 'Acquired', 'Brain', 'Injury', '|', 'People', 'with', 'acquired', 'brain', 'injury', '(', 'ABI', ')', 'often', 'experience', 'persistent', 'language', 'challenges', 'that', 'are', 'subtle', 'in', 'nature', 'and', 'not', 'readily', 'observable', 'to', 'others', '.', 'These', 'challenges', 'can', 'have', 'substantial', 'negative', 'effects', 'on', 'vocational', 'and', 'social', 'endeavors', 'despite', 'their', 'subtlety', '.', 'Even', 'though', 'these', 'challenges', 'are', 'prevalent', 'in', 'the', 'ABI', 'population', ',', 'limited', 'methods', 'exist', 'for', 'quantifying', 'and', 'remediating', 'them', '.', 'The', 'two', 'purposes', 'of', 'Phase', 'I', 'of', 'this', 'research', 'are', 'to', '(', 'a', ')', 'explore', 'methods', 'of', 'using', 'event', 'related', 'potential', '(', 'ERP', ')', 'recordings', 'to', 'quantify', 'language', 'processing', 'differences', 'between', 'people', 'with', 'and', 'without', 'ABI', 'and', '(', 'b', ')', 'correlate', 'behavioral', 'observations', 'from', 'language', 'tests', 'with', 'ERP', 'findings', '.', 'The', 'purpose', 'of', 'Phase', 'II', 'is', 'to', 'explore', 'the', 'use', 'of', 'game', '-', 'based', ',', 'group', 'activities', 'as', 'an', 'intervention', 'for', 'people', 'with', 'ABI', 'who', 'experience', 'word', '-', 'retrieval', 'challenges', '.', 'The', 'purpose', 'of', 'Phase', 'III', 'is', 'to', 'collect', 'post', '-', 'intervention', 'data', 'for', 'comparison', 'with', 'Phase', 'I', 'data', 'and', 'provide', 'evidence', 'about', 'the', 'effectiveness', 'of', 'the', 'intervention', 'program', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 44,
                "end": 65,
                "text": "Acquired Brain Injury",
                "type": "CONDITION"
            },
            {
                "start": 80,
                "end": 101,
                "text": "acquired brain injury",
                "type": "CONDITION"
            },
            {
                "start": 103,
                "end": 106,
                "text": "ABI",
                "type": "CONDITION"
            },
            {
                "start": 136,
                "end": 155,
                "text": "language challenges",
                "type": "CONDITION"
            },
            {
                "start": 384,
                "end": 387,
                "text": "ABI",
                "type": "CONDITION"
            },
            {
                "start": 658,
                "end": 661,
                "text": "ABI",
                "type": "CONDITION"
            },
            {
                "start": 792,
                "end": 820,
                "text": "game-based, group activities",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 856,
                "end": 859,
                "text": "ABI",
                "type": "CONDITION"
            },
            {
                "start": 875,
                "end": 900,
                "text": "word-retrieval challenges",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02958605",
        "text": "Smartphone Medical Applications to Reduce Treatment Dosage Errors in Pediatric Resuscitation; a Randomized Simulation Trial | Medication errors are common in children. Characteristics of errors during critical situations in the Emergency Department are ill-defined and might be more frequent than previously thought. However, optimal strategies to eliminate the risk of prescribing errors remain unknown.\n\nMany smartphone apps have been suggested over the last years with some of them designed to calculate medication dosage for children. The impact of these apps to decrease dosage error has never been evaluated in resuscitation setting.\n\nThe aim of the study is to evaluate whether the use of a smartphone application designed to calculate medication doses decreases prescribing errors among residents during pediatric simulated resuscitations.\n\nThis will be a crossover-randomized trial using high fidelity simulation among 40 residents rotating in the pediatric emergency department.",
        "tokens": "['Smartphone', 'Medical', 'Applications', 'to', 'Reduce', 'Treatment', 'Dosage', 'Errors', 'in', 'Pediatric', 'Resuscitation', ';', 'a', 'Randomized', 'Simulation', 'Trial', '|', 'Medication', 'errors', 'are', 'common', 'in', 'children', '.', 'Characteristics', 'of', 'errors', 'during', 'critical', 'situations', 'in', 'the', 'Emergency', 'Department', 'are', 'ill', '-', 'defined', 'and', 'might', 'be', 'more', 'frequent', 'than', 'previously', 'thought', '.', 'However', ',', 'optimal', 'strategies', 'to', 'eliminate', 'the', 'risk', 'of', 'prescribing', 'errors', 'remain', 'unknown', '.', '\\n\\n', 'Many', 'smartphone', 'apps', 'have', 'been', 'suggested', 'over', 'the', 'last', 'years', 'with', 'some', 'of', 'them', 'designed', 'to', 'calculate', 'medication', 'dosage', 'for', 'children', '.', 'The', 'impact', 'of', 'these', 'apps', 'to', 'decrease', 'dosage', 'error', 'has', 'never', 'been', 'evaluated', 'in', 'resuscitation', 'setting', '.', '\\n\\n', 'The', 'aim', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'whether', 'the', 'use', 'of', 'a', 'smartphone', 'application', 'designed', 'to', 'calculate', 'medication', 'doses', 'decreases', 'prescribing', 'errors', 'among', 'residents', 'during', 'pediatric', 'simulated', 'resuscitations', '.', '\\n\\n', 'This', 'will', 'be', 'a', 'crossover', '-', 'randomized', 'trial', 'using', 'high', 'fidelity', 'simulation', 'among', '40', 'residents', 'rotating', 'in', 'the', 'pediatric', 'emergency', 'department', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 31,
                "text": "Smartphone Medical Applications",
                "type": "OTHER"
            },
            {
                "start": 42,
                "end": 65,
                "text": "Treatment Dosage Errors",
                "type": "CONDITION"
            },
            {
                "start": 79,
                "end": 92,
                "text": "Resuscitation",
                "type": "CONDITION"
            },
            {
                "start": 126,
                "end": 143,
                "text": "Medication errors",
                "type": "CONDITION"
            },
            {
                "start": 370,
                "end": 388,
                "text": "prescribing errors",
                "type": "CONDITION"
            },
            {
                "start": 576,
                "end": 588,
                "text": "dosage error",
                "type": "CONDITION"
            },
            {
                "start": 698,
                "end": 759,
                "text": "smartphone application designed to calculate medication doses",
                "type": "OTHER"
            },
            {
                "start": 770,
                "end": 788,
                "text": "prescribing errors",
                "type": "CONDITION"
            },
            {
                "start": 832,
                "end": 846,
                "text": "resuscitations",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05557968",
        "text": "Effects of Action Observation Therapy on Stair Walking, Balance, and Self-efficacy in Chronic Stroke | This study focuses on the effects of Action Observation therapy on stair walking, balance and self-efficacy in chronic stroke patients. This study will be conducted in Helping Hands Institute of Rehabilitation Sciences and Shifa Surgical Hospital Mansehra.\n\nIt is a Randomized Control Trial. Non probability convenient sampling technique will be used to assess a total number of 40 respondents. Questionnaires and consent forms will be filled by the respondents. Each patient will be screened by using a simple selection Performa relevant to inclusion and exclusion criteria.\n\nTotal 30 patients will be included in the study and then divided into two groups i.e. Action observation therapy and Convention Therapy group with 15 individuals in each. Each group will be assessed thrice i.e. pre, post and follow up surveys. Each of them will receive the convention therapy for 30 mins except for the Action Observation therapy (AOT) group, which will also receive the additional 30 minutes session of action observational training. Total 18 sessions, 3 days a week for a total of six weeks will be performed on each patient.\n\nFugel Meyer Assessment Scale for lower limb, Timed Up and Go test, Timed Stair Test, Step test and self-efficacy scale will be used for the assessment. Baseline assessments of both group will be done on 1st week before the application of protocol, second assessment will be done on 4th week and then final assessment will be done on 6th week of the protocol.",
        "tokens": "['Effects', 'of', 'Action', 'Observation', 'Therapy', 'on', 'Stair', 'Walking', ',', 'Balance', ',', 'and', 'Self', '-', 'efficacy', 'in', 'Chronic', 'Stroke', '|', 'This', 'study', 'focuses', 'on', 'the', 'effects', 'of', 'Action', 'Observation', 'therapy', 'on', 'stair', 'walking', ',', 'balance', 'and', 'self', '-', 'efficacy', 'in', 'chronic', 'stroke', 'patients', '.', 'This', 'study', 'will', 'be', 'conducted', 'in', 'Helping', 'Hands', 'Institute', 'of', 'Rehabilitation', 'Sciences', 'and', 'Shifa', 'Surgical', 'Hospital', 'Mansehra', '.', '\\n\\n', 'It', 'is', 'a', 'Randomized', 'Control', 'Trial', '.', 'Non', 'probability', 'convenient', 'sampling', 'technique', 'will', 'be', 'used', 'to', 'assess', 'a', 'total', 'number', 'of', '40', 'respondents', '.', 'Questionnaires', 'and', 'consent', 'forms', 'will', 'be', 'filled', 'by', 'the', 'respondents', '.', 'Each', 'patient', 'will', 'be', 'screened', 'by', 'using', 'a', 'simple', 'selection', 'Performa', 'relevant', 'to', 'inclusion', 'and', 'exclusion', 'criteria', '.', '\\n\\n', 'Total', '30', 'patients', 'will', 'be', 'included', 'in', 'the', 'study', 'and', 'then', 'divided', 'into', 'two', 'groups', 'i.e.', 'Action', 'observation', 'therapy', 'and', 'Convention', 'Therapy', 'group', 'with', '15', 'individuals', 'in', 'each', '.', 'Each', 'group', 'will', 'be', 'assessed', 'thrice', 'i.e.', 'pre', ',', 'post', 'and', 'follow', 'up', 'surveys', '.', 'Each', 'of', 'them', 'will', 'receive', 'the', 'convention', 'therapy', 'for', '30', 'mins', 'except', 'for', 'the', 'Action', 'Observation', 'therapy', '(', 'AOT', ')', 'group', ',', 'which', 'will', 'also', 'receive', 'the', 'additional', '30', 'minutes', 'session', 'of', 'action', 'observational', 'training', '.', 'Total', '18', 'sessions', ',', '3', 'days', 'a', 'week', 'for', 'a', 'total', 'of', 'six', 'weeks', 'will', 'be', 'performed', 'on', 'each', 'patient', '.', '\\n\\n', 'Fugel', 'Meyer', 'Assessment', 'Scale', 'for', 'lower', 'limb', ',', 'Timed', 'Up', 'and', 'Go', 'test', ',', 'Timed', 'Stair', 'Test', ',', 'Step', 'test', 'and', 'self', '-', 'efficacy', 'scale', 'will', 'be', 'used', 'for', 'the', 'assessment', '.', 'Baseline', 'assessments', 'of', 'both', 'group', 'will', 'be', 'done', 'on', '1st', 'week', 'before', 'the', 'application', 'of', 'protocol', ',', 'second', 'assessment', 'will', 'be', 'done', 'on', '4th', 'week', 'and', 'then', 'final', 'assessment', 'will', 'be', 'done', 'on', '6th', 'week', 'of', 'the', 'protocol', '.']",
        "token_bio_labels": "['O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 11,
                "end": 37,
                "text": "Action Observation Therapy",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 86,
                "end": 100,
                "text": "Chronic Stroke",
                "type": "CONDITION"
            },
            {
                "start": 140,
                "end": 166,
                "text": "Action Observation therapy",
                "type": "OTHER"
            },
            {
                "start": 214,
                "end": 228,
                "text": "chronic stroke",
                "type": "CONDITION"
            },
            {
                "start": 766,
                "end": 792,
                "text": "Action observation therapy",
                "type": "OTHER"
            },
            {
                "start": 797,
                "end": 815,
                "text": "Convention Therapy",
                "type": "CONTROL"
            },
            {
                "start": 954,
                "end": 972,
                "text": "convention therapy",
                "type": "CONTROL"
            },
            {
                "start": 1000,
                "end": 1026,
                "text": "Action Observation therapy",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 1028,
                "end": 1031,
                "text": "AOT",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 1101,
                "end": 1130,
                "text": "action observational training",
                "type": "BEHAVIOURAL"
            }
        ]
    },
    {
        "nctid": "NCT01540604",
        "text": "An Open-label, Un-controlled, Single-centre Trial Investigating the Efficacy and Safety of CRD007 in Children With Duchenne Muscular Dystrophy (DMD) or Becker Muscular Dystrophy (BMD) or Children Being Symptomatic Carriers for DMD or BMD | This is an investigation of the efficacy and safety of CRD007 in Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD) and symptomatic carriers.",
        "tokens": "['An', 'Open', '-', 'label', ',', 'Un', '-', 'controlled', ',', 'Single', '-', 'centre', 'Trial', 'Investigating', 'the', 'Efficacy', 'and', 'Safety', 'of', 'CRD007', 'in', 'Children', 'With', 'Duchenne', 'Muscular', 'Dystrophy', '(', 'DMD', ')', 'or', 'Becker', 'Muscular', 'Dystrophy', '(', 'BMD', ')', 'or', 'Children', 'Being', 'Symptomatic', 'Carriers', 'for', 'DMD', 'or', 'BMD', '|', 'This', 'is', 'an', 'investigation', 'of', 'the', 'efficacy', 'and', 'safety', 'of', 'CRD007', 'in', 'Duchenne', 'Muscular', 'Dystrophy', '(', 'DMD', ')', ',', 'Becker', 'Muscular', 'Dystrophy', '(', 'BMD', ')', 'and', 'symptomatic', 'carriers', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 91,
                "end": 97,
                "text": "CRD007",
                "type": "DRUG"
            },
            {
                "start": 115,
                "end": 142,
                "text": "Duchenne Muscular Dystrophy",
                "type": "CONDITION"
            },
            {
                "start": 144,
                "end": 147,
                "text": "DMD",
                "type": "CONDITION"
            },
            {
                "start": 152,
                "end": 177,
                "text": "Becker Muscular Dystrophy",
                "type": "CONDITION"
            },
            {
                "start": 179,
                "end": 182,
                "text": "BMD",
                "type": "CONDITION"
            },
            {
                "start": 202,
                "end": 237,
                "text": "Symptomatic Carriers for DMD or BMD",
                "type": "CONDITION"
            },
            {
                "start": 295,
                "end": 301,
                "text": "CRD007",
                "type": "DRUG"
            },
            {
                "start": 305,
                "end": 332,
                "text": "Duchenne Muscular Dystrophy",
                "type": "CONDITION"
            },
            {
                "start": 334,
                "end": 337,
                "text": "DMD",
                "type": "CONDITION"
            },
            {
                "start": 340,
                "end": 365,
                "text": "Becker Muscular Dystrophy",
                "type": "CONDITION"
            },
            {
                "start": 367,
                "end": 370,
                "text": "BMD",
                "type": "CONDITION"
            },
            {
                "start": 376,
                "end": 396,
                "text": "symptomatic carriers",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05375240",
        "text": "A Randomized, Blank-controlled, Open Label Study of the Safety and Efficacy of Propranolol in Reducing Stroke Associated Pneumonia and Urinary Tract Infection | Stroke-associated pneumonia (SAP) is one of the important risk factors influencing poor outcomes and death in stroke patients. Over the past two decades, accumulating evidence suggests that post-stroke brain injury mobilizes the adrenergic system, which induces post-stroke immunosuppression and SAP. This study is designed to test the safety and efficacy of an adrenergic \u03b2-receptor blocker, propranolol, with or without combination of antibiotics, in reducing SAP in stroke patients. The underlying immune mechanisms will be investigated.",
        "tokens": "['A', 'Randomized', ',', 'Blank', '-', 'controlled', ',', 'Open', 'Label', 'Study', 'of', 'the', 'Safety', 'and', 'Efficacy', 'of', 'Propranolol', 'in', 'Reducing', 'Stroke', 'Associated', 'Pneumonia', 'and', 'Urinary', 'Tract', 'Infection', '|', 'Stroke', '-', 'associated', 'pneumonia', '(', 'SAP', ')', 'is', 'one', 'of', 'the', 'important', 'risk', 'factors', 'influencing', 'poor', 'outcomes', 'and', 'death', 'in', 'stroke', 'patients', '.', 'Over', 'the', 'past', 'two', 'decades', ',', 'accumulating', 'evidence', 'suggests', 'that', 'post', '-', 'stroke', 'brain', 'injury', 'mobilizes', 'the', 'adrenergic', 'system', ',', 'which', 'induces', 'post', '-', 'stroke', 'immunosuppression', 'and', 'SAP', '.', 'This', 'study', 'is', 'designed', 'to', 'test', 'the', 'safety', 'and', 'efficacy', 'of', 'an', 'adrenergic', '\u03b2', '-', 'receptor', 'blocker', ',', 'propranolol', ',', 'with', 'or', 'without', 'combination', 'of', 'antibiotics', ',', 'in', 'reducing', 'SAP', 'in', 'stroke', 'patients', '.', 'The', 'underlying', 'immune', 'mechanisms', 'will', 'be', 'investigated', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 14,
                "end": 19,
                "text": "Blank",
                "type": "CONTROL"
            },
            {
                "start": 79,
                "end": 90,
                "text": "Propranolol",
                "type": "DRUG"
            },
            {
                "start": 103,
                "end": 109,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 121,
                "end": 130,
                "text": "Pneumonia",
                "type": "CONDITION"
            },
            {
                "start": 135,
                "end": 158,
                "text": "Urinary Tract Infection",
                "type": "CONDITION"
            },
            {
                "start": 161,
                "end": 188,
                "text": "Stroke-associated pneumonia",
                "type": "CONDITION"
            },
            {
                "start": 190,
                "end": 193,
                "text": "SAP",
                "type": "CONDITION"
            },
            {
                "start": 271,
                "end": 277,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 351,
                "end": 362,
                "text": "post-stroke",
                "type": "CONDITION"
            },
            {
                "start": 363,
                "end": 375,
                "text": "brain injury",
                "type": "CONDITION"
            },
            {
                "start": 423,
                "end": 434,
                "text": "post-stroke",
                "type": "CONDITION"
            },
            {
                "start": 435,
                "end": 452,
                "text": "immunosuppression",
                "type": "CONDITION"
            },
            {
                "start": 457,
                "end": 460,
                "text": "SAP",
                "type": "CONDITION"
            },
            {
                "start": 523,
                "end": 552,
                "text": "adrenergic \u03b2-receptor blocker",
                "type": "DRUG"
            },
            {
                "start": 554,
                "end": 565,
                "text": "propranolol",
                "type": "DRUG"
            },
            {
                "start": 598,
                "end": 609,
                "text": "antibiotics",
                "type": "DRUG"
            },
            {
                "start": 623,
                "end": 626,
                "text": "SAP",
                "type": "CONDITION"
            },
            {
                "start": 630,
                "end": 636,
                "text": "stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03195608",
        "text": "Using Advanced Driver Assistance Systems (ADAS) as an Intervention Strategy for Drivers With Parkinson's Disease | Parkinson's disease (PD) impacts an individual's fitness to drive in a number of ways that increase the crash risk in this population. Current vehicle automation technologies are available, that although designed for the general public, may help drivers with PD stay on the roads longer and safer than currently possible. Using a driving simulator (a safe and cost-effective alternative with no impact on licensing for participants), this study will investigate the feasibility and preliminary efficacy of utilizing in-vehicle technology (i.e., a simulated lane change assistance system) to address critical driving errors in individuals with mild to moderate Parkinson's disease.",
        "tokens": "['Using', 'Advanced', 'Driver', 'Assistance', 'Systems', '(', 'ADAS', ')', 'as', 'an', 'Intervention', 'Strategy', 'for', 'Drivers', 'With', 'Parkinson', \"'s\", 'Disease', '|', 'Parkinson', \"'s\", 'disease', '(', 'PD', ')', 'impacts', 'an', 'individual', \"'s\", 'fitness', 'to', 'drive', 'in', 'a', 'number', 'of', 'ways', 'that', 'increase', 'the', 'crash', 'risk', 'in', 'this', 'population', '.', 'Current', 'vehicle', 'automation', 'technologies', 'are', 'available', ',', 'that', 'although', 'designed', 'for', 'the', 'general', 'public', ',', 'may', 'help', 'drivers', 'with', 'PD', 'stay', 'on', 'the', 'roads', 'longer', 'and', 'safer', 'than', 'currently', 'possible', '.', 'Using', 'a', 'driving', 'simulator', '(', 'a', 'safe', 'and', 'cost', '-', 'effective', 'alternative', 'with', 'no', 'impact', 'on', 'licensing', 'for', 'participants', ')', ',', 'this', 'study', 'will', 'investigate', 'the', 'feasibility', 'and', 'preliminary', 'efficacy', 'of', 'utilizing', 'in', '-', 'vehicle', 'technology', '(', 'i.e.', ',', 'a', 'simulated', 'lane', 'change', 'assistance', 'system', ')', 'to', 'address', 'critical', 'driving', 'errors', 'in', 'individuals', 'with', 'mild', 'to', 'moderate', 'Parkinson', \"'s\", 'disease', '.']",
        "token_bio_labels": "['O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 6,
                "end": 40,
                "text": "Advanced Driver Assistance Systems",
                "type": "OTHER"
            },
            {
                "start": 42,
                "end": 46,
                "text": "ADAS",
                "type": "OTHER"
            },
            {
                "start": 93,
                "end": 112,
                "text": "Parkinson's Disease",
                "type": "CONDITION"
            },
            {
                "start": 115,
                "end": 134,
                "text": "Parkinson's disease",
                "type": "CONDITION"
            },
            {
                "start": 136,
                "end": 138,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 374,
                "end": 376,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 631,
                "end": 652,
                "text": "in-vehicle technology",
                "type": "OTHER"
            },
            {
                "start": 662,
                "end": 701,
                "text": "simulated lane change assistance system",
                "type": "OTHER"
            },
            {
                "start": 758,
                "end": 794,
                "text": "mild to moderate Parkinson's disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT02589262",
        "text": "A Randomised, Double-blind, Placebo-controlled, Single and Repeated Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AUT00206 in Healthy Volunteers. | The study medicine is a potential future treatment for schizophrenia, an illness that affects the way that people think, feel or behave. It is not clear what causes schizophrenia, but it's been linked to chemical imbalance in the brain. It is hoped that the study medicine will activate specific sites in the brain to help correct that imbalance. Current treatments for schizophrenia don't work very well and can cause unpleasant side effects. It is hoped that the study medicine will work better, and have fewer side effects than existing medicines.\n\nIn this 2 part study (Parts A and B), the primary aim is to assess how safe the study medicine is in healthy men, aged 18-45 years, and how much of it gets into the blood. Its effects on the brain will also be tested.\n\nIn Part A, up to 24 participants will receive up to 5 single doses of the study medicine (AUT00206 or placebo) by mouth, either after fasting or after a high fat breakfast. The study medicine has never been given to humans before, so the initial doses will be small and the dose level will be increased as the study progresses. Participants may take up to 14 weeks to finish the study. They'll make up to 22 outpatient visits, and stay on the ward up to 5 times, for 3 nights in a row each time.\n\nIn Part B, 24 participants will receive daily doses of the study medicine (AUT00206 or placebo) for up to 28 days. Participants will take up to 10 weeks to finish the study. They'll make 6 outpatient visits, and stay on the ward for up to 30 nights, depending on how long we expect it to take until blood levels of the study medicine level off.\n\nA pharmaceutical company, Autifony Therapeutics Limited, is funding the study. The study will take place at 1 centre in London.",
        "tokens": "['A', 'Randomised', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', ',', 'Single', 'and', 'Repeated', 'Dose', 'Escalation', 'Study', 'to', 'Assess', 'the', 'Safety', ',', 'Tolerability', ',', 'Pharmacokinetics', 'and', 'Pharmacodynamics', 'of', 'AUT00206', 'in', 'Healthy', 'Volunteers', '.', '|', 'The', 'study', 'medicine', 'is', 'a', 'potential', 'future', 'treatment', 'for', 'schizophrenia', ',', 'an', 'illness', 'that', 'affects', 'the', 'way', 'that', 'people', 'think', ',', 'feel', 'or', 'behave', '.', 'It', 'is', 'not', 'clear', 'what', 'causes', 'schizophrenia', ',', 'but', 'it', \"'s\", 'been', 'linked', 'to', 'chemical', 'imbalance', 'in', 'the', 'brain', '.', 'It', 'is', 'hoped', 'that', 'the', 'study', 'medicine', 'will', 'activate', 'specific', 'sites', 'in', 'the', 'brain', 'to', 'help', 'correct', 'that', 'imbalance', '.', 'Current', 'treatments', 'for', 'schizophrenia', 'do', \"n't\", 'work', 'very', 'well', 'and', 'can', 'cause', 'unpleasant', 'side', 'effects', '.', 'It', 'is', 'hoped', 'that', 'the', 'study', 'medicine', 'will', 'work', 'better', ',', 'and', 'have', 'fewer', 'side', 'effects', 'than', 'existing', 'medicines', '.', '\\n\\n', 'In', 'this', '2', 'part', 'study', '(', 'Parts', 'A', 'and', 'B', ')', ',', 'the', 'primary', 'aim', 'is', 'to', 'assess', 'how', 'safe', 'the', 'study', 'medicine', 'is', 'in', 'healthy', 'men', ',', 'aged', '18', '-', '45', 'years', ',', 'and', 'how', 'much', 'of', 'it', 'gets', 'into', 'the', 'blood', '.', 'Its', 'effects', 'on', 'the', 'brain', 'will', 'also', 'be', 'tested', '.', '\\n\\n', 'In', 'Part', 'A', ',', 'up', 'to', '24', 'participants', 'will', 'receive', 'up', 'to', '5', 'single', 'doses', 'of', 'the', 'study', 'medicine', '(', 'AUT00206', 'or', 'placebo', ')', 'by', 'mouth', ',', 'either', 'after', 'fasting', 'or', 'after', 'a', 'high', 'fat', 'breakfast', '.', 'The', 'study', 'medicine', 'has', 'never', 'been', 'given', 'to', 'humans', 'before', ',', 'so', 'the', 'initial', 'doses', 'will', 'be', 'small', 'and', 'the', 'dose', 'level', 'will', 'be', 'increased', 'as', 'the', 'study', 'progresses', '.', 'Participants', 'may', 'take', 'up', 'to', '14', 'weeks', 'to', 'finish', 'the', 'study', '.', 'They', \"'ll\", 'make', 'up', 'to', '22', 'outpatient', 'visits', ',', 'and', 'stay', 'on', 'the', 'ward', 'up', 'to', '5', 'times', ',', 'for', '3', 'nights', 'in', 'a', 'row', 'each', 'time', '.', '\\n\\n', 'In', 'Part', 'B', ',', '24', 'participants', 'will', 'receive', 'daily', 'doses', 'of', 'the', 'study', 'medicine', '(', 'AUT00206', 'or', 'placebo', ')', 'for', 'up', 'to', '28', 'days', '.', 'Participants', 'will', 'take', 'up', 'to', '10', 'weeks', 'to', 'finish', 'the', 'study', '.', 'They', \"'ll\", 'make', '6', 'outpatient', 'visits', ',', 'and', 'stay', 'on', 'the', 'ward', 'for', 'up', 'to', '30', 'nights', ',', 'depending', 'on', 'how', 'long', 'we', 'expect', 'it', 'to', 'take', 'until', 'blood', 'levels', 'of', 'the', 'study', 'medicine', 'level', 'off', '.', '\\n\\n', 'A', 'pharmaceutical', 'company', ',', 'Autifony', 'Therapeutics', 'Limited', ',', 'is', 'funding', 'the', 'study', '.', 'The', 'study', 'will', 'take', 'place', 'at', '1', 'centre', 'in', 'London', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 28,
                "end": 35,
                "text": "Placebo",
                "type": "CONTROL"
            },
            {
                "start": 167,
                "end": 175,
                "text": "AUT00206",
                "type": "DRUG"
            },
            {
                "start": 1062,
                "end": 1070,
                "text": "AUT00206",
                "type": "DRUG"
            },
            {
                "start": 1074,
                "end": 1081,
                "text": "placebo",
                "type": "CONTROL"
            },
            {
                "start": 1544,
                "end": 1552,
                "text": "AUT00206",
                "type": "DRUG"
            },
            {
                "start": 1556,
                "end": 1563,
                "text": "placebo",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT02805634",
        "text": "Correlation Between the 'Nine Holes Peg Test' Performance and the Triple Stimulation Technique Within a Group a Patients With Multiple Sclerosis | The main goal of this study is to determine if the Triple Stimulation Technique (TST) can be correlated to performance in the manual dexterity 'nine holes peg' test, within a control group and a group of patients with multiple sclerosis.\n\nTST (Triple stimulation technique) combines two techniques used in neurologic diagnosis: magnetic stimulation and electroneuromyography. It is based on the principle of two collisions between the descending central stimulation (magnetic stimulation) and the ascending peripheric stimulation. TST allows to better quantify central nervous system diseases. The abnormal amplitude registered by TST is proportional to the intensity of conduction disorders. The evaluation of these disorders is more precise than with the magnetic stimulation technique alone.\n\nThe Nine Hole Pegs technique is a simple manual dexterity test, commonly used in ergotherapy. The participant tries to place 9 pegs in a 9 holes perforated plate, and then tries to remove them as quickly as possible. The hand must stay in a depression within the plate, thereby insuring a constant distance between the hand and the pegs.\n\nThe nine hole peg will be realized first, and the triple stimulation examination performed after. The acquired data will be analyzed in order to find a correlation between the impairment level given by these two tests.",
        "tokens": "['Correlation', 'Between', 'the', \"'\", 'Nine', 'Holes', 'Peg', 'Test', \"'\", 'Performance', 'and', 'the', 'Triple', 'Stimulation', 'Technique', 'Within', 'a', 'Group', 'a', 'Patients', 'With', 'Multiple', 'Sclerosis', '|', 'The', 'main', 'goal', 'of', 'this', 'study', 'is', 'to', 'determine', 'if', 'the', 'Triple', 'Stimulation', 'Technique', '(', 'TST', ')', 'can', 'be', 'correlated', 'to', 'performance', 'in', 'the', 'manual', 'dexterity', \"'\", 'nine', 'holes', 'peg', \"'\", 'test', ',', 'within', 'a', 'control', 'group', 'and', 'a', 'group', 'of', 'patients', 'with', 'multiple', 'sclerosis', '.', '\\n\\n', 'TST', '(', 'Triple', 'stimulation', 'technique', ')', 'combines', 'two', 'techniques', 'used', 'in', 'neurologic', 'diagnosis', ':', 'magnetic', 'stimulation', 'and', 'electroneuromyography', '.', 'It', 'is', 'based', 'on', 'the', 'principle', 'of', 'two', 'collisions', 'between', 'the', 'descending', 'central', 'stimulation', '(', 'magnetic', 'stimulation', ')', 'and', 'the', 'ascending', 'peripheric', 'stimulation', '.', 'TST', 'allows', 'to', 'better', 'quantify', 'central', 'nervous', 'system', 'diseases', '.', 'The', 'abnormal', 'amplitude', 'registered', 'by', 'TST', 'is', 'proportional', 'to', 'the', 'intensity', 'of', 'conduction', 'disorders', '.', 'The', 'evaluation', 'of', 'these', 'disorders', 'is', 'more', 'precise', 'than', 'with', 'the', 'magnetic', 'stimulation', 'technique', 'alone', '.', '\\n\\n', 'The', 'Nine', 'Hole', 'Pegs', 'technique', 'is', 'a', 'simple', 'manual', 'dexterity', 'test', ',', 'commonly', 'used', 'in', 'ergotherapy', '.', 'The', 'participant', 'tries', 'to', 'place', '9', 'pegs', 'in', 'a', '9', 'holes', 'perforated', 'plate', ',', 'and', 'then', 'tries', 'to', 'remove', 'them', 'as', 'quickly', 'as', 'possible', '.', 'The', 'hand', 'must', 'stay', 'in', 'a', 'depression', 'within', 'the', 'plate', ',', 'thereby', 'insuring', 'a', 'constant', 'distance', 'between', 'the', 'hand', 'and', 'the', 'pegs', '.', '\\n\\n', 'The', 'nine', 'hole', 'peg', 'will', 'be', 'realized', 'first', ',', 'and', 'the', 'triple', 'stimulation', 'examination', 'performed', 'after', '.', 'The', 'acquired', 'data', 'will', 'be', 'analyzed', 'in', 'order', 'to', 'find', 'a', 'correlation', 'between', 'the', 'impairment', 'level', 'given', 'by', 'these', 'two', 'tests', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 126,
                "end": 144,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 365,
                "end": 383,
                "text": "multiple sclerosis",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04502927",
        "text": "Measurements of Displacement Amplitude and Angular Velocities During Passive Extension of the Wrist and Hand Complex in Stroke Patients | The main objective of this monocentric prospective study is to evaluate the amplitudes and angular velocities of extension of the hand and wrist joints during passive mobilization by a physiotherapist in healthy subjects and stroke patients with spastic hands.\n\nSecondary objectives:\n\nTo compare amplitude and angular velocity values between the group of stroke patients and the group of healthy volunteers,\nTo compare amplitude and angular velocity values according to the two types of mobilization (i,e, thumb or fifth finger),\nTo assess pain due to mobilization in stroke patients.",
        "tokens": "['Measurements', 'of', 'Displacement', 'Amplitude', 'and', 'Angular', 'Velocities', 'During', 'Passive', 'Extension', 'of', 'the', 'Wrist', 'and', 'Hand', 'Complex', 'in', 'Stroke', 'Patients', '|', 'The', 'main', 'objective', 'of', 'this', 'monocentric', 'prospective', 'study', 'is', 'to', 'evaluate', 'the', 'amplitudes', 'and', 'angular', 'velocities', 'of', 'extension', 'of', 'the', 'hand', 'and', 'wrist', 'joints', 'during', 'passive', 'mobilization', 'by', 'a', 'physiotherapist', 'in', 'healthy', 'subjects', 'and', 'stroke', 'patients', 'with', 'spastic', 'hands', '.', '\\n\\n', 'Secondary', 'objectives', ':', '\\n\\n', 'To', 'compare', 'amplitude', 'and', 'angular', 'velocity', 'values', 'between', 'the', 'group', 'of', 'stroke', 'patients', 'and', 'the', 'group', 'of', 'healthy', 'volunteers', ',', '\\n', 'To', 'compare', 'amplitude', 'and', 'angular', 'velocity', 'values', 'according', 'to', 'the', 'two', 'types', 'of', 'mobilization', '(', 'i', ',', 'e', ',', 'thumb', 'or', 'fifth', 'finger', ')', ',', '\\n', 'To', 'assess', 'pain', 'due', 'to', 'mobilization', 'in', 'stroke', 'patients', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 120,
                "end": 126,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 363,
                "end": 369,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 384,
                "end": 391,
                "text": "spastic",
                "type": "CONDITION"
            },
            {
                "start": 493,
                "end": 499,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 678,
                "end": 682,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 706,
                "end": 712,
                "text": "stroke",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04354298",
        "text": "Effects of Improvisational Dance on Cognition and Daily Function Among People With Parkinson Disease | The long-term goal of this work is to maintain or improve daily function of people with PD by addressing cognition. The overall objective is to discover interventions that aid in cognitive functioning. The central hypothesis is that engagement in an improvisational dance (ID) class will benefit cognition among people with PD. Improvisational dance involves spontaneously generated movement, similar to how one moves in everyday life. The literature shows that ID classes positively impact motor impairments associated with PD, such as balance, gait, and functional mobility. Along with being physically demanding, ID requires the use and coordination of a number of cognitive capacities to properly execute movements. This type of activity challenges, and thus may strengthen, cognitive processes such as motor planning, decision making, flexible thinking, initiation, and execution, which may give people cognitive based strategies to be utilized in various aspects of daily life. By improving motor function and/or cognition, ID may also contribute to improved daily functioning, or the ability to perform and participate in daily activities. Despite these theoretical links, evidence for the effect of ID on cognition and overall daily function is limited. The current project objective is to address this gap and better understand the effects of ID for people with PD. Specifically, it will test the effect of IMPROVment\u00ae, a method of ID designed for people with PD, on cognition and daily function.\n\nParticipants' cognition will be assessed at baseline (T1) using the NIH Toolbox Cognitive Battery, the Alternate Uses Task, and the Weekly Calendar Planning Activity. Global cognition will be assessed using the Montreal Cognitive Assessment. They then will be randomly assigned to either the immediate intervention (ID) or waitlist-control (WC) group. The ID group will start the 12-week IMPROVment\u00ae intervention, which consists of weekly ID classes that progress according to a standardized method while the WC group will receive no intervention and continue with their regular daily routine and activity level. After 12 weeks, both groups will complete cognitive testing again (T2). Cognitive test scores will be compared across time points and between groups using a mixed model repeated measures ANOVA. The investigators hypothesize that IMPROVment\u00ae will have positive effects on the cognitive abilities of people with PD. Participants will also complete two questionnaires to assess daily function at T1 and T2: Older Americans Resources and Services Scale- Extended Version and PROMIS Satisfaction with Participation in Discretionary Social Activities. These scores will be compared similar to the above aim. The investigators hypothesize that IMPROVment\u00ae will have positive effects on daily function in people with PD.\n\nParticipant mood will be assessed in two different ways. The first being to investigate the immediate effect of participating in an IMPROVment\u00ae class on mood, fatigue, and anxiety. The investigators hypothesize that mood will positively improve from pre to post of each class. To assess this, participants will respond to a scale assessing mood, specifically sadness, nervousness, energy, and overall well-being before and after each class every week. The second measurement is to investigate the effect of IMPROVment\u00ae on anxiety, fatigue, and depression. The investigators hypothesize that IMPROVment\u00ae class will decrease feelings of depression for those with PD. All participants will fill out the Parkinson's Anxiety Scale, the Parkinson's Disease Fatigue Scale, and the Geriatric Depression Scale short form before and after participating in the 12-week IMPROVment\u00ae program.\n\nAchievement of these aims will provide further support for the IMPROVment\u00ae method for people with PD experiencing cognitive deficits. The long-term impact will better cognition and daily functioning in people with PD, and thus enhanced everyday lives.",
        "tokens": "['Effects', 'of', 'Improvisational', 'Dance', 'on', 'Cognition', 'and', 'Daily', 'Function', 'Among', 'People', 'With', 'Parkinson', 'Disease', '|', 'The', 'long', '-', 'term', 'goal', 'of', 'this', 'work', 'is', 'to', 'maintain', 'or', 'improve', 'daily', 'function', 'of', 'people', 'with', 'PD', 'by', 'addressing', 'cognition', '.', 'The', 'overall', 'objective', 'is', 'to', 'discover', 'interventions', 'that', 'aid', 'in', 'cognitive', 'functioning', '.', 'The', 'central', 'hypothesis', 'is', 'that', 'engagement', 'in', 'an', 'improvisational', 'dance', '(', 'ID', ')', 'class', 'will', 'benefit', 'cognition', 'among', 'people', 'with', 'PD', '.', 'Improvisational', 'dance', 'involves', 'spontaneously', 'generated', 'movement', ',', 'similar', 'to', 'how', 'one', 'moves', 'in', 'everyday', 'life', '.', 'The', 'literature', 'shows', 'that', 'ID', 'classes', 'positively', 'impact', 'motor', 'impairments', 'associated', 'with', 'PD', ',', 'such', 'as', 'balance', ',', 'gait', ',', 'and', 'functional', 'mobility', '.', 'Along', 'with', 'being', 'physically', 'demanding', ',', 'ID', 'requires', 'the', 'use', 'and', 'coordination', 'of', 'a', 'number', 'of', 'cognitive', 'capacities', 'to', 'properly', 'execute', 'movements', '.', 'This', 'type', 'of', 'activity', 'challenges', ',', 'and', 'thus', 'may', 'strengthen', ',', 'cognitive', 'processes', 'such', 'as', 'motor', 'planning', ',', 'decision', 'making', ',', 'flexible', 'thinking', ',', 'initiation', ',', 'and', 'execution', ',', 'which', 'may', 'give', 'people', 'cognitive', 'based', 'strategies', 'to', 'be', 'utilized', 'in', 'various', 'aspects', 'of', 'daily', 'life', '.', 'By', 'improving', 'motor', 'function', 'and/or', 'cognition', ',', 'ID', 'may', 'also', 'contribute', 'to', 'improved', 'daily', 'functioning', ',', 'or', 'the', 'ability', 'to', 'perform', 'and', 'participate', 'in', 'daily', 'activities', '.', 'Despite', 'these', 'theoretical', 'links', ',', 'evidence', 'for', 'the', 'effect', 'of', 'ID', 'on', 'cognition', 'and', 'overall', 'daily', 'function', 'is', 'limited', '.', 'The', 'current', 'project', 'objective', 'is', 'to', 'address', 'this', 'gap', 'and', 'better', 'understand', 'the', 'effects', 'of', 'ID', 'for', 'people', 'with', 'PD', '.', 'Specifically', ',', 'it', 'will', 'test', 'the', 'effect', 'of', 'IMPROVment', '\u00ae', ',', 'a', 'method', 'of', 'ID', 'designed', 'for', 'people', 'with', 'PD', ',', 'on', 'cognition', 'and', 'daily', 'function', '.', '\\n\\n', 'Participants', \"'\", 'cognition', 'will', 'be', 'assessed', 'at', 'baseline', '(', 'T1', ')', 'using', 'the', 'NIH', 'Toolbox', 'Cognitive', 'Battery', ',', 'the', 'Alternate', 'Uses', 'Task', ',', 'and', 'the', 'Weekly', 'Calendar', 'Planning', 'Activity', '.', 'Global', 'cognition', 'will', 'be', 'assessed', 'using', 'the', 'Montreal', 'Cognitive', 'Assessment', '.', 'They', 'then', 'will', 'be', 'randomly', 'assigned', 'to', 'either', 'the', 'immediate', 'intervention', '(', 'ID', ')', 'or', 'waitlist', '-', 'control', '(', 'WC', ')', 'group', '.', 'The', 'ID', 'group', 'will', 'start', 'the', '12', '-', 'week', 'IMPROVment', '\u00ae', 'intervention', ',', 'which', 'consists', 'of', 'weekly', 'ID', 'classes', 'that', 'progress', 'according', 'to', 'a', 'standardized', 'method', 'while', 'the', 'WC', 'group', 'will', 'receive', 'no', 'intervention', 'and', 'continue', 'with', 'their', 'regular', 'daily', 'routine', 'and', 'activity', 'level', '.', 'After', '12', 'weeks', ',', 'both', 'groups', 'will', 'complete', 'cognitive', 'testing', 'again', '(', 'T2', ')', '.', 'Cognitive', 'test', 'scores', 'will', 'be', 'compared', 'across', 'time', 'points', 'and', 'between', 'groups', 'using', 'a', 'mixed', 'model', 'repeated', 'measures', 'ANOVA', '.', 'The', 'investigators', 'hypothesize', 'that', 'IMPROVment', '\u00ae', 'will', 'have', 'positive', 'effects', 'on', 'the', 'cognitive', 'abilities', 'of', 'people', 'with', 'PD', '.', 'Participants', 'will', 'also', 'complete', 'two', 'questionnaires', 'to', 'assess', 'daily', 'function', 'at', 'T1', 'and', 'T2', ':', 'Older', 'Americans', 'Resources', 'and', 'Services', 'Scale-', 'Extended', 'Version', 'and', 'PROMIS', 'Satisfaction', 'with', 'Participation', 'in', 'Discretionary', 'Social', 'Activities', '.', 'These', 'scores', 'will', 'be', 'compared', 'similar', 'to', 'the', 'above', 'aim', '.', 'The', 'investigators', 'hypothesize', 'that', 'IMPROVment', '\u00ae', 'will', 'have', 'positive', 'effects', 'on', 'daily', 'function', 'in', 'people', 'with', 'PD', '.', '\\n\\n', 'Participant', 'mood', 'will', 'be', 'assessed', 'in', 'two', 'different', 'ways', '.', 'The', 'first', 'being', 'to', 'investigate', 'the', 'immediate', 'effect', 'of', 'participating', 'in', 'an', 'IMPROVment', '\u00ae', 'class', 'on', 'mood', ',', 'fatigue', ',', 'and', 'anxiety', '.', 'The', 'investigators', 'hypothesize', 'that', 'mood', 'will', 'positively', 'improve', 'from', 'pre', 'to', 'post', 'of', 'each', 'class', '.', 'To', 'assess', 'this', ',', 'participants', 'will', 'respond', 'to', 'a', 'scale', 'assessing', 'mood', ',', 'specifically', 'sadness', ',', 'nervousness', ',', 'energy', ',', 'and', 'overall', 'well', '-', 'being', 'before', 'and', 'after', 'each', 'class', 'every', 'week', '.', 'The', 'second', 'measurement', 'is', 'to', 'investigate', 'the', 'effect', 'of', 'IMPROVment', '\u00ae', 'on', 'anxiety', ',', 'fatigue', ',', 'and', 'depression', '.', 'The', 'investigators', 'hypothesize', 'that', 'IMPROVment', '\u00ae', 'class', 'will', 'decrease', 'feelings', 'of', 'depression', 'for', 'those', 'with', 'PD', '.', 'All', 'participants', 'will', 'fill', 'out', 'the', 'Parkinson', \"'s\", 'Anxiety', 'Scale', ',', 'the', 'Parkinson', \"'s\", 'Disease', 'Fatigue', 'Scale', ',', 'and', 'the', 'Geriatric', 'Depression', 'Scale', 'short', 'form', 'before', 'and', 'after', 'participating', 'in', 'the', '12', '-', 'week', 'IMPROVment', '\u00ae', 'program', '.', '\\n\\n', 'Achievement', 'of', 'these', 'aims', 'will', 'provide', 'further', 'support', 'for', 'the', 'IMPROVment', '\u00ae', 'method', 'for', 'people', 'with', 'PD', 'experiencing', 'cognitive', 'deficits', '.', 'The', 'long', '-', 'term', 'impact', 'will', 'better', 'cognition', 'and', 'daily', 'functioning', 'in', 'people', 'with', 'PD', ',', 'and', 'thus', 'enhanced', 'everyday', 'lives', '.']",
        "token_bio_labels": "['O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 11,
                "end": 32,
                "text": "Improvisational Dance",
                "type": "PHYSICAL"
            },
            {
                "start": 83,
                "end": 100,
                "text": "Parkinson Disease",
                "type": "CONDITION"
            },
            {
                "start": 191,
                "end": 193,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 353,
                "end": 374,
                "text": "improvisational dance",
                "type": "PHYSICAL"
            },
            {
                "start": 376,
                "end": 378,
                "text": "ID",
                "type": "PHYSICAL"
            },
            {
                "start": 427,
                "end": 429,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 431,
                "end": 452,
                "text": "Improvisational dance",
                "type": "PHYSICAL"
            },
            {
                "start": 565,
                "end": 567,
                "text": "ID",
                "type": "PHYSICAL"
            },
            {
                "start": 628,
                "end": 630,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 719,
                "end": 721,
                "text": "ID",
                "type": "PHYSICAL"
            },
            {
                "start": 1133,
                "end": 1135,
                "text": "ID",
                "type": "PHYSICAL"
            },
            {
                "start": 1310,
                "end": 1312,
                "text": "ID",
                "type": "PHYSICAL"
            },
            {
                "start": 1455,
                "end": 1457,
                "text": "ID",
                "type": "PHYSICAL"
            },
            {
                "start": 1474,
                "end": 1476,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 1519,
                "end": 1529,
                "text": "IMPROVment",
                "type": "PHYSICAL"
            },
            {
                "start": 1544,
                "end": 1546,
                "text": "ID",
                "type": "PHYSICAL"
            },
            {
                "start": 1572,
                "end": 1574,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 1926,
                "end": 1928,
                "text": "ID",
                "type": "PHYSICAL"
            },
            {
                "start": 1933,
                "end": 1949,
                "text": "waitlist-control",
                "type": "CONTROL"
            },
            {
                "start": 1951,
                "end": 1953,
                "text": "WC",
                "type": "CONTROL"
            },
            {
                "start": 1966,
                "end": 1968,
                "text": "ID",
                "type": "PHYSICAL"
            },
            {
                "start": 1998,
                "end": 2008,
                "text": "IMPROVment",
                "type": "PHYSICAL"
            },
            {
                "start": 2049,
                "end": 2051,
                "text": "ID",
                "type": "PHYSICAL"
            },
            {
                "start": 2119,
                "end": 2121,
                "text": "WC",
                "type": "CONTROL"
            },
            {
                "start": 2452,
                "end": 2462,
                "text": "IMPROVment",
                "type": "PHYSICAL"
            },
            {
                "start": 2533,
                "end": 2535,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 2860,
                "end": 2870,
                "text": "IMPROVment",
                "type": "PHYSICAL"
            },
            {
                "start": 2932,
                "end": 2934,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 3069,
                "end": 3079,
                "text": "IMPROVment",
                "type": "PHYSICAL"
            },
            {
                "start": 3096,
                "end": 3103,
                "text": "fatigue",
                "type": "CONDITION"
            },
            {
                "start": 3109,
                "end": 3116,
                "text": "anxiety",
                "type": "CONDITION"
            },
            {
                "start": 3444,
                "end": 3454,
                "text": "IMPROVment",
                "type": "PHYSICAL"
            },
            {
                "start": 3459,
                "end": 3466,
                "text": "anxiety",
                "type": "CONDITION"
            },
            {
                "start": 3468,
                "end": 3475,
                "text": "fatigue",
                "type": "CONDITION"
            },
            {
                "start": 3481,
                "end": 3491,
                "text": "depression",
                "type": "CONDITION"
            },
            {
                "start": 3528,
                "end": 3538,
                "text": "IMPROVment",
                "type": "PHYSICAL"
            },
            {
                "start": 3572,
                "end": 3582,
                "text": "depression",
                "type": "CONDITION"
            },
            {
                "start": 3598,
                "end": 3600,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 3795,
                "end": 3805,
                "text": "IMPROVment",
                "type": "PHYSICAL"
            },
            {
                "start": 3880,
                "end": 3890,
                "text": "IMPROVment",
                "type": "PHYSICAL"
            },
            {
                "start": 3915,
                "end": 3917,
                "text": "PD",
                "type": "CONDITION"
            },
            {
                "start": 4031,
                "end": 4033,
                "text": "PD",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT05484219",
        "text": "Functional Navigation in Surgery of Cerebral Tumors and Vascular Malformations: a Prospective, Single Arm Clinical Trial | The purpose of the study is to assess accuracy, advantages of functional neuronavigation and calculate safe distance from motor areas to brain tumors and vascular malformations in image-guided surgery.",
        "tokens": "['Functional', 'Navigation', 'in', 'Surgery', 'of', 'Cerebral', 'Tumors', 'and', 'Vascular', 'Malformations', ':', 'a', 'Prospective', ',', 'Single', 'Arm', 'Clinical', 'Trial', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'assess', 'accuracy', ',', 'advantages', 'of', 'functional', 'neuronavigation', 'and', 'calculate', 'safe', 'distance', 'from', 'motor', 'areas', 'to', 'brain', 'tumors', 'and', 'vascular', 'malformations', 'in', 'image', '-', 'guided', 'surgery', '.']",
        "token_bio_labels": "['B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 32,
                "text": "Functional Navigation in Surgery",
                "type": "SURGICAL"
            },
            {
                "start": 36,
                "end": 51,
                "text": "Cerebral Tumors",
                "type": "CONDITION"
            },
            {
                "start": 56,
                "end": 78,
                "text": "Vascular Malformations",
                "type": "CONDITION"
            },
            {
                "start": 185,
                "end": 211,
                "text": "functional neuronavigation",
                "type": "SURGICAL"
            },
            {
                "start": 260,
                "end": 272,
                "text": "brain tumors",
                "type": "CONDITION"
            },
            {
                "start": 277,
                "end": 299,
                "text": "vascular malformations",
                "type": "CONDITION"
            },
            {
                "start": 303,
                "end": 323,
                "text": "image-guided surgery",
                "type": "SURGICAL"
            }
        ]
    },
    {
        "nctid": "NCT01864941",
        "text": "Phase I/II Interventional Clinical Trial of Balloon Venoplasty for Chronic Cerebrospinal Venous Insufficiency in Multiple Sclerosis Patients | To investigate the safety and tolerability of balloon venoplasty compared to sham in Multiple Sclerosis patients with Chronic Cerebrospinal Venous Insufficiency (CCSVI) as measured by adverse events occurring within 48 weeks of the procedure.",
        "tokens": "['Phase', 'I', '/', 'II', 'Interventional', 'Clinical', 'Trial', 'of', 'Balloon', 'Venoplasty', 'for', 'Chronic', 'Cerebrospinal', 'Venous', 'Insufficiency', 'in', 'Multiple', 'Sclerosis', 'Patients', '|', 'To', 'investigate', 'the', 'safety', 'and', 'tolerability', 'of', 'balloon', 'venoplasty', 'compared', 'to', 'sham', 'in', 'Multiple', 'Sclerosis', 'patients', 'with', 'Chronic', 'Cerebrospinal', 'Venous', 'Insufficiency', '(', 'CCSVI', ')', 'as', 'measured', 'by', 'adverse', 'events', 'occurring', 'within', '48', 'weeks', 'of', 'the', 'procedure', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'B-CTRL', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 44,
                "end": 62,
                "text": "Balloon Venoplasty",
                "type": "SURGICAL"
            },
            {
                "start": 67,
                "end": 109,
                "text": "Chronic Cerebrospinal Venous Insufficiency",
                "type": "CONDITION"
            },
            {
                "start": 113,
                "end": 131,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 189,
                "end": 207,
                "text": "balloon venoplasty",
                "type": "SURGICAL"
            },
            {
                "start": 220,
                "end": 224,
                "text": "sham",
                "type": "CONTROL"
            },
            {
                "start": 228,
                "end": 246,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 261,
                "end": 303,
                "text": "Chronic Cerebrospinal Venous Insufficiency",
                "type": "CONDITION"
            },
            {
                "start": 305,
                "end": 310,
                "text": "CCSVI",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03517787",
        "text": "The Effect of Functional Electrical Stimulation and Therapeutic Exercise on Functional Properties of Skeletal Muscles, Sitting Postural Stability and Quality of Life in Traumatic Spinal Cord Injury Patients | Aim of the current study is to evaluate the effect functional electrical stimulation and therapeutic exercise on traumatic spinal cord injured participants'skeletal muscle characteristics, sitting balance, lung function and quality of life.",
        "tokens": "['The', 'Effect', 'of', 'Functional', 'Electrical', 'Stimulation', 'and', 'Therapeutic', 'Exercise', 'on', 'Functional', 'Properties', 'of', 'Skeletal', 'Muscles', ',', 'Sitting', 'Postural', 'Stability', 'and', 'Quality', 'of', 'Life', 'in', 'Traumatic', 'Spinal', 'Cord', 'Injury', 'Patients', '|', 'Aim', 'of', 'the', 'current', 'study', 'is', 'to', 'evaluate', 'the', 'effect', 'functional', 'electrical', 'stimulation', 'and', 'therapeutic', 'exercise', 'on', 'traumatic', 'spinal', 'cord', 'injured', \"participants'skeletal\", 'muscle', 'characteristics', ',', 'sitting', 'balance', ',', 'lung', 'function', 'and', 'quality', 'of', 'life', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 14,
                "end": 47,
                "text": "Functional Electrical Stimulation",
                "type": "OTHER"
            },
            {
                "start": 52,
                "end": 72,
                "text": "Therapeutic Exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 169,
                "end": 197,
                "text": "Traumatic Spinal Cord Injury",
                "type": "CONDITION"
            },
            {
                "start": 260,
                "end": 293,
                "text": "functional electrical stimulation",
                "type": "OTHER"
            },
            {
                "start": 298,
                "end": 318,
                "text": "therapeutic exercise",
                "type": "PHYSICAL"
            },
            {
                "start": 322,
                "end": 351,
                "text": "traumatic spinal cord injured",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00411723",
        "text": "Phase 1 Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis | RTL1000 is a new agent that has not been previously tested in humans. It is thought that RTL may specifically control the abnormal immune response or attack against the insulation on the nerves that occurs in multiple sclerosis.\n\nThe purpose of this study is to evaluate the possible side effects of a single intravenous dose of RTL1000 in subjects with multiple sclerosis. Some subjects will also be asked to participate in one or both of two substudies, one to test blood samples to see how the body's immune system responds after administration of RTL1000, and the other to test blood samples to see how the body absorbs and eliminates the RTL1000.",
        "tokens": "['Phase', '1', 'Safety', 'Study', 'of', 'RTL1000', '(', 'Recombinant', 'T', 'Cell', 'Receptor', 'Ligand', ')', 'in', 'Subjects', 'With', 'Multiple', 'Sclerosis', '|', 'RTL1000', 'is', 'a', 'new', 'agent', 'that', 'has', 'not', 'been', 'previously', 'tested', 'in', 'humans', '.', 'It', 'is', 'thought', 'that', 'RTL', 'may', 'specifically', 'control', 'the', 'abnormal', 'immune', 'response', 'or', 'attack', 'against', 'the', 'insulation', 'on', 'the', 'nerves', 'that', 'occurs', 'in', 'multiple', 'sclerosis', '.', '\\n\\n', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'possible', 'side', 'effects', 'of', 'a', 'single', 'intravenous', 'dose', 'of', 'RTL1000', 'in', 'subjects', 'with', 'multiple', 'sclerosis', '.', 'Some', 'subjects', 'will', 'also', 'be', 'asked', 'to', 'participate', 'in', 'one', 'or', 'both', 'of', 'two', 'substudies', ',', 'one', 'to', 'test', 'blood', 'samples', 'to', 'see', 'how', 'the', 'body', \"'s\", 'immune', 'system', 'responds', 'after', 'administration', 'of', 'RTL1000', ',', 'and', 'the', 'other', 'to', 'test', 'blood', 'samples', 'to', 'see', 'how', 'the', 'body', 'absorbs', 'and', 'eliminates', 'the', 'RTL1000', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O']",
        "entities": [
            {
                "start": 24,
                "end": 31,
                "text": "RTL1000",
                "type": "DRUG"
            },
            {
                "start": 33,
                "end": 67,
                "text": "Recombinant T Cell Receptor Ligand",
                "type": "DRUG"
            },
            {
                "start": 86,
                "end": 104,
                "text": "Multiple Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 107,
                "end": 114,
                "text": "RTL1000",
                "type": "DRUG"
            },
            {
                "start": 196,
                "end": 199,
                "text": "RTL",
                "type": "DRUG"
            },
            {
                "start": 316,
                "end": 334,
                "text": "multiple sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 436,
                "end": 443,
                "text": "RTL1000",
                "type": "DRUG"
            },
            {
                "start": 461,
                "end": 479,
                "text": "multiple sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 658,
                "end": 665,
                "text": "RTL1000",
                "type": "DRUG"
            },
            {
                "start": 750,
                "end": 757,
                "text": "RTL1000",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT00171886",
        "text": "Octreotide Efficacy and Safety in First-line Acromegalic Patients | Primary Acromegaly is a clinical and metabolic disease caused by growth hormone (GH) hypersecretion from a pituitary adenoma and is an insidious, chronic disease that is associated with bony and soft tissue overgrowth. Goals of therapy are to eradicate the tumor, suppress GH secretion, normalize IGF-I levels, and preserve normal pituitary function.\n\nThis study will evaluate the safety and efficacy of octreotide as primary therapy for the treatment of acromegaly and as therapy for patients with acromegaly and a pituitary macroadenoma or microadenoma.",
        "tokens": "['Octreotide', 'Efficacy', 'and', 'Safety', 'in', 'First', '-', 'line', 'Acromegalic', 'Patients', '|', 'Primary', 'Acromegaly', 'is', 'a', 'clinical', 'and', 'metabolic', 'disease', 'caused', 'by', 'growth', 'hormone', '(', 'GH', ')', 'hypersecretion', 'from', 'a', 'pituitary', 'adenoma', 'and', 'is', 'an', 'insidious', ',', 'chronic', 'disease', 'that', 'is', 'associated', 'with', 'bony', 'and', 'soft', 'tissue', 'overgrowth', '.', 'Goals', 'of', 'therapy', 'are', 'to', 'eradicate', 'the', 'tumor', ',', 'suppress', 'GH', 'secretion', ',', 'normalize', 'IGF', '-', 'I', 'levels', ',', 'and', 'preserve', 'normal', 'pituitary', 'function', '.', '\\n\\n', 'This', 'study', 'will', 'evaluate', 'the', 'safety', 'and', 'efficacy', 'of', 'octreotide', 'as', 'primary', 'therapy', 'for', 'the', 'treatment', 'of', 'acromegaly', 'and', 'as', 'therapy', 'for', 'patients', 'with', 'acromegaly', 'and', 'a', 'pituitary', 'macroadenoma', 'or', 'microadenoma', '.']",
        "token_bio_labels": "['B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 10,
                "text": "Octreotide",
                "type": "DRUG"
            },
            {
                "start": 45,
                "end": 56,
                "text": "Acromegalic",
                "type": "CONDITION"
            },
            {
                "start": 68,
                "end": 86,
                "text": "Primary Acromegaly",
                "type": "CONDITION"
            },
            {
                "start": 175,
                "end": 192,
                "text": "pituitary adenoma",
                "type": "CONDITION"
            },
            {
                "start": 472,
                "end": 482,
                "text": "octreotide",
                "type": "DRUG"
            },
            {
                "start": 523,
                "end": 533,
                "text": "acromegaly",
                "type": "CONDITION"
            },
            {
                "start": 567,
                "end": 577,
                "text": "acromegaly",
                "type": "CONDITION"
            },
            {
                "start": 584,
                "end": 606,
                "text": "pituitary macroadenoma",
                "type": "CONDITION"
            },
            {
                "start": 610,
                "end": 622,
                "text": "microadenoma",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00828958",
        "text": "Local Site Tolerability of Multiple Dose Treatment With Deltoid Intramuscular Injection of RISPERDAL CONSTA in Subjects With Chronic Schizophrenia. | The purpose of this study is to examine the discontinuation rate of schizophrenia patients receiving multiple sequential 2 mL injections of long acting injectable risperidone (an atypical antipsychotic medication) when administered into the deltoid muscle once every 2 weeks.",
        "tokens": "['Local', 'Site', 'Tolerability', 'of', 'Multiple', 'Dose', 'Treatment', 'With', 'Deltoid', 'Intramuscular', 'Injection', 'of', 'RISPERDAL', 'CONSTA', 'in', 'Subjects', 'With', 'Chronic', 'Schizophrenia', '.', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'examine', 'the', 'discontinuation', 'rate', 'of', 'schizophrenia', 'patients', 'receiving', 'multiple', 'sequential', '2', 'mL', 'injections', 'of', 'long', 'acting', 'injectable', 'risperidone', '(', 'an', 'atypical', 'antipsychotic', 'medication', ')', 'when', 'administered', 'into', 'the', 'deltoid', 'muscle', 'once', 'every', '2', 'weeks', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 91,
                "end": 100,
                "text": "RISPERDAL",
                "type": "DRUG"
            },
            {
                "start": 125,
                "end": 146,
                "text": "Chronic Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 218,
                "end": 231,
                "text": "schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 313,
                "end": 324,
                "text": "risperidone",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT05018832",
        "text": "Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Traumatic Brain Injury | This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of traumatic brain injury",
        "tokens": "['Safety', 'of', 'Cultured', 'Allogeneic', 'Adult', 'Umbilical', 'Cord', 'Derived', 'Mesenchymal', 'Stem', 'Cell', 'Intravenous', 'Infusion', 'for', 'the', 'Treatment', 'of', 'Traumatic', 'Brain', 'Injury', '|', 'This', 'trial', 'will', 'study', 'the', 'safety', 'and', 'efficacy', 'of', 'intravenous', 'infusion', 'of', 'cultured', 'allogeneic', 'adult', 'umbilical', 'cord', 'derived', 'mesenchymal', 'stem', 'cells', 'for', 'the', 'treatment', 'of', 'traumatic', 'brain', 'injury']",
        "token_bio_labels": "['O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND']",
        "entities": [
            {
                "start": 10,
                "end": 80,
                "text": "Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell",
                "type": "SURGICAL"
            },
            {
                "start": 123,
                "end": 145,
                "text": "Traumatic Brain Injury",
                "type": "CONDITION"
            },
            {
                "start": 221,
                "end": 292,
                "text": "cultured allogeneic adult umbilical cord derived mesenchymal stem cells",
                "type": "SURGICAL"
            },
            {
                "start": 314,
                "end": 336,
                "text": "traumatic brain injury",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT04574973",
        "text": "Optimizing Transcranial Direct Current Stimulation for Motor Recovery From Severe Post-stroke Hemiparesis | Individuals who experienced a stroke over one year ago will be randomly assigned to receive 1 of 4 different conditions of brain stimulation. All individuals will receive therapy of the hand and arm following the stimulation. This study will try to determine which brain stimulation condition leads to the greatest improvement in hand and arm function.",
        "tokens": "['Optimizing', 'Transcranial', 'Direct', 'Current', 'Stimulation', 'for', 'Motor', 'Recovery', 'From', 'Severe', 'Post', '-', 'stroke', 'Hemiparesis', '|', 'Individuals', 'who', 'experienced', 'a', 'stroke', 'over', 'one', 'year', 'ago', 'will', 'be', 'randomly', 'assigned', 'to', 'receive', '1', 'of', '4', 'different', 'conditions', 'of', 'brain', 'stimulation', '.', 'All', 'individuals', 'will', 'receive', 'therapy', 'of', 'the', 'hand', 'and', 'arm', 'following', 'the', 'stimulation', '.', 'This', 'study', 'will', 'try', 'to', 'determine', 'which', 'brain', 'stimulation', 'condition', 'leads', 'to', 'the', 'greatest', 'improvement', 'in', 'hand', 'and', 'arm', 'function', '.']",
        "token_bio_labels": "['O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 11,
                "end": 50,
                "text": "Transcranial Direct Current Stimulation",
                "type": "OTHER"
            },
            {
                "start": 75,
                "end": 105,
                "text": "Severe Post-stroke Hemiparesis",
                "type": "CONDITION"
            },
            {
                "start": 138,
                "end": 144,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 231,
                "end": 248,
                "text": "brain stimulation",
                "type": "OTHER"
            },
            {
                "start": 373,
                "end": 390,
                "text": "brain stimulation",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT02407951",
        "text": "Tel Aviv Sourasky Medical Center | Tourette Syndrome (TS) is a disorder characterized by motor and vocal tics. The most studied and promising intervention is Habit Reversal Training (HRT) and its variations: Behavioral Comprehensive Intervention for Tics (CBIT). Group intervention for children with TS has not been evaluated. The aim of this study is to assess the efficacy of CBIT group intervention compared with Psycho-Educational-Supportive group in terms of tic severity.",
        "tokens": "['Tel', 'Aviv', 'Sourasky', 'Medical', 'Center', '|', 'Tourette', 'Syndrome', '(', 'TS', ')', 'is', 'a', 'disorder', 'characterized', 'by', 'motor', 'and', 'vocal', 'tics', '.', 'The', 'most', 'studied', 'and', 'promising', 'intervention', 'is', 'Habit', 'Reversal', 'Training', '(', 'HRT', ')', 'and', 'its', 'variations', ':', 'Behavioral', 'Comprehensive', 'Intervention', 'for', 'Tics', '(', 'CBIT', ')', '.', 'Group', 'intervention', 'for', 'children', 'with', 'TS', 'has', 'not', 'been', 'evaluated', '.', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'assess', 'the', 'efficacy', 'of', 'CBIT', 'group', 'intervention', 'compared', 'with', 'Psycho', '-', 'Educational', '-', 'Supportive', 'group', 'in', 'terms', 'of', 'tic', 'severity', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'B-COND', 'O', 'O']",
        "entities": [
            {
                "start": 35,
                "end": 52,
                "text": "Tourette Syndrome",
                "type": "CONDITION"
            },
            {
                "start": 54,
                "end": 56,
                "text": "TS",
                "type": "CONDITION"
            },
            {
                "start": 89,
                "end": 109,
                "text": "motor and vocal tics",
                "type": "CONDITION"
            },
            {
                "start": 158,
                "end": 181,
                "text": "Habit Reversal Training",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 183,
                "end": 186,
                "text": "HRT",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 208,
                "end": 254,
                "text": "Behavioral Comprehensive Intervention for Tics",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 256,
                "end": 260,
                "text": "CBIT",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 263,
                "end": 281,
                "text": "Group intervention",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 300,
                "end": 302,
                "text": "TS",
                "type": "CONDITION"
            },
            {
                "start": 378,
                "end": 401,
                "text": "CBIT group intervention",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 416,
                "end": 451,
                "text": "Psycho-Educational-Supportive group",
                "type": "CONTROL"
            },
            {
                "start": 464,
                "end": 467,
                "text": "tic",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00908492",
        "text": "Pilot Study of the Environmental Skill Building Program for Dementia Caregivers | The purpose of this study is to pilot the home Environmental Skill-Building Program (ESP) and an educational control intervention with persons with dementia and their caregivers (n=40) in preparation for a larger double-blind randomized controlled trial. Caregivers of persons with dementia often deal with difficult behaviors. The ESP is an occupational therapy intervention that helps caregivers adapt to their environment and build care-giving skills. The areas addressed include changes to the home set-up, adaptive equipment, instruction in strategies of problem-solving, energy conservation, safe task performance, and fall recovery techniques. A trial is needed with methodological rigor and to determine if the intervention is feasible in the Canadian health care system. Results will contribute to understanding how caregivers and people with dementia can be supported in their home environments.",
        "tokens": "['Pilot', 'Study', 'of', 'the', 'Environmental', 'Skill', 'Building', 'Program', 'for', 'Dementia', 'Caregivers', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'pilot', 'the', 'home', 'Environmental', 'Skill', '-', 'Building', 'Program', '(', 'ESP', ')', 'and', 'an', 'educational', 'control', 'intervention', 'with', 'persons', 'with', 'dementia', 'and', 'their', 'caregivers', '(', 'n=40', ')', 'in', 'preparation', 'for', 'a', 'larger', 'double', '-', 'blind', 'randomized', 'controlled', 'trial', '.', 'Caregivers', 'of', 'persons', 'with', 'dementia', 'often', 'deal', 'with', 'difficult', 'behaviors', '.', 'The', 'ESP', 'is', 'an', 'occupational', 'therapy', 'intervention', 'that', 'helps', 'caregivers', 'adapt', 'to', 'their', 'environment', 'and', 'build', 'care', '-', 'giving', 'skills', '.', 'The', 'areas', 'addressed', 'include', 'changes', 'to', 'the', 'home', 'set', '-', 'up', ',', 'adaptive', 'equipment', ',', 'instruction', 'in', 'strategies', 'of', 'problem', '-', 'solving', ',', 'energy', 'conservation', ',', 'safe', 'task', 'performance', ',', 'and', 'fall', 'recovery', 'techniques', '.', 'A', 'trial', 'is', 'needed', 'with', 'methodological', 'rigor', 'and', 'to', 'determine', 'if', 'the', 'intervention', 'is', 'feasible', 'in', 'the', 'Canadian', 'health', 'care', 'system', '.', 'Results', 'will', 'contribute', 'to', 'understanding', 'how', 'caregivers', 'and', 'people', 'with', 'dementia', 'can', 'be', 'supported', 'in', 'their', 'home', 'environments', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 19,
                "end": 55,
                "text": "Environmental Skill Building Program",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 60,
                "end": 68,
                "text": "Dementia",
                "type": "CONDITION"
            },
            {
                "start": 129,
                "end": 165,
                "text": "Environmental Skill-Building Program",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 167,
                "end": 170,
                "text": "ESP",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 230,
                "end": 238,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 364,
                "end": 372,
                "text": "dementia",
                "type": "CONDITION"
            },
            {
                "start": 414,
                "end": 417,
                "text": "ESP",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 934,
                "end": 942,
                "text": "dementia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT03219073",
        "text": "Transcranial Direct Current Stimulation to Lower Neuropathic Pain in People With Multiple Sclerosis: a Mechanistic FDG-PET Study | Transcranial Direct Current Stimulation (tDCS) is a noninvasive brain stimulation technique that utilizes low amplitude direct currents applied via scalp electrodes to apply currents to the brain and modulate the level of cortical excitability. tDCS applied over the dorsolateral prefrontal and motor cortex has been reported to be able to decrease pain sensation and to increase pain threshold in healthy subjects and is effective in reducing central chronic pain in patients with multiple sclerosis (PwMS.) In spite of the encouraging results of tDCS in PwMS, detailed mechanisms accounting for its analgesic effect have not yet been elucidated.\n\nThis will be the first study to determine the effects of tDCS on whole and regional brain activity in PwMS with neuropathic pain to identify potential mechanisms of the analgesic effects of tDCS. These findings will provide targets for future studies investigating different stimulation areas, possible short- and long-term side effects, and specific target areas for other precise stimulation techniques such as transcranial magnetic stimulation.",
        "tokens": "['Transcranial', 'Direct', 'Current', 'Stimulation', 'to', 'Lower', 'Neuropathic', 'Pain', 'in', 'People', 'With', 'Multiple', 'Sclerosis', ':', 'a', 'Mechanistic', 'FDG', '-', 'PET', 'Study', '|', 'Transcranial', 'Direct', 'Current', 'Stimulation', '(', 'tDCS', ')', 'is', 'a', 'noninvasive', 'brain', 'stimulation', 'technique', 'that', 'utilizes', 'low', 'amplitude', 'direct', 'currents', 'applied', 'via', 'scalp', 'electrodes', 'to', 'apply', 'currents', 'to', 'the', 'brain', 'and', 'modulate', 'the', 'level', 'of', 'cortical', 'excitability', '.', 'tDCS', 'applied', 'over', 'the', 'dorsolateral', 'prefrontal', 'and', 'motor', 'cortex', 'has', 'been', 'reported', 'to', 'be', 'able', 'to', 'decrease', 'pain', 'sensation', 'and', 'to', 'increase', 'pain', 'threshold', 'in', 'healthy', 'subjects', 'and', 'is', 'effective', 'in', 'reducing', 'central', 'chronic', 'pain', 'in', 'patients', 'with', 'multiple', 'sclerosis', '(', 'PwMS', '.', ')', 'In', 'spite', 'of', 'the', 'encouraging', 'results', 'of', 'tDCS', 'in', 'PwMS', ',', 'detailed', 'mechanisms', 'accounting', 'for', 'its', 'analgesic', 'effect', 'have', 'not', 'yet', 'been', 'elucidated', '.', '\\n\\n', 'This', 'will', 'be', 'the', 'first', 'study', 'to', 'determine', 'the', 'effects', 'of', 'tDCS', 'on', 'whole', 'and', 'regional', 'brain', 'activity', 'in', 'PwMS', 'with', 'neuropathic', 'pain', 'to', 'identify', 'potential', 'mechanisms', 'of', 'the', 'analgesic', 'effects', 'of', 'tDCS', '.', 'These', 'findings', 'will', 'provide', 'targets', 'for', 'future', 'studies', 'investigating', 'different', 'stimulation', 'areas', ',', 'possible', 'short-', 'and', 'long', '-', 'term', 'side', 'effects', ',', 'and', 'specific', 'target', 'areas', 'for', 'other', 'precise', 'stimulation', 'techniques', 'such', 'as', 'transcranial', 'magnetic', 'stimulation', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 39,
                "text": "Transcranial Direct Current Stimulation",
                "type": "OTHER"
            },
            {
                "start": 49,
                "end": 65,
                "text": "Neuropathic Pain",
                "type": "CONDITION"
            },
            {
                "start": 81,
                "end": 100,
                "text": "Multiple Sclerosis:",
                "type": "CONDITION"
            },
            {
                "start": 131,
                "end": 170,
                "text": "Transcranial Direct Current Stimulation",
                "type": "OTHER"
            },
            {
                "start": 172,
                "end": 176,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 376,
                "end": 438,
                "text": "tDCS applied over the dorsolateral prefrontal and motor cortex",
                "type": "OTHER"
            },
            {
                "start": 480,
                "end": 484,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 511,
                "end": 515,
                "text": "pain",
                "type": "CONDITION"
            },
            {
                "start": 583,
                "end": 595,
                "text": "chronic pain",
                "type": "CONDITION"
            },
            {
                "start": 613,
                "end": 631,
                "text": "multiple sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 679,
                "end": 683,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 837,
                "end": 841,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 892,
                "end": 908,
                "text": "neuropathic pain",
                "type": "CONDITION"
            },
            {
                "start": 970,
                "end": 974,
                "text": "tDCS",
                "type": "OTHER"
            },
            {
                "start": 1193,
                "end": 1226,
                "text": "transcranial magnetic stimulation",
                "type": "OTHER"
            }
        ]
    },
    {
        "nctid": "NCT04430309",
        "text": "The Feasibility and Efficacy of Baduanjin Exercise on Cognition and Physical Fitness Among Patients With Schizophrenia:Randomized Controlled Trial | As an ancient, popular Chinese exercise, Baduanjin is characterized by symmetrical posture, deep breathing and meditation and easy to learn. Previous studies showed immediate effect of Baduanjin on cognition in patients with schizophrenia.The purpose of this study is to investigate the immediate effect and chronic effect of Baduanjin exercise on physical fitness, cognition and daily functions in middle-aged and older adults with schizophrenia.",
        "tokens": "['The', 'Feasibility', 'and', 'Efficacy', 'of', 'Baduanjin', 'Exercise', 'on', 'Cognition', 'and', 'Physical', 'Fitness', 'Among', 'Patients', 'With', 'Schizophrenia', ':', 'Randomized', 'Controlled', 'Trial', '|', 'As', 'an', 'ancient', ',', 'popular', 'Chinese', 'exercise', ',', 'Baduanjin', 'is', 'characterized', 'by', 'symmetrical', 'posture', ',', 'deep', 'breathing', 'and', 'meditation', 'and', 'easy', 'to', 'learn', '.', 'Previous', 'studies', 'showed', 'immediate', 'effect', 'of', 'Baduanjin', 'on', 'cognition', 'in', 'patients', 'with', 'schizophrenia', '.', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'investigate', 'the', 'immediate', 'effect', 'and', 'chronic', 'effect', 'of', 'Baduanjin', 'exercise', 'on', 'physical', 'fitness', ',', 'cognition', 'and', 'daily', 'functions', 'in', 'middle', '-', 'aged', 'and', 'older', 'adults', 'with', 'schizophrenia', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",
        "entities": [
            {
                "start": 32,
                "end": 41,
                "text": "Baduanjin",
                "type": "PHYSICAL"
            },
            {
                "start": 105,
                "end": 118,
                "text": "Schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 190,
                "end": 199,
                "text": "Baduanjin",
                "type": "PHYSICAL"
            },
            {
                "start": 334,
                "end": 343,
                "text": "Baduanjin",
                "type": "PHYSICAL"
            },
            {
                "start": 374,
                "end": 387,
                "text": "schizophrenia",
                "type": "CONDITION"
            },
            {
                "start": 475,
                "end": 484,
                "text": "Baduanjin",
                "type": "PHYSICAL"
            },
            {
                "start": 582,
                "end": 595,
                "text": "schizophrenia",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT00600873",
        "text": "Pharmacokinetics and Nitrative-Oxidative Stress Pharmacodynamics in Amyotrophic Lateral Sclerosis Subjects Taking Daily High-Dose R(+) Pramipexole Dihydrochloride for Six Months | R(+)pramipexole is administered in escalating doses to patients with early ALS. Plasma and spinal fluid levels of R(+)PPX are monitored, in addition to biochemical markers of oxidative stress.",
        "tokens": "['Pharmacokinetics', 'and', 'Nitrative', '-', 'Oxidative', 'Stress', 'Pharmacodynamics', 'in', 'Amyotrophic', 'Lateral', 'Sclerosis', 'Subjects', 'Taking', 'Daily', 'High', '-', 'Dose', 'R(+', ')', 'Pramipexole', 'Dihydrochloride', 'for', 'Six', 'Months', '|', 'R(+)pramipexole', 'is', 'administered', 'in', 'escalating', 'doses', 'to', 'patients', 'with', 'early', 'ALS', '.', 'Plasma', 'and', 'spinal', 'fluid', 'levels', 'of', 'R(+)PPX', 'are', 'monitored', ',', 'in', 'addition', 'to', 'biochemical', 'markers', 'of', 'oxidative', 'stress', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 68,
                "end": 97,
                "text": "Amyotrophic Lateral Sclerosis",
                "type": "CONDITION"
            },
            {
                "start": 130,
                "end": 162,
                "text": "R(+) Pramipexole Dihydrochloride",
                "type": "DRUG"
            },
            {
                "start": 180,
                "end": 195,
                "text": "R(+)pramipexole",
                "type": "DRUG"
            },
            {
                "start": 249,
                "end": 258,
                "text": "early ALS",
                "type": "CONDITION"
            },
            {
                "start": 294,
                "end": 301,
                "text": "R(+)PPX",
                "type": "DRUG"
            }
        ]
    },
    {
        "nctid": "NCT04948749",
        "text": "Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial: a Prospective, Randomized, Open-labelled, Blinded End-point Trial (DREAM-PRIDE) | The aim of DREAM-PRIDE is to evaluate whether implantation of drug-eluting stent (DES) combined with aggressive medical treatment is more efficacious in prevention of 1-year stroke recurrence than standard medical treatment alone for symptomatic intracranial atherosclerotic disease.",
        "tokens": "['Drug', 'Eluting', 'Stenting', 'and', 'Aggressive', 'Medical', 'Treatment', 'for', 'Preventing', 'Recurrent', 'Stroke', 'in', 'Intracranial', 'Atherosclerotic', 'Disease', 'Trial', ':', 'a', 'Prospective', ',', 'Randomized', ',', 'Open', '-', 'labelled', ',', 'Blinded', 'End', '-', 'point', 'Trial', '(', 'DREAM', '-', 'PRIDE', ')', '|', 'The', 'aim', 'of', 'DREAM', '-', 'PRIDE', 'is', 'to', 'evaluate', 'whether', 'implantation', 'of', 'drug', '-', 'eluting', 'stent', '(', 'DES', ')', 'combined', 'with', 'aggressive', 'medical', 'treatment', 'is', 'more', 'efficacious', 'in', 'prevention', 'of', '1', '-', 'year', 'stroke', 'recurrence', 'than', 'standard', 'medical', 'treatment', 'alone', 'for', 'symptomatic', 'intracranial', 'atherosclerotic', 'disease', '.']",
        "token_bio_labels": "['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 21,
                "text": "Drug Eluting Stenting",
                "type": "OTHER"
            },
            {
                "start": 26,
                "end": 54,
                "text": "Aggressive Medical Treatment",
                "type": "OTHER"
            },
            {
                "start": 70,
                "end": 86,
                "text": "Recurrent Stroke",
                "type": "CONDITION"
            },
            {
                "start": 90,
                "end": 126,
                "text": "Intracranial Atherosclerotic Disease",
                "type": "CONDITION"
            },
            {
                "start": 278,
                "end": 296,
                "text": "drug-eluting stent",
                "type": "OTHER"
            },
            {
                "start": 298,
                "end": 301,
                "text": "DES",
                "type": "OTHER"
            },
            {
                "start": 317,
                "end": 345,
                "text": "aggressive medical treatment",
                "type": "OTHER"
            },
            {
                "start": 390,
                "end": 407,
                "text": "stroke recurrence",
                "type": "CONDITION"
            },
            {
                "start": 422,
                "end": 445,
                "text": "medical treatment alone",
                "type": "CONTROL"
            },
            {
                "start": 450,
                "end": 498,
                "text": "symptomatic intracranial atherosclerotic disease",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01867268",
        "text": "Evaluating the Effect of Acetazolamide Administration and Prone Positioning Following Lumbosacral Spinal Surgery in Preventing Cerebro Spinal Fluid Leakage and Collection and Wound Dehiscence in Children. | Purpose of study : to determine the preventive effect of acetazolamide administration, prone positioning, and the combination of both following the neurosurgical interventions in lumbosacral region for cerebrospinal fluid (CSF) leak, CSF collection and wound dehiscence.\nSample size: 144\n\nintervention groups:\n\nGroup A: Acetazolamide administration for 10 days\nGroup B: prone positioning for 10 days\nGroup C: Acetazolamide administration and prone positioning for 10 days\nGroup D: no intervention\nPeriod of study: Autumn 2012 to the end of winter of 2015",
        "tokens": "['Evaluating', 'the', 'Effect', 'of', 'Acetazolamide', 'Administration', 'and', 'Prone', 'Positioning', 'Following', 'Lumbosacral', 'Spinal', 'Surgery', 'in', 'Preventing', 'Cerebro', 'Spinal', 'Fluid', 'Leakage', 'and', 'Collection', 'and', 'Wound', 'Dehiscence', 'in', 'Children', '.', '|', 'Purpose', 'of', 'study', ':', 'to', 'determine', 'the', 'preventive', 'effect', 'of', 'acetazolamide', 'administration', ',', 'prone', 'positioning', ',', 'and', 'the', 'combination', 'of', 'both', 'following', 'the', 'neurosurgical', 'interventions', 'in', 'lumbosacral', 'region', 'for', 'cerebrospinal', 'fluid', '(', 'CSF', ')', 'leak', ',', 'CSF', 'collection', 'and', 'wound', 'dehiscence', '.', '\\n', 'Sample', 'size', ':', '144', '\\n\\n', 'intervention', 'groups', ':', '\\n\\n', 'Group', 'A', ':', 'Acetazolamide', 'administration', 'for', '10', 'days', '\\n', 'Group', 'B', ':', 'prone', 'positioning', 'for', '10', 'days', '\\n', 'Group', 'C', ':', 'Acetazolamide', 'administration', 'and', 'prone', 'positioning', 'for', '10', 'days', '\\n', 'Group', 'D', ':', 'no', 'intervention', '\\n', 'Period', 'of', 'study', ':', 'Autumn', '2012', 'to', 'the', 'end', 'of', 'winter', 'of', '2015']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 25,
                "end": 38,
                "text": "Acetazolamide",
                "type": "DRUG"
            },
            {
                "start": 58,
                "end": 75,
                "text": "Prone Positioning",
                "type": "OTHER"
            },
            {
                "start": 127,
                "end": 170,
                "text": "Cerebro Spinal Fluid Leakage and Collection",
                "type": "CONDITION"
            },
            {
                "start": 175,
                "end": 191,
                "text": "Wound Dehiscence",
                "type": "CONDITION"
            },
            {
                "start": 264,
                "end": 277,
                "text": "acetazolamide",
                "type": "DRUG"
            },
            {
                "start": 294,
                "end": 311,
                "text": "prone positioning",
                "type": "OTHER"
            },
            {
                "start": 409,
                "end": 439,
                "text": "cerebrospinal fluid (CSF) leak",
                "type": "CONDITION"
            },
            {
                "start": 441,
                "end": 455,
                "text": "CSF collection",
                "type": "CONDITION"
            },
            {
                "start": 460,
                "end": 476,
                "text": "wound dehiscence",
                "type": "CONDITION"
            },
            {
                "start": 527,
                "end": 540,
                "text": "Acetazolamide",
                "type": "DRUG"
            },
            {
                "start": 577,
                "end": 594,
                "text": "prone positioning",
                "type": "OTHER"
            },
            {
                "start": 616,
                "end": 629,
                "text": "Acetazolamide",
                "type": "DRUG"
            },
            {
                "start": 649,
                "end": 666,
                "text": "prone positioning",
                "type": "OTHER"
            },
            {
                "start": 688,
                "end": 703,
                "text": "no intervention",
                "type": "CONTROL"
            }
        ]
    },
    {
        "nctid": "NCT01684176",
        "text": "Pharmacist Intervention Programme to Improve Medication Adherence in Stroke Patients | Patient suffering a Transient Ischemic Attack (TIA) or stroke are subsequently at high risk of a new stroke, however, poor adherence to secondary prevention medications occurs frequently within this patient group. The purpose of this study is to evaluate whether a complex tailored pharmacist intervention will lead to increased adherence to secondary stroke prevention medications and less new stroke events when compared to a usual care group. Interventions focus on motivational interviewing, medication review and telephone follow up.",
        "tokens": "['Pharmacist', 'Intervention', 'Programme', 'to', 'Improve', 'Medication', 'Adherence', 'in', 'Stroke', 'Patients', '|', 'Patient', 'suffering', 'a', 'Transient', 'Ischemic', 'Attack', '(', 'TIA', ')', 'or', 'stroke', 'are', 'subsequently', 'at', 'high', 'risk', 'of', 'a', 'new', 'stroke', ',', 'however', ',', 'poor', 'adherence', 'to', 'secondary', 'prevention', 'medications', 'occurs', 'frequently', 'within', 'this', 'patient', 'group', '.', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'whether', 'a', 'complex', 'tailored', 'pharmacist', 'intervention', 'will', 'lead', 'to', 'increased', 'adherence', 'to', 'secondary', 'stroke', 'prevention', 'medications', 'and', 'less', 'new', 'stroke', 'events', 'when', 'compared', 'to', 'a', 'usual', 'care', 'group', '.', 'Interventions', 'focus', 'on', 'motivational', 'interviewing', ',', 'medication', 'review', 'and', 'telephone', 'follow', 'up', '.']",
        "token_bio_labels": "['B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'B-BEH', 'I-BEH', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O']",
        "entities": [
            {
                "start": 0,
                "end": 33,
                "text": "Pharmacist Intervention Programme",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 69,
                "end": 75,
                "text": "Stroke",
                "type": "CONDITION"
            },
            {
                "start": 107,
                "end": 132,
                "text": "Transient Ischemic Attack",
                "type": "CONDITION"
            },
            {
                "start": 134,
                "end": 137,
                "text": "TIA",
                "type": "CONDITION"
            },
            {
                "start": 142,
                "end": 148,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 188,
                "end": 194,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 360,
                "end": 392,
                "text": "tailored pharmacist intervention",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 439,
                "end": 445,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 482,
                "end": 488,
                "text": "stroke",
                "type": "CONDITION"
            },
            {
                "start": 556,
                "end": 581,
                "text": "motivational interviewing",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 583,
                "end": 600,
                "text": "medication review",
                "type": "BEHAVIOURAL"
            },
            {
                "start": 605,
                "end": 624,
                "text": "telephone follow up",
                "type": "BEHAVIOURAL"
            }
        ]
    },
    {
        "nctid": "NCT00649207",
        "text": "A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of ABT-888 in Combination With Whole Brain Radiation Therapy in Subjects With Brain Metastases | This Phase I clinical trial is studying the side effects and best dose of ABT-888 when given together with Whole Brain Radiation Therapy (WBRT) in treating patients with brain metastases.",
        "tokens": "['A', 'Phase', '1', 'Study', 'Evaluating', 'the', 'Safety', ',', 'Tolerability', 'and', 'Pharmacokinetics', 'of', 'ABT-888', 'in', 'Combination', 'With', 'Whole', 'Brain', 'Radiation', 'Therapy', 'in', 'Subjects', 'With', 'Brain', 'Metastases', '|', 'This', 'Phase', 'I', 'clinical', 'trial', 'is', 'studying', 'the', 'side', 'effects', 'and', 'best', 'dose', 'of', 'ABT-888', 'when', 'given', 'together', 'with', 'Whole', 'Brain', 'Radiation', 'Therapy', '(', 'WBRT', ')', 'in', 'treating', 'patients', 'with', 'brain', 'metastases', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",
        "entities": [
            {
                "start": 76,
                "end": 83,
                "text": "ABT-888",
                "type": "DRUG"
            },
            {
                "start": 104,
                "end": 133,
                "text": "Whole Brain Radiation Therapy",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 151,
                "end": 167,
                "text": "Brain Metastases",
                "type": "CONDITION"
            },
            {
                "start": 244,
                "end": 251,
                "text": "ABT-888",
                "type": "DRUG"
            },
            {
                "start": 277,
                "end": 306,
                "text": "Whole Brain Radiation Therapy",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 308,
                "end": 312,
                "text": "WBRT",
                "type": "RADIOTHERAPY"
            },
            {
                "start": 340,
                "end": 356,
                "text": "brain metastases",
                "type": "CONDITION"
            }
        ]
    },
    {
        "nctid": "NCT01448473",
        "text": "Is a Two-Film Skull X-ray Series as Sensitive as a Four-Film Series in the Diagnosis of Skull Fractures in Paediatric Patients With Minor Head Trauma? | Minor head injuries are a common presenting complaint in the pediatric emergency department. Skull x-rays are a useful tool in the evaluation of paediatric patients with a history of minor head trauma. However, there exists ongoing controversy regarding the ideal number of views that should be obtained in a skull series. This study aims to determine if there is a significant difference in the diagnostic accuracy of skull x-rays in the diagnosis of fracture in paediatric minor head trauma patients when a 2-film series as opposed to a 4-film series is provided to participating pediatric emergency physicians.",
        "tokens": "['Is', 'a', 'Two', '-', 'Film', 'Skull', 'X', '-', 'ray', 'Series', 'as', 'Sensitive', 'as', 'a', 'Four', '-', 'Film', 'Series', 'in', 'the', 'Diagnosis', 'of', 'Skull', 'Fractures', 'in', 'Paediatric', 'Patients', 'With', 'Minor', 'Head', 'Trauma', '?', '|', 'Minor', 'head', 'injuries', 'are', 'a', 'common', 'presenting', 'complaint', 'in', 'the', 'pediatric', 'emergency', 'department', '.', 'Skull', 'x', '-', 'rays', 'are', 'a', 'useful', 'tool', 'in', 'the', 'evaluation', 'of', 'paediatric', 'patients', 'with', 'a', 'history', 'of', 'minor', 'head', 'trauma', '.', 'However', ',', 'there', 'exists', 'ongoing', 'controversy', 'regarding', 'the', 'ideal', 'number', 'of', 'views', 'that', 'should', 'be', 'obtained', 'in', 'a', 'skull', 'series', '.', 'This', 'study', 'aims', 'to', 'determine', 'if', 'there', 'is', 'a', 'significant', 'difference', 'in', 'the', 'diagnostic', 'accuracy', 'of', 'skull', 'x', '-', 'rays', 'in', 'the', 'diagnosis', 'of', 'fracture', 'in', 'paediatric', 'minor', 'head', 'trauma', 'patients', 'when', 'a', '2', '-', 'film', 'series', 'as', 'opposed', 'to', 'a', '4', '-', 'film', 'series', 'is', 'provided', 'to', 'participating', 'pediatric', 'emergency', 'physicians', '.']",
        "token_bio_labels": "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",
        "entities": [
            {
                "start": 88,
                "end": 103,
                "text": "Skull Fractures",
                "type": "CONDITION"
            },
            {
                "start": 132,
                "end": 149,
                "text": "Minor Head Trauma",
                "type": "CONDITION"
            },
            {
                "start": 153,
                "end": 172,
                "text": "Minor head injuries",
                "type": "CONDITION"
            },
            {
                "start": 336,
                "end": 353,
                "text": "minor head trauma",
                "type": "CONDITION"
            },
            {
                "start": 605,
                "end": 613,
                "text": "fracture",
                "type": "CONDITION"
            },
            {
                "start": 628,
                "end": 645,
                "text": "minor head trauma",
                "type": "CONDITION"
            }
        ]
    }
]